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ABSTRACT
The work presented in this thesis employs clinical and molecular genetic
techniques to study genetic aberrations involving the gene for Familial Adenomatous
Polyposis (FAP) in colorectal carcinogenesis and in the clinical syndrome of FAP.
Epidemiological data are reviewed and demonstrate that colorectal cancer is
a major public health problem in westernised societies, with little improvement in
mortality for 50 years. Putative aetiological factors are briefly reviewed and the
evidence for the adenoma-carcinoma sequence in colorectal carcinogenesis is
presented. The heritable syndrome of FAP is described in detail and is proposed as
an in vivo model of sporadic colorectal carcinogenesis. The gene for FAP (APC) was
previously regionally mapped to chromosome 5 and has been implicated as a
tumour suppressor gene, involved in both the familial and sporadic forms of
colorectal cancer. A review of epidemiological, statistical, cytogenetic, molecular
genetic and somatic cell hybridisation evidence supports the existence of tumour
suppressor genes and data specifically relating to APC are examined. Knowledge of
APC involvement in sporadic and familial colorectal neoplasms prior to the
commencement of this work is discussed.
Fifteen probands affected by FAP were identified and eleven of these kindreds
were exhaustively ascertained and the clinical FAP phenotype of all affected family
members fully evaluated. Nine families served as the resource for genetic linkage
analysis. Blood leukocyte and archival paraffin-embedded pathology tissue DNA
from family members were analysed by Southern blot and DNA hybridisation
techniques. 155 family members (90 meioses) were genotyped for DNA probes
exhibiting restriction fragment length polymorphisms (RFLP's). A genetic linkage
map of 6 RFLP probes was constructed around the APC gene by genetic linkage
analysis and by identification of crucial recombinants. These are the first data
which have allowed mapping of all of these markers and support a locus order of
centromere-pi227-Cl 1P1 l-ECB27-L5.62-APC-EF5.44-YN5.48-telomere.
This work was the first to apply these markers to the clinical care of FAP
families. Preclinical diagnosis of FAP was carried out in 41 at-risk family members
(aged 0-39 years). The clinical value and validity of DNA probe derived risk
estimations were demonstrated. Four at-risk family members who had been
discharged from clinical screening were shown to be affected by DNA analysis and
cancer prevented by prophylactic colectomy. The calculated residual risk for the
majority of those apparently unaffected was sufficiently low as to allow a reduction
in the frequency of colonic screening. Recommendations are made for an integrated
approach to screening for FAP.
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The linkage map suggests that the probe EF5.44 is very close to APC and so
analysis of large DNA fragments at the EF5.44 locus in 2 sporadic cases of FAP
using pulse field gel electrophoresis was carried out. However, no rearrangements
were detected up to 800kb from the EF5.44 locus in the cases examined and so final
mapping of the APC gene using PFGE in this study was not possible.
The high resolution map of 6 DNA probes around APC gene generated by
genetic linkage analysis was used to examine the frequency, nature and extent of
losses of genetic material from that chromosome in FAP and non-FAP colorectal
neoplasms. A further 7 polymorphic DNA markers spanning chromosome 5 were
also examined. Loss of constitutional heterozygosity in tumour DNA was assessed
at all 13 loci using blood leukocyte and normal colonic mucosa DNA as controls. A
deletion map was then constructed for each tumour which exhibited any
chromosome 5 allele losses. The composite deletion map generated from allele loss
data in carcinomas allows independent ordering of many of the markers and the
locus order derived from linkage analysis is supported. There were no chromosome
5 allele losses in 28 informative FAP adenomas. Twenty of these adenomas were
informative at markers flanking the APC gene and spanning a distance of as little as
2 megabases. This stringent assessment of APC gene status in FAP adenomas
suggests that the inherited APCmutation allows adenomatous change in the colonic
epithelium of FAP patients without the requirement for a 'second hit'.
Fifty one sporadic colorectal carcinomas were analysed. APC-related allele
loss was demonstrated in 67% of carcinomas informative at any locus and in 56% of
tumours where markers closely flanking the APC gene were both informative. The
nature of the defects in chromosome 5 were small interstitial deletions (64%), mitotic
recombination events (33%) and whole chromosome loss (3%). There were no
particular associations between chromosome 5 allele loss and clinico-pathological
features or ploidy level by flow cytometry, suggesting the early involvement ofAPC in
colorectal carcinogenesis.
Twenty sporadic adenomas were collected and an overall loss of
heterozygosity of 17% at any chromosome 5 locus was demonstrated. There was a
highly significant difference in the allele loss frequency between sporadic adenomas
and FAP adenomas. There was also a statistically significant difference in allele loss
frequency detected at any informative chromosome 5 locus between sporadic
adenomas and carcinomas. The data suggest that inactivation of the APC gene is
permissive of early tumour development and appears to be involved in the selection
of cells within an already adenomatous colonic epithelium for progression to
malignancy.
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The role of APC defects in the FAP syndrome and in colorectal carcinogenesis
has been investigated and a number of novel discoveries presented. The gene has
been mapped to a small region of chromosome 5q and this region analysed in benign
and malignant colorectal neoplasms. The demonstration of the consistent and
specific deletion ofAPC emphasise its importance in colorectal carcinogenesis.
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This chapter reviews the importance of colorectal cancer as a major public
health problem in the developed world and discusses putative aetiological factors
related to diet. Evidence is presented which demonstrates that a heritable
predisposition to colorectal cancer exists and there appears to be a genetic-
environmental interaction. A brief review is given of current research into possible
methods of improving the prognosis of colorectal cancer.
The evidence for the adenoma-carcinoma sequence and the importance of the
adenoma as a premalignant lesion is reviewed. Understanding the fundamental
molecular changes in genetic material that result in adenomatous and then
carcinomatous change in the colonic epithelium might lead to novel treatment
approaches and perhaps even to identification of individuals at high risk of
developing colorectal malignancy. Evidence is presented that the syndrome of
Familial Adenomatous Polyposis (FAP) is a genetic condition reflecting the events
involved in non-polyposis colorectal carcinogenesis. Hence FAP might be considered
a model of the neoplastic process in the colorectum. The clinical syndrome of
Familial Adenomatous Polyposis is described in detail with particular emphasis on
stigmata which can be used to identify gene carriers before the onset of polyps.
Evidence is presented that the gene for Familial Adenomatous Polyposis (APC) is a
tumour suppressor gene and that the genes for retinoblastoma and Wilms' tumour
represent paradigms for such genes. The statistical, epidemiological and
experimental evidence for such tumour suppressor genes is reviewed. Specific
genetic aberrations reported in FAP and in colorectal cancer are discussed with
particular reference to possible tumour suppressor gene involvement. In the light of
that knowledge, the aims of this project are presented and the experimental
approach described.
1.1 Clinical aspects of colorectal carcinoma and Familial Adenomatous
Polyposis.
1.1.1 The incidence and geographic distribution of colorectal cancer.
Carcinoma of the colon and rectum is predominantly a disease of
westernised societies (Burkitt 1971, Haenszel 1971). It is the second most common
cause of death due to cancer in the United Kingdom, second only to lung cancer.
25,000 new cases are diagnosed each year and around 19,000 patients die from the
disease annually. Scotland is the region with the highest incidence of colorectal
cancer within the UK (Kemp 1985) with a crude rate of 52/100,000 (male and
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female) and an age standardised incidence in males of 34.2/100,000 (cf.
Birmingham (33.0), Oxford (30.7), South Thames (28.0) ). The incidence rate in
Scottish females is also high (27.5) when compared to other regions within the UK.
Within Scotland there are striking geographical aggregations of cases and these
differences in incidence rates are highly statistically significant (Kemp 1985). There
is a very high rate for males in the Tweedale district (80.4/100,000 crude rate, 55.3
standardised rate) and for males and females in north-east Scotland (around
85/100,000 crude rate, 50 standardised rate) with a four-fold difference between the
highest and lowest incidences within Scotland. These discrepancies remain
unexplained but may suggest a local high exposure to an environmental risk factor
or a high prevalence of a cancer predisposing gene, perhaps through relative in¬
breeding within the local population.
The incidence rates for colorectal cancer in the United Kingdom as a whole,
and Scotland in particular, are high in comparison to other countries (Waterhouse
1982). There is generally a tenfold increased incidence in North Western Europe
and North America when compared with developing countries such as sub-Saharan
Africa, India and many regions of South America (Burkitt 1971, Doll 1980, Haenszel
1971, Waterhouse 1982). The age-standardised incidence rate for males in
Connecticut, USA is 20 times greater than that for males in Senegal (Waterhouse
1982). No other malignancy so closely parallels the affluence of a society in its
incidence around the world.
In westernised countries, colorectal cancer is a disease primarily affecting
those in the 7th and 8th decades of life (Cancer Registration Statistics, Scotland,
Goligher 1984, Kemp 1985). Less than 5% of cases arise in patients under 35 years
of age (Goligher 1984) and when the disease occurs in such young individuals, there
is frequently a family history of colorectal cancer.
The Scottish incidence rate is rising (Cancer Registry Statistics, Scotland
1971-1980). Surgical treatment has achieved only a modest improvement in
mortality from the disease since the classical publications on tumour staging and
outcome (Dukes 1929-30, Dukes 1931, Dukes 1940, Lockhart-Mummery 1926) The
minimal improvements in outlook for these patients (Bailar 1986, Gill 1978,
Goligher 1984, Giles 1982) are probably due mainly to a reduction in operation-
related mortality, with improved anaesthetics and post-operative support.
Therefore, the number of patients dying of colorectal cancer has remained
substantially unchanged in 55 years (1930-1985) (Registar General (Scotland) 1985).
Clearly, colorectal cancer is a significant health problem in westernised countries,
both in terms of its incidence and also due to the overall poor prognosis with less
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than one third of patients alive 5 years after presentation (Falterman 1974, Gill
1978, Goligher 1984, Jass 1987).
Since colorectal cancer is a major health problem which has been little
influenced by modern medical care, it would seem logical to gain greater
understanding of the aetiological factors involved in order to develop novel treatment
approaches. What is already known about the cause of colorectal cancer?
1.1.2 Aetiological factors in colorectal cancer.
The high incidence of colorectal cancer in developed countries has been
attributed to environmental factors present in the western diet. The evidence for
this comes from geographic variations in the incidence of the disease (Burkitt 1971,
Doll 1980, Haenszel 1971, Waterhouse 1982) and from studies which show that
migrant populations assume the incidence of the indigenous population within 2-3
generations (Haenszel 1971). The dietaiy factors implicated as carcinogens have
been identified in the main by experimental colorectal carcinogenesis and are not
always supported by case-control or cohort studies (Bruce 1987). Burkitt (1971)
suggested that a high fibre intake reduces the intestinal transit time and dilutes
potential faecal carcinogens. Hence the exposure of the colonic epithelium to
carcinogens might be reduced. However there is virtually no evidence to support
this in man or in laboratory animals (Stubbs 1983). A low fibre and high fat content
in the diet appears to result in high faecal pH which has been shown to enhance bile
acid toxicity. Cellular proliferation also appears to be reduced when the faeces are
acidified (Bruce 1987). However there have been no direct tests of the effect of faecal
pH manipulation on colonic epithelial proliferation. Only one study has assessed
the influence of faecal acidification by ingestion of vitamins C and E on the
development of colorectal adenomas or carcinomas and this revealed no effect
(McKeown-Eyssen 1988). However, the time period of the study was relatively short
and the authors themselves suggest a further larger and more prolonged study.
High dietary intake of animal fat has been suggested as an important aetiological
factor and its mode of action may be via an increase in faecal bile acids with gut
bacterial conversion to carcinogenic compounds related to methylcholanthrene
(Stubbs 1983). Bile acids themselves have been shown to have a toxic effect on
colonic epithelium and high fat intake mobilises bile acids. However there are no
clear differences apparent in dietaiy fat consumption between colon cancer cases
and a control population in case-control studies (Bruce 1987, Stubbs 1983). In
addition there is evidence to suggest that individuals with low serum cholesterol are
actually at higher risk of colorectal cancer (Doll 1981), although the association of
plasma cholesterol concentration and colorectal cancer mortality appears to be 'U'-
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shaped with an increased rate of colorectal cancer deaths at cholesterol
concentrations above and below the mean population level (Isles 1989).
It has been suggested that the bio-availability of bile acids is important.
Calcium has been proposed as an agent which might reduce the availability of bile
acids. Dietary calcium supplements have been shown to reduce colonic epithelial
proliferative indices to normal levels in patients at high risk of colorectal cancer,
such as those with multiple polyps and affected members of colon cancer families
(Lipkin 1985, Rozen 1989, Wilson 1990). However international case-control studies
have so far failed to show a clinical effect (Bruce 1987).
A summary of the state of understanding of aetiological factors in colorectal
cancer is difficult since the field is full of contradictory and negative evidence. For
the present, there remains little doubt that diet is of great importance in the high
incidence of colorectal cancer in the western world but the exact factor or factors
involved still require to be elucidated. As a result, it is not yet possible to
recommend rational dietary intervention. Until further epidemiological, case-control
and interventional studies identify the agents responsible, we must look to other
methods of reducing colorectal cancer mortality.
1.1.3 Towards reduction in mortality from colorectal cancer.
There is a need for novel approaches to reducing the mortality from
colorectal cancer. Three broad strategies are possible: alteration in treatment
modalities, identification of the disease in a pre-malignant phase or at an early,
treatable stage and dietary intervention with the aim of preventing neoplastic change
in the first place.
Optimising current surgical management
Aggressive surgical treatment regimes have been advocated. Some studies
have reported a beneficial effect of radical surgery involving extended
lymphadenectomy (Koyama 1984) and radical excision of the mesorectum (Heald
1986). These studies have suggested that survival can be improved and/or local
recurrence reduced, but there are no properly controlled randomised trials and so at
present the results of ever more radical surgery cannot be assessed objectively. In
addition, significant morbidity and mortality may well be associated with such
extensive surgery. At a more practical level, there are substantial differences in the
outcome for patients with colorectal cancer dependent on the surgeon who carried
out the operation (Phillips 1986) and on certain crucial aspects of technique (Quirke
1986). This suggests that improvements in survival are possible by identifying the
key operative techniques employed by those surgeons producing the best results
and applying these universally.
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The generally poor outlook following surgery for colorectal cancer has
prompted many authors to propose adjuvant therapy as a necessary part of
treatment (Gill 1978). Two adjuvant treatment modalities have been evaluated but
the results have been of mixed success and the message concerning use of these
modalities in routine clinical practice remains somewhat unclear.
Adjuvant therapy
Radiotherapy has been shown to be of no value in cancer of the colon (Lancet
editorial 1985). However, this is not the case for rectal cancer, where benefit has
been demonstrated by randomised controlled trials (reviewed by Buyse 1988,
Cummings 1989, Duncan 1985, Gaze 1988). Several of these trials have shown a
statistically significant reduction in the incidence of pelvic recurrence (Gerard 1985,
MRC 3 Trial, Stockholm Rectal Cancer Group 1987). However, local recurrence is
by no means eradicated by pelvic irradiation and so adjuvant radiotherapy is by no
means routine clinical practice. It has also proven difficult to establish whether
adjuvant radiotherapy confers survival benefit in rectal cancer. The results of all
trials of radiotherapy published up to 1986 in English (3062 patients) were reviewed
by Buyse (Buyse 1988) and failed to show a statistically significant improvement in
survival. The most recent results from the MRC trial of adjuvant radiotherapy in
rectal cancer have shown a significant reduction of pelvic recurrence from 22% in
controls to 8% in those in the radiotherapy arm (pcO.OOl) but the reduction in
mortality from 21% to 13% just fails to achieve statistical significance (p=0.06) (Prof.
WJ MacKillop, personal comm.) The trend towards a reduction in mortality in
several studies has lead to the suggestion that very large trials are now required
(Buyse 1988). It is important to note that the proven benefit in reducing local
recurrence and potential benefit of reduction in mortality are gained at a cost since
there is morbidity associated with pelvic irradiation.
Chemotherapy has also been assessed as a means of improving outcome
(Buyse 1988, Hunt 1989, Wooley 1988). Only regimes containing 5-fluorouracil
have shown any benefit. A met-analysis of all trials of adjuvant chemotherapeutic
regimes containing 5-FU up to 1986 (4700 patients) demonstrated that there is only
a 2.3-5.7% improvement in 5-year survival and this does not achieve statistical
significance (Buyse 1988). Very recently, a trial of adjuvant 5-fluorouracil combined
with levamisole has shown significant benefit in survival for patients in the
treatment arm (Moertel 1990). This trial demonstrated a reduction in death rate of
33% for patients with Dukes stage C disease (p=0.006). Clearly this is a step
forwards but the results of this trial must be interpreted with caution until verified
by independent studies. It is also important to note that the survival rate of the
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treated patients was still only 60% and so this drug combination clearly cannot be
considered as the ultimate in adjuvant treatments.
Although there is a rationale for treatment which might supplement surgical
excision of colorectal cancer, there is no incontrovertible evidence demonstrating
benefit and so, for the present, routine use of such adjuvant therapy must be left to
the individual clinician involved in the patients care. If the MRC Trial of adjuvant
radiotherapy for rectal carcinoma does subsequently show a significant benefit and
the combination of 5-FU and levamisole in Dukes stage C disease is confirmed by
independent studies then this may well change treatment policy in the near future.
Even if proven beneficial, these treatments will remain as adjuvants modalities with
surgery as the mainstay of treatment for the foreseeable future.
Screening for malignant and premalignant colorectal lesions.
Surgical treatment of early colorectal cancers is generally highly successful,
the majority of patients surviving 5 years (Dukes 1929-30, Dukes 1932, Fielding
1986, Jass 1987). However, such early cancers are relatively rare and the majority
of tumours have already metastasised at the time of clinical presentation (Dukes
1929-30, Falterman 1974, Gill 1978, Goligher 1984, Jass 1987). Therefore, the
potential benefit of surgical treatment is limited by the natural history of the
disease. It is reasonable to assume that detection of the disease at an early stage
might overcome this problem and hence the rationale of screening for colorectal
cancer has been born (Hardcastle 1989b).
Detection and removal of premalignant polyps and excision of cancer before
it has spread intuitively seems to offer the best hope of a reduction in mortality from
colorectal cancer. However, there are no prospective controlled data to support this.
The study reported by Gilbertson (Gilbertson 1974) does appear to show benefit but
the data are uncontrolled. Therefore it must be assumed that early detection of
cancers will indeed follow the pattern of those tumours arising in patients reported
in retrospective studies.
Screening for colorectal cancer can be approached by screening the whole
population or by targeting high risk groups for more intensive screening procedures.
Such cancer screening programs are subject to a number of potential sources of
bias: lead-time bias arises where a tumour is simply diagnosed earlier but without
affecting its natural history and so the disease is sub-clinical for less time and
clinical for longer; length bias occurs where less aggressive tumours which grow
slowly are identified by screening rather than aggressive tumours which become
clinically apparent very quickly and so those patients with screen-detected cancers
appear to do well when compared to the whole patient group with colorectal cancer.
However, such patients would have done better in any case since the natural history
6
for their disease was of a less aggressive time course. A further potential bias is of
patient selection where those likely to respond to an invitation for screening may be
more health conscious and perhaps have a diet which is fundamentally less likely to
favour the development, or even the progression, of colorectal cancer. Therefore, the
screened population would have a reduced incidence of colorectal cancer simply
because they responded to the screening invitation in the first place. Such sources
of bias can only be overcome by assessing the effect of screening for colorectal
cancer in a randomised controlled trial over a long time course.
Four randomised controlled trials of population screening with faecal occult
blood testing are currently underway (Gilbertson 1980, Hardcastle 1989a, Kewenter
1988, Kronberg 1987). The largest of these is the Nottingham trial with 107,349
subjects randomised to date with a follow-up period of 6 months to 5 years (average
3 years) (Hardcastle 1989a). Preliminary data from this study are encouraging with
more favourable prognostic indicators consistently shown in screen-detected cancers
versus the control group. The incidence of cancer in the control group was
0.72/1000 patient years whereas an initial screen revealed 8 cancers per 1000
subjects screened. Hardcastle calculates that the sensitivity of occult blood
screening is around 55%. There were also large numbers of adenomas detected and
treated in the study population which may well lead to a long term reduction in the
incidence of colorectal cancer in this group. The proportion of Dukes stage A
cancers detected in the screened population (53%) was significantly higher than for
those arising in the control group (11%). Screen detected cancers also showed a
trend towards more favourable degree of tumour differentiation and fixity. The
proportion of severely dysplastic adenomas was also lower in the screened versus
the control groups. However, despite all of these encouraging signs, it is too early to
tell whether there is actually a survival benefit for the screened versus the control
population and so population screening by faecal occult blood testing should not be
recommended until the trials of Hardcastle and others are completed.
The practicalities of implementing a population screening service with the
knock-on effects on colonoscopic and radiological services are daunting. Another
promising way ahead may be to identify and offer screening to individuals who are at
very high risk of colorectal cancer as the return of cases identified would be high
and the subjects positively motivated in the knowledge of their high risk. Such a
program has recently been carried out with a high level of compliance. Five patients
with cancer and 62 with polyps were identified of 382 high risk patients who were
colonoscoped (Houlston 1990). Empiric risks had been derived from previous data
on family history of colorectal cancer and the risk for each patient was then
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calculated on the basis of their individual family history. However, this study has
all the problems of being wholly uncontrolled.
The method of screening of high risk groups merits comment. The St. Mark's
group found that faecal occult blood testing was of no value in detecting cancers in
their study population and so they strongly recommend colonoscopy as the
screening procedure of choice. Hardcastle's group have also assessed the value of
faecal occult blood screening of high risk groups with a strong family history of
colorectal cancer and found occult blood testing did not identify colorectal
neoplasms with any greater frequency than in a control screened population not
selected on the basis of family history (Armitage 1986). It would therefore appear
that the screening tool best suited to individuals at high risk due to possible
inheritance of a colorectal cancer is colonoscopy. However, two previously reported
controlled studies of screening for colorectal cancer using colonoscopy in high risk
sub-groups suggest little, if any, benefit for the screened population (Grossman
1988, Grossman 1989). These studies were somewhat unsatisfactory due to poor
control data and the yields of neoplasms were assessed only at a single screen. It
was not established whether there was any long term benefit to screened
individuals. There is clearly a need for a controlled long-term trial of intensive
screening for colorectal cancer in subjects with a strong family histoiy of large bowel
malignancy.
Dietary manipulation
The third possible method of reduction of colorectal cancer mortality is to
reduce the overall incidence of the disease by dietary manipulation. This is an
attractive proposition but the aetiological factors involved have not been fully
established and this is discussed in section 1.1.2. Nationwide abandonment of
current dietary habits for an African-style diet is clearly impossible. However,
interventional studies of dietary manipulation based on current knowledge are
under way. Only one randomised clinical trial has been published to date
(McKeown'-Eyssen 1988). It assesses the recurrence of colonic adenomas following
polypectomy in patients with and without dietary supplementation of vitamins C
and E . Such anti-oxidants were thought to reduce the level of the mutagenic
substances in the stools by alteration of faecal pH. However, no significant
difference was noted in recurrence rate between the two groups. Further studies
have examined the effect of added dietary calcium on colorectal epithelial cell
proliferation in patients at high risk of colorectal cancer (Lipkin 1985, Rozen 1989,
Wilson 1990). These studies demonstrated a reduction in cellular proliferation to
levels seen in individuals at low risk. However there are no published clinical data
which demonstrate benefit derived from dietary calcium supplementation. The way
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ahead must now be to identify which dietary constituents have the potential to
reduce the carcinogenic effect of the western diet and to test their putative beneficial
effect in large interventional controlled trials.
There may not be the political will or the economic and practical capability
for a national alteration in dietary habits but if it were possible to identify a high risk
sub-population, it might well be possible to alter the diet of such a selected group of
patients. Criteria identifying populations of individuals at high risk of colorectal
cancer are already well established. Family history indicates a strong genetic input
and this is discussed below in section 1.1.7. A pathological marker of high risk of
large bowel cancer is the adenomatous polyp and the theme of this work is based
around the adenoma-carcinoma sequence with particular reference to the syndrome
of Familial Adenomatous Polyposis in which that progression can be studied.
1.1,4 The adenoma-carcinoma sequence in colorectal carcinogenesis.
The evidence for the adenoma-carcinoma sequence in the development of
colorectal malignancy is substantial, if not overwhelming. Practical and ethical
considerations mean that adenomas are not left in situ and simply observed
repeatedly until malignancy supervenes. Therefore, the evidence indicating that the
adenoma as the benign precursor of colorectal carcinoma usually relies on indirect
evidence. Notwithstanding this, the evidence from observational data is so
convincing as to be beyond all reasonable doubt and this is reviewed here.
Demographic variations in incidence of colorectal carcinoma closely parallel
the demographic incidence of adenomas. The prevalence of colorectal adenomas in
an autopsy study in Liverpool, with its high rate of large bowel cancer, (Williams
1982) was very much higher than the prevalence in Nigeria, where colorectal cancer
is uncommon (Williams 1975). There is also a parallel increase in the prevalence of
colorectal adenomas and carcinomas when a population from a low incidence area
migrates to an area with a high incidence. The prevalence of adenomas in native
Japanese over the age of 50 is 27% (Sato 1976) whereas Hawaiian-Japanese have a
prevalence of 63% in the same age-group (Stemmerman 1973). Large bowel
adenomas are very uncommon in indigenous African populations such as Nigerians
(Williams 1975) and the South African Bantu (Bremner 1970). However the
prevalence of adenomas in American negroes in New Orleans is actually higher than
in the white population in the same city (Correa 1977).
The topographical distribution of carcinomas and the larger adenomas along
the length of the colorectum also exhibits a strong degree of concordance.
Approximately 66-75% of colorectal cancers arise in the rectum and sigmoid colon
(Falterman 1974, Goligher 1984) and there is also a predilection of large adenomas
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for these regions (Williams 1982). In a series of 1187 adenomas, 47% occurred in
the sigmoid colon with the proportion of adenomas decreasing proximally to the
right colon (8.2%) (Morson 1983). In this study and that of Williams (1982), the
proportion of adenomas greater than 1cm was higher in the sigmoid than elsewhere
in the colon although this was not the case for adenomas less than 5mm in
diameter which were distributed evenly throughout the colon and rectum.
Benign, adenomatous tissue adjacent to malignant tumour in resected
colorectal cancers is well described. In one study, 14.2% ofmalignant tumours were
partly composed of benign tissue (Muto 1975). The proportion of malignant
tumours which contain a benign element has been shown to be related to the extent
of spread of the carcinoma through the bowel wall. In early carcinomas, limited to
the submucosa, the frequency of detecting a benign component is 57%, with spread
limited to the bowel wall, it is 18% and where there is transmural involvement there
is benign tissue detectable in only 8% of malignancies (Morson 1966). In addition,
in-situ carcinoma has never been demonstrated without adjacent benign tissue
(Lane 1976). This is strong evidence to suggest that the natural histoiy of the
malignant tumour involves the replacement of a benign precursor by invasion
and/or destruction (Lane 1976).
Approximately 30% of colorectal cancer resection specimens contain
adenomatous polyps, again suggesting a association. This is further supported by
the fact that the life risk of developing a second (metachronous) cancer in the
residual bowel is around 5% overall but 10% in those cases where polyps were
present in the resected specimen (Heald 1975, Morson 1984, Muto 1975). The risk
also increases with increasing numbers of polyps to 70% if 6 or more polyps were
present (Muto 1975). Similarly, the incidence of associated polyps in colons
resected for synchronous cancers was 50% (Heald 1975). Such associations of
benign and malignant colorectal neoplasms strongly suggest that the benign lesion
is the precursor of the malignant one. Another explanation of such associations is
that the carcinogenic effluent in the colon may simply favour the development of
neoplasms, both benign and malignant. However, the weight of other evidence
would argue against this hypothesis.
The age distribution for the diagnosis of adenomas and carcinomas also
suggest that the benign lesion predates the malignancy. In one study, the average
age of onset of a single adenoma (58.1 years) preceded the average age of onset for a
single carcinomas (62.1 years) by around 4 years (Muto 1975). However this may
underestimate the true difference as adenomas are frequently symptomless for many
years.
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The autosomal dominant syndrome of Familial Adenomatous Polyposis,
described in detail in section 1.1.5, may represent a model of sporadic colorectal
carcinogenesis and this is discussed in section 1.1.6. The hundreds or thousands of
adenomatous polyps which characterise this disorder render the affected individual
at such high risk of cancer that prophylactic colectomy is routinely advised. The
cancer risk associated with this syndrome again supports the notion that the polyp
is the precursor of the cancer in the colorectum.
Further supporting evidence for the adenoma-carcinoma sequence is the
demonstration that sigmoidoscopic screening and prophylactic removal of
rectosigmoid adenomas is paralleled by an apparent reduction in the incidence of
carcinomas in the rectosigmoid in the screened population (Gilbertson 1974).
However, this study did not include a control arm and requires confirmation as
discussed in section 1.1.3. Anecdotal clinical evidence also exists of a carcinoma
developing at the site of a documented adenoma which had not been excised.
There is also direct molecular genetic evidence to support the adenoma-
carcinoma sequence and the parallel increase in malignant potential with increasing
size and villous component of the adenoma. Ras gene mutations, mainly consisting
Kiras mutations can be detected in 40-50% of colorectal cancers (Bos 1987, Delattre
1989, Forrester 1987, Vogelstein 1988). It has been shown that in small adenomas
with low "grade dysplasia, ras mutations can be demonstrated in only 13% of
tumours. However, in the larger, more cytologically aggressive lesions, the
frequency of ras mutations is the same as for that in carcinomas (Vogelstein). A
further crucial piece of evidence comes from the analysis of Kiras mutations in
carcinomas with residual adenomatous tissue, where mutations can be
demonstrated in both the adenoma and carcinomatous tissue (Vogelstein). It is also
important to consider that all of these studies show that such events occur
sometimes and clearly does not happen every time. Hence not all individual
adenomas are premalignant.
All of the above evidence strongly supports the concept of the adenoma-
carcinoma sequence and much of the rationale for the work presented in this thesis
is based on this premise. The well-defined genetic disorder of Familial Adenomatous
Polyposis alluded to above allows study of the adenoma-carcinoma sequence at a
molecular genetic, as well as a pathological level.
1.1.5 Clinical aspects of Familial Adenomatous Polyposis.
Familial Adenomatous Polyposis is an autosomal dominant disorder which is
characterised by the development of multiple colorectal and other gastrointestinal
neoplastic polyps with almost certain progression to colorectal cancer without
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appropriate treatment. The syndrome is not solely an intestinal one, affecting optic
retina, thyroid, bone, skin and connective tissue. This section describes and
discusses clinical aspects of FAP with particular regard to the early diagnosis by
screening'for colonic and extra-colonic manifestations of the disorder such that
prophylactic surgery can be undertaken to minimise the risk of cancer.
Historical and pathological review
The first case of Familial Adenomatous Polyposis (FAP) appears to have been
reported in 1881 (Sklifasowski 1881) and the realisation that the disorder might be
inherited came in 1882 when the disease was reported in a brother and sister
(Cripps 1882). Malignant progression was first described by Smith (Smith 1887)
and now the risk of colorectal cancer is recognised to be so high in these patients
(approaching 100%), that prophylactic colectomy is required (Bussey 1975, Morson
1974, Murday 1989, Muto 1975).
The disease is characterised by the presence of more than 100 adenomatous
polyps of the rectum and colon with the average number being around 1000,
although the polyps can number up to 5000 (Bussey 1975). Carcinoma will almost
inevitably supervene unless prophylactic colectomy is performed. The pathology of
the adenomatous lesions has been well documented at the macroscopic, microscopic
(Bussey 1975, Morson 1983) and ultrastructural level (Mughai 1978). The
adenomas and the carcinomas which supervene show similar pathological features
to those seen in non-FAP cases. The various histological types of adenoma (tubular,
tubulo-villous and villous) are found in similar proportions in familial and non-
familial cases (Morson 1983) and the carcinomas are comparable as regards tumour
site, stage, degree of differentiation, and outcome (Utsunomiya 1978). The only
difference appears to be that of number of polyps. The very high risk of development
of colorectal cancer in FAP with a much lower risk in non-FAP cases might at first
seem to be one major difference. However, when the large number of adenomas
present in the colon of a patient with FAP is considered along with the fact that
there is usually only one or perhaps two carcinomas arise in a complicated case, it
is clear that the risk of malignant conversion of any one FAP adenoma is actually
quite low. Hence the frequency of malignant conversion in FAP and non-FAP
adenomas come more into line.
Epidemiological, genetic aspects and screening
The burden of FAP in the general population is difficult to estimate due to
problems of disease registration but the incidence is probably around 1/10,000
(Bulow 1987, Bussey 1975, Reed 1955). The disease appears to be distributed
around the world with comparable frequency (Bulow 1987, Hill 1982, Reed 1955,
Utsunomiya 1978).
12
Familial Adenomatous Polyposis is inherited as an autosomal dominant
disorder (Bussey 1975, Reed 1955). A substantial proportion of affected individuals
have no affected relatives and the majority of these are sporadic cases due to new
mutations within the gene for FAP. The overall proportion of such new mutations
appears to be around 40% (Bulow 1987, Bussey 1975, Utsonomiya 1978). This high
mutation rate suggests that the gene involved may be quite large, offering a large
target for mutagenic events. The offspring of apparent new mutations also have
50% risk of inheriting the mutant gene. Gene penetrance is age dependent with the
peak age incidence for presentation of polyps depending on whether the population
studied was screened for the disease or not (Bulow 1987, Bussey 1975, Murday
1989). The correct assessment of age-dependent penetrance is important since risk
estimations are partly derived from such calculations. The age of onset of polyps is
frequently biased upwards as what is measured is the age when polyps first present
clinically. The correct assessment of age-dependent penetrance is only possible by
calculations based on a screened population as described by Murday (Murday
1989). Penetrance approaches 100% at 60 years of age (Bulow 1987, Murday 1989).
The peak age of detection of the onset of adenomas for screened and non screened
individuals is 23.7 and 27 years respectively. The same figures for the onset of
carcinomas is 33 and 39.2 years respectively (Bussey 1975). It is clear that there is
a 'window' when the disease can be diagnosed in a premalignant stage and so all
offspring of affected individuals must be screened for the disease as their risk is 50%
of having inherited the gene defect.
The value of screening is demonstrated by comparing the incidence of
carcinoma in non-screened individuals which approaches 100% (Bussey 1975) and
the incidence in call-up patients of 3-9% (Bulow 1987, Bussey 1975). Screening for
the disease in at-risk individuals involves clinical examination of the rectum and
sigmoid colon by rigid or flexible sigmoidoscopy. More involved tests such as
colonoscopy or barium contrast studies are unnecessary as a routine since rectal
polyps inevitably occur even in cases where colonic polyps are the initial
presentation (Bulow 1987). Clinical screening of at-risk family members should
involve yearly examinations from puberty to the age of 35 and then 3-5 yearly until
the age of -60 years (Bulow 1987).
Prophylaxis in gene carriers
The rationale for early detection of Familial Adenomatous Polyposis is that
prophylactic colectomy can be offered to affected individuals at a stage before
malignancy supervenes. Surgery involves removal of all, or the majority, of the
premalignant colorectal mucosa. This is achieved by proctocolectomy, subtotal
colectomy and ileorectal anastomosis, or total colectomy and ileo-anal anastomosis
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with an ileal pouch reservoir serving as a neo-rectum. Proctocolectomy was
considered to be the operation of choice in many centres until recently as it offers
complete removal of the premalignant colorectal epithelium but it has the
disadvantage of leaving the patient with a permanent ileostomy. A further
disadvantage of proctocolectomy is that at-risk relatives may be adversely influenced
by the prospect of a stoma such that as to avoid surveillance and hence expose
themselves to risk of malignancy. The procedure is still commonly carried out on
FAP patients, especially when rectal cancer has already developed. Proctocolectomy
was carried out 48% of FAP cases in one series (Bulow 1987) but in only 14% in the
St. Mark's series (Bussey 1985) which reflects a special interest in colectomy with
ileorectal anastomosis at that centre. Colectomy with ileorectal anastomosis is now
considered the method of choice in controlling the onset of malignancy in FAP
patients. It allows normal defaecation although the stool may be a little more loose
and frequent and also avoids post-operative problems with bladder control, potency
or fertility which can occur rarely with any pelvic excision. There are disadvantages
to this procedure and these are due to the persistence of rectal mucosa which allows
further adenomas to develop. However, this can be controlled by life-long
surveillance and cauteiy of rectal adenomas (Bussey 1975). There remains a risk of
development of malignancy in the retained rectum and this has been estimated at
13% at 10 years (Bulow 1984) in one series and 13% after 25 years with a
cumulative risk of dying of rectal cancer of only 4% at 30 years (Bussey 1985).
Colectomy with ileorectal anastomosis should also be considered in patients with
rectal adenomas at the time of diagnosis as there are well documented cases of
polyp regression following the procedure (Bussey 1975, Hubbard 1957, Williams
1966). This phenomenon has been more rigourously assessed and the phenomenon
of polyp regression is now well established (Nicholls 1988). Polyp regression does
not reduce the need for careful surveillance of the retained rectum but does reduce
the need for repeated fulguration. There is little to be lost by performing colectomy
and ileorectal anastomosis since recurrence of rectal polyps can still be treated by
proctocolectomy or the more recently described operation of total colectomy and
mucosal proctectomy with ileal pouch-anal anastomosis (Parks 1980). The
functional results from this operation are good in experienced hands (Nicholls 1985),
but it should probably only be carried out in specialist centres. The patients are
able to defaecate normally although the frequency is usually increased to greater
than 4 movements daily (Nicholls 1985). Post operative problems are common and
for the present it is reasonable to consider this as a second line treatment of
Familial Adenomatous Polyposis if recurrent polyps are a problem after colectomy
with ileorectal anastomosis.
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Extra-colonic features of FAP
Familial Adenomatous Polyposis is a multisystem disorder which indicates
the constitutional nature of the genetic defect. The various clinical features which
make up the syndrome are not only related to the colon and serve to emphasise this
point.
Multiple polyposis is well described in the upper gastrointestinal tract.
Gastric polyps have been detected in 70% of FAP patients in some studies (Bulow
1987, Fausa 1989, Utsonomiya 1978) and in 55% of patients in one prospective
screening study (Spigelman 1989). However, it has been shown that only a minority
(8%) of gastric polyps are adenomas (Spigelman 1989), while the majority show
cystic enlargement of the fundic glands characteristic of fundic gland polyposis,
which does not amount to adenomatous change. Duodenal polyposis is also very
common and was demonstrated in 93% of patients in one study (Fausa 1989). More
conservative estimations of the incidence of duodenal adenomas suggest that the
incidence is around 50-70% (Bulow 1985, Burt 1984). However, in Spigelman's
prospective study of 102 FAP patients (Spigelman 1989), while macroscopic
duodenal polyps could be discerned in 86% of cases, on random biopsy histological
changes of dysplasia or hyperplasia were demonstrated in 98% of patients. The
periampullary region was particularly prone to polyp formation and Spigelman
attributes these findings to the effects of bile on the upper gastrointestinal mucosa.
Duodenal and or peri-ampullary carcinoma is also part of the FAP syndrome
(Jagelman 1988, Jones 1980, Pauli 1977). It has been estimated that there is up to
a 200-fold increased risk of this tumour in FAP patients (Pauli 1977) and the overall
life risk of periampullary cancer for patients cured of their colonic disease is around
7% (Bulow 1985, Bussey 1972). One large study from the Leeds Castle Polyposis
Group (Jagelman 1988) consisting of 1255 patients showed a prevalence of invasive
upper gastrointestinal cancer of 4.5%, with duodenal and periampullary carcinoma
making up 68% of all cases. Because of the risk of upper GI malignancy, it has
been advocated that FAP patients should be followed up indefinitely by upper GI
endoscopy at 5-yearly intervals. Unfortunately it is not clear if screening and
intervention will have any effect on mortality from upper GI malignancy in FAP and
it is somewhat alarming to consider the prospect of a prophylactic pancreatico¬
duodenectomy! However, it is pertinent to consider that after sub-total colectomy
and ileorectal anastomosis, FAP patients are more likely to die of upper GI cancer as
of carcinoma of the retained rectum.
The presence of small bowel adenomas has also been reported in FAP (Bulow
1987, Utsonomiya 1978) but the incidence of progression to malignancy appears to
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be veiy low since very few cases of small intestinal carcinoma in FAP patients have
been reported to date (Jagelman 1988, Ross 1974).
The association of bone tumours and Familial Adenomatous Polyposis was
first noted by Gardner (Gardner 1951, Gardner 1952) and these lesions have
subsequently been shown to be osteomas (Ooya 1976). This association, combined
with epidermoid cysts (vide infra), was thought to be a distinct clinical syndrome
and was given the eponym Gardner's Syndrome. However, it has been shown that
cranio-facial osteomas are very commonly associated with adenomatous polyposis.
In controlled studies using orthopantomography, osteomas have been demonstrated
in 81%-93% of cases (Utsunomiya 1975, Ushio 1976) and it is now routine practice
in some centres to carry out bone surveys in all FAP patients (Utsunomiya 1978).
The median number ofmandibular osteomas in FAP patients is 2, with a range 1-6
(Bulow 19'84b) The appearance of osteomas tends to precede the onset of polyps by
18-20years (Duncan 1968). In at-risk individuals, the appearance of osteomas can
be taken to indicate that the patient is indeed affected, even if polyps have yet to
become apparent. In individuals who have multiple osteomas but no family history
of FAP, serious consideration should be given to the need for screening of the colon
as the patient may be a sporadic case of FAP. The high frequency of cranio-facial
osteomas in FAP has led some authors to suggest that ortho-pantomography of the
mandible could be used as a screening tool for at-risk individuals (Bulow 1987).
However, the incidence of osteomas in the general population is between 4% (Bulow
1985, Sondergaard 1985) and 16% (Utsunomiya 1975) and so, at worst, screening
for FAP in at-risk family members by such a modality would have a sensitivity of
76% (Bulow 1985, Jarvinen 1982); a specificity of 82% (Utsunomiya 1975); a
predictive value of a positive test of 81% and a predictive value of a negative test of
77%. In addition, no studies have addressed the possibility that the appearance of
these lesions is age-dependent. Hence, screening for FAP by searching for osteomas
cannot be used in isolation but can be used as an aid to conventional screening, as
suggested by some authors (Utsunomiya 1978).
There are no recorded cases of malignancy developing in the osteoma of a
patient with FAP. However, these lesions can cause local pain and discomfort.
Relief of symptoms can be achieved by surgical excision of troublesome tumours,
but in general the tumours are best left alone.
The association of desmoid tumours with Familial Adenomatous Polyposis
was first described by Smith (Smith 1958). These lesions are classified with other
fibromatous conditions such as Dupuytren's contracture and keloid scar but their
exact nature is not clearly understood (Anderson 1978). When not associated with
FAP, desmoids tend to arise in the rectus abdominis muscle of multiparous women
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and compress and destroy muscle tissue without metastasising (Anderson 1978,
McAdam 1970). The incidence of desmoid tumours in FAP patients is around 4%
(Bulow 1986, Bussey 1975, Smith 1958) and 89% occur in women (Bulow 1986).
These capricious lesions occur intra-abdominally in 51% of cases (Bulow 1986) and
can obstruct the ureters and other intra-abdominal viscera (McAdam 1970). They
can be sensitive to hormonal manipulation but in general no treatment has any
lasting benefit and the patient progressively deteriorates as the tumour continues to
compress, obstruct and destroy intra-abdominal organs. The lesions can cause a
great deal of pain and discomfort which can be difficult to control. Surgical excision
has little to offer as frequently the tumour progresses even more quickly after
surgical manipulation. Desmoid disease is one of the great disappointments in the
treatment of FAP patients since patients may undergo successful restorative
proctocolectomy only to succumb to the effects of a 'benign' lesion which causes
great distress and frequently results in the patients demise. This problem may
become more common with the increasing success rate of screening programs and
timely surgery for true gastrointestinal malignancy which allows more and more FAP
patients to avoid early death due to cancer.
Multiple epidermoid cysts are also part of the FAP phenotype originally
thought to indicate the presence of Gardner's syndrome but, as in the case of
osteomas, when an active search is made, these lesions are common in all forms of
Familial Adenomatous Polyposis. The term 'sebaceous cyst' has been used to
describe these lesions but since this is a generic term including epidermoid and
pilar cyst as well as steatocystoma multiplex (pilo-matrixoma), the lesions are best
referred to as epidermoid cysts which are the only type associated with FAP (Leppard
1975). They occur in 53% of cases of FAP (Leppard 1974) and in one study 33% had
one or more lesions removed in childhood (Leppard 1975). The cysts tend to occur
on the face and scalp in FAP patients but more frequently on the back in non-FAP
cases (Leppard 1974). The mean number of lesions has been reported to be 4 but
with up to 20 in one individual (Leppard 1974). The appearance of an epidermoid
cyst on the face or scalp of a prepubesent child should be regarded with some
interest as these lesions are veiy uncommon in this age group when not associated
with Familial Adenomatous Polyposis.
A pigmented lesion of the optic retina known as Congenital Hypertrophy of
the Retinql Pigment Epithelium (CHRPE) has recently been described in association
with Familial Adenomatous Polyposis. CHRPE lesions consist of multiple, isolated,
flat, well-demarcated, hyperpigmented areas which frequently affect both eyes. The
hyperpigmented areas are usually surrounded by a hypo-pigmented halo and patchy
depigmentation may occur within a hyperpigmented lesion. Histologically, the
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lesions exhibit hypertrophy of the pigment epithelial cells with increase in the size of
the pigment granules within these cells and degeneration of the overlying
photoreceptors also occurs (Purcell 1975). Congenital Hypertrophy of the Retinal
Pigment Epithelium does not appear to cause symptoms or affect visual fields or
acuity. The CHRPE lesions are best visualised by indirect ophthalmoscopy as they
are frequently peripheral. The first report of an association between CHRPE and
Familial Adenomatous Polyposis was published in 1982 (Blair 1982). Since the
original description, there have been many reports which have further defined this
association (Chapman 1989, Diaz-Llopis 1988, Iwama 1990, Lynch 1987,
Polkinghorne 1990, Stein 1988, Traboulsi 1987). The importance of the CHRPE
phenotype lies in the possibility that eye examination might allow presymptomatic
diagnosis of the disease. One study (Chapman 1989) suggested that 3 or more
pigmented lesions, particularly when occuring in both eyes, was both a sensitive
(100%) and specific (100%) test of FAP status. The controls in this study were not
unaffected family members, but a totally unrelated group and so the true specificity
of the test could not be assessed. Other authors have reported the sensitivity of the
presence of CHRPE indicating inheritance of FAP as 55% (Iwama 1990), 97%
(Polkinghorne 1990), 100% (Stein 1988) and 78% (Traboulsi 1987). Clearly CHRPE
is a useful tool for demonstrating the presence of FAP but it is of lesser value in
excluding inheritance of the mutant gene. It is also important to note that CHRPE
lesions also occur in normal controls (Stein 1988, Traboulsi 1987) but whereas some
patients with FAP have less than 3 CHRPE lesions, no normal controls have been
shown to have more than 3 in one study (Chapman 1989) or more than 4 in another
(Traboulsi 1987). It is clear however that some FAP families do not have CHRPE
lesions as part of the FAP phenotype (Traboulsi 1987, Polkinghorne 1990). The
presence of multiple typical CHRPE lesions in an at-risk individual must be
considered to indicate the presence of the disease. The absence of such lesions can
only allow confident presymptomatic disease-state prediction where affected
members of the same family have been shown to have CHRPE lesions as part of the
expression of the disease. There is also evidence that the number of pigmented
lesions correlates with the age of onset of polyps (Chapman 1989) and so individuals
who have been screened negative by colonic examination and do not have CHRPE
lesions can probably be cautiously reassured and subjected to less intensive
screening protocols. However the confidence with which this advice can be given
could be greatly increased by an independent genetic test of disease state and this is
an important part of the experimental work for this thesis.
Thyroid carcinoma has also been described in association with Familial
Adenomatous Polyposis (Aim 1973, Plail 1987) and it would appear that women
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below the age of 35 years with FAP are at 160 times greater risk of thyroid
carcinoma than a healthy female counterpart. The histology tends to be
predominantly of papillary type. Careful palpation of the thyroid must now be
included in the follow-up protocol for young females affected by FAP, with early
institution of fine needle aspiration and ultrasound screening of any suspicious
nodules .
FAP is due to a constitutional gene mutation
It is clear from the above description that the syndrome of Familial
Adenomatous Polyposis is not simply a colorectal polyposis, but clinical and
pathological changes can be detected in most body tissues. This serves to highlight
the fact that the inherited mutation is a constitutional phenomenon. The
involvement of multiple tissues in the FAP phenotype suggests that the gene
involved may have pleiotropic effects involving endoderm, mesoderm, and ectoderm
and alteration in its function results in the diversity of the clinical syndrome. An
alternative explanation is that there is a whole group of genes located physically
close to the gene for FAP and that alteration in the gene for FAP such as by deletion
would also influence the surrounding genes. The argument against this second
explanation is that the clinical presentation of the syndrome should breed true in
any given family since each affected family member would inherit the same
characteristic group of deleted genes and this is clearly not the case, as discussed
above. It seems most likely that the gene for FAP is involved in biological activity in
many different tissues. Identification of the gene for Familial Adenomatous
Polyposis will be of great interest, not least because of the widespread effects of the
causative mutation. There is also evidence to suggest that the gene for FAP may
have a key role in sporadic colorectal carcinogenesis.
1.1.6 Fafnilial Adenomatous Polyposis as a model of sporadic colorectal
carcinogenesis.
Familial Adenomatous Polyposis has long been considered a model of
sporadic colorectal cancer at a pathological level (Lane 1963). As discussed in
Section 1.1.5, there are striking similarities between the stages of neoplastic growth
in colonic epithelium of FAP and non-FAP cases using a variety of modalities of
investigation. The changes are similar with regard to the development of uni-ciyptal
adenomas (Oohara 1980) to large polypoidal lesions (Morson 1983). The different
histopathological types of adenoma are found in similar proportions in familial and
non-familial cases (Morson 1983). The stage, degree of differentiation, and the
clinical prognosis of carcinomas are also comparable (Utsunomiya 1978). The
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anatomical distribution of polyps and of cancer developing in FAP patients tends to
be in the rectum and sigmoid and closely parallels that seen in sporadic adenomas
and carcinomas (Bussey 1975, Utsunomiya 1978). The progression of adenomas to
carcinomas also holds for Familial Adenomatous Polyposis. In one large series, 36%
of 199 colorectal cancers arising in patients with FAP were partially comprised of a
benign element compared with 14.2% for non-FAP carcinomas (Bussey 1975). The
reason for this high rate of benign tissue is probably related to the early
presentation of patients with cancers complicating FAP due to symptoms from the
burden of adenomas rather than due to symptoms from the carcinoma itself.
However the progression to malignancy in FAP is entirely in keeping with the notion
that FAP is a model of sporadic colorectal carcinogenesis.
At a clinical level there is also evidence to suggest that FAP reflects the
changes seen in sporadic colorectal cancer. There is a 10 year difference in the
screen-detected peak age of detection of polyps without a cancer and the screen-
detected peak age of detection of polyps complicated by cancer for patients with FAP
(Morson 1983). The difference of peak age distributions for the diagnosis of a single
polyp or cancer in non-FAP cases is at least 4 years, which is remarkably
concordant when it is considered that a single polyp will remain asymptomatic for
very substantially longer than the large number of polyps in the colon and rectum of
a patient with FAP.
It can be seen from the discussion above that the process of neoplastic
change in the colorectum of FAP patients does appear closely to mirror that which
leads to sporadic colorectal cancer, the outstanding difference being only in the
number of adenomas. It is certainly reasonable to propose that Familial
Adenomatous Polyposis can be considered a human model of colorectal cancer.
Study of the genetic factors underlying FAP is therefore important for two distinct
but inter-related reasons. At the level of patient care, it may be possible to identify
gene carriers and appropriate screening and treatment instigated. Clinicians in the
United Kingdom have a high level of awareness of the need for screening and
prophylactic colectomy for affected individuals and so cases of FAP-related colorectal
cancer make up only a very small proportion of the total caseload of large bowel
cancer in this country (<0.2%). Should changes in the gene responsible for the
syndrome of FAP prove to occur in non-FAP colorectal cancers, then this may
suggest that genetic factors have a far more wide-reaching influence on the
development of colorectal cancer. Study of the genetic aberration(s) responsible for
FAP may therefore lead to more fundamental understanding of the molecular
mechanisms of sporadic colorectal carcinogenesis.
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1.1,7 Evidence for a genetic influence on the development of sporadic colorectal
carcinoma.
The existence of the syndrome of FAP indicates the involvement of a heritable
gene defect conferring susceptibility to colorectal cancer. There are also clinical
clues to the presence of genetic disorders which may involve other genes in addition
to that causing FAP. Alternatively, a proportion of these syndromes may result from
a different class of mutation within the gene for FAP. This section discusses the
involvement of the gene for FAP in genetic susceptibility to non-FAP colorectal
cancer.
There is little doubt from the discussion in section 1.1.2 that dietary factors
are implicated in the aetiology of large bowel malignancy. There is substantial
evidence to suggest that genetic susceptibility to colorectal cancer interacts with
environmental factors. There are well documented pedigrees exhibiting an obvious
autosomal dominant form of inherited colorectal cancer and these have been
described by Lynch (Lynch 1985, Lynch 1988). These dominant colon cancer
syndromes make up at least 5% of the burden of colorectal cancer (Mecklin 1987).
Other dominant colon cancer syndromes exist with specific associations such as
Muir's syndrome (Anderson 1980, Muir 1967) where multiple skin tumours are also
inherited.
Many studies have shown familial clustering of cases of colorectal cancer
(Bonelli 1988, Burt 1985, Cannon-Albright 1988, Duncan 1982, Lovett 1976,
Macklin 1960, Woolf 1958, Woolf 1955) which is not restricted to cases in which a
dominant gene appears to be operant, resulting in 50% of the offspring of an affected
individual inheriting the disease (Hereditary Non-polyposis Colorectal Cancer). Such
clustering of cases cannot be accounted for by the simple hypothesis of common
exposure to high levels of environmental carcinogens since the incidence in spouses
of affected, patients is that of the general population (Cannon-Albright 1988, Jensen
1980). Published data support the existence of a gene defect transmitted in a
Mendelian dominant mode resulting in colorectal adenomas and carcinomas with a
population frequency of 19% (Cannon-Albright 1988). Since inheritance of the
mutant gene only confers susceptibility to colorectal neoplasia, not all individuals
with the gene defect develop colorectal cancer.
It seems likely that there may be more than one colorectal cancer
predisposing gene but there are already some pointers as to the likely phenotype of
this putative cancer susceptibility gene defect. Skin tags have been reported to be
more common in patients with colorectal adenomas than in the general population
(Leavit 1983, Kune 1985) although there is some contradictoiy evidence (Gould
1988) Although it is possible that carcinogens which come into contact with the
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skin may also be consumed orally, it seems more likely that such patients have
inherited a defect in a gene with pleiotropic effects involving skin and colonic
epithelium. Mandibular osteomas are common in patients with Familial
Adenomatous Polyposis (FAP) and these lesions also occur with a higher frequency
in patients with apparently non-familial colorectal cancer than in a control
population (Sondergaard 1985). Mandibular osteomas are also more common in
patients with colorectal adenomas although the association does not achieve
statistical significance (Sondergaard 1986). In some kindreds with cancer family
syndrome there is also an increased incidence ofmandibular osteomas (Sondergaard
1985). This evidence suggests that one of the 'colorectal cancer genes' may actually
be the gene for FAP but perhaps carrying a different class of mutation within it.
There has been recent molecular genetic evidence to suggest that a class of
mutations in the gene for FAP may confer an increased risk of colorectal cancer to a
much greater extent than that limited to the classical syndrome of FAP. Recently,
genetic linkage analysis has been carried out in one large kindred (Leppert 1990)
and linkage has been established to a disease gene resulting in variable numbers of
adenomatous colorectal polyps using chromosome 5q DNA markers known to be
linked to the gene for FAP which is now known as APC. While some patients clearly
had FAP, many of the affected family members had only a very few colorectal polyps
and so the type of APC mutation is this family has more subtle effects than that of
the usual class of APC mutation. It is conceivable that other APC mutations may
have the effect of inducing the formation of even more limited numbers of polyps
and could be responsible for at least a proportion of the genetic influence on the
incidence of colorectal cancer discussed above.
Identification of a gene or genes which predispose to colorectal cancer would
have resounding implications for the screening and early detection of colorectal
neoplasms in addition to the development of novel treatment approaches. Isolation
of the gene for FAP may therefore have far reaching implications outside that
syndrome alone.
1.2 The gene for Familial Adenomatous Polyposis (APC): Localisation and
possible tumour suppressor activity.
The potential involvement of the gene for FAP (APC) in the genesis of
colorectal cancer in patients FAP and in those with sporadic bowel cancer has been
discussed above. Further assessment of the involvement of that gene in colorectal
carcinogenesis will require localisation and ultimately cloning, sequencing and full
characterisation of the non-mutant gene function. Much of the experimental work
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in this thesis involves localisation of the APC gene and its assessment in sporadic
colorectal cancers. However, final assessment of APC function must wait until its
full characterisation. This section discusses a putative role for the APC gene as a
so-called tumour suppressor gene and the evidence to support such a role.
1,2,1 The importance of identification of the APC gene.
Identification of the gene for Familial Adenomatous Polyposis is of great
importance due to its causal involvement in a heritable cancer syndrome, its
probable involvement in the biology of colorectal cancer and its possible implication
as a gene predisposing to non-FAP colorectal cancer.
Following identification of the APC gene, presymptomatic diagnosis of FAP
would be possible by a simple blood test rather than the protracted endoscopic
screening program which is currently required. This would avoid screening the 50%
of at-risk individuals who are currently having unnecessary examinations and would
also relieve some of the psychological morbidity of uncertainty of diagnosis in
patients who are actually affected.
The involvement of the APC gene in the biology of colorectal cancer is also of
great importance. As described in section 1.1.6, the inherited mutation of FAP
appears to result in the formation of multiple adenomas which have the same
topographic distribution, histo-pathological and ultra-structural features, and the
same natural history as the sporadic counterpart. The presence of each adenoma
confers on that individual the same risk of developing a carcinoma within that
particular polyp as the risk associated with sporadic adenomas. It is simply the
large number of adenomas occurring at an early age which results in the high
frequency of carcinomatous change in the colorectum of patients with Familial
Adenomatous Polyposis (Morson 1983) and in the differences in clinical
presentation. Therefore it is reasonable to hypothesize that the gene for Familial
Adenomatous Polyposis might also be involved in some aspect of sporadic colorectal
carcinogenesis and that APC involvement might well be an early occurrence.
The involvement of a gene defect resulting in a heritable cancer syndrome
and also in the sporadic counterpart of that tumour was formally proposed by
Knudson (Knudson 1971) (see section 1.3.1). Although specifically referring to
retinoblastoma, Knudson has also suggested that the gene for Familial
Adenomatous Polyposis might be implicated in sporadic colorectal cancer (Knudson
1989). The model proposed by Knudson suggests that two mutations are required
to inactivate the target gene, one for each gene copy. Thus, although transmission
of the disease shows a classical autosomal dominant pattern, these genes are
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recessive at a cellular level. Supporting evidence for the existence of such tumour
suppressor genes is reviewed in sections 1.3 and 1.4.
Another aspect of the APC gene is its possible implication as a colorectal
cancer predisposition gene. The existence of a class of inherited APC mutations
might well explain the prevalence of mandibular osteomas in apparently sporadic
colorectal cancer and also might account for the familial aggregation of some cases
of large bowel malignancy (see section 1.1.7).
1.2.2 Attempts to localise APC by cytogenetic analysis.
Demonstration of a cytogenetic abnormality in FAP in itself might define a
marker of the disease for presymptomatic diagnosis. Disease state prediction using
cytogenetic analysis is already in widespread clinical use for disorders such as
Down's Syndrome where prenatal diagnosis is also possible. Perhaps more
important in an autosomal dominant disorder involving a single gene defect such as
FAP, identification of a cytogenetic lesion would provide a signpost to the
chromosomal region harbouring the gene. This would allow detailed analysis at a
sub-microscopic level using the techniques ofmodern molecular biology.
In 1982, a consistent deletion of chromosome 2 was reported in all of 17
karyotyped patients with FAP (Gardner 1982) but independent investigators were
unable to confirm this cytogenetic aberration using high resolution chromosome
banding techniques (Kasukawa 1983). The original authors also failed to repeat
their own findings and ascribed the apparent aberration to artefact (Fineman 1984).
Widespread chromosomal instability of cultured cells from FAP patients is well
described (Danes 1978, Delhanty 1983) and so it is not surprising that such artefact
was identified since it is well known to cytogeneticists that incorrect preparation of
metaphase spreads in normal patients without chromosomal instability can give
apparently consistent site-specific chromosomal lesions due entirely to artefact. An
intensive study of 5 FAP patients using high resolution chromosome banding failed
to show any karyotypic abnormality (Nielsen 1985).
A single case report of an interstitial deletion of 5q in a patient with multiple
congenital abnormalities was the first clue to the whereabouts of the gene for
Familial Adenomatous Polyposis (Herrera 1986). The deletion appeared to involve
the region 5ql3-ql5 or 5ql5-q22. Clearly this was an extremely fortuitous finding
given the apparent rarity of such deletions. Other investigators were unable to
confirm these findings by demonstration of deletions involving a similar
chromosomal region in a different population of patients (Endo 1987) but Herrera's
cytogenetics appeared to be sound. Since that time only two further cases of
cytogenetic abnormalities have been reported in association with FAP. These cases
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comprised two brothers with an interstitial deletion involving 5q21-22 (Hockey
1989). Therefore, the identification of the single case of Herrera opened the way for
detailed study of the region using genetic linkage analysis with polymorphic DNA
markers.
1.2.3 Genetic linkage analysis and the localisation of APC to chromosome 5q21-22,
Following Herrera's report of a chromosome 5q deletion in a patient with
FAP, two groups, in London and in Utah, joined in a race to establish, or to refute,
genetic linkage of the gene for FAP to polymorphic DNA markers known to map to
that chromosomal region. In August 1987 Bodmer and colleagues published the
first report establishing the localisation of APC to 5q21-22 by demonstrating genetic
linkage to the polymorphic DNA probe CI IP 11 (Bodmer 1987). CI IP 11 was an
anonymous DNA fragment which had been cloned as part of a random search for
probes recognising DNA restriction fragment length polymorphisms (RFLP) and the
existence of such a marker in the region allowed rapid regional localisation of APC.
Bodmer detected no recombinants between APC and CI IP 11 and suggested
that CI IP 11 was very close to the APC gene indeed. However, there was no evidence
of linkage disequilibrium and the lod score was only 3.26 for linkage of C11P11 to
APC, resulting in wide 95% probability limits. Localisation of C11P11 by in situ
hybridisation placed the APC gene in the chromosomal bands 5q21-22 (Bodmer
1987). Shortly after the establishment of primary genetic linkage in FAP by Bodmer,
the Utah group also reported linkage of APC to C11P11 (Leppert 1987). Again no
recombinants were detected between CI IP 11 and APC in this study and the
combined lod scores from London and Utah were 6.63 and so strongly supported the
localisation ofAPC close to CI IP 11 at 5q21-22.
Regional localisation was only the first step in isolation of the APC gene itself
and so a high density genetic and physical map of the region was now required.
However with such information as to the whereabouts of APC, it was then possible
to examine the status of chromosome 5 in malignant tissue from sporadic colorectal
cancers.
1.2.4 Chromosome 5 allele losses in sporadic colorectal carcinomas suggesting
APC tumour suppressor activity.
Loss of genetic material can be detected by cytogenetic analysis when
relatively large chromosomal fragments are involved. Sub-microscopic losses can be
detected by demonstration of loss of DNA marker probes known to map to that
region.
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Tumour kaiyology in colorectal cancer is technically extremely difficult, both
in the preparation of chromosome spreads and in reading the widely aberrant,
hyperdiploid karyotypes which result. However, one report identified chromosome 5
as frequently structurally abnormal, although many other aberrations were also
described (Reichmann 1981). In addition, a specific interstitial deletion of the long
arm of chromosome 5 was reported in one tumour karyotype (Ferti-
Passantonopoulou 1986). Notwithstanding the technical difficulties of tumour
karyology,- these findings combined with the localisation of the APC gene on the long
arm of chromosome 5 strongly suggest a possible tumour suppressing activity for
APC.
Loss of genetic material from 5q was more critically assessed by the use of
polymorphic chromosome 5q DNA markers (Solomon 1987). The probe lambda MS8
which recognises a hypervariable (mini-satellite) region near the tip of chromosome
5 at 5q35, and another polymorphic DNA marker LI.4, were used to search for loss
of constitutional heterozygosity. Demonstration of such allele loss would indicate by
inference that the APC gene was also lost. Solomon found that up to 40% of
sporadic colorectal cancers exhibited loss of genetic material from chromosome 5 by
this approach.
The cytogenetic findings and the allele loss study of Solomon indicate that
loss of the region of chromosome 5 including APC appears to occur in a non-random
fashion in colorectal cancer tissue. The two mutation hypothesis requires that both
alleles of a tumour suppressor gene are inactivated. The detection of substantial
loss of genetic material from the long arm of chromosome 5 on which the gene for
FAP had been localised strongly supported a recessive determinism, or tumour
suppressing function, for APC. The assumption is made that the remaining APC
allele is inactivated by a mechanism such as a very small deletion or perhaps a point
mutation and so the chromosome 5 loss in the cancer tissue serves to unmask a
mutant gene on the remaining chromosomal homologue.
It is important to note that loss of APC can only be inferred from these
studies and the specific involvement of APC was still to be confirmed.
Notwithstanding this, these findings are strongly supportive of the proposal that the
gene for Familial Adenomatous Polyposis is indeed a tumour suppressor gene.
1.3 Statistical and epidemiological support for the existence of tumour
suppressor genes
This section reviews the evidence for tumour suppressor genes from
statistical analysis of the epidemiology of the rare heritable childhood cancer
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syndromes, especially retinoblastoma. However there is also evidence from the
epidemiology of common adult cancers that a two mutation, or possible recessive
determinism compatible with homozygous inactivation of putative tumour
suppressor genes, is operating at least as a rate limiting step in some of the common
human malignancies.
1.3.1 Statistical analysis of the epidemiology of retinoblastoma.
Retinoblastoma is an uncommon tumour of childhood and the disease can
occur in sporadic form, where there is no family history, or as a inherited familial
trait. Familial and sporadic cases are identical pathologically but familial cases
occur at an earlier age and the tumours are usually multiple and bilateral, whereas
sporadic cases occur at a later age and the tumours tend to be unilateral. Rnudson
noted that the germline mutation was not sufficient in itself for tumour development
since some obligate gene carriers never developed tumours but did pass on the
mutant gene to their offspring (Knudson 1971). The numbers of tumours developing
in the eyes of familial cases were counted and shown to fit a Poisson distribution
(Knudson 1971), suggesting a random event which Knudson proposed to be a
somatic second mutation. When the incidence rate of tumours was plotted on a
logarithmic axis against age, there was a curvilinear decline of tumour development
in the sporadic, unilateral, cases. In contrast, incidence in bilateral (ie familial)
cases declined with age in a linear fashion on the semilogarithmic plot. This was
powerful evidence to support a two mutation theoiy for retinoblastoma, thereby
inferring a recessive mode of action with mutations requiring to inactivate the
retinoblastoma gene for the development of tumours. Implicit in this two hit
hypothesis is the notion that mutations of the same gene occur in both the familial
and the sporadic forms of cancer. It is important to note that these calculations are
mathematical derivations designed to fit a hypothesis and cannot exclude
possibilities which have not yet been considered. Such a hypothesis based on
mathematical considerations clearly requires substantiation from biological
observation.
Knudson's seminal statistical analysis of the epidemiology of retinoblastoma
has stood the test of time and has been extensively reviewed by him (eg. Knudson
1985, Knudson 1989). Subsequent molecular genetic analysis has confirmed this
two-hit hypothesis. However it was 14 years prior to Knudson's original paper that
a two mutation theory of carcinogenesis was first shown to hold for many common
adult cancers.
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1.3.2 Epidemiological analysis in the common adult cancers.
Epidemiological support for a two-hit theoiy of carcinogenesis has been
evident for many years. Armitage and Doll are widely quoted as having
demonstrated the involvement of several mutational steps in carcinogenesis when
they assumed a variable level of environmental carcinogen (Armitage 1954).
However, Piatt suggested that only two mutations might be involved in
carcinogenesis (Piatt 1955). The first mutation would allow clonal proliferation and
a growth advantage predisposing that clone to a second mutation which would
induce malignancy. Armitage and Doll re-examined their original data but in this
analysis assumed a constant exposure to carcinogen (Armitage 1957). This analysis
favoured a two-mutation hypothesis for carcinogenesis and appeared to account for
the observed incidence of many of the common adult cancers, notably breast and
colon cancer. Ashley also proposed that cancer could arise via two different
physiological stages but calculated that 3-7 mutations were involved in the genesis
of gastric cancer in females (Ashley 1969). He also proposed that the multiple hit
and the two hit theories were not mutually exclusive.
Current knowledge of the involvement of activating mutations in oncogenes
and as well as the inactivation of both alleles of recessive tumour suppressor genes
clearly cannot be explained on the basis of only two mutations. However a two-step
theoiy of mutagenesis would fit for the critical rate-limiting steps along the pathway
to selection for a malignant clone (Knudson 1989). Events at other loci may confer
further growth advantage or promote tumour progression and metastasis . The
initiating mutation may render the proliferating clone more susceptible to such
subsequent mutations.
It is still too early to be sure that common adult cancers are indeed rate-
limited by the need for two inactivating mutations at the same tumour suppressor
locus. However it is tempting to believe that the paradigm of retinoblastoma holds
not only for embiyonal tumours but also for colorectal cancer and other common
malignancies.
1.4 Experimental evidence for tumour suppressor genes
1.4,1 Evidence from somatic cell hybrids.
Early experiments utilising somatic cell hybridisation techniques suggested
that cancer genes behaved in a dominant fashion. When cells of a low malignant
potential were fused with those of high malignant potential, the resultant hybrid
remained of the same phenotype as the most malignant of the parent cells (Barski
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1962, Scaletta 1965). However these findings were contradicted by evidence for
tumour suppressing effects of normal or wild-type genes.
The discovery that certain 'cancer' genes are recessive was first demonstrated
by the cell fusion experiments of Harris and Klein (Harris 1969a, Harris 1969b).
Fusion of normal mouse fibroblasts with a tumorigenic cell line resulted in
extinction of tumorigenicity in the resultant hybrids so long as specific
chromosomes were not lost. The expulsion of certain chromosomes resulted in the
reappearance of the tumorigenic phenotype. Harris first suggested that loss of only
a single chromosome might be sufficient for the re-emergence of the malignant
phenotype (Harris 1969a). This has subsequently been confirmed in at least some
crosses and the particular involvement of mouse chromosome 4, homologous to
human chromosome 1, has been demonstrated (Jonasson 1977). Specific loss of
human chromosome 11 from a normal-malignant human-human fusion hybrid as
demonstrated by allele loss of a polymorphic chromosome 11 DNA marker has also
been shown to result in the reappearance of the malignant phenotype (Stanbridge
1981).
The involvement of chromosome 11 has been investigated further by an
elegant experiment in which a single normal human chromosome 11 was introduced
into a tumorigenic HeLa-human fibroblast hybrid (which lacked chromosome 11).
This resulted in suppression of the malignant phenotype (Saxon 1986). This work
was taken further by the introduction of a single chromosome 11 into a tumorigenic
Wilms' tumour cell line which resulted in reversion to a non-tumorigenic phenotype
(Weissman 1987). This is powerful evidence to support the notion of a recessive
mode of action of tumour suppressing genes and is consistent with the view that
inactivating mutations within these genes can result in a heritable cancer syndrome.
A recent study from Stanbridge's group has demonstrated another specific
chromosome capable of tumour suppression in a tumorigenicity assay. A normal
human chromosome 6 was introduced into a tumorigenic human melanoma cell line
and suppression of tumorigenicity was demonstrated (Trent 1990). The reason for
selection of chromosome 6 for such a study was that human melanoma tumour
tissue has been shown to have consistent karyotypic abnormalities involving
chromosome 6q. Thus this is another example of tumour suppressor loci being
identified by tumour cytogenetics (see section 1.4.4 and 1.4.5).
Studies involving human intraspecies hybrids have suggested tumour
suppressor activity on many chromosomes such as chromosomes 1,2,4,11,13,17
and 20 (Stanbridge 1988). It is likely that inactivation of any one or a number of
these genes might be involved in the genesis of particular tumour or in individual
steps towards the malignant phenotype in a particular class of malignancy.
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However deletion of certain genes may well be a common molecular end point in the
biology of progression and metastasis ofmany tumour types.
The ability of genetic material from normal cells to suppress malignancy
sometimes requires multiple copies of a particular chromosome to have an effect
(Evans 1982) and the ratio of malignant-derived chromosomes to normal
chromosomes is important (Harris 1988). Therefore it is seems that for at least
some tumour suppressor genes there is a gene dosage effect.
The mechanism of suppression of tumorigenicity by normal genetic material
is now becoming more clearly understood. Comings (Comings 1973) proposed that
genes active during embryonic development are suppressed and the target cell is
induced to differentiate by a controlling or suppressing gene. This remarkable piece
of insight now appears to be well founded. Knudson also proposed a balance
between genes promoting proliferation and those regulating growth and inducing
differentiation (Knudson 1985). He originally coined the term antioncogene to
indicate the relationship with dominant oncogenes but the term 'tumour suppressor
gene' is now preferred. Recently, direct experimental evidence has been published
which demonstrates that putative tumour suppressor loci do indeed exert control
over cells exhibiting excessive proliferation and which have lost a degree of
differentiation. When a malignant cell line is crossed with a normal fibroblast, and
tumour suppression is achieved, the non-tumorigenic hybrids have been induced to
undergo terminal differentiation, have histological features of fibrocytes and even
produce collagen (Harris 1985, Stanbridge 1981).
The dominant cellular transforming genes or oncogenes (Cooper 1982) have
now been shown to have diverse functions but appear to play a role in cellular
proliferation. Mutational activation of an oncogene could lead to uncontrolled
proliferation and de-differentiation. Hence the hypothesis of Comings may apply to
tumour suppressor genes which could be the natural regulators of oncogenes. The
interaction between the two may be unbalanced by either mutational activation of
the oncogene or inactivation of the tumour suppressor gene, or perhaps even by a
combination of both.
1.4,2 Somatic cell hybrids and tumour suppressing effects of specific chromosomal
loci.
A great deal of normal genetic material is transferred by cell fusion
techniques and the chromosome complement of the resultant fusion hybrid tends to
be unstable. Even when a single whole chromosome is introduced into a
tumorigenic cell line and tumour suppression results, the amount of DNA being
transferred is large. Therefore identification of any particular locus with onco-
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suppressor activity by this method alone will be extremely difficult, isolation of the
gene involved and analysis of its function even more so.
The ultimate test of the tumour suppressing activity of any chromosomal
locus is the reversion of a tumorigenic phenotype in a cell line by introduction of a
single putative tumour suppressor gene. This has been achieved for the
retinoblastoma gene and this is discussed below.
1.4,3 The paradigms of retinoblastoma and Wilms' tumour
The gene responsible for retinoblastoma stands out as a paradigm for all
putative tumour suppressor genes. As discussed above, epidemiological analysis
had predicted a requirement for two hits at the same gene locus for tumour
development. This was followed by cytogenetic analysis which demonstrated visible
constitutional deletions of chromosome 13 which always involved the region 13ql4
(Yunis 1978). More than 30 cytogenetic deletions have now been reported and all
involve the same chromosomal region (Hansen 1988). A gene close by on
chromosome 13q, the esterase D gene, was shown to be close to the putative Rb
gene in genetic linkage studies (Sparkes 1983). Shortly afterwards retinoblastoma
tumour tissue was shown to have lost genetic material specifically from chromosome
13q involving the esterase D gene by analysis using RFLP DNA markers (Cavenee
1983). Loss of heterozygosity occurred in more 73% of tumours (Hansen 1988).
Most important for support of the two hit hypothesis was the discovery that, in
familial cases, the allele which was retained in the retinoblastoma tumour tissue
was the mutant one inherited from the affected parent (Cavenee 1985).
Subsequently, 2 tumours of the 37 examined in one study exhibited homozygous
loss of a tightly linked RFLP marker (Dryja 1986). These deletions occurred in the
germline or as somatic mutations (Dryja 1986). These findings suggest that
although a germline mutation is heterozygous, when a subsequent genetic event
inactivates the remaining retinoblastoma gene allele in the retinocyte, the result is of
homozygous loss of that gene function. Two somatic inactivating mutations could
have the same net effect, conferring growth advantage to that retinal epithelial cell
and resulting in expansion of that (now neoplastic) clone. The probe found to show
homozygous deletions was then used to isolate fragments of DNA from the
surrounding region and the resultant clones tested for the hallmarks of a
transcribed gene and in particular for the likely traits of the putative retinoblastoma
tumour suppressor gene. The gene (known as Rb-1) was cloned shortly afterwards
(Friend 1986) and so the tumour suppressing activity of this gene could then be put
to the ultimate test. Transfection of the cloned Rb-1 gene into a tumorigenic
retinoblastoma cell line using a retroviral vector has recently been achieved and this
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has shown suppression of the malignant phenotype (Huang 1988). This is the first
direct evidence which demonstrates tumour suppressing activity for the
retinoblastoma gene and lends considerable weight to the notion of recessive tumour
suppressing genes in general.
The function of the Rb-1 gene remains to be fully elucidated but the process
of identification of this gene has proven invaluable in work on other tumour
suppressor genes. Clearly, this work confirmed that two hits were required at the
same gene locus, resulting in homozygous inactivation of the Rb-1 gene and two
somatic mutations can have the same effect as one germline and one somatic event.
Another embryonal cancer, Wilms' tumour, serves to introduce complexity
into the field, in contrast to the relatively straightforward case of retinoblastoma and
the explanation of tumour suppressor genes based on that paradigm. It was
predicted that Wilms' tumour was also due to two events required to inactivate both
alleles of the same gene and that these events were at the same locus in the familial
and sporadic forms of the disease (Knudson 1972). Cytogenetic studies
demonstrated a translocation involving chromosome 11 (Ladda 1974) and several
deletions have now been described which all involve llpl3 (Knudson 1985). RFLP
markers have demonstrated loss of genetic material from the same region (Koufos
1984) but genetic linkage analysis in the rare familial type of Wilms' tumour has
excluded the region 1 lpl3 as that carrying the heritable form of the disease (Grundy
1988, Huff 1988). A further complication is the association of the Beckwith-
Wiedemann syndrome which predisposes to Wilms' tumour. The gene responsible
appears to map to chromosome lip 15 and clearly does not involve the
Wilms'/aniridia locus (Scrable 1987). Notwithstanding these complexities, the data
on Wilms' tumour do support the notion that the Wilms'/aniridia gene is indeed a
tumour suppressor gene but that more than one gene is involved.
1.4.4 Cytogenetic observations in colorectal cancer.
Tumour karyology was an important pointer in helping to localise the APC
gene (Ferti-Passantonopoulou 1986). A number of other possible tumour
suppressor loci involved in colorectal carcinogenesis have been indicated by tumour
cytogenetics and these include chromosomes 8 and 14 (Mitelman 1974); 8,17 and
18 (Muleris 1985); l,8p,13,17 and 18 (Reichmann 1981). The losses or structural
rearrangements detected in these studies were of a non-random nature and these
findings must be taken to indicate a strong possibility that tumour suppressor genes
are present at these loci. There are few cytogenetic data on blood lymphocytes of
colorectal cancer patients but one study has shown a constitutional chromosome
8:12 translocation which was present in the colorectal cancer tissue and was also
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passed on to the patients offspring who developed a rare testicular malignancy
(Pathak 1986). This is an exciting discovery since it may indicate a tumour
suppressor gene involved not only in tumour biology, but also in the inheritance of
cancer susceptibility.
1.4,5 Structural alterations at putative tumour suppressor genes in colorectal
cancer.
Three tumour suppressor loci have now been well characterised in colorectal
carcinogenesis, the gene for p53 on chromosome 17p, the DCC gene on chromosome
18q and the APC gene on chromosome 5 to which this thesis is addressed.
Discussion of the experimental work presented in this thesis and its relevance to
recent findings relating to the role of APC in familial and sporadic colorectal cancer
is reserved for Chapter 9. This section is restricted to discussion of the involvement
of putative tumour suppressor genes on chromosomes 17 and 18.
The gene for p53 on chromosome 17p
Tumour cytogenetics had indicated a possible recessive colorectal cancer
gene on the short arm of chromosome 17 (Muleris 1985, Reichmann 1981) but the
first molecular genetic evidence for a recessive tumour suppressor locus on
chromosome 17p (Fearon 1987) was the demonstration of clonal loss of genetic
material at a highly polymorphic locus YNZ22 which mapped to the short arm of
chromosome 17 (Nakamura 1987) in a high frequency of colorectal cancers. The
frequency of YNZ22 allele loss in the cancers was 76% while the frequency in
adenomas at the same locus was only 3%. Fearon was also able to show that, in
carcinomas which exhibited allele loss and which had a benign element adjacent
from which the malignancy would be presumed to have arisen, 2 out of the 3 benign
tumours had not lost heterozygosity. This work suggested that not only was there a
tumour suppressor locus on chromosome 17p, but also that it was involved in the
biology of the malignant but not the benign neoplasm.
The findings of 17p allele losses in colorectal cancer with a reduced
frequency in colorectal adenomas have been confirmed by many investigators (Baker
1989, Delattre 1989, Fey 1989, Law 1988, Lothe 1988, Monpezat 1988, Vogelstein
1988, Vogelstein 1989). Notably 17p allele losses were also noted in colorectal
cancer arising in patients with FAP (Sasaki 1989). The region of chromosome 17p
which was consistently deleted in colorectal cancers included the gene which codes
for a protein, p53, (Baker 1989) which had been implicated as an oncogene capable
of inducing cellular transformation or at least of enhancing the effect of other
transforming genes such as ras (Editorial 1988). Baker demonstrated that in
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colorectal cancers which had lost one p53 allele, the retained allele was mutant.
Baker suggests that p53 interacts with other agents to result in suppression of
neoplastic change. Mutant p53 may compete with normal p53 for the binding sites
required for tumour suppression and loss of the normal allele by structural deletion
would produce a more pronounced effect. Thus p53 seems to have both tumour
suppressing and oncogenic activity, depending on whether it is mutant or not. The
tumour suppressing nature of non-mutant p53 was confirmed later that year when
it was shown to inhibit oncogene-induced cellular transformation (Finlay 1989). The
function of p53 has not been fully elucidated but wild type p53 has been found
bound to transforming proteins from oncogenic viruses (Editorial 1988) and Baker
has suggested that the tumour suppressing capability of p53 is due to its ability to
block virus-associated neoplastic change (Baker 1989). Increased levels of mutant
p53 also has been demonstrated in lung cancer (Iggo 1990) and it may be that p53
is involved in many different cancers. The work on p53 is at an exciting stage. The
biological function of the first cloned and sequenced gene with demonstrable tumour
suppressor activity can now be elucidated. There is also the possibility of targeting
tumour cells in vivo by designing monoclonal antibodies to mutant p53 in order to
deliver chemotherapeutic agents or radioisotopes for imaging or treatment of cancer.
The DCC gene on chromosome 18q
In a similar manner to chromosome 17p, tumour karyology suggested that
there may be a recessive gene or genes on chromosome 18 involved in the biology of
colorectal cancer (Muleris 1985, Reichmann 1981). This has been supported by
allele loss studies which show chromosome 18 deletions in almost 80% of colorectal
cancers (Delattre 1989, Law 1988, Monpezat 1988, Vogelstein 1988, Vogelstein
1989) and a similar frequency of allele loss is seen in FAP carcinomas (Sasaki 1989).
In contrast to the situation with the gene for p53 on chromosome 17p, there was no
candidate target gene on chromosome 18q. Hence, identification and sequencing of
the responsible gene was required. This has been achieved by an elegant series of
experiments by Vogelstein and his colleagues (Fearon 1990). A common region of
deletion in colorectal cancer tissue had been identified (Vogelstein 1988) and the
breakpoint of a rearrangement in a single cancer was cloned. From this point a
massive tour de force of chromosomal walking has resulted in cloning of a 1.2
megabase gene with a 12kb mRNA which is now almost completely sequenced
(Vogelstein personal communication 1990). The gene has been called the DCC
(deleted in colon cancer) gene and somatic mutation have been identified within it at
an apparent mutational 'hot-spot'. Expression of DCC has been demonstrated in a
number of tissues, including colonic mucosa and greatly reduced or absent in
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colorectal cancer tissue. This, combined with the finding of a homozygous intra¬
genic deletion is powerful evidence to suggest that DCC is indeed another tumour
suppressor gene. Preliminary DCC amino acid sequence data suggest similarity to
known cell-adhesion molecules. Therefore DCC may play a role in cell to cell
interactions, an attractive concept in view of the well-known derangement of normal
growth inhibition in cancer.
There is little doubt that DCC is involved in the biology of colorectal cancer
but another exciting aspect of the involvement of DCC in colorectal carcinogenesis is
the possibility that it may be involved in the inheritance of colorectal cancer
susceptibility. Tentative genetic linkage to the Kidd blood group was established in
one family with Cancer Family Syndrome by Lynch and colleagues in 1985 (Lynch
1985b). At that time the Kidd blood group locus (JK) was believed to map to
chromosome 2. However, JK has been reassigned to chromosome 18 (Geitvik 1987)
and with it the possible CFS locus (Boman 1988). Recently genetic linkage has been
demonstrated between JK and polymorphic RFLP marker from within DCC
(Vogelstein personal communication 1990). These extremely important findings may
represent the first steps towards identification of a blood test to identify individuals
at high risk of colorectal cancer such that screening and prophylaxis could be
undertaken to reduce overall mortality from the disease.
Other potential tumour suppressor loci
It is likely that there are tumour suppressor loci at other chromosomal
locations and these are indicated by non-random allele losses and rearrangements
at a number of loci such as chromosomes 6, 8, 12, 14 and 22 (Sasaki 1989, Thein
1987, Vogelstein 1989). Some of these may represent genes involved in different
aspects of malignancy such as invasion and metastasis.
This is an exciting time in fundamental understanding of colorectal cancer
with particular regard to tumour suppressor genes and there is reason to be
optimistic.that research will make real improvements to the burden of colorectal
cancer in the world population. Abnormalities of tumour suppressor genes are not
the only genetic alterations described in colorectal cancer and some of these other
changes are detailed below.
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1.5 Genetic changes in colorectal cancer which do not involve aberrations
of putative tumour suppressor gene loci.
This section briefly reviews the genetic changes noted in colorectal carcinoma
other than changes to putative tumour suppressor genes. It is not intended to be an
exhaustive review since the main theme of this work was an analysis of the
involvement of the APC gene in colorectal carcinogenesis.
1.5.1 DNA methvlation status in colorectal cancer.
Methylation of DNA is a structural modification mainly of the cytosine-
guanine dinucleotides in the mammalian genome. The majority of cytosine residues
are methylated in normal, fully differentiated cells (Razin 1980). A decrease in the
level ofmethylation appears to be associated with gene activation (Razin 1980).
Since DNA methylation status is correlated with differentiation and with gene
activation, and colorectal cancer tissue is abnormal in both of these respects, Goelz
examined DNA methylation status in colorectal adenomas and carcinomas (Goelz
1985). Using methylation-sensitive restriction endonucleases (Hpa II and Hha 1)
which cut at CG residues, Goelz examined the methylation status of a total of 10
genes at random by probing genomic Southern blots from benign and malignant
colorectal neoplasms with the respective gene probe. The endonuclease Msp.l
served as a control for Hpa II since it cleaves at the same CCGG recognition site
regardless of the methylation status of the internal C residue. The methylation
status of the adjacent normal tissue served as a tissue control.
Goelz found that 4 genes in particular of the 10 studied were significantly
hypomethylated in all 23 neoplasms examined and that adenomas and carcinomas
were hypomethylated to a similar degree. The genes involved were growth hormone,
gamma-globin,«-chorionic gonadotropin and gamma-ciystallin. These genes are not
thought to be specifically involved in carcinogenesis but this work implies and
overall activation of genes, including those involved in the neoplastic process. It was
also noted that the changes were quite heterogeneous in that different sites of
methylation occurred in the same tumour types arising in different individuals.
Goelz proposed that hypomethylation could lead to expression of dormant genes in
the colonic epithelium which might then confer growth advantage.
Hypomethylation might also interfere with chromosomal condensation and
subsequent reassortment at the time of mitosis. This might then lead to
chromosomal breakages and it is tempting to postulate that loss of specific tumour
suppressor loci by this mechanism would then confer a selective growth advantage
and the continuation of that abnormal clone.
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Little work appears to have been carried out on DNA methylation status in
colorectal carcinogenesis since the work of Goelz. However, DNA hypomethylation
does appear to be an early event and certainly precedes malignant transformation.
Whether DNA hypomethylation is a cause or an effect of neoplasia remains to be
elucidated.
1.5.2 Flow cytometry and ploidv levels in colorectal cancer.
Tumour cytogenetic analysis has demonstrated that colorectal cancer cells
are seldom, if ever, diploid for every chromosome (Ferti-Passantonopoulou 1986,
Mitelman 1974, Muleris 1985, Pathak 1986, Reichmann 1981). However, tumour
cytogenetics is laborious and is best suited to the examination of specific
chromosomal abnormalities. A more global examination of the amount of DNA
(ploidy level) in colorectal cancer tissue can be undertaken by analysis of the total
nuclear DNA content using flow cytometry. Tumours vary in the degree of
abnormality of DNA level (aneuploidy) which they exhibit and this can be compared
to the biological behaviour of the tumour.
In various studies, the ploidy level of colorectal cancer has been shown to
distinguish two populations of tumours; those that are severely aneuploid and those
that are predominantly diploid. The predominantly diploid tumours may well
include a minority of cells which are aneuploid but, overall, the main population
tend to be diploid and hence 'mask' the minority. The aneuploid group comprise
around 40%-55% of all tumours (Armitage 1985, Jones 1988, Wolley 1982). There
is no correlation with the presence of aneuploidy and tumour histological grade or
pathological stage. There are conflicting data on the relationship of ploidy level and
survival. In some studies, the presence of aneuploidy in colorectal cancer is highly
significantly correlated with poor survival (Armitage 1985, Wolley 1982). In one of
these studies, the 5 year survival for patients who had a diploid tumour resected
was 43% compared with 19% for those patients with an aneuploid tumour (Armitage
1985). However, there is evidence that DNA ploidy status confers no independent
prognostic value after resectibility, pathological classification and patient age (Jones
1988). It has been shown that DNA diploid rectal carcinomas are less likely to recur
locally after surgery and adjuvant radiotherapy and DNA ploidy seems predict the
response to adjuvant radiotherapy in these tumours (Jones 1989). Careful, long-
term follow-up of prospectively collected patient populations will be required to
clarify the situation.
DNA aneuploidy has been demonstrated to be less frequent in colorectal
adenomas than in carcinomas (Quirke 1986). Quirke found that 6% of adenomas
were aneuploid and this was significantly associated with size of the adenoma.
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Since tumour size has been shown to be a strong predictor of subsequent malignant
transformation (Morson 1983, Muto 1975), this supports the notion that aneuploidy
is associated with aggression. Quirke also demonstrated that carcinomas with
synchronous adenomas tended to show aneuploidy less frequently than those
carcinomas without synchronous adenomas. This suggests that the tumours with
associated adenomas may be a less aggressive sub-group of colorectal cancers.
The mechanism by which aneuploidy occurs is unknown, but one hypothesis
suggests that it occurs due to a failure to reassort chromosomes correctly at mitosis
(Nowell 1986, Wyllie 1989). This would allow the loss or gain of any chromosomal
loci postulated to be important in the pathogenesis of colorectal cancer. Those
clones with a growth advantage would then be subject to positive selection. Thus a
mechanism for loss of tumour suppressor genes would be embraced by such a
process. This scheme would also concur with that postulated by Goelz (Goelz 1985).
Aneuploidy may be due to abnormalities of DNA methylation status or of genes,
such as p53, which may influence spindle formation and result in disruption correct
chromosomal reassortment.
1.5.3 Oncogene alterations.
This section briefly describes the nature of oncogenes in general and
indicates those reported to have a specific involvement in colorectal carcinogenesis.
The main theme of this thesis is concentrated on tumour suppressor genes with
particular reference to APC. The purpose of this section is to give an overview of this
class of genes whose action is believed to require the modulating effect of tumour
suppressor genes for the maintenance of a natural balance of cellular activity and
proliferation (Comings 1973, Knudson 1985).
Oncogenes are genetic elements which can initiate and/or maintain a
transformed phenotype in a cell and are thus said to act dominantly. There are now
over 40 known oncogenes. In addition to classical in vitro transformation assays
using mouse NIH 3T3 cells, these genes were found to be capable of transforming
rodent and human cells into cells which form tumours in vivo (Cooper 1982, Bishop
1985).
The native human oncogenes, or proto-oncogenes are involved in normal
cellular activity, particularly those functions associated with cellular proliferation.
The precise functions of these genes are diverse; they include growth factors, growth
factor receptors, signal transducers, protein kinases and transcriptional activators
(Bishop 1985, Land 1984). Many proto-oncogene functions appear to promote cell
growth and proliferation. It is abnormal expression, or activation, of these genes
which has been shown to account for their characteristic transforming properties
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(Bishop 1985, Cooper 1982, Duesberg 1985, Slamon 1984). There are several ways
that a proto-oncogene can be converted into a transforming oncogene which will
promote excessive cellular proliferation and some examples are given here.
A non-mutant proto-oncogene may be expressed in an abnormal,
unregulated way by translocation to a site without an oncogene regulator region, as
in the case of the involvement of the c-myc oncogene in Burkitts lymphoma. The
myc proto-oncogene is normally located on chromosome 8 but Burkitts lymphoma is
associate^ with a chromosome 8:2, 8:14 or 8:22 translocation which brings the myc
locus into close proximity with the immunoglobulin enhancer sequences. In some
instances the expressed sequences of myc itself can be removed from the regulatory
influence of its own untranslated first exon. The net result for both of these
mechanisms is overexpression of myc gene product. Oncogenes can also be
activated by gene amplification (duplication) as in the case of N-myc which is found
in multiple copies (up to 300) in around 50% of neuroblastomas and this is
associated with a poor prognosis (Weber 1987).
Another mechanism for conversion of an oncogene into a transforming gene
is by mutation within the gene itself. Although the ras gene had been shown to
induce a transformed phenotype in NIH 3T3 transformation assays (Bishop 1985,
Duesberg 1985, Land 1983), it was not initially realised that the gene resulting in
transformation was a mutant form of the ras proto-oncogene (Cooper 1982).
However, it was later shown that activation of ras was due to a point mutation
(Tabin 1982) and that two different point mutations at the 12th codon could both
activate the gene (Capon 1983). The result of such mutations is to substitute a
valine or cysteine for the normal glycine found at codon 12 in the ras gene product
(p21). Mutations at codons 13 and 61 are also now well described and appear to
have the same functional effect (Barbacid 1987) as a codon 12 mutation. The three
amino acids coded by these sites all reside in the GTP binding region of the p21
product. The result is that ras appears to be 'switched on' in an uncontrolled
fashion and causes inappropriate signals at the membrane for the cell to keep
cycling (Bishop 1985).
Oncogene abnormalities which have been reported to be involved in
colorectal carcinogenesis include abnormal levels of expression of fos, myc, rasHa
and rasKi (Slamon 1984). However, the role of fos involvement is disputed
(Alexander 1986). In addition, the src oncogene protein product (pp60) has been
demonstrated in abnormal amounts in colorectal cancer tissue (Bolen 1987).
Amplification of myc has been demonstrated (Alexander 1986) and elevated levels of
c-myc mRNA and protein product have also been demonstrated (Erisman 1985).
However it is not clear whether myc expression merely reflects proliferative activity
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rather than influences it because no amplification or activating mutations have been
detected even in cancers which are over-expressing myc (Erisman 1985).
The family of ras oncogenes is the most extensively studied group of
transforming genes in colorectal cancer. Elevated expression of the ras p21 protein
product has been shown to occur in 100% of colorectal cancers in one study (Hand
1987). Over-expression of the ras mRNA (Spandidos 1984) and of the p21 protein
product (Williams 1985) has been demonstrated in both colorectal adenomas and
carcinomas, suggesting that ras activation may be an early event in colorectal
carcinogenesis. This is supported by the finding that, although p21 expression was
enhanced in primary carcinomas above that in adjacent normal colorectal mucosa,
it was relatively lower in more pathologically advanced cancers and expression was
lower in distant colorectal metastases than in the primary tumour (Gallick 1985).
The mechanism of ras activation in colorectal neoplasia is most frequently by
mutations in the Ki ras oncogene (Vogelstein 1988). The point mutations involved
can occur at codons 12, 13 and 61 of the ras gene but codon 12 lesions are the
most common (Bos 1987). Ki ras mutations have been demonstrated in around 40%
of colorectal cancers (Bos 1987, Delattre 1989, Forrester 1987, Vogelstein 1988).
One of the most striking findings is that mutational activation can precede the
development of malignancy since mutations have been detected in adenomas (Bos
1987, Forrester 1987, Vogelstein 1988) and the frequency of detection of Ki ras
mutations is highest in adenomatous tissue within a carcinoma (Bos 1987,
Vogelstein 1988). This is compelling evidence to suggest the early involvement of Ki
ras mutations in colorectal carcinogenesis. The frequency of Ki ras mutations in
adenomas from FAP patients has been reported by various authors as 7% (Farr
1988), 13% (Sasaki 1990) and 13% (Vogelstein 1988) which is substantially lower
than that seen in sporadic adenomas. However most of these lesions were small
and of low grade dysplasia and as will be discussed in Chapter 6 the malignant
potential of any one FAP adenoma is low given the hundreds of lesions present in
the colon of affected patients. The frequency of Ki ras mutations in carcinomas
arising in patients with FAP is 36% which is very similar to that seen in sporadic
cases (Sasaki 1990). The published data suggest that mutation of Ki ras is not
involved in the genesis of adenomatous change but is involved at the progression of
adenoma to carcinoma.
The role of activated oncogenes in colorectal cancer is now becoming more
clear but the interaction such genes and their regulators, which may well be a class
of tumour suppressor genes, remains to be elucidated.
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1.6 Aims of the project
The central theme of this project was to extend knowledge of the APC gene,
its role in the inheritance of Familial Adenomatous Polyposis and its putative role as
a tumour suppressor gene in sporadic colorectal carcinogenesis.
Following regional localisation of APC to chromosome 5q21-22 just prior to
the start of this work, the aims of the project were to construct a high resolution
genetic linkage map of the chromosomal region around the gene in family studies of
kindreds affected by FAP. It would then be possible to ascertain whether the
inherited mutation was sufficient for the development of FAP adenomas or whether a
further event at that locus was required. The map would also allow examination of
the nature, extent and APC specificity of the loss of genetic material from
chromosome 5 reported in sporadic colorectal carcinomas. The stage of
tumorigenesis at which chromosome 5 deletion occurs could then be examined by a
search for deletions in sporadic colorectal adenomas. The most immediately
clinically relevant aim was to assess the value and the validity of linkage analysis
derived risk estimation for presymptomatic diagnosis of Familial Adenomatous
Polyposis in at-risk family members.
1.7 Experimental approach
A substantial clinical resource was collected for molecular genetic analysis
and includes blood samples from patients with colorectal adenomas and carcinomas
and members of FAP families, in addition to stockpiling tumour tissue from such
lesions. One affected member of each family has been karyotyped in the hope of
detecting an invaluable translocation.
The identification and complete ascertainment of kindreds affected with
,Familial Adenomatous Polyposis required to be initiated as there was no Polyposis
Registry in Scotland. The kindreds were fully ascertained by myself and Chapter 3
describes the results of screening of the family members for the presence of polyps
and extra-colonic features of the syndrome.
Chapter 4 presents the results of genetic linkage analysis in FAP kindreds
using DNA probes which recognise polymorphisms on chromosome 5 in the region
thought to harbour the APC gene. A genetic linkage map of the region around the
APC gene was constructed and Chapter 5 presents the application of this map and
other RFLP markers spanning chromosome 5 to deletion analysis in a large number
of sporadic colorectal carcinomas. A similar analysis of allele loss applied to familial
and sporadic adenomas is presented in Chapter 6.
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Genetic linkage and deletion analysis strongly suggested one of the markers
might be very close to the APC gene itself. In view of this evidence, a search for
constitutional rearrangements of large DNA fragments which included this locus
was carried out by analysis with pulse field gel electrophoresis. This is presented in
Chapter 7.
The use of DNA analysis in Familial Adenomatous Polyposis in the clinical
setting is described in Chapter 8. Presymptomatic diagnosis of FAP using RFLP
markers mapped by genetic linkage analysis combined with deletion analysis in
sporadic colorectal carcinomas was possible for a large number of the at-risk family





This chapter describes the methods used for clinical and family
ascertainment in addition to a description of the laboratory techniques employed.
The description is necessarily general with regard to restriction enzymes and probe
combinations but more specific information is given in the results chapter where
each of the experiments is described.
2.1 Collection of families with Familial Adenomatous Polyposis (FAP).
The families with Familial Adenomatous Polyposis which participated in this
project are all of Scottish descent and are not included in published genetic linkage
studies other than those pertaining to this work. The probands of these families
were largely identified through contact with local surgeons and a few via the Clinical
Genetics Department at the Western General Hospital, Edinburgh. The diagnostic
criteria for probands with FAP were those now universally accepted (Bussey, 1975),
namely more than 100 adenomatous polyps of the colorectum. Fewer polyps were
accepted as diagnostic in offspring of confirmed gene carriers. Prior to any direct
patient contact, the general practitioner of every patient or nuclear family group was
contacted and his/her agreement obtained. All family, clinical and paternity testing
data has been strictly confidential throughout.
Genetic linkage analysis relies on accurate phenotypic and genealogical
information in addition to reliable experimental data. The ascertainment of pedigree
infonnation and diagnostic classification of individuals within the families collected
in this study has been exhaustive and I believe family data are wholly valid to date.
2,1,1 Ascertainment of FAP families.
Fifteen probands with FAP were identified. Eleven of these were suitable for
full ascertainment and, with their families, comprise the study group. The families
of these probands were ascertained by three main methods.
In some families pedigree information was already well documented but
required extension and updating (particularly KMD 1, which was known to Mr.A.A.
Gunn of Bangour General Hospital, West Lothian and to the MRC Human Genetics
Unit since 1975). However family data and validation of diagnosis was checked in
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every case from hospital and pathology records and by cross-checking with public
records as detailed below.
Probands and family members were interviewed by myself to construct
preliminary pedigrees but although many knew of the existence of some of their
relatives, the pedigree information was generally scanty. Pedigree information from
other sources was also cross-checked at the time of interviewing family members in
every family.
Genealogical investigation was carried out by examination of public records
of births, deaths and marriages at Register House, Edinburgh. I am most grateful to
Susan Collyer and Rona de May of the Registry at the MRC Human Genetics Unit
who carried out this work. Families with FAP were traced back as far as was
practicable or until there was evidence that the disease had arisen as a new
mutation (ie parents and siblings unaffected). Pedigree tracing prior to the
instigation of a Scottish national register of births, deaths and marriages in 1852 is
extremely time consuming as local Parish registers have to be examined and so no
attempt was made to trace families prior to this date. Thus, within the limitations of
public records information, there is no evidence that any of the 11 families which
have been ascertained were in any way inter-related.
The clinical and pathology records of all individuals reputed to be affected
were personally scrutinised in order to confirm the diagnosis. Where family
members were identified by genealogical investigation, every attempt was made to
confirm disease state. Many hospitals have a policy of destroying records which
have not been required after 20 years or even sooner if the patient is deceased. In
these cases attempts were made to locate pathology records. Unfortunately, due to
the veiy long time periods in question, many of the hospitals involved are no longer
in existence or have moved site. In addition, without the exact date of operation,
extracting pathology records was impossible in some cases. Therefore, there were a
few family members (particularly in KMD 1) where no absolute confirmation that
they had FAP could be established. In these cases I have relied on death certificate
information alone or supplemented by a history from some of the older family
members.
The pedigrees derived from genealogical investigation for all 11 FAP kindreds
are shown in Appendix A.
2,1,2 Ascertainment of families by clinical screening.
In order to ensure completeness and accuracy of ascertainment, I personally
screened as many family members as possible. This proved invaluable because it
allowed me to develop a rapport with the families which would not have been
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possible otherwise. This has resulted in a very high proportion of the family
members agreeing to help with the research aspect of the work. In addition,
because I verified cases clinically who had been discharged from screening
programs, several new cases were identified who had been previously mis-classified
as unaffected. The clinical screening also facilitated the collection of tumour tissue
for molecular analysis. The screening modalities employed are detailed in Chapter 3
but in brief, colonic screening was carried out by endoscopic and/or radiological
means, the presence of CHRPE lesions was ascertained by ophthalmoscopy and
clinical examination for the presence of other extra-colonic stigmata was
undertaken.
2,2 Collection of clinical material and controls.
Collection of clinical material was carried out personally in almost all
instances. Some blood samples were taken by the patient's own family doctor if
there were great distances involved but in general I preferred personal contact to
take the family history and to allow the patient to make enquiries as to the nature
and possible benefits of the work.
I collected all tumour samples personally from the operating theatres at the
Western General Hospital, Edinburgh and immediately transported them to the
pathology department there to avoid degradation of the material. Collection of
clinical material for this project has been approved by the local ethical committee.
2.2.1 Blood samples.
30ml of peripheral venous blood was drawn from FAP family members (10ml
in Lithium Heparin anticoagulant for EBV transformation of B-lymphocytes and
short-term culture for chromosome analysis, and a further 20ml in Potassium EDTA
anticoagulant for DNA purification) and 20ml of blood was drawn from patients with
sporadic colorectal neoplasms to serve as control for allele loss studies (all in
Potassium EDTA for DNA purification). During transport or if there was any delay
before processing, the blood in Lithium Heparin was kept at room temperature and
the blood for DNA purification stored at 4°C.
2.2.2 Collection of adenomas from patients with FAP.
A total of 40 adenomas were collected from 4 patients with FAP at the time of
prophylactic colectomy. The lesions were removed in the operating theatre side-
room as soon as the specimen was available. The macroscopic examination and
removal of polyps was carried out by a pathologist (Dr. AH Wyllie). The colectomy
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specimen was opened on a bed of ice and cold isotonic saline poured over the
mucosa to avoid drying. The polyps were removed avoiding any of the surrounding
normal mucosa, placed in Eppendorf vials, snap frozen in liquid nitrogen and then
stored at -70°C until ready for DNA extraction.
Histological confirmation of adenomatous change was carried out in several
polyps from each case and assessment of all other similar lesions by a pathologist
(Dr. AH Wyllie) confirmed the diagnosis.
2.2.3 Collection of sporadic neoplasms.
A total of 51 nonpolyposis colorectal carcinomas were collected from 49
patients (26 male and 23 female) who underwent colectomy. Twenty adenomas were
harvested from 14 colectomy specimens removed for coexisting carcinoma. The
resected colonic specimens were transported on ice and examined in the fresh state
by a pathologist as part of the normal clinical diagnostic procedure.
Histopathological assessment was carried out on a portion of tumour immediately
adjacent to the sample taken for DNA analysis. All sporadic adenomas were
obtained from colectomy specimens carried out for symptoms or due to the co¬
existence of a colorectal malignancy. The tumour tissue was stored at -70°C until
ready for DNA extraction.
At the same time as harvesting carcinoma and adenoma tissue from
colectomy specimens, macroscopically normal colonic mucosa, dissected free from
muscularis propria, was also collected from the same specimen at a point 10cm or
more from the nearest tumour.
2.2.4 Collection of archival paraffin-embedded material.
Deceased members of FAP kindreds who had undergone surgical procedures
were identified during pedigree ascertainment and a search was made of pathology
records for paraffin-embedded archival material sent for pathology examination at
the time of surgeiy. Blocks of tissue were collected from 11 different patients. In
order to ensure that only normal tissue was analysed, histological assessment was
carried out in every case prior to DNA extraction. If tumour tissue was noted and
wholly normal blocks were not available for that patient, normal material was
obtained by dissecting tumour tissue away from the normal remainder.
2.3 Establishment of a renewable source of DNA.
The establishment of a renewable source of DNA was of great importance to
this project in order to avoid depleting irreplaceable resources of DNA, especially
since many patients were old and some have died since this project began.
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2.3.1 Epstein-Barr virus transformation of peripheral blood lymphocytes: storage
and maintenance of EBV transformed lymphoblastoid cell lines.
The transformation and maintenance of peripheral blood lymphocytes from
family members was carried out by Dr. M Steel, Liz Harvey and myself but the
method used was consistent throughout.
Ten ml of fresh heparinised blood was layered onto 10ml of Ficoll Hypaque
(s.g. 1.071) and centrifuged at 2500rpm for 15 mins. with 50% brake applied. The
white cell interface was collected with a pastette and washed twice with PBS. After
counting, 1-1.5x106 cells were taken for transformation and the remainder stored
(in case the transformation failed) in 5% DMSO in FCS and frozen sequentially at -
20°C in the freezer and -140°C in liquid nitrogen to avoid intracellular crystal
formation. The cells for transformation were incubated in small glass tubes at 370C
in 5% C02 in transformation medium comprising 1.5ml RPMI, 5% Fetal Calf Serum
(FCS), 1% glutamine, lOOul cyclosporin (lOug/ml) and lOOul B95-8 supernatant.
B95-8 is an Epstein-Barr virus infected marmoset lymphoid cell line infected with
which is grown as a monolayer in 200ml flasks and when deprived of nutrients for
10 days infectious virus is shed into the medium (Miller 1973). The medium was
changed weekly or before if a colour change from red to yellow was noted. The cells
were seen to have transformed when there was clear evidence of increasing
numbers, increased cell size and cell clumping. At this stage the cells were
transferred to larger glass tubes or 50ml culture flasks for bulking up. Maintenance
culture conditions consisted of RPMI with 5% FCS at 37QC in 5% C02 and medium
was changed weekly. After washing, at least 3x106 transformed cells were then split
from the main culture, spun down and the pellet resuspended in storage medium
(5% DMSO in FCS). The cells were then frozen sequentially at -20°C and -140°C, as
for fresh lymphocytes. The remainder of the culture was bulked up until a further
lxlO7 cells were obtained and these were then spun down for DNA extraction.
2.4 Cytogenetic studies.
At least one affected member of every FAP kindred was examined by
cytogenetic analysis in the hope of discovering a deletion or critical translocation
with a breakpoint in the APC gene. Metaphase spreads were prepared by myself but
chromosome analysis was performed by experienced cytogeneticists. Initially I
hoped to cariy out karyotype analysis with the help of an automated metaphase
finder and karyotype analyser (Piper 1982) but this proved impractical.
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2,4.1 Preparation, staining and analysis of chromosome spreads.
The chromosomes were prepared for analysis by high resolution 'G'-banding
in the following manner developed by the MRC Human Genetics Unit. Three
separate cultures were set up for each patient sample. 1ml of blood anticoagulated
in Lithium-Heparin was added to the culture medium (8.3ml F10 culture medium,
1.5ml FCS, O.lml phytohaemagglutinin and 0.1ml 100X [GEJKST) in a glass
universal container and incubated at 370C for 72hrs. Two of the three cultures
were blocked using 10~7M methotrexate to synchronise the cell cycles and
incubated for a further 16hrs. The third culture was arrested with 0. lug/ml
colcemid for 15mins and the cells harvested by centrifugation at 1200rpm (200g) for
8 minutes in a 15ml conical tube. The supernatant was removed, 8ml of 0.075M
KC1 was added and incubation continued at 370C for lOmins to lyse the cells.
Chromosomes were then fixed over 24 hours with 3 rounds of centrifugation at 200g
for 8 minutes and addition of fresh fixative (3 parts absolute methanol 1 part glacial
acetic acid).
The two cultures which had been blocked with methotrexate were released by
replacement of fresh complete medium without methotrexate containing 10~f>M
Thymidine in one and lOOug/ml BUdR in the other. After a further 5hrs 30mins
incubation at 370C, the cultures were arrested with colcemid and harvested as
above.
Chromosome spreads were made by resuspending the fixed cell pellet in a
small volume of fresh fixative and dropping on to a clean microscope slide. The
unstained, air-dried spread was examined to assess the quality and spreading of
metaphases and the cell density. When satisfactory metaphase spreads had been
obtained the chromosomes were GT-banded (Giemsa-Trypsin). Slides were
incubated for 1-3 hours in 2xSSC at 60°C, rinsed thoroughly in de-ionised water
and incubated in 1% Difco Bacto Trypsin in PBS. After a further thorough rinse in
de-ionised water, the slides were stained with 2.5% Giemsa (1.0ml Gurr's R66 to
38.0ml phosphate buffer pH6.8) for 30 minutes, rinsed briefly in de-ionised water,
air dried, soaked in xylene and mounted with DPX.
Chromosome spreads were then analysed by the cytogenetic section of the
MRC Human Genetics Unit.
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2.5 DNA purification protocols.
The DNA purification protocols employed in this project follow well
established phenol/chloroform extraction methods (Maniatis 1982) with slight
modifications to suit the type and quantities of tissue involved.
2.5.1 Purification of DNA from fresh peripheral blood leukocytes.
10-20mls. of whole blood was mixed with an equal volume of lysis buffer (2%
SDS, 0.1M Tris-HCl pH7.5, 20mM NaCl, ImM EDTA) for 5 mins. An equal volume
of water-saturated phenol was then added, mixed well but gently to minimise DNA
shearing and the aqueous and phenol phases separated by centrifugation at
3000rpm for 10 mins. The aqueous phase was pipetted into a fresh tube and the
DNA was precipitated by adding 1/2 vol. 7.5M NH4COOH and 2vols. isopropyl
alcohol. Spooled DNA was then resuspended in lOmM Tris-HCl pH 7.5, 150mM
NaCl, lOmM EDTA and treated with 50ug/ml RNase for 30 mins. at 37oC, followed
by lOOug/ml proteinase K at 37oC overnight in the presence of 0.2% SDS. After
sequential extractions using centrifugation at 3000rpm for 10 minutes with equal
volumes of phenol, a 50:48:2 mix of phenol/chloroform/iso-amyl alcohol and an
equal volume of 24:1 chloroform:iso-amyl alcohol, the DNA was precipitated from
the aqueous phase by adding 1/2 volume of 7.5M NH4COOH and 2 volumes
ethanol. The precipitated DNA was spooled, air-dried, dissolved in TE (lOmM Tris,
0.5mM EDTA) stored in screw-top Eppendorf vials at 4oC until ready for analysis.
2.5.2 Purification of DNA from solid tumour material.
Tumour tissue was either processed immediately, fresh from the hospital
pathology laboratory or stored in clean, sterile containers at -70°C. The fresh
tumour tissue was frozen for 1-2 hours at -400C to allow dicing of the sample. The
tumour tissue which had been stored in the deep cold was diced while still solid.
DNA was purified from approximately lcm3 of tumour tissue and the remainder
stored at -70°C. Dicing of the tumour samples was carried out by hand using a
fresh single-sided razor blade for each tumour. The tumours were cut into cubes of
less than 0.5mm and transferred immediately into lysis buffer described in section
2.5.1. FrQm this point, the tumour samples were processed in the same manner as
for whole blood. Tumour tissue tended to yield large quantities of DNA, requiring
much larger volumes of TE for dissolution to give the preferred working
concentration of lmg/ml.
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2.5.3 Purification of DNA from EBV transformed lvmphoblastoid cell lines.
Lymphoblastoid cell lines were used as a renewable source of DNA for family
studies. However, due to the practical problem of bulking up and feeding sufficient
numbers of such cells from around 180 individual family members, cell line DNA
was required only if there was a limited yield of DNA from fresh whole blood. This
was the case in around 20% of samples. The DNA purification protocol for
lymphoblastoid cell lines was essentially the same as that used for whole blood.
1x10? cells were harvested by centrifugation from the culture medium and
transferred immediately into the lysis buffer detailed in section 2.5.1. Once in lysis
buffer, the lymphoblastoid cell line was dealt with in the same manner as for whole
blood.
2.5.4 DNA purification from formalin-fixed paraffin-embedded archival material.
The method used here is derived from an amalgamation of published
methods (Dubeau 1986, Goelz 1985, Warford 1988). Histologically confirmed
normal tissue from deceased FAP family members was sectioned into 5um slices on
the microtome to give around lOOmg of tissue, including residual paraffin. Paraffin
was dissolved in 10ml of xylene and removed with 3 xylene washes. The xylene was
removed in 100% ethanol and the tissue progressively rehydrated in 99% ethanol (3
washes), 95% ethanol (2 washes), 70% ethanol (1 wash) and distilled water (1 wash).
The tissue was then resuspended in lOmM Tris-HCl pH 7.5, 150mM NaCl, lOmM
EDTA and treated with lOOug/ml proteinase K at 370C overnight in the presence of
2% SDS. Phenol/chloroform extraction and ethanol precipitation was then carried
out as for whole blood. DNA was recovered by centrifugation at 12000rpm for
30mins, resuspended in TE, treated with 50ug/ml RNase for 30 mins. at 370C,
followed by lOOug/ml proteinase K at 370C overnight in the presence of 0.2% SDS.
After phenol/chloroform extraction and ethanol precipitation, the DNA was pelletted
by centrifugation at 12000rpm and redissolved in TE.
2.5.5 Estimation of DNA concentration.
DNA concentrations of genomic DNA and probe preparations were measured
by optical 'densitometiy on a Pye Unicam SP6-400 UV Spectrophotometer. Readings
were taken at 260nm and 280nm and the 260/280 ratio of 1.8 taken as optimum
purity of DNA. DNA was dissolved to a concentration of around lmg/ml for ease of
handling
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2.6 DNA analysis with restriction fragment length polymorphisms
The methods described here are all well established (Maniatis 1989) and so
an exhaustive list of references is not given. Key references for certain techniques
are provided.
2,6.1 DNA digestion with restriction endonuclease.
5ug of purified DNA (lmg/ml) was used for each digestion. Electrophoretic
rates were influenced by the volume of the test DNA required, due to differences in
the amount of EDTA and salts in the digestion mix. Stock DNA samples were all
kept at lmg/ml and where necessary re-precipitated in 1/10 vol. 3M NaCOOH and
2.5 vols, of ethanol and redissolved in TE to lmg/ml.
DNA samples were digested with the appropriate restriction endonuclease in
a 40ul digestion mix in individually labelled, screw-top Eppendorf vials to avoid
contamination from the water bath. The reagents were added in a set order to
minimise the risk of contaminating one digestion mix with the DNA of another.
Sterile distilled water was added first, the volume calculated depending on the
required volume of test DNA solution. 4ul of 10X incubation buffer appropriate for
the restriction endonuclease used for the digestion was then added (as provided by
the manufacturers). Restriction endonuclease (Boehringer Mannheim, Northumbria
Laboratories, Bethesda Research Laboratories or Biolabs) was then added at 4
units/ug of test DNA, usually requiring a volume of 2ul as the manufacturers
supply the enzyme at a concentration of 8-12 units/ul. 5ug of test DNA was then
added and the disposable pipette tip left in the Eppendorf tube until all DNA
samples had been added. This minimised any possible risk of cross-contamination
of DNA samples or a mix-up with the labelled tubes. The test DNA and the reagents
were then gently pipetted up and down to ensure thorough mixing prior to the
addition of spermidine, which might precipitate any localised concentration of the
DNA. Spermidine was added from a stock solution of lOOmM to give a
concentration in the digestion mix of 5mM and the reagents gently mixed by
pipetting. Spermidine enhances restriction endonuclease activity by mopping up
inhibitory salts in the reaction mix.
The genomic DNA digestion mixtures were then incubated overnight in a
water bath at the temperature appropriate for the enzyme in use. The majority of
restriction enzymes required incubation at 370C but a few required other
temperatures for optimum activity (Taq 1 at 65°C, Bel 1 at 50°C and BstXl at
55°C). The sample tubes were spun down in the microcentrifuge the following
morning and a further aliquot of 10 units of restriction enzyme was added to each
A**Tt,OV
sample and incubated for a further 4 hours to ensure that the reaction went to
completion. After complete digestion, the samples were ready for fractionation by gel
electrophoresis.
2,6.2 Fractionation of digested DNAbv gel electro-phoresis and Southern transfer.
Horizontal gel electrophoresis (Bethesda Research Laboratories
electrophoresis tank) in agarose through TAE buffer (40mM Tris acetate ImM EDTA)
was used throughout for fractionation of the restriction endonuclease digested
genomic DNA purified from blood leukocytes, cell lines or tumour tissue. The
concentration of agarose in the gel depended on the size of the DNA fragments to be
resolved, higher concentrations of agarose (eg. 1.5%) being used for resolution of
smaller DNA fragments (eg. around 500bp) and 0.8% gels used for larger fragments
(eg. around lOkb). The gels were run overnight with recirculation of the buffer
through an ice-bath to avoid heating artifact. The voltage was adjusted between 1.5-
4V/cm to give good separation over the 18hrs. of the run.
After digestion, samples were spun briefly in the microcentrifuge to ensure
complete recovery of the DNA sample and the dye bromophenol blue with sucrose
was mixed to a final concentration of 0.025% and 7% respectively. The dye allows
more controlled manipulation of the sample and visualisation of the DNA sample in
the well of the gel. It also serves as a marker when the electric field is applied to
demonstrate how far the DNA fragments have run. The bromophenol blue runs with
an electrophoretic mobility similar to 700bp of DNA. The sucrose serves as a carrier
to ensure that the DNA sample sits in the well when loaded into the agarose gel.
Whenever a size marker was required, Hind III digested lambda phage was
loaded into the first and/or the last well in the gel. This gives constant DNA
fragments at 23130, 9416, 6557, 4361, 2322, 2027, 564 and 125 kb.
After electrophoresis, the DNA was stained with the fluorescent, intercalating
dye ethidium bromide at 0.5ug/ml added to the running buffer for 30mins. The gel
was then destained in distilled water for lOmins and photographed under ultra¬
violet light (260nm) to assess the quantity and quality of the DNA and the
completeness of the digestion. The DNA was then rendered single stranded by
denaturation in 1.5M NaCl, 0.5M NaOH for 45mins followed by neutralisation in 2M
NaCl, 0.5M Tris HC1 pH 5.5 for 60mins.
The fractionated genomic DNA was transferred to a nylon membrane by
Southern blot (Southern 1975). A piece a 5mmWhatman blotting paper was spread
over a glass plate suspended on a tank filled with 20X SSC so that the ends were
immersed in the SSC and acted as a wick. The gel was placed on top of the 5mm
paper and an appropriate sized piece of Hybond-N (Amersham International) was
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laid on top of the gel. A glass rod was used to remove any air bubbles and two
pieces of dry 3mm Whatman paper and a stack of dry paper towels were laid on top
of the Nylon membrane. A rigid plate and a lKg weight were used to compress the
paper towels to allow a flow of liquid from the reservoir through the gel and nylon
membrane so that the DNA fragments were eluted out of the gel on to the
membrane. The gel was surrounded with Cling-Film to prevent evaporation of the
SSC. DNA transfer was complete overnight and then the filter air dried for 2-3
hours prior to permanent cross-linking of the DNA to the nylon by trans¬
illumination with ultraviolet light (302-305nm at 90W) for 3mins 30secs and baking
at 80°C for 60mins in a vacuum oven.
2.6,3 Radiolabelling of DNA probes.
Radiolabelling of DNA probes was carried out by the random priming method
(Feinberg and Vogelstein, 1983) using a commercial 'Multiprime Labelling Kit'
(Amersham) according to the manufacturers instructions. 25-50ng of DNA probe
was labelled either as plasmid or after endonuclease excision of the insert from the
vector and purification of the insert. Probe DNA was dissolved in dH20 in an
Eppendorf centrifuge tube to give a final volume of 50ul and denatured by heating to
95- 100°C for 2mins (insert) or 12mins (whole plasmid) with subsequent chilling on
ice. 4ul of the unlabelled nucleotide solutions (dTTP, dATP, dGTP) provided with the
kit were added on ice followed by 5ul of reaction buffer (Tris HC1 pH 7.8, 50mM
MgCl2, lOOmM 2-mercaptoethanol), 5ul of DNA oligo-nucleotide primer solution
(aqueous random hexa-nucleotides with nuclease-free BSA), 50 uCi 32p dCTP and
1-2 units of the 'Klenow' fragment of DNA polymerase 1 (in 50mM KPO4 pH 6.5,
lOmM 2-mercaptoethanol, 50% glycerol). After gentle mixing, the reaction mixture
was incubated at 370C for 30mins and the amount of incorporation of the 32p
labelled dCTP into the probe DNA measured by Cerenkov counting, lul of the
reaction solution was transferred to a Whatman GF/C glass fibre filter disc. The
disintegrations from the radio-isotope were measured in a scintillation counter as
counts per minute (cpm). The disc was then washed with 5% TCA to precipitate the
probe DNA and remove any unincorporated radiolabeled nucleotide. The
scintillation count was repeated and the percentage and absolute incorporation of
the radio-isotope calculated. Incorporation of more than 40% of the radio-isotope
was accepted and labelling of the probe to a specific activity was in the range 0.5-
2x109 cpm/ug of probe DNA.
Unincorporated radiolabeled nucleotide was removed from the radiolabeled
probe solution to reduce non-specific background 'noise' signal during
autoradiography. 200ug of sonicated salmon sperm DNA (to act as a carrier) and
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l/10th vol (ie 7ul) of 3M NaCOOH, pH 5.2 with 2.5vols ethanol were added to
precipitate the radio-labelled DNA probe. The solution was vortexed and the probe
pelletted by centrifugation in a microcentrifuge at 12000rpm for 5mins. The
supernatant was discarded, 500ul of sonicated salmon sperm DNA (lOmg/ml) added
to the pellet in the microcentrifuge tube and the solution heated to 95-100°C for
12mins to denature probe and salmon sperm DNA. The salmon sperm DNA blocks
non-specific hybridisation of the probe DNA to sequences which are not uniquely
human. The solution was then kept on ice prior to hybridisation to the genomic
DNA digests on the nylon filter.
2,6.4 DNA hybridisation and autoradiography.
Prehybridisation and hybridisation of the digested genomic DNA on the nylon
filters was carried out in double sealed polythene bags. The filters were
prehybridised for 2-3hours in 25ml of the hybridisation solution (6X SSC, 5X
Denhardt's solution: [1% Ficoll/1% polyvinylpyrrolidone/1% BSA], 0.5% SDS, 10%
dextran sulphate) at 65°C, agitated in a water-bath. The radiolabeled DNA probe
solution containing salmon sperm DNA was added to 2-3ml of hybridisation solution
and mixed in a fresh 10ml tube to reduce the concentration of the radio-isotope at
the point of insertion into the bag. This solution was then added to the
hybridisation bag through a small hole and the bag resealed, avoiding entry of air
bubbles. The hybridisation was carried out at 65°C overnight. For probes with a
high content of repeat sequences such as MLZ 7.5 or MC5.61 (see description of
probes), the stringency of the hybridisation was increased by carrying out the
hybridisation at 69°C and with pre-annealing of the probe DNA to denatured
sonicated total human DNA (5ug/ng of probe DNA).
After hybridisation, 2 x 5min low stringency washes (2X SSC, 0.1% SDS)
were carried out followed by 2 x 5min high stringency washes (0. IX SSC, 0.1%
SDS), all at 65°C The probed membrane was partially air dried and wrapped in
cling film, DNA side up, with a 3mm Whatman paper backing prior to
autoradiography.
The cling film wrapped membrane was then placed in direct contact with
Kodak XAR film in a standard X-ray cassette for 24-48 hours at -70°C. The film
was developed to reveal the hybridisation of the radiolabelled probe. If the signal
was poor, the exposure was repeated and the X-ray film developed after 1-2 weeks.
54
2.7 DNA probes.
All DNA probes used in this project were kindly donated by workers who had
cloned the markers as random DNA clones or were obtained through my
collaboration with Dr Y Nakamura as part of work towards cloning the APC gene
itself. The markers used in this project consist of DNA probe fragments which
recognise natural polymorphisms at flanking restriction endonuclease cleavage sites
and are known as restriction fragment length polymorphism (RFLP) markers.
2.7,1 Probe plasmid preparation.
All DNA marker probes were received as whole plasmid constructs and so
there was no need for any ligation procedures to introduce insert into the vector.
Plasmids were expanded to generate stock supplies in quantities sufficient for
experimental work. The probe insert, incorporated into an appropriate plasmid
vector, was introduced into E. Coli by standard techniques (Maniatis 1989), modified
to the routine method used at the MRC Human Genetics Unit.
Stocks of E. Coli (strain JM83) rendered competent (receptive to the
introduction of extraneous DNA) by a calcium chloride method (Maniatis 1989) are
held at the MRC Human Genetics Unit. Around 1x108 of these bacteria were
transformed with approximately 25ng of whole plasmid by the following method.
Plasmid solution was added to the bacteria, left on ice for 30 minutes, heat shocked
at 420C for 90 seconds and then put back in ice for 2 minutes. 800ul of L-broth
with Mg2+ and 0.2% glucose were added and shaken at 370C for 1 hour. A control
of lOng/ul of Bluescribe plasmid was treated in the same manner to assess the
transformation efficiency. 50ul and 200ul of the culture medium was plated with a
sterile glass spreader onto H Amp+Xgal plates (H agar, 50ug/ml ampicillin, 40ul of
20mg/ml Xgal per 20ml of agar) for pUC plasmid vectors and H Amp plates (without
Xgal) for pBR322 vectors. The same volumes of lOng/ul of the Bluescribe-
transformed control bacteria were spread onto H Amp+Xgal plates. The plates were
incubated upside down at 37°C overnight. Single colonies of bacteria which had
undergone the characteristic blue-white colour change (implying both that
transformation was successful and also that the transfected plasmid contained
insert, since the expressed plasmid galactosidase gene is disrupted by the
recombination of probe DNA insert into the polylinker cloning site of the pUC vector)
were picked. These colonies were grown up in 500mls of T-Broth with 50mls of
stock KH2PO4 at 370c in the orbital incubator in order to provide bulk quantities of
the cloned marker DNA fragment. All bacterial protein and DNA were removed and
plasmid DNA purified by the following method.
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The culture medium with the transformed bacteria was aliquoted into large
tubes and carefully balanced before spinning at 6000rpm in a Sorval ultracentrifuge
for 5 minutes to pellet the bacteria. The pellet was resuspended in 20mls GTE (1%
of a 50mM solution of glucose, 25mM Tris pH8, 50mM EDTA) with lOmg/ml
lysozyme and 40ml of alkaline SDS (1% SDS, 0.2M NaOH). The DNA in solution at
this point comprised bacterial and probe DNA. The bulk of the bacterial DNA
content was then removed by differential precipitation and centrifugation. 30mls of
high salt (3M KCOOH pH 4.8 with acetic acid) was added and left on ice for 30
minutes, then spun at 12,000rpm for 30 minutes. The supernatant was strained
through muslin and 0.6 volume of isopropanol added and left at room temperature
for 5 minutes, before a further spin at 8,000rpm for 15 minutes. The resultant DNA
pellet comprising plasmid and insert was then washed with 70% ethanol and air
dried. The pellet was then dissolved in around 2mls ofTE and the final purification
steps involved ultra-centrifugation at 40,000rpm for 20 hours on a CsCl gradient
(3.55g CsCl in 3.21ml + 0.34ml ethidium bromide lOmg/ml in a 5ml centrifuge
tube). The plasmid band could then be visualised under UV light and removed by
pushing a needle and syringe through the side of the plastic centrifuge tube at the
level of the plasmid band and aspirating. The plasmid solution in CsCl was made
up to 25ml in TE, taken up to 50ml with butan-l-ol and repeatedly extracted with
butan-l-ol to remove the ethidium bromide. In order to remove CsCl from the
plasmid preparation, the plasmid DNA was precipitated from the solution by adding
2 volumes of 70% ethanol at -70°C for 30 minutes then warming to 370C and
subsequently pelleting the DNA by spinning at 10,000rpm for 15 minutes. The
pellet was redissolved in 1ml of TE and reprecipitated with 0.1vol. 3M NaOAc and
2.5 vols EtOH. The precipitated DNA was pelleted by centrifuge at 10,000 for 15
minutes. The DNA was taken up in TE, optical density measured to assess
concentration and an aliquot run out on a mini agarose gel as a rough check of
concentration and to assess the degree of ENA contamination. The preparations
usually required removal of RNA by treatment with RNAase. A phenol chloroform
extraction and salt reprecipitation was then carried out to remove excess RNAase
enzyme.
The probe insert alone was used for PFGE studies and this was prepared by
cutting the whole plasmid with the appropriate restriction enzyme to remove the
insert from the polylinker plasmid cloning cartridge and fractionating on a mini
agarose gel. Uncut probe, cut probe and a size marker (eg EcoRl/Hindlll double-
digested lambda phage DNA) were run out on an Ultra-pure Low Melting Point
agarose g.el, ethidium bromide stained at 5ug/ml and the probe insert band
physically excised from the gel with a scalpel under UV light. The fragment of gel
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with insert was then melted and stored in separate aliquots in Eppendorf vials in
quantities suitable for a single radio-labelling by random priming as described in
section 2.6.3.
The identity of each probe was confirmed by demonstration that the DNA
probe insert was the appropriate size on a test mini gel according to details obtained
from the worker who originally cloned the probe. The RFLP alleles generated were
also checked to ensure that they were the appropriate sizes according to published
probe data.
2,7,2 Description of DNA probes.
Details of insert size, locus recognised, cloning vector, restriction enzyme
used to generate original cloned fragment (if different from vector cloning site), and
original reference pertaining to each probe are shown in Table 2.1. C11P11 was
originally from P. Scambler of St. Maiy's Medical School, London. Probes pL5.62
and pEF5.44 were kindly donated by Y. Nakamura with whom I collaborated on the
linkage mapping aspect of this project. These probes are subclones from a genomic
cosmid library generated from a mouse-human hybrid with a portion of chromosome
5q as the only human component. Generation of the cosmid libraiy, RFLP screening
and sub-cloning into plasmid vector was carried out by Y. Nakamura and his group
using a strategy similar to that previously reported (Nakamura 1988a).
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Probe and restriction enzyme combination recognising each polymorphic
locus are shown in Table 2.2. The sizes of each possible DNA fragment generated for
each polymorphic locus are shown. Published allele frequencies are shown for each
RFLP and are documented in the relevant reference. However, as linkage analysis
require knowledge of local allele frequencies, the results of a series of experiments to
ascertain allele frequencies in a Scottish population are presented in Chapter 4
(Table 4.1).
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Table 2.2 Polymorphism(s) recognised by each probe and references to original
reports elucidating RFLP data.
Probe Enzyme Allele Reference
recognising sizes (kb) frequency
polymorphism
X MS8 Multiple but Multiple 90% Wong 1987
Hinfl used (2.4-9.5) heterozygosity
MC5.61 Mspl 5.5/5.0 0.49/0.51 Nakamura 1988a
YN5.48 Mspl 9.0/8.0 0.51/0.49 Nakamura 1988a
EF5.44 Mspl 2.9/2.1 No published data
L5.62 BglH 9.0/5.5 No published data
ECB27 BglH 11.9/10.5 0.38/0.62 Varesco 1989
C11P11 Taql 4.4/3.9 0.08/0.92 Bodmer 1987
0.17/0.83 Leppert 1987
0.11/0.89 Meera Khan 1988
pi227 Pstl 4.3/3.0 0.16/0.84 Stewart 1987
it Bell 3.0/1.8/1.2 0.2/0.37/0.43 and
.. BstXl 2.7/2.3 0.3/0.7 Meera Khan 1988
ti Mbol 0.55/0.45 0.44/0.56
105-798Rb Mspl 2.3/1.8 0.57/0.43 Leppert 1987
105-153Ra Mspl 8.0/5.0 0.4/0.6 Leppert 1987
105-599Ha Taql 17.0/14.0/10.00.32/0.16/0.52 Leppert 1987
MLZ7.5 EcoRl 2.9/2.2 0.49/0.51 Leppert 1987
LI.4 EcoRl Pearson 1984
YNZ22 Multiple, but >10 alleles 86% Nakamura 1987
Taql used (1.3-10) heterozygosity
29C1 Multiple, but >10 alleles hypervariable Cooke 1985
Taql used (0.5-8.0)
2.8 Genetic linkage analysis.
The general concept of genetic linkage and linkage analysis are discussed
briefly in this section. Further introductory explanations are given by Emery and
Ott (Emery 1986, Ott 1986).
With regard to human diseases, genetic linkage analysis in its simplest form
tests the degree to which a marker genetic trait (clinical, biochemical, cytogenetic or
DNA polymorphism) and a disease are co-inherited, or exhibit genetic linkage. If
there is complete non-linkage, such as might occur between a disease and a marker
locus which are located on different chromosomes, then one might expect totally
random inheritance of the disease and marker traits with no evidence of co-
inheritance. There can also be incomplete co-inheritance of a disease and a marker
trait, even when they have been shown to be close to each other using physical
methods. This incomplete co-inheritance implies crossing-over (recombination)
between the two loci. Such recombinations occur throughout the genome at the
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time of meiosis and, although there are known to be recombination hot-spots, they
are considered to occur randomly for the purposes of genetic linkage analysis. The
proportion of such recombinant meioses out of all meioses studied is known as the
recombination fraction and is a function of the genetic distance between the disease
and the marker gene loci. The most widely used method of genetic linkage analysis
is the maximum likelihood, or lod score, method. The odds ratio (expressed as logio
of the odds for linkage or log of the odds, acronym - lod score) that the observed data
represent linked loci, as against chance, can be assessed by the equation
zmax(©)=logio[©wU-©)x/(0.5)y for phase-known, fully informative loci; Zmax(0)=
peak lod -score achieved out of all recombination fractions (0) calculated; w =
recombinant meioses, x = non-recombinant meioses and y = all meioses studied.
The larger the lod score, the more faith one can have that the observed deviation
from chance does indeed represent genetic linkage. The probability that loci are
linked can be assessed for a given set of observations at all recombination fractions
from 0.00 (completely linked) to 0.50 (unlinked). Generally, linkage is considered
established when Zmax(©) achieves a lod score of 3.0 or greater. This corresponds
to a ratio of the odds that the loci are linked to the odds on non-linkage of around
1:1000 chance at that recombination fraction. In some situations it is possible to
use this equation to calculate lod scores by hand but because of confounding factors
such as missing genotype data on some family members and reduced penetrance,
most linkage analyses require a computer program as detailed below.
For a disease and a marker locus of unknown map locations, the
recombination fraction at which the Zmax occurs provides a measure of the genetic
distance between the two loci. There are mapping equations which calculate genetic
distance (measured in centi-Morgans) from recombination fraction but in general,
up to a recombination fraction (Zmax) of 25%, it is sufficiently accurate simply to
convert the Zmax to centi-Morgans. Thus a peak lod score achieved at a
recombination fraction of 5% corresponds to 5 centi-Morgans (or around 5
megabases of DNA). Clearly the more observations that are made for those two loci,
the higher will be the peak lod-score, the narrower will be the 95% confidence
(probability) limits and so the more certain will be the mapping data. Calculation of
the 95% probability limits involves summing the area under the graph delineated by
the lod score curve. 95% of this area is then calculated and applied to the graph,
equally distributed about the peak lod-score and the 95% limits on the axis are then
read off. An easier method, which approximates quite accurately to the 95%
probability limits, is to reduce the peak lod-score by 1 unit and then read off the
recombination fraction on the axis which corresponds to this lod-score above and
below the recombination fraction at which the Zmax occurs. Thus genetic linkage
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analysis allows the construction of a map of any given region based on the
estimation of genetic distance between loci and also gives an assessment of the
confidence with which that localisation fits the available data.
2.8.1 Recombinant mapping.
Genotypes for 6 probes (pi227, C11P11, ECB27, L5.62, EF5.44 and YN5.48;
see Tables 2.1 and 2.2) were obtained and used to construct 7-locus haplotypes
(including APQ for all family members. This facilitated the identification of
recombinant events both between marker and disease loci and also in intervals
between marker loci which also included recombinations between marker loci. Due
to the number of markers studied, a number of recombinations were informative at
multiple loci and so by analysing the grouping of these markers around the
recombination event, it was possible to order some of the loci unequivocally into a
recombinant map.
2.8.2 Linkage analysis.
Linkage analysis for the mapping study (presented in Chapter 4) was carried
out using the MLINK package in the LINKAGE 4.7 group of programs (Lathrop 1985)
on an Atari IBM-compatible desk-top microcomputer. No discrepancies in
frequencies of recombinations between male and female have been observed (Leppert
1987, Meera-Khan 1988) and so the linkage analyses described here combine male
and female data. The 1-lod unit of support was taken as representative of 95%
probability limits. Multi-point linkage analysis was not felt to be valid for this study
since only affected families were analysed, without CEPH (Centre Etude de
Polymorphisme Humaine) data. Instead, the data are presented as a series of pair-
wise analyses between marker and disease loci and between all pairs ofmarker loci.
Linkage analyses for risk estimations were carried out towards the end of the project
when a more powerful computer and a new version of LINKAGE were available. Risk
estimations were calculated using multipoint linkage analysis with the MLINK
program in LINKAGE 5.02 on an IBM Series 70 80386 computer with a math
coprocessor.
Paternity testing was inherent in the multiple two-point analyses which were
carried out as part of experimental work and any discrepancies would have revealed
the possibility of non-paternity. In addition, all family members were genotyped for
the hypervariable chromosome 17 probe YNZ22 (Nakamura 1987). All APC-marker
obligate recombinants were also tested with the probe 29C1 which recognises a
pseudoautosomal hypervariable sex chromosome polymorphism (Cooke 1985). Both
of these probes are extremely useful for paternity testing since they have a high
frequency of heterozygosity, producing multi-allelic systems and individuals can be
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typed using standard Southern blot analysis. The probe 29C1 is extremely useful
for paternity testing as Cooke found no two individuals out of 83 studied had the
same genotype.
2.9 Allele loss analysis.
The polymorphic DNA fragments revealed by marker probes are derived from
maternally and paternally inherited chromosomes. Loss of one of these alleles has
been taken in the past to indicate loss of that whole chromosome, or at least a whole
chromosome arm. However, intuitively this is incorrect and, as has been shown for
chromosome 17p allele losses in colorectal cancer (Baker 1989), this assumption is
not always, or even usually, a valid one. Allele loss simply implies an alteration at
the probed locus and this can be due to deletion of a portion of DNA which includes
the probed locus or whole chromosome loss. The remaining allele may or may not
be reduplicated by non-disjunction or mitotic recombination. Reduplication of the
remaining allele would be better termed acquired homozygosity. For the purposes of
simplicity in this thesis, allele loss is considered a generic term encompassing all of
these mechanisms. As discussed in Chapter 1, a high frequency of allele loss in
tumour tissue with any given probe may imply inactivation of a tumour suppressor
gene located close to the probed locus.
2,9.1 Assessment of allele loss at polymorphic loci.
The relative intensities of the bands revealed after hybridization of p32
labelled probe were compared in blood and/or normal colonic mucosa versus
tumour tissue. Initially 2 controls were used comprising leukocyte DNA and normal
colonic mucosa but when no allele losses were detected in colonic mucosa at any of
the 13 loci tested, this policy was abandoned and only blood leukocyte DNA was
used as control for the latter part of the study.
Loss of heterozygosity at probed loci was established when there was absence
or marked diminution of one of the fragments revealed in the control tissue by probe
DNA hybridisation. Initially an attempt was made to quantitate the intensity of
alleles using laser densitometry. However, an empirical level of reduction in
intensity had to be set which was no improvement on simply comparing allele
intensities visually. The potential for mis-classifying the allele loss status of a
tumour is due to the presence of small amounts of residual normal tissue and
lymphocytes which reflect the host's constitutional heterozygosity. Only one
published allele loss study has employed laser densitometry (Solomon 1987), all
others have also relied on an element of subjective assessment of the relative allele
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intensities.. Accordingly, the results on allele loss assessment presented in Chapters
5 and 6 are based on visual assessment of allele loss status at each locus. In the
vast majority of cases, recognition of allele loss was unambiguous but in those cases
where there was some doubt, an independent assessment was obtained. If no
agreement could be reached, then the tumour was classed as not informative at that
locus. I am grateful to Dr. CM Steel for his assessment of these autorads.
2.9.2 Deletion manning.
The central strategy of the analysis of colorectal tumours employed in this
thesis is the construction of a high resolution genetic linkage map around the APC
gene and then assessment of allele loss status at each of these loci and a further 6
previously mapped loci. This has allowed the delineation of the nature, extent and
specificity for APC of any losses demonstrated. Allele losses can only be identified if
the host is constitutionally heterozygous at the probed locus. Not all tumours are
informative at every locus and hence precise mapping of the ends of deletions is not
always possible. Therefore allele loss analysis indicates the maximum size of the
deletion in any given cancer, although the lesion could be substantially smaller.
2.10 Pulse field gel electrophoresis (PFGE).
Digestion with restriction endonucleases which cut DNA only very
infrequently due to the rarity of their recognition sites allows the generation of large
DNA fragments. The fragments are so large as to require support to prevent non¬
specific shearing. This is achieved by performing cell lysis, DNA purification,
restriction endonuclease digestion and loading of the high molecular weight DNA
into the gel apparatus with the cells being analysed embedded in agarose
throughout. Resolution of such large fragments of DNA requires a special gel
electrophoresis apparatus which relies on a two dimensional electric field to
separate fragments. The electric field is pulsed in one direction and then the other
alternately to give the desired resolution depending on the duration of the pulse.
2,10,1 Embedding high molecular weight DNA in soft agarose plugs.
Cells used for pulse field gel electrophoresis were either EBV-transformed cell
lines or lymphocytes separated from fresh blood by ficoll hypaque. In each case,
cells were harvested and washed in phosphate buffered saline (PBS), counted and
resuspended in PBS at 2.0xl07 cells /ml of PBS. An equal volume of molten, 1%
ultra-pure low melting point agarose in PBS was then added and aliquoted into a
mould designed for the PFGE apparatus. The plugs set at 40C and then pushed out
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of the mould into 20 ml NDS(0.5M EDTA, 1% lauryl sarcosine, lOmM Tris pH 9.5).
lOmg proteinase K was added to the NDS and plugs and Incubated at 55°C for 48
hrs, with a complete change of solution and enzyme at 24hrs. The plugs were then
stored for later use at 40C in fresh NDS.
2.10.2 Digestion of DNA in plugs with restriction endonuclease.
It is important to remove all residual proteinase K from the agarose plugs to
avoid digestion of the restriction endonuclease. Therefore, each plug was incubated
at 50°C for 30 mins. in 5ml TE (lOmM Tris, 0.5mM EDTA, pH7.8) with the powerful
protease inhibitor, phenylmethyl sulfonyl fluoride (PMSF) (5ul of a freshly made
solution at 20mg/ml in isopropanol). This was repeated with fresh TE and PMSF
and then incubated at 50°C for a further 30 mins. The plugs were then washed
twice in fresh 5ml TE at 40C for 30mins and then twice at 40C for 30mins in 1ml of
the manufacturers restriction buffer for the appropriate restriction enzyme. lOOul of
fresh restriction buffer, 5mM spermidine, 0.01% triton X and then 15 units of
restriction endonuclease were added to the plug and incubated overnight.
2.10.3 PFGE and DNA transfer.
The digested DNA was size-fractionated by gel electrophoresis. Conventional
unidirectional electrophoresis is not capable of resolution of DNA fragments over
30kb or so whereas 2 megabase fragments can be resolved by PFGE. The
equipment used in this study was the CHEF-DR II (Bio-Rad Laboratories). Other
equipment for PFGE consisted of the CHEF-DR II drive module, a Pulsewave 760
Switcher, a pump for circulating the buffer and a Model 200/2.0 Power Supply, all
from Bio-Rad Laboratories. A Maxi-cool Varitemp liquid cooler (IMI Cornelius UK)
was used to cool the circulated electrophoresis buffer.
Gels used for all experiments were 1% agarose gels in 0.5xTBE (Tris Borate
EDTA buffer). The gel was cast in the mould provided with the electrophoresis
equipment. The digested DNA samples in the plugs were then carefully transferred
into the wells of the gel. A little molten agarose was then used to seal the plugs in
the wells. Marker yeast chromosomes were added to at least one of the wells
(Sacromyces cerevisiae, strain YP148). Gel electrophoresis was carried out in
0.5xTBE at 140C and the conditions for each experiment are stated in the results
section. In general the longer the pulse time, the larger the fragments resolved.
After electrophoresis, the gel was stained with ethidium bromide (0.5ug/ml of
0.5xTBE buffer) for 1 hour and then destained for 30 mins. in distilled water. After
photography under ultra-violet light, the DNA in the gel was depurinated in 0.25M
HC1 for 30 mins., exposure to standard denaturing solution was for 50 mins. and
64
neutralising solution for 1 hour. The gel was then transferred to a nylon filter
(Hybond-N, Amersham International) by standard Southern blot using 20xSSC, with
a blotting time of at least 48 hours.
2,10,4 DNA hybridisation and autoradiography after PFGE.
Once immobilised on the nylon membrane, large DNA fragments separated
by PFGE can be dealt with in the same manner as DNA fractionated by conventional
electrophoresis. However, there are sequences in some of the marker yeast
chromosomes homologous to PBR322 sequences which cross-hybridize to sequences
in many plasmids. Such hybridisation produces very dense signals on
autoradiography such as to interfere with the signals from the sequences
homologous to the probe DNA. Therefore, probe insert alone, without any vector
DNA sequences, was used in all PFGE hybridisation experiments. Autoradiography
and development were carried out as described before in section 2.6.4.
2.11 Flow cytometry.
An attempt was made to analyse all sporadic colorectal cancers and
adenomas by flow cytometry, in addition to a representative sample of 4 FAP
adenomas. Although there was no problem with FAP adenomas, results from
around 30% of the sporadic tumours were unsatisfactory. The reason for this was
that there' was a time period from the initial collection and DNA extraction until
resampling for flow cytometry. There was evidence of tissue degradation over that
time, thought to be due to a freezer thaw.
Flow cytometric analysis of the tumours collected for this project was carried
entirely by Dr. CA Purdie of Edinburgh University Pathology Department. The
method used was as follows: Portions of frozen tumour were thawed and prepared
into suspensions of single nuclei by a detergent-trypsin method (Vindelov 1983).
Chicken red blood cells served as internal controls, producing a peak equivalent to
around 35% of normal human diploid DNA content. Nuclei were stained with 0.62M
propidium iodide and analysed in a Coulter Epics CS flow cytometer at a wavelength
of 488nm. Aneuploidy was considered present when two distinct Go/Gi peaks were
visible and a DNA index calculated for each tumour (1.0 being diploid).
2.12 Pathology assessment.
Pathological assessment of all sporadic tumours was carried out at the
Pathology Department of the Western General Hospital in the same manner as for
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routine specimens. The sampling and macroscopic assessment of the fresh
specimen was the only variation from routine practice in the department. As
discussed in section 2.2.3, tumour samples for DNA analysis were taken adjacent to





A number of family members from the 11 families which comprise the study
population (KMD 1-6, 8, 10, 11, 14, 16) required clinical screening for FAP. Clinical
screening of at-risk individuals was an important integral part of this thesis and
ensured that the affectation status of all family members was both accurate and up
to date. Confirmation of the accuracy of diagnosis became a major part of this work
as a number of individuals had been reassured that they were not affected and
discharged from follow-up but were actually affected. In two cases of such mis-
classification, the gene defect had also been passed on to the next generation. The
identification of a number of gene carriers who required prophylactic colectomy also
facilitated the collection of adenomas from patients with FAP which tend to be
encountered only rarely in routine surgical practice. An assessment has also been
made of the frequency of extra-colonic stigmata of FAP in the study group. In
addition to clinical screening, cytogenetic analysis was carried out on at least one
affected member from each family in a search for a translocation which might be the
key to cloning the APC gene itself and results of cytogenetic analysis are presented
here.
3.2 Methods
At-risk family members were defined as the offspring of gene carriers. The
age limit for classification as at-risk was 0-60 years and all such individuals were
offered screening by rigid sigmoidoscopy as recommended by Bulow (Bulow 1987).
Colonoscopy was carried out in a number of cases as was the routine practice of the
consultant in charge of those patients. In all but a very few cases, I was personally
involved in the clinical surveillance of the colon and rectum. Barium enema was
also carried out in some patients at the request of the consultant in charge. All
polyps were biopsied for histological confirmation of their adenomatous nature.
Two independent observers carried out retinal examination after mydriasis
with 0.5% Tropicamide using direct and indirect ophthalmoscopy. Those with 3 or
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more and/or bilateral CHRPE lesions were classified as CHRPE +ve as recommended
by Chapman (Chapman 1989).
A number of affected family members were screened for the presence of
mandibular osteomas by orthopantomography (OPG). The presence of an osteoma
was confirmed by a radiologist who was unaware of the diagnosis. These lesion were
defined as circumscribed homogeneously radio-opaque areas with no surrounding
radio-lucent zone. All patients were examined clinically for such tumours and any
with palpable lesions were invited for radiography. Children were not subjected to
OPG as it would not have affected their clinical management and would therefore
have meant subjecting them to unnecessary radiation.
Karyotypes were prepared and analysed from the peripheral blood
lymphocytes of at least one affected member of each family.
3.3 Results
There were 38 previously diagnosed affected patients surviving in the 11
kindreds under study. The total number of affected individuals increases to 57
when cases are included who were designated as gene carriers on the basis of
positive screening for polyps, CHRPE or osteomas carried out as part of this project.
The overall numbers of at-risk family members screened and the new cases detected
by each of the screening modalities are shown in Table 3.1. The number of new
cases identified emphasises the importance of a clinician with a special interest in
this disorder in avoiding mis-classification of gene carriers who might be discharged
prematurely from screening. Registration of FAP families with a local clinical
genetics department and, preferably, the setting up of a regional/national Polyposis
register is vital.
Table 3.1 Overall numbers of at-risk family members screened and detection of
gene carriers in the study population by each screening modality.
Total screened (any modality) 71
Number previously screened 15
New cases identified by:
Any screening modality 19
Colonic examination showing adenomas 8
Retinal examination showing CHRPE 9
Presence of gross osteomas 2
3.3.1 Screening of the colon.
There were 50 individuals screened for colonic lesions including 5 patients
who had undergone previous sub-total colectomy and ileo-rectal anastomosis who
required surveillance of the retained rectum. One of those patients has
subsequently required excision of the retained rectum due to excessive rectal polyp
growth. Two probands (KMD 10/2-3, KMD 11/3-7) appeared to be new, sporadic
cases of FAP and so 8 first degree relatives from KMD 10 and 12 from KMD 11 were
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screened to ensure that the probands from these families (3-7 and 2-3 respectively)
were indeed new mutations for FAP.
Ten patients were shown to have colorectal polyposis during the study period
and the age range was 18-38 years. Two of these were patients who had been
previously diagnosed as affected with only limited numbers of small polyps and had
opted to undergo repeated colonic examination initially in order to postpone surgery.
The remaining 8 cases were new diagnoses. In 4 cases the patients had previously
been screened negative (KMD 2/3-4, KMD 2/3-6, KMD 8/4-4 and KMD 1/5-7; at
ages 27, 23, 22 and 18 respectively), reassured that all was well and discharged
from follow-up and in 3 of these cases the patients had offspring who also required
screening. In the 4 remaining cases screening had never been carried out (current
ages 18, 19, 23 and 25).
Eight of the ten patients diagnosed during the study period have now
undergone prophylactic colectomy (1 proctocolectomy at the patient's request, 1
total colectomy and ileal pouch and 6 sub-total colectomy with ileorectal
anastomosis). Adenomas harvested from 4 of these cases were used for the
assessment of allele losses as presented in Chapter 6. The remainder have been
stored for further analysis when the APC gene itself is cloned. Polyps detected
during this screening program were small sessile lesions with the largest
encountered only 1.5cm in diameter. The polyp from this patient (KMD 1/5-7) was
in the caecum and showed very dysplastic appearances amounting to carcinoma in
situ (see Figure 3.Id). The typical macroscopic appearances of polyps detected in
this patient population is shown in Figure 3.1 (from patient KMD 1/5-17). Some of
the adenomas were extremely small and amounted to monocryptal neoplastic
changes (Figure 3.1c)).
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Fig. 3.1 a. Macroscopic appearance of the mucosal surface of the sigmoid
colon of a colectomy specimen from patient KMD 1/5-17 showing
small, flat, sessile polyps typical of the FAP adenomas occurring in
this patient population.
b. Histological features of one of the polyps from patient KMD 1/5-17.
c. Monocryptal adenoma from patient KMD2/2-6.
d. Histological features of a 1.5cm flat caecal adenoma from





Thirty patients were screened negative for the presence of colonic polyps (age
range 14-64). This total includes the parents and siblings of the sporadic cases of
FAP (KMD 11/3-7 and KMD 10/2-£), who can all be reassured that they are not
affected and that they cannot have passed on the defective gene. The remaining
family members have all been assigned residual risk estimations as detailed in
Chapter 8 and the requirement for further follow-up will henceforth be tailored to
that risk. The continued commitment to those individuals still requiring screening
has been passed on to a local surgeon with an interest in colorectal disease or back
to the original consultant in charge.
3.3.2 Retinal screening
Retinal examinations were carried out on a total of 54 family members. The
numbers of individuals screened and the findings for each group classified by
disease status is shown in Table 3.2. Seventy-four percent of the affected
individuals had eye lesions and a further 2 affected individuals had less than 3
CHRPE lesions and hence are classified as CHRPE -ve. Five of the CHRPE -ve gene
carriers came from one family (KMD 8) in which the CHRPE phenotype only affects
one APC gene carrier. The remaining CHRPE -ve gene carrier was a sporadic case of
FAP (KMD 10/2-1). None of her children have eye lesions and they are too young for
colonic screening.
Table 3.2 Retinal screening for FAP in 54 family members comprising gene
carriers (as shown by the presence of colonic polyps), non-gene
carriers and adults who had never been screened or children under
the age for colonic screening (uncertain phenotype).
Disease status Total CHRPE
+ve -ve
Gene carriers 23 17(74%) 6(26%)
Non-gene carriers 13 0(0%) 13(100%)
Uncertain phenotype 18 9(50%) 9(50%)
Total screened 54 26(48%) 28(52%)
The youngest child examined was 3 years of age and an excellent view was
obtained with no CHRPE lesions present. The youngest child shown to have CHRPE
lesions was 4 years old and so the lesions certainly appear to arise prior to the
development of polyps and may well be congenital. Eight children and one adult
who has refused colonic examination or treatment were diagnosed as being affected
solely on the presence of typical CHRPE lesions. There were 2 cases where the eyes
lesions were present in unaffected individual but these were a solitary unilateral
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lesion in one case and 2 lesions in one eye in another. There were 13 individuals
who were negative for both retinal and colorectal lesions. Overall the data presented
here suggest that if one affected family member exhibits CHRPE lesions then for the
rest of that family colonic polyps and eye lesions appear to be co-inherited as part of
the FAP phenotype. The presence of CHRPE lesions in a child under the age for
colonic screening indicates the inheritance of the mutant APC allele. Although the
overall penetrance of CHRPE is 74%, for families with CHRPE as part of the FAP
phenotype the penetrance is 100%.
Typical examples of the various appearances of CHRPE lesions are shown for
family KMD 3 in Figure 3.2 and demonstrate the co-inheritance of retinal and
colonic stigmata of FAP. Patient KMD 3/1-1 shows an area of pigmentation and
depigmentation, KMD 3/2-1 shows a densely pigmented lesion, KMD 3/2-3 shows a
pigmented lesion with a halo of depigmentation (not well seen in the print) and KMD
3/3-1 had several of these large (up to 3 disc diameters) pigmented lesions. A




Pedigree KMD 3 showing co-inheritance of colonic polyps and CHRPE lesions in
two generations. Both children in the youngest generation have inherited the
gene mutation since they have CHRPE lesions, although they are below the age
where colonic screening is required.
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3.3.3 Screening for osteomas and epidermoid cysts.
A total of 15 patients with FAP were assessed for the presence of cranio-facial
osteomas. Nine patients (60%) had one or more lesions of the cranium or the
mandible. Four patients had lesions in the mandible with an average of 2.5
tumours (range 1-6). In two cases the tumours were symptomatic, with pain and
tenderness at the angle of the mandible. Figure 3.3 shows an example of large
symptomatic bilateral mandibular osteomas (from patient KMD 11/3-7 ).
Figure 3.3 Example of 1cm bilateral osteomas at the angle of the mandible (from
patient KMD 11/3-11).
Osteomas of the cranial vault occurred in 5 cases. No patients had both
mandibular and cranial osteomas. However, it is notable that cranial and
mandibular osteomas affected different individuals within the same family and so
the particular gene mutation causing the disease in any given family does not
appear to have a direct influence on the site of osteoma formation. Two at-risk
children (KMD 8/4-5 and 4-6) under the age requiring colonic screening had such
gross cranial osteomas as to allow a confident clinical diagnosis of FAP before
puberty and this is confirmed on DNA analysis as shown in Chapter 8.
In addition to the presence of osteomas, an assessment was made for the
presence of other extra-colonic features of FAP. Of the 46 surviving patients
designated as obligate gene carriers on the basis of having colonic adenomas, only
one patient (2%) had desmoid disease out of the 11 families studied. While it is
difficult to test for the presence of desmoid disease, it is unlikely that any of these
lesions would be missed since the diagnosis is usually made early in the course of
tumour growth (Bulow 1987).
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I was able to carry out a thorough examination of the skin to determine the
presence or absence of epidermoid cysts in 22 affected family members and these
lesions were present or had been previously removed from 6 patients (22%). They
were mostly multiple about the head and face but frequently had occurred as
solitary lesions before puberty.
3.3.4 Cytogenetic analysis.
The results of cytogenetic analysis were disappointing but predictable since
karyotypic abnormalities associated with FAP have been reported in only 3 patients
from two families in the world literature to date (Herrera 1986, Hockey 1989). In
this study, there were no karyotypic abnormalities which could be substantiated.
One karyotype from a sporadic case appeared to show a small interstitial deletion in
the region 5q21-22 which was present in more than 40% of cells examined (Figure
3.4). However this apparent small deletion was due to artifact since the patient was
re-sampled and a new spread carried out which showed a completely normal
karyotype (Figure 3.5). Cytogenetics was an integral part of this project but
unfortunately has not provided useful data.
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Figure 3.4 Provisional karyotype from an affected individual in whom the FAP
syndrome arises as a result of a new APC mutation (KMD 10/2-^).
The arrow indicates what initially appeared to be an interstitial
deletion but which was not confirmed by repeat analysis.
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Figure 3.5 Karyotype of the individual shown in Figure 3.4 after re-sampling and
re-preparation of the chromosome spread, showing two completely
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3.4 Discussion
The success of this project should not only be measured in terms of
academic advances in the understanding of FAP and colorectal cancer, but also in
terms of the number of patients who have been identified as gene carriers and have
now undergone successful prophylactic treatment, but who would never have been
screened otherwise. A number of these patients had been unjustifiably reassured
that they were unaffected and one of these patients had carcinoma in situ in the
resected specimen. There can be little doubt that a number of these patients would
have developed an invasive carcinoma without appropriate treatment. The reason
for this success in prophylaxis is solely due to a particular interest on the part of a
clinician and in general, the routine care of these families prior to this project has
been less than optimal. The results of the screening program presented here only
serve to strengthen the proposal that follow-up of patients at risk of FAP should be
formalised into a regional or centralised register (Gunn 1990, Macrae 1990, Vasen
1990). Such a register would be entrusted with ensuring that screening was not
only of a high standard but also was not discontinued prematurely. In addition, it
should also ensure that timely prophylactic surgery is undertaken.
The method of surveillance of at-risk patients deserves some comment.
Initially I followed the recommendations of Bulow (Bulow 1987) that only rigid
sigmoidoscopy was required as all affected individuals eventually developed polyps
in the rectosigmoid. I now feel that formal bowel preparation as an outpatient with
a laxative such as sodium picosulphate and examination of the rectum, sigmoid and
descending colon with a fibreoptic sigmoidoscope is preferable. The reason for this
change is the certainty of affectation status afforded by DNA analysis which is
detailed in Chapter 8. If DNA analysis predicts that the patient is affected with more
than 99% certainty but polyps are not present in the rectum then the clinician
should be able to visualise the colon well proximal of the rectum to ensure that it is
not a case with relative rectal sparing. The use of the fibreoptic scope also allows
multiple random biopsies to be taken in cases where the adenomas are still very
small flat lesions. In all 8 cases where colectomy was carried out the diagnosis
would have been confirmed since polyps were present in the sigmoid despite relative
rectal sparing in 2 cases.
The demonstration of pigmented eye lesions in a 4 year old child in this
study and previously in a 3 month old child (Traboulsi 1987) confirm the congenital
nature of these lesions. The overall sensitivity of CHRPE lesions in indicating the
presence of colorectal polyps was 74% but in those families which had retinal
lesions as part of the syndrome, CHRPE lesions faithfully co-segregated with
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colorectal polyps in 100% of cases. Hence it is important to examine the affected
parent to assess the family category before assigning affectation status to an at-risk
individual, particularly in the case of children below the age requiring colonic
examination. The nature of the lesions detected here are similar to those described
elsewhere (Iwama 1990, Traboulsi 1987) and the numbers and laterality of the
lesions were also comparable (Chapman 1989, Iwama 1990, Polkinghorne 1990,
Traboulsi 1987). Chapman reported that there were no exceptions to the presence
of CHRPE lesions in gene carriers in 25 different families from Northeast England
(Chapman 1989) but this is at odds with the findings of this study and of others
(Iwama 1990, Traboulsi 1987) that certain families do not have eye lesions.
However, since publication, the Newcastle group has found more than one family
which do not have CHRPE lesions (J Burn personal communication 1990). The
CHRPE phenotype provides a useful once-and-for-all screening tool which is
independent of colonic screening which has the disadvantage of age-dependent
penetrance. The two screening modalities can be combined with RFLP linkage data
using Bayesian methods to allow the assignment of a combined risk which can then
influence subsequent patient management and this work is presented in Chapter 8.
In this series 60% of patients with FAP had overt or occult cranio-facial
osteomas which is lower than in other reported series (Bulow 1987, Jarvinen 1982,
Ushio 1976, Utsunomiya 1975). This discrepancy is probably due to the smaller
numbers studied here but may be due to differences in the patient population
studied. Differences in anatomical distribution of osteomas in different members of
the same family and the presence in some family members and not in their affected
relatives suggests that genetic factors are not the only determinant of the FAP
phenotype and that other factors must play a role in the development of these
lesions. It is difficult to postulate what these factors might be but perhaps the
genetic lesion results in an abnormal response to minor bony trauma in the affected
areas. Hence only patients who traumatised the mandible or skull at a certain age
or point in bone growth would develop osteomas.
Desmoid tumours occurred in 2% of this study population which fits well
with other reported series (Bulow 1987). The patient with an intra-abdominal
desmoid tumour was extremely unfortunate, having undergone prophylactic
colectomy with an early carcinoma in the resected specimen, only to develop a
painful untreatable benign tumour which has caused her a great deal of distress.
The affected patient was a 39 year old female which is the typical sex and age group
(Bulow 1986).
Epidermoid cysts were detected in 22% of this study group which agrees
reasonably well with published series which range from 3% (Bulow 1986) to 53%
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(Leppard 1974). In this series, the lesions had developed in childhood in 3 of the 6
patients (50%) with epidermoid cysts. It is important that clinicians take note of the
presence of multiple epidermoid cysts as such lesions are extremely uncommon in
normal individuals before puberty (Leppard 1974) and so may indicate the
development of FAP at a later date.
The personal undertaking of clinical screening of colorectum and retina of
these patients has been an important aspect of this project. The validity of
affectation status has been assured in every case and the fundamental clinical basis
of the linkage analysis is sound (presented in Chapter 4). The personal relationship
which I have had with these families has given me great insight into their problems
and what they would hope future developments in treatment and blood tests using





This chapter describes the construction of a genetic linkage map of 6 marker
DNA probes recognising restriction fragment length polymorphisms around APC.
Genotypes were obtained for all 6 probes in every member of the kindreds described
in Chapter 2 in whom a blood sample or archival pathology material was available.
The data presented here comprise identification of crucial crossings-over which have
allowed recombinant mapping and confident ordering of parts of the map. The data
are also presented as a series of two-point linkage analyses between each marker
and APC, and also between each marker and all other markers.
4.2 Methods
Kindreds KMD 1-6,8,14 and 16 comprise the nine families which were
selected for study on the basis of informativity, with sufficient meioses to provide
data for genetic linkage analysis (see Appendix A). 155 individuals have been
genotyped and phenotyped. This provided in excess of 90 meioses for linkage
analysis if all families were fully informative for any marker.
Clinical, pathological and genealogical ascertainment of all kindreds is
described in Chapter 2. The data presented in this chapter and in Chapter 8 overlap
to a certain extent in that this final mapping exercise includes a number of
individuals who were assigned risk estimations and subsequently screened clinically
as part of this project. In chapter 8 the recombination fraction for linkage of each
probe to APC was derived from an amalgamation of published data, supported by
order derived from the deletion analysis shown in Chapter 5 and including data from
a preliminary linkage analysis not including those assigned risk estimations. I have
not shown the results of this analysis for the sake of clarity but there were no
substantial differences from those shown here in the final analysis, only the lod
scores were somewhat lower.
For the purposes of this genetic linkage analysis, penetrance of FAP was
assigned as 1.0 for family members in whom colorectal screening had been
personally undertaken and who were over the age of 30 years. Individuals over 15
83
years of age who did not have CHRPE lesions but are members of families which
have been demonstrated to exhibit CHRPE as part of the FAP phenotype (KMD
1,2,3,6) and were screened negative for polyps were classified unaffected. If an
individual was negative on colonic examination but not part of a CHRPE expressing
family, then that individual was assigned to the 'FAP unknown' category. Affectation
status of those under the age of 15 years was ascertained by fundoscopy alone as
such children were not subjected to colorectal screening. The status of 8 affected
and 5 unaffected children who were members of families which expressed the
CHRPE phenotype were ascertained by this method (see Chapter 3).
Genotyping was carried out as described in Chapter 2.5-2.8. DNA was
purified from lymphoblastoid cell lines wherever possible to conserve DNA stocks
but in a number of cases, DNA was extracted from fresh peripheral blood leukocytes
as cell lines from these individuals were not available. Genotypes were obtained for
6 DNA probes which recognise restriction fragment length polymorphisms on
chromosome 5. DNA purified from 50 unselected individuals, comprising leukocyte
DNA from laboratory staff, or DNA purified from fresh placenta was also genotyped,
in order to ascertain allele frequencies for all marker DNA probes in a control
Scottish population.
Recombinant mapping using rare recombinant events informative at 3 or
more loci have allowed confident locus ordering for some parts of the map. Linkage
analysis was carried out as described in Chapter 2.8.2. The lod scores for linkage
between markers are relatively low because the families were not specifically
selected for a high level of infonnativity such as is the case with CEPH families. As
described in Chapter 2, birth certificates were checked for all family members as
part of the process of kindred ascertainment. Precautions to ensure valid paternity
by molecular genetic techniques are also described in 2.8.2.
4.3 Results
The results of the experiments to ascertain the allele sizes and frequencies in
a local control population are tabulated in Table 4.1. These data were then
incorporated into the LINKAGE computer programs during the linkage analyses.
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Table 4.1 Allele size and frequency recognised by 6 polymorphic chromosome
5q DNA marker loci in a control Scottish population. The restriction
endonuclease allowing recognition of the polymorphism at each probe










EF5.44(Msp 1) 0.18/2.9 0.82/2.1 84
L5.62(BglII) 0.93/9.0 0.07/5.5 76
YN5.48(Mspl) 0.45/9.0 0.55/8.0 60
ECB27(BglII) 0.39/11.9 0.61/10.5 74
CI 1P1 l(Taql) 0.14/4.4 0.86/3.9 100
pi227(Pstl) 0.25/4.3 0.75/3.0 66
pi227(Bcll) 0.17/3.0 0.46/1.8 0.37/1.2 54
pi227(BstXl) 0.29/2.7 0.71/2.3 28
pi227(Mbo 1) 0.25/0.55 0.75/0.45 20
Complete raw data on affectation status and genotype information for all
probes studied are shown in Appendix B and can be correlated directly with the
respective pedigrees in Appendix A. An example analysis of C11P11 genotype for
individuals in part of KMD 1 is shown in Figure 4.1. The disease segregates with the
(rare) A1 'allele in this large family and so 6-7 or his father is recombinant for
C11P11-APC.
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Figure 4.1 Part of KMD 1 pedigree showing C11P11 alleles in three generations.
Ar — ' -A i
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Twelve critical recombination events were identified where markers were
informative at 3 or more loci thereby allowing ordering of loci in 5q21-22. An
example recombination event is shown in Figure 4.2 where a crossing-over has
occurred in the interval between C11P11 and APC which is cancelled by both
YN5.48 and EF5.44. The small units of genetic distance between loci (see below)
preclude any double recombination events and so YN5.48 and EF5.44 must be on
the APC side of CI IP 11 and are most likely on the opposite side of APC from
CI IP 11 given the recombination fractions (Tables 4.3, 4.4). The phenotype data
shown in Figure 4.2 are those after the final screening round. Figure 4.2 is also
shown as Figure 8.1 prior to the final round of screening.
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Figure 4.2 Example family (KMD 2) showing FAP disease status and genotypes
for markers pi227, C11P11, EF5.44 and YN5.48. The chromosome
carrying the disease (d) gene is shaded and there has been a








k227 1 3 3 ii
C11P11 1 1 1 il
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The results of identification of other important rare recombinations in these
families is detailed in Table 4.2 with each of these recombination events grouping
loci together in different sets. All recombination events which were fully informative
for 3 or more loci are shown with the vertical line representing the recombination
event in each case and the informative markers ranged either side of the breakpoint
depending on the haplotypes resulting from the recombination. This allows the
construction of a composite recombinant map of loci as shown in Figure 4.3. The
shaded area represents all possible locations ofAPC relative to the markers studied.
Thus, APC could overlap EF5.44 or YN5.48 but cannot overlap L5.62, ECB27,
CI IP 11 or pi227 due to the presence of recombinants.
Table 4.2 Recombination events where 3 or more loci were informative. The
vertical line represents where the recombination has occurred in
relation to each of the informative loci.
C11P11 APC APC








ECB27 YN5.48 ECB27 EF5.44
C11P11 YN5.48








Figure 4.3 Markers ordered from rare recombination events as detailed in Table
4.2. APC represented by shaded area and site of marker locus











There is a fundamental problem with genetic linkage when the loci being
tested are physically very close to each other. Recombination events are very rare in
this situation and so complete ordering of markers by recombinant mapping is not
always possible. However, this study has identified 12 important rare recombinant
events informative at multiple loci due to the large numbers of meioses available.
Linkage analysis also provides vital information for further detailed mapping of the
region. The results of the analysis for linkage of APC to each of the 6 polymorphic
DNA marker loci are presented in Table 4.3. Peak lod scores (Zmax) and
recombination fraction (9) indicating the maximum likelihood of marker location
relative to APC with 95% probability limits are tabulated together with lod score
tables. No recombinants have been identified between APC and YN5.48, or between
APC and EF5.44. Peak lod score for APC--YN5.48 was 7.00 at 6=0.00, with 95%
probability limits 0.00-0.07. EF5.44 was not very informative in these families and
so the peak lod score for APC--EF5.44 was only 3.5 at 9=0.00, with resultant wide
95% probability limits.
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Table 4.3 Linkage analysis in 9 Scottish FAP kindreds (KMD 1-6,8,14, and 16):
Peak lod score (Zmax) for each marker vs. APC at recombination
fraction (9) with 95% probability limits and lod score tables at 9=
0.00, 0.05, 0.10, 0.15, 0.20, 0.25.
Linkage 7max e 95% probability Recombination fraction (6)
vs. APC limits 0.00 0.05 0.10 0.15 0.20 0.25
EF5.44 3.50 0.00 0.000-0.160 3.50 3.22 2.91 2.58 2.23 1.86
YN5.48 7.00 0.00 0.000-0.070 7.00 6.31 5.56 4.79 4.01 3.24
L5.62 13.31 0.02 0.005-0.095 - 12.99 11.94 10.65 9.21 7.65
ECB27 1.88 0.06 0.002-0.260 - 1.89 1.75 1.50 1.20 0.90
C11P11 5.45 0.09 0.025-0.210 - 5.23 5.43 5.13 4.59 3.90
pi227 4.40 0.11 0.035-0.235 - 4.00 4.40 4.26 3.88 3.35
Tests for linkage between each pair ofmarker loci revealed no discrepancies
to suggest non-paternity or mis-typing. There were no cases of non-paternity on
testing with the probes YNZ22 or 29C1.
Lod score calculations were carried out for linkage between each pair of
markers and this is shown in Table 4.4. Recombination fraction is indicated above
the diagonal and peak lod score below the diagonal for each marker-marker
combination. No recombination events were detected between the following pairs of
markers: L5.62--ECB27, ECB27--C11P11, CllPll-pi227 and EF5.44~L5.62.
However the lod scores for EF5.44~L5.62 and for L5.62--ECB27 were low due to
poor informativity of these markers in the local population.
Table 4.4 Two-point lod scores (below diagonal line) and recombination fraction
(above diagonal line) for linkage between marker loci in 9 FAP
kindreds.
EF5.44 YN5.48 L5.62 ECB27 C11P11 pi227
EF5.44 -^007 0.00 0.15 0.16 0.25
YN5.48 2.11 ^__0.11 0.19 0.1 1 0.25
L5.62 1.23 0.98 0.00 0.04 0.04
ECB27 0.69 0.52 1.03 0.00 0.12
C11P11 0.64 1.60 4.11 1.86 0.00
pi227 0.00 1.05 1.48 1.72 3.05
The data presented here from lod score tables and from rare recombination
events suggest that YN5.48 and L5.62 delineate a small region which spans APC.
The interval L5.62--YN5.48 could be as much as llcM (see Table 4.4), or 7cM (since
L5.62~EF5.44 is OcM and EF5.44--YN5.48 is 7cM), or as little as 2cM (since L5.62--
APC is 2cM and APC--YN5.48 is OcM). The latter (2cM) seems most likely since lod
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scores are highest for linkage of each of the markers to APC. When two-point
linkage analysis is added to the order derived from recombination events and given
that C11P11 is centromeric to APC (Varesco 1989) and that YN5.48 is telomeric to
APC (Nakamura 1988), these data support the locus order centromere—pi227—
CI 1P11—ECB27—L5.62—APC—EF5.44—YN5.48—telomere. Although EF5.44 could
lie in the interval L5.62--APC or, least likely, in the interval ECB27--L5.62.
4.4 Discussion
The genetic linkage analysis described in this chapter has provided a high
resolution genetic linkage map of 6 polymorphic DNA markers which lie very close to
the APC gene on chromosome 5q. The large number of meioses studied and the
detection of a number of rare recombination events which were informative at
multiple loci has allowed confident ordering of parts of the map. The possibility of
double recombinations for these events is remote since the genetic area under
scrutiny is very small indeed.
No APC-YN5.48 recombinants were detected but when the relevant two-point
linkage analysis data are added into the map derived from recombination events, the
localisation of YN5.48 to the other side of APC from pi227, C11P11, ECB27 and
L5.62 is highly likely. It has been shown by in situ hybridisation analysis that
pi227, C11P11 and ECB27 are centromeric to APC (Varesco 1989). Localisation of
YN5.48 distal to APC (Nakamura 1988) now appears certain following the recent
identification of an APC-YN5.48 recombinant which was non-recombinant for APC-
pi227 (Tops 1989). In addition, physical mapping data (Nakamura personal
communication 1990) show that EF5.44 and L5.62 are indeed around 2mB apart,
supporting the linkage analysis presented here. When these data are incorporated
with the recombinant data and the linkage analysis described in this chapter, a
preferred locus order of centromere-pi227-Cl 1P11-ECB27-L5.62-APC-EF5.44-
YN5.48-telomere is strongly supported.
The present study suggests that YN5.48 and L5.62 delineate a small region
of chromosome 5 which could be as little as 2cM and within this region the locus
recognised by EF5.44 lies very close to the APC itself. This finding is a step towards
the isolation of APC itself. It will now be possible to isolate clones from this region
and screen these for the presence of expressed sequences. Any such sequences
must be strong candidates for the APC gene itself, given the relatively small area
between these markers and that APC is probably a fairly large gene since the rate of
new mutations giving rise to sporadic cases of Familial Adenomatous Polyposis is
high (Reed 1955).
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Having demonstrated that EF5.44 lies very close to APC, it can now be used
to screen pulse-field DNA fragments for rearrangements in patients with FAP and
this analysis is described in Chapter 7.
The data presented here, combined with those already published for linkage
of several of these markers to the APC gene, give lod scores sufficiently high (and
hence 95% probability limits sufficiently narrow) to allow their use in
presymptomatic diagnosis of FAP. The combined estimates for linkage for the
markers published as lod score tables, including data from this analysis, are as
follows: YN5.48-APC, approx. 18.5 at 0=0.025 (Nakamura 1988, Tops 1989); pi227-
APC, 18.95 at 0=0.075 (Meera Khan 1988, Murday 1989, Tops 1989); C11P11-APC,
11.97 at 0=0.025 (Bodmer 1987, Leppert 1987, Murday 1989). Assessment of the
practical value and the validity of the use of these markers for presymptomatic
diagnosis of FAP is described in Chapter 8.
The establishment of a high density map of the region around APC is of great
importance since, until isolation of the gene itself, multiple markers will be required
for presymptomatic diagnosis of FAP. Even after the APC gene is cloned and
sequenced, it is likely that there will be a need for linked markers in some families.
This analysis has detected no evidence of genetic heterogeneity in 9 Scottish FAP
kindreds, with linkage being apparent for at least one of the 6 markers studied in all
families and to date there are no families in the world literature which do not exhibit
linkage to 5q21-22. This is of paramount importance to clinicians who will use
genetic linkage data to influence management of families and at-risk individuals
under their care.
The construction of this high resolution map allows a stringent assessment
of the role of deletion of the APC gene in the biology of familial and sporadic
colorectal adenomas and carcinomas. This analysis is described in Chapter 5 and 6.
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CHAPTER 5
ALLELE LOSS AND DELETION ANALYSIS IN
SPORADIC COLORECTAL CARCINOMAS
5.1 Introduction
The hypothesis that a dominantly inherited gene defect might exert its effect
in a recessive manner at the cellular level (Knudson 1971) and the paradigms of
such tumour suppressor genes, the retinoblastoma and Wilms' tumour genes, have
been discussed in Chapter 1. Solomon's demonstration of allele loss on
chromosome 5 (Solomon 1987) indicated that the role of APC in FAP and sporadic
colorectal cancer might be analogous to the situation in retinoblastoma and Wilms'
tumour, implicating APC as a tumour suppressor gene involved in the biology, if not
the genesis, of non-polyposis colorectal cancer. A search for allele loss at
polymorphic marker loci close to the target locus is a powerful strategy for assessing
a possible recessive determinism for APC in the respect that not only deletions
involving APC can be detected, but also mitotic recombinations in the tumour tissue
since the marker allele will also be reduplicated and be apparent as acquired
homozygosity. However, allele loss studies using markers which are not within the
target gene have an inherent disadvantage since the marker locus may be some
distance from the gene of interest and may not faithfully detect all deletions or
mitotic recombinations. Solomon examined the allele loss status of one of the
probes (^MS8) which is a considerable distance from APC (Wong 1987) and so the
status of APC itself is open to question due to the large amount of DNA between
*MS8 and APC. Prior to the work presented here, there was no critical assessment of
chromosome 5 allele loss in colorectal carcinomas and whether such loss of genetic
material did indeed include APC itself.
This chapter presents a detailed assessment of the allele loss status of 7
polymorphic DNA probe markers closely linked to APC utilising the genetic linkage
map from Chapter 4 to infer the nature and extent of loss of genetic material around
APC. A total of 13 marker loci spanning chromosome 5 have been analysed in 51
colorectal 'cancers in an attempt to gain greater understanding of the mechanism of




Fifty-one consecutive histologically confirmed sporadic colorectal carcinomas
with control blood and normal colonic mucosa from 49 patients undergoing
colectomy specimens were collected, processed and DNA purified as described in
Chapter 2. Controls initially consisted of both leukocyte and normal mucosa DNA
but after a large number of experiments it was clear there was no allele loss
observed at any locus in normal mucosa and so in later experiments only leukocyte
DNA served as a control.
Analysis of allele loss status at all 13 loci in all 51 cancers was assessed
using paired tumour/control DNA samples as described in sections 2.6 and 2.9.
Allele losses can only be are determined if the host is constitutionally heterozygous
at the probed locus (ie exhibits two restriction fragment length alleles in the control
blood or normal mucosa) and this results in the problem that not all tumours are
informative at every locus. Tumours in which the host was constitutionally
heterozygous (informative) for the markers pi227 and MC5.61 or pairs of markers
internal to these loci on both sides of APC are referred to as informative close
flanking markers. Mapping of the end of a deletion in a carcinoma by
demonstration of allele losses at probed loci of known map locations is somewhat
imprecise in some cases due to the inherent problem of incomplete informativity at
eveiy locus. The allele loss status for each cancer indicates the maximum size of the
deletion in any given tumour but the lesion could be substantially smaller.
Complete probe details are presented in Chapter 2 (Tables 2.1 and 2.2) and a
schematic diagram of the localisation of the chromosome 5 marker probes which
have been examined in this analysis are shown in Figure 5.1. The region around
APC is an exploded view and the location of the 7markers given is derived from an
amalgamation of data presented in Chapter 4 and mapping data from other workers
(Bodmer 1987, Leppert 1987, Meera Khan 1988, Murday 1989, Nakamura 1988,
Varesco 1989). The map locations of other probes not included in the linkage map
presented in Chapter 4 are referenced in Chapter 2.
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Figure 5.1 Locations of 13 polymorphic loci on chromosome 5 used for deletion
analysis.
Chromosome 5
tc227 C11P11 ECB27 LS.62 APC EF544 YN5.48 MC5.61
11cM
Since loss of heterozygosity ofmarkers mapping to 17p (implying inactivation
of the gene for p53) has been shown to be a common event in colorectal cancer
(Fearon 1987), the 17p probe, YNZ22, was also assessed for allele loss to establish
whether there was any association between allele losses at 17p, 5q and clinico-
pathological features. In addition, this analysis serves as a positive control to
ensure that the experimental system and the population of tumours analysed were
comparable with published data. -
Flow cytometry was carried out on all tumours and aneuploidy was
considered to be present when two distinct Go/Gi peaks were distinguishable,
indicating two cell populations or, if there was only a single peak was visible, this
was compared with the chicken erythrocyte control as described in Chapter 2.
5.3 Results
The average age of the 49 patients from whom 51 adenocarcinomas were
taken was 69 years (range 29-87 years, median 58 years) and there were 2 patients
under 40 years. There were one or more adenomas present in 10 of the resected
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specimens (20%). Clinicopathological features of the carcinomas studied is shown
in Table 5.1.
Table 5.1 Clinicopathological features of 51 colorectal cancers studied by
deletion analysis. The boundary of the right and left colon has been
considered to be the mid-point of the transverse colon.
Clinicopathological feature Number (%)
Site (n=51)
Caecum 9 18
Right colon 5 10

















One carcinoma could not be fully staged as it was removed by local excision,
although there were no metastases apparent on liver ultrasound scan.
Unfortunately, not all carcinomas could be analysed by flow cytometry as in some
cases the material had degraded probably due to a freezer thaw. The proportion of
aneuploid carcinomas was made up of both hypodiploid and hyperdiploid tumours.
Allele losses were detected in many tumours and apart from 105-153Ra
(D5S39), there were no marker loci at which allele loss was not detected in at least
one tumour. Figure 5.2 shows an example experiment demonstrating loss of
constitutional heterozygosity in carcinomas at the loci recognised by 3MS8. There is
a reduction in intensity or complete absence of one of the bands in those tumours
which have lost constitutional heterozygosity. In some cases there is a residual faint
band which represents contaminating normal stroma and lymphocytes. Figure 5.3
shows example allele losses from a number of different cancers superimposed on an
idiogram of chromosome 5 which also includes a summary linkage map around APC
as detailed in Chapter 4. The allele losses shown are all from my own series of
cancers except the loss with 105-153Ra which was a tumour from the Edinburgh
University series (see below).
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Figure 5.2 Example experiments showing allele loss in two different carcinomas
at the locus recognised by 2-MS8. There are two alleles in the
constitutional (leukocyte) DNA and absence of one allele in each of
the tumours. The residual hybridisation is due to a small amount of
contaminating leukocyte and stromal DNA in the tumour. N=normal
(leukocyte) DNA, T=carcinoma DNA.
NT NT
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Figure 5.3 Example allele losses at each of the loci examined showing their map
locations and including a simple abbreviated linkage map around
APC.
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Table 5.2 shows the frequency with which allele loss was detected at each
chromosome 5 locus. There appears to be a trend towards increasing frequency of
detection of allele loss with increasing proximity of the marker examined to APC
although, due to the problem of incomplete informativity, with some markers the
numbers of tumours involved is small.
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Table 5.2 Frequency of allele losses detected by each of the chromosome 5
probes. The number of carcinomas exhibiting loss is presented as a
percentage (in parentheses) of those tumours informative at that
locus. The relative order of loci are as for the linkage map in Chapter
4 and the map location of APC is included.
Probe Carcinomas















All 51 carcinomas were informative at one or more chromosome 5 marker
loci and the overall frequency of detection of allele loss at any of these loci was
34/51 (67%). The allele loss frequency when close flanking markers were examined
was broadly similar with 14 of 25 cancers (56%) exhibiting loss of constitutional
heterozygosity. Complete data for all 51 cancers, tabulating allele losses for all 13
probes are shown in Table 5.3. In every case apart from T132C, the allele loss
patterns are consistent with loss of genetic material involving APC . Tumour T132C
has not lost heterozygosity at L5.62 which lies between APC and pi227 and D5S78
which do show allele loss. This may be due to a random loss of DNA which has
been shown to occur as a 'background' loss (Vogelstein 1989), or perhaps due to a
local inversion-deletion within chromosome 5. Another explanation is that the map
locations for the markers are incorrect. This seems highly unlikely given the
confidence of the ordering shown in Chapter 4, published linkage mapping and the
proportion of tumours which do have deletions consistent with APC as the target.
Tumour T84C merits special mention since, although the deletion is consistent with
APC involvement, the centromere also appears to have been deleted. This would not
be permitted by the cell and the remaining chromosome 5q fragment should have
been lost. Therefore it must be assumed that the remaining fragment has been
involved in a mitotic recombination or some form of fusion to another chromosome
with a centromere and this would be permitted. Tumour T188C also is of particular
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interest since there appears to be a retained segment amidst an otherwise large
deleted area. The pi227 locus shows no evidence of allele loss while loci either side
of this (D5S78 and ECB27) do show allele loss. The reason for this must be a
retained fragment of DNA (carrying the locus recognised by pi227) which has
become incorporated into another chromosome or perhaps, due to its very small
size, has become sequestered within the nucleus in its own right.
In many carcinomas the loss involves one side of APC and not the other,
while in other tumours (eg. T197C2) the deleted material can be clearly be seen to
involve a relatively small region of chromosome 5 which specifically includes APC.
Those tumours in which an area of loss of heterozygosity is clearly delineated
by an area of retention of heterozygosity are referred to as interstitial deletions.
Tumours where the end of the deleted region cannot be assessed with any certainty
could harbour an interstitial deletion or a mitotic recombination but the
methodology used here is limited because of incomplete rnformativity of markers.
Mitotic recombination occurs at the time ofmalignant mitosis, early in the evolution
of the neoplastic process when there is a crossing-over between chromosomal
homologues with a breakpoint which must lie between the marker which shows
allele loss and the one which does not. If this crossing-over, or recombination,
confers a survival advantage (such as loss of a putative tumour suppressor gene)
then the clone carrying the chromosome with the recombination will out-grow the
other cell populations. For the purposes of this analysis, those tumours with allele
loss at the tip of either arm have been considered to carry mitotic recombinations.
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Table 5.3 Analysis of heterozygosity status for each carcinoma for loci
recognised by each probe. Allele loss is represented by X, no loss and
informative by O and constitutional homozygosity (non-informative)
by-.
TumourLI.4 MLZ7.5D5S76 D5S39 D5S78 pi227 C11P11ECB27 L5.62 APC EF5.44 YN5.48 MC5.61 ^ MS8
T80C _ . _ O . O . O o o
T83C - o - - O - - - - o - o
T84C X X - - - X - - - - - -
T85C - o - - o o o - - o .
T87C - o o - o o o - X - - -
T94C - o - - - - - - - - - -
T95C1 o o - - - X - X - - -
T95C2 o o - - - o - o - - -
T97C - o o - - o o - - - - o
T98C o o - - o o - o - - X o
T99C o o - - o - - - X - - o
TIOOC - - - - o o - - - - o o
T101C - o - - o o - - - - - o
T102C - - - - X X - - - - X X
T103C - o - - X X - - - - - -
T104C - o - - o o - X X - o - o
T106C - o - o - - - X - - - o
T109C - o - - o o - - - - - X
T125C - o - - X X - - - - X X
T130C - o - - - o - o - - o o
T131C o o - - - o - o o - - o
T132C o - - - X X - o - - - o
T140C - - - - - o o o - o o -
T141C o - X - - X - - - - X o
T143C - - o - o o - o - o o o
T144C - - - - - X - - - - - X
T145C o o X - - X X - - - - X
T151C - - o - o - - - X - - -
T152C o o - - o X X - - X X o
T153C - - - - - X - - - - X
T171C - - X - X - - - - X - X
T177C o - o - - - - o o o o o
T178C - o - - X - - - - X
T181C - - o - - - o - - o - o
T182C X - X - - - - - - X X X
T187C - o - - o o o - - o - o
T188C X - X - X o - X X X o -
T189C o - o - X - - - - X X X
T191C - - o - - o - X - - X X
T192C - o o - o o - o o o - o
T193C o o o - - o - X - - - o
T194C o o - - - X - - - X X X
T195C - - - - X - - - X - o
T196C o o X - X X - - - - -
T197C1 - - o - - X X - - X X o
T197C2 - - o - - o o - - X o o
T198C o o - - X - - - o - - o
T199C - o - - - X - - X X X X
T200C - o o - o X - X - o o
T201C o o o - - - - - - - X o
T237C - - - - - - - - - o o -
The nature and extent of the loss of genetic material from chromosome 5 in
any one carcinoma can be inferred in those tumours which have sufficient loci
informative to delineate the ends of the deletion. This is shown diagrammatically in
the example of cancer T152C in Figure 5.4. It can be seen that the deleted region
must involve loss of APC and that the nature of that loss is interstitial deletion
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involving a maximum interval of D5S78 to MC5.61 and a minimum interval
stretching from pi227 to YN5.48 (around 25cM). It is should be noted that the area
around APC is an exploded view and so the deleted region is veiy small in relation to
the whole of chromosome 5. Therefore, somatic deletions involving chromosome 5 in
sporadic colorectal cancers appear to be relatively specific for the APC gene.
Figure 5.4 Delineation of the extent of a deletion in a sporadic colorectal
carcinoma using a strategy of assessment of allele loss status at
multiple chromosome 5 loci (example T152C). The maximum limits of
the deleted region are represented by the cross-hatched segment.
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Deletion
The deletion analysis has been extended to combine all tumours with
sufficient markers informative to delineate the extent of the loss of genetic material
into a composite deletion map. Due to the analysis of 13 markers in each ofmy own
series of tumours it was possible to characterise the deletion in 24 tumours (see
Table 5.3). Incomplete probe informativity reduced the number of tumours giving
data sufficient for deletion mapping and so data from my co-workers in Edinburgh
University have been included to strengthen the data for my own series (see Table
5.2). Using the same battery of probes, 104 colorectal carcinomas from Edinburgh
University Department of Pathology were analysed in parallel, although 13 markers
were not assessed in every case, as in my own series. Experimental technique was
uniform for the two data sets and is described above. In all there were 36 tumours
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of the first 119 combined tumour data set with sufficient informative markers to
allow construction of a composite deletion map. These are shown in Figure 5.5 and
it can be seen that there is a relatively specific deletion of APC which is usually due
to interstitial deletion (64%) and only rarely due to whole chromosome loss. Cancer
T132C has been excluded as it clearly is an exception to the observation in all other
tumours that the deletion consistently involves APC.
Figure 5.5 Composite deletion map derived from 36 colorectal carcinomas with
sufficient markers informative to allow delineation of the nature and
the extent of the loss of genetic material from chromosome 5. SRO=
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Allele losses were distributed evenly throughout the different clinico-
pathological classes of carcinomas (Table 5.4). There was no predilection for APC
inactivation (as demonstrated by the occurrence of allele losses at any informative
5q locus or at close flanking loci) with respect to any particular site, Dukes' stage,
ploidy level or degree of differentiation. Notably, both Dukes' stage A tumours
exhibited loss at 5q and this supports the notion that APC inactivation is an early
event and precedes tumour progression.
Table 5.4 Allele loss frequencies at any informative 5q marker, APC close
flanking markers and YNZ22 classed by site. Dukes' stage, ploidy
level, degree of differentiation and the presence of 17p allele loss. The
numerator in each case is the number with loss and the denominator
the number informative for those markers .
Cancer status
Any 5q




Caecum 4/9(44%) 3/7(43%) 5/8(63%)
Right 5/5(100%) 1/1(100%) 1/5(20%)
Left 2/4(50%) 0/2 1/3(33%)
Sigmoid 12/16(75%) 7/9(78%) 9/12(75%)
Rectum 11/17(65%) 3/6(50%) 9/13(69%)
Dukes' Stage
A 2/2(100%) - -
B 14/26(54%) 7/15(47%) 14/22(64%)
C 10/13(77%) 3/5(60%) 7/11(64%)
D 8/9(89%) 4/5(80%) 3/6(50%)
Ploidy
Diploid 7/12(58%) 1/4(25%) 8/12(67%)
Aneuploid 15/22(68%) 9/14(64%) 9/16(56%)
Degree of differentiation
Well - - -
Moderate 25/39(64%) 8/17(47%) 20/31(65%)
Poor 9/12(75%) 6/8(75%) 5/10(50%)
17p allele loss
Loss 16/25(64%) 8/12(67%) -
No loss 10/16(63%) 2/9(22%) -
Data derived from experiments using the probe YNZ22 to detect loss of
genetic material from chromosome 17p are also shown in Table 5.3. Allele losses
detected by YNZ22 occurred in 25 of the 41 (61%) informative carcinomas and there
was no tendency for 5q allele loss and 17p allele loss to occur in the same tumours.
The majority of tumours had lost alleles at one or more loci with 16 (31%) having
lost 17p and 5q alleles, 29 (57%) having lost either and only 6 (12%) having lost
neither. Those tumours with both 5q and 17p deletions were not of any particular
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Dukes' stage (8 stage B, 5 stage C and 3 stage D) and were of similar ploidy levels (6
aneuploid and 4 diploid) and so there does not appear to be a progressive
accumulation of genetic defects associated with poor prognosis in this data set. The
data do suggest that loss ofAPC and p53 take place independently of each other and
of all features currently classed as reflecting tumour progression. One previous
report has suggested a strong polarisation of allele losses towards the tumours in
the distal colon (Delattre 1990) but the data presented here do not support this (see
Table 5.3), although the numbers of tumours analysed for this thesis and presented
here are relatively small. Even when caecal and right colonic tumours are classed
as proximal lesions and all others as distal, the allele loss frequencies remain
similar (9/14 (64%) proximal, 25/37 (68%) distal lost any 5q marker; 6/13 (46%)
proximal, 19/28 (68%) distal lost YNZ22). Ploidy levels were also similar in proximal
and distal tumours (5/11 (45%) analysable proximal tumours and 8/15 (53%) distal
tumours were aneuploid .
5.4 Discussion
The data set of colorectal cancers presented here appears to be broadly
similar to reported series with respect to the age of the affected patients (Falterman
1974), tumour stage (Dukes' 1929-30 and 1940, Falterman 1974, Gill 1978,
Jarvinen 1988, Phillips 1984), degree of differentiation (Jass 1987), topographical
distribution (Falterman 1974, Jarvinen 1988), DNA ploidy level measured by flow
cytometry (Armitage 1985, Jones 1988) and the frequency of detection of loss of
genetic material from chromosome 17p (Baker 1989, Fearon 1987, Law 1988, Lothe
1988, Monpezat 1988, Okamoto 1988, Sasaki 1989, Vogelstein 1988). Therefore in
all these respects, this collection of tumours is similar to other non-selected groups.
However, the frequency of detection of APC-related allele loss is substantially higher
than in published reports (Law 1988, Okomato 1988, Sasaki 1989, Solomon 1987,
Vogelstein 1988, Wildrick 1988). This discrepancy is due entirely to the use of
markers mapping very close to, and flanking, the APC gene. The frequency of
detection of allele loss at each locus in this study is similar to, or in some cases
actually lower than, published allele loss frequencies using the respective probe,
thus Solomon detected 40% HMS8 loss compared to 34% in this series and Okamoto
detected 33% loss at C11P11 compared to the 27% shown here. In the case of
sporadic retinoblastoma, a similar increased frequency of detection of allele losses
was found when markers closely flanking the Rb-1 gene on chromosome 13ql4 were
assessed (Dryja 1986). The frequency of detection of allele losses with further
markers which map still closer to APC might therefore be higher still and it is likely
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that some lesions will confined to APC itself. A further reason for the increased
frequency of APC related allele loss found here is the density of markers used. In
almost every case, each tumour has been assessed for allele loss at 13 loci spanning
the whole of chromosome 5. As shown in Figure 5.5, interstitial deletions and
mitotic recombinations can extend in either direction from APC and so previous
studies which rely on the assessment of allele loss at one locus, on one side of APC
will undoubtedly miss a number of deletions which involve a considerable portion of
chromosome 5 on the opposite side ofAPC.
The technique employed in this study for detection of allele loss involves an
element of subjective assessment of the relative intensities of each of the alleles
revealed on the X-ray film by p32 labelled probe. There is potential for mis-
classifying tumour allele loss status due to the presence of small amounts of
residual normal tissue and lymphocytes which reflect the host's constitutional
heterozygosity. Initially laser densitometry was employed to introduce more
objectivity to the assessment of the relative intensity of each allele. Unfortunately
this objectivity is not practically achievable since the level of diminished intensity set
on the laser densitometer is set originally on an arbitrary, subjective assessment of
the level of allele intensity difference which represents allele loss. Therefore laser
densitometry was abandoned and visual comparison of relative allele intensities
employed throughout and this is the standard method now used by most other
authors. In the majority of cases, there was no dubiety when allele loss was present
or absent. In those cases where there was some doubt, an independent assessment
was obtained and if no agreement could be reached, then the tumour was classed as
not informative at that locus. To overcome the problem of contamination, some
authors have recommended section and microdissection of the cancer tissue to
separate it from adjacent normal or benign tissue (Vogelstein 1988) while others
have suggested separation of cell populations within any given tumour by flow
cytometry (Monpezat 1988). However, these methods are extremely time-
consuming, require resources outside the scope of this project and provide little
advantage over the method used here. Sampling a macroscopically representative
malignant portion of tumour tissue immediately adjacent to the sections taken for
routine histological assessment has ensured that the tissue being analysed is indeed
mostly carcinoma. The validity of this strategy is demonstrated by the fact that the
frequency of allele loss with probe YNZ22 in this series is very similar to those
reports using selectively isolated tumour tissue (Monpezat 1988, Vogelstein 1988)
and indeed 5q allele losses are much higher than in other reports. Contamination of
cancer tissue with benign or normal tissue could only have the effect of reducing the
apparent frequency of allele loss at any locus. The similarity of YNZ22 allele loss
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frequency in this study to reported series also serves as an independent control and
suggests that the experimental technique involving the extraction and hybridisation
of tumour DNA with probe DNA is sound.
This study has utilised the linkage map of the region around APC presented
in Chapter 4 to allow the construction of the first detailed deletion map of the
chromosomal region around APC in colorectal carcinoma. The identification of a
large number of markers very close to APC and ordering of these relative to each
other and to APC has been fundamental to this deletion analysis. The work
presented here has shown that the mechanism of APC loss is predominantly due to
interstitial deletion and only rarely due to whole chromosome loss, in contrast to
some other tumours (Hansen 1988, Ponder 1988). Avery limited 5q deletion map in
colorectal cancer has been published (Vogelstein 1988) and this supports the
findings presented here that interstitial deletion is a frequent finding. The
chromosome 5q deletions shown in Table 5.2 are also highly specific for APC, with
the deletion involving APC in all but one case. This discrepancy may be due to
rearrangement of a portion of chromosome 5 which includes APC in this tumour or
may be due to non-specific 'background' loss of genetic material which may well
occur at a level of around 10% (Vogelstein 1989).
These data demonstrate that deletions can extend in either direction from
APC (telomeric or centromeric). This has important implications for mapping of APC
itself. Linkage mapping becomes ever more laborious as markers closer to the gene
of interest are identified since recombinations occurring in the very small interval
between become ever less frequent. Deletion mapping in cancers could hold the key
to final isolation of APC. If, in one tumour, a retained marker can be shown to
delineate the centromeric end of a deletion extending towards the telomere, while in
another tumour that same marker is retained and delineates the telomeric end of a
deletion which extends towards the centromere, then that marker must be very close
to, if not within, APC itself. This is currently one of the strategies being employed by
Dr. Yusuke Nakamura in the search for APC.
The data presented in this chapter leaves little doubt that the target gene on
chromosome 5 is indeed APC. Unless there is some unrelated, coincidental
predisposition to genetic alterations in this region, loss of APC must confer growth
advantage on affected clones and result in positive selection for a cell population
which is APC-deleted.
The reason for interstitial deletion rather than whole chromosome loss as the
predominant mechanism of APC loss cannot be explained by these, or any published
data but merits some discussion. One hypothesis is that hemizygous loss of the
whole of chromosome 5 (which is a relatively large chromosome) would result in
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haploid insufficiency of sufficient genes which are important to cell survival that the
result would be cell lethal. However, clearly some tumours do lose the whole
chromosome and so this cannot be the whole explanation. Another possibility is
that one or a number of crucial genes are already in the haploid state in the region
around APC. The net result of deletion of the remaining homologue would be
homozygous deletion of these important genes, which could not be sustained. This
scenario allows for the occurrence of both whole chromosome loss and of interstitial
deletions.
Genes located close to APC (and indeed APC itself, see discussion in Chapter
6) might be rendered haploid due to random somatic or constitutional mutations
which are known to occur fairly frequently. However, unless there is a specific
mutational hotspot around this region, this explanation seems unlikely. Another,
more attractive mechanism by which haploid inactivation could be achieved is by
the phenomenon of genomic imprinting. Genomic imprinting is due to differential
modification of the phenotype of any given gene depending on its parental origin
(Editorial, Genes and Dev. 1989, Reik 1989, Sapienza 1989). It has been suggested
that genomic imprinting is common and may affect large numbers of genes
(Sapienza-1989). Imprinting may be due to differential parent-of-origin mediated
methylation or to DNA packaging and is usually only implicated as showing an effect
during embryogenesis (Editorial, Genes and Dev. 1989). However, data from
sporadic osteosarcoma (Toguchida 1989) suggest that, while imprinting certainly
exerts effects on recessive embryonal cancer genes (Reik 1989, Scrable 1989), these
effects are not solely manifest in childhood. Hence genomic imprinting may result in
functional haploid inactivation of a number of genes in the region of APC.
Genotypic inactivation of the residual functioning copy of one of these genes by
somatic hemizygous loss would be cell lethal and so there would be selection against
such an occurrence. However, a large deletion affecting a number of genes would be
allowable if those genes were already functionally in the haploid state due to
imprinting. This hypothesis would explain the findings presented in this chapter
with regard to the variable extent of somatic deletions seen in colorectal cancer
tissue and the fact that both interstitial deletions and whole chromosome loss both
occur. The number and location of imprinted genes close to APC will determine the
allowable 'mechanism of APC loss. The extent of the involvement of genomic
imprinting in the APC deletions will become testable once APC is cloned and
intragenic defects which occur in colorectal cancer has been established.
Another explanation for the occurrence of substantial hemizygous losses of
chromosome 5q could be due to mitotic recombination or whole chromosome loss by
non-disjunction and chromosomal reduplication. The net result of both of these
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mechanisms is reduplication of the mutant ape with the maintenance of the diploid
state of the genes necessary for cell survival. Gene dosage studies would allow an
experimental test of this notion by comparing tumours with interstitial deletions to
those with mitotic recombinations. Tumours with acquired homozygosity at apc-
linked marker loci should exhibit a doubling of the intensity of the retained allele if
allele loss was due to recombination or non-disjunction with reduplication, whereas
such a doubling of allele intensity would not be apparent if the observed allele loss
were due to interstitial deletion. However, this series of experiments was not within
the scope of this project.
The data presented here suggest that inactivation of APC occurs
independently of all of the parameters currently thought to reflect tumour
progression, implying that APC loss occurs early in colorectal carcinogenesis. If the
FAP syndrome is considered to reflect the stages of colorectal tumour initiation and
progression then it is tempting to propose that ape lesions may actually be
implicated as one of perhaps a small number of possible causative events. The
timing of ape deletions in the adenoma-carcinoma sequence is discussed further in
Chapter 6. However, it is certainly reasonable to propose that ape inactivation is not
involved in the later stages of metastasis and invasion since there is no increased
frequency of 5q allele losses in more advanced tumours. The data presented here
show no increase in the frequency of 17p allele loss in the more advanced tumours
but such allele loss is very common and the number of informative tumours was
relatively small. However, in one study 17p allele loss was shown to parallel tumour
progression but 5q allele loss did not (Delattre 1990). Therefore, the data presented
here and all published data concur in suggesting that APC inactivation is an early
event in the progression of normal colorectal mucosal cells along the pathway to
malignancy. It would be of great interest to know of the survival of patients who had
tumours with ape deletions and those with p53 deletions to assess whether such
lesions do predetermine outcome. One would expect that APC loss should not if it is
indeed implicated in the genesis of colorectal cancer but the loss of p53 implied by
YNZ22 loss may well provide a prognostic indicator, independent of those currently
in use.
These data are the first to show the true high frequency of APC loss in
colorectal cancer tissue and to delineate the nature and extent of that loss. Clearly,
there is still a lot to learn about the involvement of APC in colorectal carcinogenesis.
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CHAPTER 6
ALLELE LOSS IN FAMILIAL AND SPORADIC ADENOMAS.
6.1 Introduction
Allele loss analysis presented in Chapter 5 has demonstrated consistent and
specific deletions of the APC gene in colorectal carcinomas. This chapter addresses
the question of whether such allele losses can be detected in adenomas arising
sporadically or in patients with FAP. It would then be possible to assess whether
the inherited APC gene mutation, which affects only one gene copy, can allow
adenomatous change in the colonic epithelium of FAP patients or whether a second,
somatic, event is required. It might also be possible to gain some measure of the
timing of APC gene inactivation in the adenoma-carcinoma sequence in the sporadic
case.
A series of observations is presented which constitute a stringent assessment
of the deletion status of the APC gene in FAP and non-FAP adenomas. Employing
mapping data from Chapter 4, multiple polymorphic DNA markers have been
utilised to examine allele loss patterns at 4 polymorphic loci close to, and flanking,
APC in FAP adenomas and at a total of 13 polymorphic loci spanning chromosome 5
in sporadic adenomas. Comparison of the frequency of 5q allele loss in FAP and
sporadic adenomas and between sporadic adenomas and carcinomas has been
made both locus-by-locus and by assessing allele loss frequency detected by use of
close flanking markers.
Previous reports have shown 17p allelic deletions in colorectal cancers and
sporadic adenomas (Lothe 1989, Sasaki 1989, Vogelstein 1988). This implies loss of
the gene for p53 which was originally thought to be an oncogene (Oncogene editorial
1988) but has subsequently been shown to have tumour suppressor activity (Finlay
1989). Hence an analysis of allele loss using a highly polymorphic 17p marker






Forty adenomas were harvested from the resected specimens of 4 patients
with FAP undergoing prophylactic colectomy, having been identified as gene carriers
by the screening program presented in Chapters 3 and 8. A total of 20 sporadic
adenomas were harvested from 14 colectomy specimens resected because of co¬
existing carcinoma or because the adenoma was large and/or symptomatic. The 51
sporadic colorectal carcinomas detailed in Chapter 5 serve for comparison.
Peripheral venous blood samples were obtained from all patients.
All tumours were placed immediately on ice and tumour size assessed in the
fresh state by measurement of maximum transverse diameter. Adjacent portions of
tumour were taken for DNA analysis, histology and flow cytometry as described in
Chapter 2. All sporadic adenomas and all FAP adenomas >5mm were examined
histologically after fixing, paraffin-embedding and H and E staining. The remaining
FAP polyps were macroscopically adenomatous with no macroscopic evidence of
malignancy but, due to the small size of these lesions, they were not all examined
histologically. Great care was taken to avoid contamination of polyp tissue with any
surrounding normal mucosa in all classes of tumour. Normal colonic mucosa and
peripheral blood leukocytes once again served as controls. For FAP adenomas,
peripheral blood leukocyte DNA from each patient served as a control since all of the
colonic epithelium can be considered abnormal.
DNA purification and analysis was as described in sections 2.5, 2.6 and 2.9.
6.2.2 DNA probes
Most FAP adenomas were small and so the number of probes used to assess
allele loss was limited to the following 4 probe/enzyme combinations in order to
conserve limited amounts of invaluable DNA: CI 1P1 l(Taql), L5.62(BglII),
EF5.44(Mspl) and YN5.48(Mspl). Additional chromosome 5 probes used for
analysis of sporadic tumours were :^MS8(Hinfl), MC5.61(Mspl), 105-798Rb(Mspl),
105- 153Ra(Mspl), 105-599Ha(Taql), L1.4(EcoRl) and MLZ7.5(EcoRl).
Chromosome 17p allele loss was assessed using YNZ22(Taql) in familial and
sporadic neoplasms. Further probe details, allele sizes and polymorphism
frequencies are shown in Chapter 2.
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6.2.3 Deletion analysis
Assessment of heterozygosity status of the polymorphic markers described in
Chapter 5 in the analysis of sporadic carcinomas was also carried out for adenomas.
Criteria for classification of allele loss and the definition of informative close flanking
markers were as before.
Chapter 5 demonstrates that in carcinomas, loss of heterozygosity does not
occur in all tumours and only a proportion of tumours are informative at any given
probe locus. Therefore, statistical analysis has been carried out to assess whether
variations in allele loss frequency constitute real differences which are a function of
the different classes of tumour examined. Statistical tests used were X2 analysis
with Yates's correction and Fisher's exact test where appropriate.
6.2.4 Flow cytometry.
Flow cytometry, as described in Chapter 2, was carried out on FAP and
sporadic adenomas to assess the overall ploidy level in order to relate this to 5q
allele loss frequency.
6.3 Results
6.3.1 Assessment of allele loss in FAP adenomas.
FAP adenomas ranged in size from 3mm to 1.4cm with only two adenomas
being over 1cm. Due to the precious nature of DNA from these tumours, flow
cytometry was only carried out on the larger adenomas. Despite their small size, all
adenomas tested were aneuploid (example tracings shown in Figure 6.1). In
addition, histological examination of even small adenomas revealed quite aggressive
cytological characteristics (see extreme example in Figure 3. Id).
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Figure 6.1 Example flow cytometric tracings from 2 FAP adenomas. There is an
Twenty-eight FAP adenomas were informative and gave satisfactory technical
results with one or more of the 4 probes used in this analysis. There was no loss of
heterozygosity in 28 adenomas informative at C11P11, 17 informative at YN5.48, 8
informative at L5.62 and 3 informative at EF5.44. Figure 6.2 shows a representative
analysis of 16 adenomas from a patient (KMD 1/5-17) using probe C11P11 in a
Southern blot and DNA hybridisation experiment and demonstrates that there was
no deletion involving the locus recognised by CI 1P11.
aneuploid population (arrowed) with the diploid peak due to
contaminating stroma or lymphocytes combined with a sub-
population of diploid neoplastic cells.
DNA ANEUPLOIDY IN FAP ADENOMAS
113
Figure 6.2 Representative experiment showing no loss of constitutional
heterozygosity at the locus recognised by probe CI IP 11 in 16
adenomas from a patient with FAP who was informative with CI 1P11.
Peripheral blood leukocyte DNA served as control DNA. A1 indicates
the 4.4kb allele, A2 the 3.9kb allele and a common, non-polymorphic
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In total there were 20 FAP adenomas informative on both sides of APC and no
allele loss was detected in any of these tumours. The number of FAP adenomas
informative and the interval spanned for each pair of flanking probe loci are shown
in Figure 6.3. All of these probes map very close to the APC gene and so the
analysis of such markers informative on both sides of APC affords a highly stringent
analysis of the deletion status of that gene.
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Figure 6.3 Combinations of marker loci and the interval delineated by these
markers in FAP adenomas with informative close flanking markers


















6.3.2 Assessment of 5a allele loss in sporadic adenomas.
Allele loss was detected in 3 of the 18 sporadic adenomas (17%) informative
at any chromosome 5 marker and 1 of the 7 adenomas (14%) with informative close
flanking markers. Sporadic adenomas ranged in size from 0.5cm-5.5cm and the
allele losses were distributed throughout the size range, occurring in adenomas of
0.5cm (tubular adenoma), 2.8cm (tubulovillous adenoma) and 1.0cm (tubulovillous
adenoma). Data on allele loss status for all sporadic adenomas are shown in Figure
6.4. This analysis gives a qualitative indication of loss of genetic material in
sporadic adenomas and the data are consistent with involvement of the APC gene in
every case. Since markers mapping considerable distances from APC also exhibited
allele loss (eg T150A), the extent of the deletions in adenomas seem to be similar to
that seen in the carcinomas presented in Chapter 5.
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Figure 6.4 Allele loss analysis in 18 sporadic adenomas informative at 1 or more
of the 13 polymorphic loci. X=allele loss, 0=no loss, -=not
informative. Maximum diameter is given for each adenoma in the
fresh state.
Tumour Size L1.4 MLZ7.5D5S76D5S39D5S78 pi227 C11P11ECB27 L5.62 APC EF5.44 YN5.48 MC5.611MS8
(cm)
T84A 0.75 00---00-0 - - - -
T87A l.O-OO-OOO- - O - - -
T105A 1.0 ----- - ... - - O O
T131A 0.5 00---0 - O- X - - X
T140A 1.8 ----- O O-O - O O -
T141A 0.5 O - O - - O ... - - O O
T150A 2.8 - - X ... . . - -
170A 2.0 ----- O - - - - - O
T180A 2.0 0---00 ... - O OO
T191A1 4.0 - - O - - O ... - - OO
T190A2 0.6 - - O - - - ... - - OO
T192A1 1.8 -00-00 - O- O O - O
T192A2 0.7 - - O ... - . - O
T237A1 5.0 ----- - ... - O O -
T237A2 5.5 ----- - ... - O O -
T237A3 1.0 ----- - ... - X O -
T237A4 2.0 ----- - ... - O O -
T237A6 3.5 ----- - ... - O O -
Due to the confounding biological problem that not all individuals are
informative for every probe, an assessment of whether FAP and sporadic adenomas
represent 2 separate populations as regards the APC deletion status has to be based
on statistical comparison of allele loss frequencies in the two classes of tumour. The
small numbers of adenomas in this series preclude valid comparison of allele loss
frequencies in sporadic adenomas and carcinomas and so the analysis presented
here has been expanded to include a further set of sporadic adenomas analysed by
my co-workers in Edinburgh University Pathology Department. The same battery of
probes were employed in both data sets and the following comparison combines my
own data on 18 informative sporadic adenomas and 28 informative FAP adenomas
with data on a further 40 informative sporadic adenomas analysed in Edinburgh
University.
There was a significant difference in allele loss frequency at any chromosome
5 locus between sporadic adenomas (18/58, 31%) and FAP adenomas (0/28)
(X2=9.195, p<0.01). However, a more critical analysis of this difference is by
comparison of allele loss frequency at close flanking markers in tumours of similar
size (ie. <1.5cm), since size may be a predictor of progression to malignancy (Muto
1975). Six of 12 sporadic adenomas (50%) in this category and none of 20 FAP
adenomas exhibited such APC related allele loss (X2=9.24, p<0.01).
The numbers of tumours analysed have been expanded by the Edinburgh
University series to allow assessment of the relative contribution of the allele loss
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frequency at each of the 4 loci examined in FAP adenomas compared to sporadic
adenomas (Table 6.1). Despite this analysis being larger than any other published
to date, the problem of incomplete informativity mean that the trend observed in
each case just fails to reach statistical significance.
Table 6.1 Frequency of allele loss detected at each of the 4 loci examined in FAP
adenomas compared with sporadic adenomas when analysed at
respective loci. The overall number of each category of tumour









6.3.3 Assessment of 5a allele losses in sporadic adenomas and carcinomas.
The frequency of detection of chromosome 5 allele losses in the 18
informative sporadic adenomas presented here was compared to the frequency of
allele losses detected in sporadic carcinomas as presented in Chapter 5. There was
a statistically significant difference in allele loss frequency detected at any
informative chromosome 5 locus between sporadic adenomas and carcinomas; 3 of
18 informative adenomas (17%) and 34/51(67%) of informative carcinomas
(X2=i 1.44, pcO.OOl; exact probability, p<0.0006). There is no bias in these data
due to carcinomas being informative more often and at loci closer to APC than the
adenomas since the mean number of informative markers mapping <15mB from
APC (ie those at or internal to pi227 and MC5.61) in adenomas was 2.9 (range 1-5)
and in carcinomas was 2.27 (range 1-5). Tumours with informative close flanking
markers were therefore compared and the difference in frequency of allele losses
detected in adenomas (1/7, 14%) and carcinomas (14/25, 56%) is maintained
although this fails to reach the level of conventional statistical significance (X2=2.33,
exact probability p=0.12).
Comparison of allele loss at each locus in sporadic adenomas and in
carcinomas is shown in Table 6.2. Data from probes 105-798Rb, 105-153Ra and
105-599Ha have been pooled, as have data from LI.4 and MLZ7.5, as these markers
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map very close to each other and are some considerable distance from APC (Leppert
1987).
Table 6.2 Allele loss frequency 5 polymorphic DNA markers in sporadic
adenomas and carcinomas. Number of tumours informative with
those exhibiting allele loss at each locus (percentage in parentheses).
Allele loss frequency
Probe Informative Adenoma Carcinoma
location probes (n=20) (n=51)
- Any chromosome 5 3/18(17%) 34/51(67%)*
- Close flanking 1/7(14%) 14/25(56%)
5q34 AMS8 1/9(11%) 13/38(34%)
MC5.61 0/11(0%) 12/21(57%)"
YN5.48 1/8(13%) 9/21(43%)
EF5.44 1/3(33%) 6/11 (55%)





5ql3 105-153Ra 1/8(13%) 14/38(37%)
105-599Ha
5p LI.4 0/6(0%) 3/36(8%)
MLZ7.5
*X2=11.44, p<0.001; **X2=7.76, p<0.01.
The trend towards a lower frequency of loss of heterozygosity at each locus in
sporadic adenomas when compared with carcinomas supports the overall data on
any informative marker although this difference only achieves statistical significance
with the probe MC5.61. There were no cases of homozygous deletion detected with
any marker in colorectal adenomas.
6.3.4 Assessment of 17p allele losses in FAP and sporadic neoplasms.
There was no YNZ22 allele loss detected in the 28 FAP adenomas which were
informative with this probe. Good technical results were only obtained for 15
sporadic adenomas and 1 of the 8 (13%) informative with YNZ22 exhibited 17p allele
loss (Table 6.3). When the small numbers of tumours analysed are considered, the
frequency of allele loss is broadly similar to that reported in other studies (Lothe
1989, Sasaki 1989, Vogelstein 1988). As detailed in Chapter 5, the frequency of 17p
allele loss in sporadic carcinomas is also similar to reported series. 17p allele losses
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are far less frequent in both sporadic and familial adenomas than in carcinomas,
suggesting two populations of tumours as regards 17p allele loss (FAP adenoma vs.
sporadic carcinoma, x2=23.4, pcO.OOl; sporadic adenoma vs. carcinoma ,
x2=4.519, p<0.05). The numbers are too small for comparison of YNZ22 loss
between FAP and sporadic adenomas.
Table 6.3. Frequency of demonstration of 17p allele loss as detected by probe
YNZ22 in FAP and sporadic neoplasms. n=number of tumours






YNZ22 0(0%) 1(13%) 25(61%)
The only sporadic adenoma which exhibited YNZ22 allele loss (T170A) was a
tubulovillous adenoma 2.0cm in diameter which had not lost any 5q markers.
Clearly, little can be inferred from this data but it does suggest that there is no
strong association between 17p and APC loss.
Comparison of histology, ploidy and allele loss data for each sporadic
adenoma is shown in Table 6.4. Flow cytometric data are incomplete due to loss of
stored tumour material after a freezer thaw. All sporadic adenomas examined were
diploid and it is notable that the adenoma which exhibited YN5.48 allele loss was a
diploid tumour, supporting the notion that APC inactivation is an early event. There
was no particular predilection for allele loss to occur in any particular size or
histological type of adenoma.
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Table 6.4 Ploidy level, histological classification, size and allele loss status at 5q
(APC) and 17p (p53) of all 20 sporadic adenomas studied. NI = non-
informative, - = no allele loss, + = allele loss.
Adenoma Ploidy Histology Size Allele loss status
level Ch.5(APO 17p(p53)
T84A - Tubular 0.75cm - NI
T87A • - Tubular 1.0cm - -
T94A - Tubulovillous 0.5cm Nl InsufT.DNA
T105A - Tubular 1.0cm - NI
T131A - Tubular 0.5cm + -
T140A - Tubulovillous 1.8cm - NI
T141A - Tubulovillous 0.5cm - -
T150A - Tubulovillous 2.8cm + NI
T170A - Tubulovillous 2.0cm - +
T180A 1.0 Tubulovillous 2.0cm - -
T182A - Tubular 0.5cm NI NI
T191A1 1.0 Tubulovillous 4.0cm - -
T191A2 - Tubulovillous 0.6cm - -
T192A1 - Tubulovillous 1.8cm - -
T192A2 - Tubulovillous 0.7cm - Insuff.DNA
T237A1 1.0 Tubulovillous 5.0cm - NI
T237A2 1.0 Tubulovillous 5.5cm - NI
T237A3 1.0 Tubulovillous 1.0cm + NI
T237A4 - Tubulovillous 2.0cm - NI
T237A6 1.0 Tubular 3.5cm - NI
6.4 Discussion
This chapter describes a stringent assessment of the deletion status of the
APC gene in familial and sporadic colorectal adenomas. Multiple polymorphic DNA
markers mapping veiy close to, and on both sides of, the APC gene have been
analysed in each category of neoplasm. The series of experiments presented in this
chapter and in Chapter 5 have been able to demonstrate clear differences in the
frequency of APC-related allele loss in FAP adenomas, sporadic adenomas and
sporadic carcinomas. These are the first data which show that the three classes of
tumour represent different populations with regard to their APC deletion status.
The results demonstrate that the development of colorectal adenomas in Familial
Adenomatous Polyposis does not require a 'second hit' at the APC locus in addition
to the inherited APC mutation, even though the tumours studied exhibited signs of
histological aggression and aneuploidy.
Allele losses in carcinomas developing in patients with FAP have been
demonstrated with markers which map to loci some considerable distance from APC
(Miyaki 1990a and b, Sasaki 1989). Such deletions would certainly have been
detected had they already been present in the aneuploid FAP adenomas analysed in
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these experiments by use of flanking markers which span APC by as little as 2-3mb
in some cases (see Chapter 4). There are published reports showing 5q allele loss in
a small minority of FAP adenomas (Rees 1989, Sasaki 1989). However, these
studies did not employ markers closely flanking ape. Hence it is possible that the
observed allele losses in those studies were non-specific and resulted from
generalised chromosomal instability. Such instability has been described, even in
extra-colopic tissues in FAP (Delhanty 1983, Harnden 1984). A further explanation
for the detection of allele losses detected in adenomas using the micro-satellite probe
AMS8 (Rees 1989) may be due to inherent instability at the locus recognised by that
probe (Wayne 1990, Wong 1987). However, another more attractive explanation
exists which suggests that adenomas (familial or sporadic) which are destined to
become carcinomas lose the remaining functional APC gene at an early stage. This
hypothesis is supported by the data presented here and elsewhere that allele losses
are detected throughout the size range of sporadic adenomas (Vogelstein 1988) and
familial adenomas (Rees 1989), including those <lcm. Progression to malignancy
for any individual FAP adenoma is an infrequent event when the vast number
present in the colorectum of an affected patient is considered (Bussey 1975). Hence,
the frequency of carcinomatous change in FAP adenomas must be substantially
lower than is the case for sporadic adenomas (Morson 1983, Muto 1975) and so it is
not surprising that these experiments have shown a significantly lower frequency of
allele loss in FAP adenomas compared to their sporadic counterparts.
Since these data suggest that, as regards APC deletion, every colorectal
mucosal cell has the wherewithall to become adenomatous, a hypothesis must be
proposed to explain why the whole of the colorectal mucosa is not adenomatous in
patients with FAP. Bodmer has suggested that there is natural variation in the level
of APC gene product which rarely if ever goes below a threshold level in the normal
homozygote (Bodmer 1987). However, in the deficient heterozygote (either due to an
inherited constitutional mutation in FAP or to an acquired mutation in one or more
colonic epithelial cells in the sporadic case) the level of APC gene product would
drop below the threshold and the adenomatous polyp could then develop. In the
deficient homozygote the APC gene product would be virtually absent and
presumably would then allow carcinomatous change to progress.
One criticism of this study might be that sporadic adenomas were collected
from patients who almost all had a co-existing carcinoma and the remainder were
symptomatic and difficult to remove by endoscopic polypectomy. However, most
published series have analysed adenomas collected from such patients and there are
practical difficulties in obtaining large numbers of adenomas not associated with
carcinoma, such as those obtained at colonoscopy. It will be of interest to ascertain
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the true frequency of allele losses in adenomas from patients who do not also have a
carcinoma.
Allele losses demonstrated in this study could represent first, or a second
inactivating events at APC. If the deletions demonstrated in sporadic adenomas
were due to a first event and a subsequent similar somatic deletion were required to
allow progression to malignancy, it seems highly improbable that homozygous
deletions of any marker mapping veiy close to APC was not detected in any of the
carcinomas analysed in Chapter 5. The most compelling evidence that the deletions
detected in these sporadic adenomas and in the sporadic carcinomas presented in
Chapter 5 represent second events is the finding that in carcinomatous tissue
arising in a number of patients with FAP, allele loss was detected at a marker locus
some distance from APC and it was the allele inherited in association with the
mutant APC allele which was retained (Miyaki 1990a and b).
Although these data, combined with published reports, suggest that the
deletions observed in sporadic adenomas represent second events, it is possible that
a substantial deletion could be a first event with subsequent homozygous deletion
occurring due to a microdeletion or point mutation. This could occur if there is
selection against two substantial losses from the region around APC. A colorectal
mucosal cell with sufficient molecular lesions to allow adenomatous change may not
be able to sustain homozygous loss of a large portion of chromosome 5 due to the
presence of other important genes which are essential for cell survival. The
observed allele losses could be all that is required genotypically while epigenetic
inactivation of the other APC allele might occur by genomic imprinting (see Chapter
4). It has been suggested, with some circumstantial supporting evidence, that the
'second hit' never happens and that repression of the remaining allele by imprinting
modification is retained into adulthood in some cells (Reik 1989, Sapienza 1989).
There are no experimental data on imprinting in colorectal cancer but the
hypothesis will be testable by search for preferential loss of one or other parental
allele using the markers described here. There are no hard data as yet as to
whether one or two events are required at APC for carcinomatous change or what
types of lesion are allowable. It is also unknown whether a carcinoma can arise
from a cell population which has two normal APC alleles. Once the APC gene has
been cloned it will be possible to provide definitive data on this by sequencing both
alleles.
Vogelstein has suggested that the role of APC is as a negative regulator of
cellular proliferation in the colorectal mucosa and that inactivation of one copy
reduces normal gene expression, allowing epithelial hyperproliferation (Vogelstein
1988). He proposes that loss of at least one allele would be required but loss of both
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alleles would not be necessary. Subsequent events leading to adenomatous, then
carcinomatous change might be Kiras mutation (Bos 1987, Forrester 1987) or loss of
tumour suppressor gene function at other chromosomal locations (Fearon 1990b),
such as the gene for p53 (Baker 1989) or the DCC gene on 18q (Fearon 1990a). The
findings of a high frequency of 5q allele loss in FAP carcinomas (Miyaki 1990a and
b, Sasaki 1989) argue against Vogelstein's original notion that one lesion on APC is
sufficient but all published data do support his proposals of the later events in
colorectal carcinogenesis involving on 17p, 18q and Kiras.
Data presented in this chapter tend to support the proposal that APC
inactivation occurs early in colorectal carcinogenesis since there appears to be no
association in adenomas of pathological and flow cytometric findings. 5q 17p allele
loss data in adenomas suggest that loss of p53 is not necessarily required in
association with APC gene loss.
This chapter has allowed some insight into the requirements for APC gene
loss in colorectal tumours and sheds some light on the timing of such deletion in
relation to the adenoma-carcinoma sequence. The definitive answer to the question
of APC inactivation by one or two events, by point mutation or deletion, and its
effect on cellular function in the colorectal mucosa will have to wait until cloning,
sequencing and full characterisation of the APC gene itself.
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CHAPTER 7
PULSE FIELD GEL ELECTROPHORESIS.
7.1 Introduction
Mapping data generated by linkage analysis in FAP families presented in
Chapter 4 and deletion analysis in sporadic colorectal carcinomas described in
Chapter 5-strongly suggest that the locus recognised by the marker EF544 lies very
close to the APC gene itself. This chapter describes an analysis of large DNA
fragments designed to detect constitutional rearrangements at the EF544 locus due
to deletions involving APC which would be causative of the FAP syndrome in that
individual patient.
Patients who develop FAP due to new mutation of APC but in whom
cytogenetic analysis of peripheral blood leukocytes is normal must carry relatively
small deletions, insertions or point mutations within APC resulting in the clinical
manifestations of the syndrome. A difference at the molecular genetic level must
exist between normal parents and affected offspring. Comparison of the fragments
bearing the marker locus shown by mapping analysis to be closest to APC might
reveal rearrangements which would be important confirmation of the proximity of
that marker. It would also be an invaluable tool in targeting a specific region with a
view to isolation and cloning ofAPC itself.
7.2 Methods
7.2.1 Clinical material.
In two separate families (KMD 10 and 11), I have screened the parents and
siblings of the probands to be clear of FAP. Therefore both probands are new APC
mutations. Since both have two surviving parents, these patients are suitable for
pulse field gel electrophoresis (PFGE) analysis.
7.2.2 Analysis by pulse field gel electrophoresis.
Protocols for PFGE are detailed in Chapter 2. For these experiments fresh
peripheral blood leukocytes (proband and parents of KMD 10) or EBV transformed
lymphoblastoid cell lines (proband and parents of KMD 11) were embedded in
agarose plugs as described in Chapter 2. Plugs were digested with 4 rare cutting
restriction endonucleases (Nrul, Mlul, Sail, Notl) and the resultant fragments were
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fractionated on a pulse field gel apparatus. Marker chromosomes were those of
Saccharomyces Cerevisiae (strain YPhl48) which gives band sizes as shown in
Chapter 2. PFGE was carried out at 100V with 200s pulse time for 5 days.
Prolonged Southern blotting was carried out and filters hybridised with probe
inserts of EF5.44 and separately with L5.62 as previously described.
7.3 Results
These results effectively exclude deletions involving APC for a distance of up
to 800kb either side of EF5.44 in the two patients analysed. Figure 7.1 shows an
example PFGE experiment with plugs digested with Sail. The ethidium bromide
stained gel photograph is also shown with S. Cerevisiae marker chromosomes. The
autoradiograph (below) shows cross-hybridisation of a small amount of labelled
contaminating pUC18 plasmid vector which carried the EF5.44 clone, despite
attempts to remove all vector. This cross-reaction is of value because it reveals the
relative positions of the 1050kb and 92kb marker yeast chromosome. The EF5.44
locus is included on a 470kb Sail fragment. No rearrangement is apparent and this
was the case for all 4 enzymes with EF5.44 hybridising to a 1.2mB Nrul fragment, a
120kb Notl fragment and a 800kb Mlul fragment.
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Figure 7.1 PFGE experiment analysing Sail EF5.44 fragments in two new APC
mutations with both sets of parents as controls. Ethidium bromide
stained gel above showing relative positions of YPhl48 marker
chromosomes.
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This chapter describes an unsuccessful attempt to identify constitutional
rearrangements involving EF5.44 which would have been an important tool for
mapping the APC gene. However, these experiments have excluded APC deletions as
the cause of the FAP syndrome in these two individual patients and are compatible
with the view that deletions involving APC are rare. This is supported by reports
showing that cytogenetically detectable 5q deletions causing FAP are extremely rare
(Herrera 1986, Hockey 1989, Endo 1987). It seems likely that the causative APC
lesion in most patients may involve a point mutation. However, small deletions
cannot be wholly excluded as they may been missed due to the limitations of
resolution achievable by the experimental technique or because such deletions did
not overlap the fragment carrying the sequences recognised by EF5.44.
The potential of this series of experiments for isolation of APC has not been
fully realised since neither patient had a deletion. However, exclusion of deletions
involving many kilobases of chromosome 5 DNA in these patients has been an
important first step in the characterisation of common mutations resulting in the
FAP syndrome. Identification and sequencing of the APC gene may well be achieved
quite soon and characterisation of different APC mutations will then be an important
part of that work.
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CHAPTER 8
PRESYMPTOMATIC DIAGNOSIS OF FAMILIAL ADENOMATOUS POLYPOSIS BY
DNA PROBE ANALYSIS.
8.1 Introduction
The emphasis of the data from FAP families presented in earlier chapters of
this thesis has been on linkage analysis for the purposes of mapping marker probes
relative to APC. Having established a map of the region around APC from linkage
and deletion studies, this can be combined with published linkage analyses and a
physical map of the region (Nakamura personal communication 1990). Such data
can be utilised for presymptomatic diagnosis of FAP in at-risk family members in
order to influence clinical management.
This chapter presents the first clinical application of DNA analysis in FAP. A
prospective evaluation of the clinical value and validity of such analysis for 41
individuals within the families studied in this project in whom FAP could not be
excluded due to young age or because screening had not been instigated or
completed.
8.2 Patients and Methods
In brief, this analysis consists of an assessment of clinical risk derived from
age at last negative colonoscopy combined with risk derived from linked DNA
markers, followed by a comparison of clinical data obtained during the round of
screening described in Chapter 3. This allows an assessment of the clinical value of
genotype data and of the validity of the risk assigned for each individual.
Forty one members of 7 of the families (KMD 1,2,3,4,6,8,14) were identified as
being at risk of FAP prior to screening. Eleven (27%) had previously undergone
examination of the colon and had been thought to be unaffected. There is a 50%
prior risk that offspring of a patient with FAP will carry the gene defect but this risk
reduces with increasing age at each negative colonic examination. Valid estimation
of such age-dependent risk can only be made from age-of-onset curves derived from
a population of patients who have previously been screened negative, but
subsequently develop polyps. The liability classes delineating age-dependent
penetrance used for this study are shown in Table 8.1 and are derived from
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published age-of-onset curves (Murday 1989). The prior risk for each individual
screened is shown in Table 8.2 and was assigned as 0.5 for those who had never
been screened. Risk was assigned for those who had previously been examined as
<0.5 depending on the age at last negative screen. For example the prior risk for an
individual, last screened negative at age 25 was 0.10, or a 10% chance of being
affected.











Genotypes were obtained for each individual and all members of that family
using 6 DNA probes as described in Chapter 4. The final linkage map presented in
Chapter 4-includes data from a number of the individuals who underwent screening.
A preliminary run with the LINKAGE program prior to any screening revealed
substantially the same mapping data, though the lod-scores were lower (data not
shown). Hence, for the purposes of this analysis, probe order and recombination
fractions for linkage to APC were derived by combining the preliminary linkage
analysis with a variety of independent data including published linkage analyses
(Bodmer 1987, Leppert 1987, Meera-Khan 1988, Nakamura 1988, Varesco 1989,
Tops 1989), in situ hybridisation analysis (Varesco 1989), physical mapping data
(Nakamura personal communication 1990) and the deletion analysis in sporadic
colorectal carcinomas presented in Chapter 5 (Ashton-Rickardt 1989). The
amalgamated data confidently support a locus order of pi227-Cl 1P11-ECB27-L5.62-
APC-EF5.44-YN5.48 with recombination fractions of 0.03, 0.03, 0.02, 0.02, 0.01,
0.02 in respective intervals. The 95% probability limits for linkage of probes pi227,
C11P11, L5.62 and YN5.48 to APC are narrow and so have not been taken into
account in risk analysis. In addition, probability limits have little influence on risk
estimation when close flanking markers are informative and when independent
clinical and genetic risk estimations are combined, as reported here.
Risk estimations for genotype data were calculated using multipoint linkage
analysis with the MLINK program in the LINKAGE 5.02 group of programs on an
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IBM Series 70 80386 computerwith math coprocessor. Computation times for KMD
1 took around 4 hours due to the number of unknown genotypes in early
generations.
A preliminary risk estimation was calculated for each individual by
combining genotype data and prior risk. All at-risk family members over 13 years of
age were then invited for screening of the large bowel by colonoscopy or by rigid
sigmoidoscopy and barium enema. All polyps were biopsied for histological
confirmation. In addition to colonic screening, affectation status was also assigned
according to the presence or absence of congenital hypertrophy of the retinal
pigment epithelium (CHRPE) (Blair 1982, Chapman 1989, Iwama 1990,
Polkinghorne 1990, Traboulsi 1987). Individuals with more than three lesions, and
those with diagnostic large and/or bilateral lesions were considered to be gene
carriers while those with less than 3 lesions were considered negative as suggested
by Chapman (Chapman 1989). Retinal assessment by direct and indirect
ophthalmoscopy was carried out by myself initially and then independently by an
ophthalmologist (Professor CI Phillips) and a fundal camera operator (Mr S Gairns).
There were no inconsistencies in the assessment of numbers, laterality and size of
the retinal pigmentation. All CHRPE lesions were photographed and examples are
shown in Chapter 3.
Empirical assignment of a penetrance value for CHRPE was required as there
are conflicting published data. One study has suggested that expression of CHRPE
tends to co-segregate faithfully with colonic manifestations of the gene defect
(Chapman 1989). However, other reports suggest around 90% of affected
individuals in any given FAP family exhibit CHRPE (Iwama 1990, Polkinghorne
1990, Traboulsi 1987). Therefore, penetrance has been taken as 0.90 in order to
minimise any possibility of false reassurance to patients. Family members were also
assessed clinically and radiologically for the presence of cranio-facial osteomas.
Orthopantomography was not carried out in children. Two children (KMD8/4-6 and
4-7) exhibited gross cranial osteomas and so have been assigned as gene carriers.
Unfortunately, it was not possible to carry out direct or indirect ophthalmoscopy in
these patients due to practical considerations.
Clinical screening by any modality was completed for 34 individuals (83%);
18 (43%) by colonic examination, 24 (59%) by ophthalmoscopy and 9 (21%)
assessment for cranio-facial osteomas (see Table 8.2). The final clinical diagnosis
based on colonic, retinal or bony findings for those who are affected is a hard end-
point against which to evaluate the genotype-derived risk estimation. However for
those who appeared to be unaffected there is no such 'gold standard'. Therefore,
following a negative screen, the new clinical data were added in to a further
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computer calculation in order to reassign the risk estimation to produce a residual
(final) risk. All relatives of these individuals who were shown to be affected by the
current round of screening were included in this calculation, thereby improving
linkage phase information. Residual risk in some cases was calculated as less than
that of the general population, thereby effectively excluding FAP and serving as a
hard end-point. In others the residual risk was sufficiently low to influence
screening policy for their future care.
8.3 Results
Table 8.2 shows the prior risk, probe derived risk, combined probe/prior risk
with residual risk for those screened negative on the current round of examinations
and all references in the text below are to these data. Risk estimation derived from
genotype data has been assigned for the majority of the study population. One or
more probes were informative in all but two cases. The frequency of probe
informativity ranked in descending order was pi227(83%; 95% confidence intervals
(CI), 71.2-94.7%), YN5.48(51%; 95% CI, 35.6-66.8%), L5.62(46%; 95% CI, 30.8-
61.9%), CI IP 11(41%; 95% CI, 26.1-56.9%), EF5.44(24%; 95% CI, 11.0-37.8%),
ECB27(2%; 95% CI, 0-7.3%). Data from informative flanking probes were obtained
for 28 of the 41 individuals studied (68%; 95% CI, 53.8-82.8%). The use of pi227
and YN5.48 in combination was particularly efficient since at least one probe was
informative in 35 instances (85%) and both probes were informative in 21 (51%) out
of all 41 individuals tested.
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Table 8.2 At-risk family member, prior risk, probe derived risk and DNA probes
informative (P=pi227, C=C11P11, EC=ECB27, L=L5.62, EF=EF5.44,
Y=YN5.48). Combined probe and prior risk is only indicated if prior
risk was <0.5, otherwise combined risk is as for probe derived risk
alone. Screening modality: 1colonoscopy and biopsy, 2=CHRPE
phenotype, 3=clinical and/or radiological osteomas. Final clinical
diagnosis is shown with residual risk in parentheses. ? indicates
unknown final clinical status (ie young child with unknown CHRPE
status). Broken lines separate individuals from different families.
The residual risk for individuals 4/4-1 and 4/4-2 was influenced























1/4-25 0.50 Y P.C.Y 0.0040 _ 1,3 -ve(<0.000007)
1/5-7 0.25 Y P,C,EC,L,EF 0.9503 0.8636 1,2,3 affected
1/5-13 0.15 Y P.Y 0.0032 0.00056 1,3 -ve(0.000003)
1/5-14 0.10 Y P,Y 0.0032 0.00036 1,3 -ve(0.000003)
1/5-15 0.25 Y P,L,Y 0.0006 0.0002 1.3 -ve(0.000006)
1/5-16 0.10 Y P,Y 0.0032 0.00036 1,3 -ve(0.000036)
1/5-17 0.50 Y P.Y 0.9968 - 1,2,3 affected
1/5-18 0.50 Y Y 0.0865 - (declined) 7(0.0865)
1/5-19 0.25 Y P,C 0.0680 0.0237 1 -ve(0.0179)
11/5-20 0.25 Y P.c 0.0680 0.0237 1 -ve(0.0179)
1/6-1 0.50 Y P,L 0.0200 - 2 -ve(O.OOll)
1/6-2 0.50 Y P,L,EF 0.9998 - 2 affected
1/6-3 0.50 Y P,L 0.9800 - 2 affected
1/6-4 0.50 Y P,L,EF 0.9998 - 2 affected
1/6-7 0.50 Y C,L,EF 0.0004 - 2 -ve (0.00002)
1/6-8 0.50 Y C,L 0.0200 - 2 -ve (0.0011)
1/6-9 0.50 Y C,L 0.0200 - 2 -ve(0.0011)
1/6-10 0.50 Y C,L 0.9799 - 2 affected
2/2-4 0.10 Y P,C,EF,Y 0.9991 0.9920 1,2 affected
2/2-6 0.15 Y P,C,EF,Y 0.8777 0.5588 1,2 affected
2/2-7 0.25 Y P,C,EF,Y 0.0007 0.0002 1,2 -ve(0.000017)
2/3-1 0.50 Y P.C.Y 0.9798 - 1,2 affected
2/3-2 0.50 Y P.Y 0.0026 - 1,2 -ve (0.00006)
3/3-1 0.50 Y P.Y 0.9612 _ 2 affected
3/3-2 0.50 Y P.Y 0.9272 - 2 affected
4/3-6 0.50 N _ _ 1 affected
4/4-1 0.50 Y P 0.4378 - (not performed) ?(0.8757)
4/4-2 0.50 Y P 0.1561 - (not performed) 7(0.3122)
6/4-1 0.50 Y P 0.0952 2 affected
6/4-2 0.50 Y P,Y 0.7728 - 2 -ve(0.1518)
6/4-3 0.50 Y P,Y 0.0032 - 2 -ve(0.0032)
8/4-1 0.50 Y P.C.L.Y 0.00065 - 1,2 -ve(0.000018)
8/4-2 0.50 Y P.C.L.Y 0.00065 - 1,2 -ve(0.000036)
8/4-4 0.25 Y P,L 0.9128 0.7772 1,2 affected
8/4-5 0.50 Y P,L,EF 0.9998 - 3 affected
8/4-6 0.50 Y P,L,EF 0.9998 - 3 affected
8/4-7 0.50 Y P.L.EF 0.9998 - (not performed) 7(0.9998)
8/4-10 0.50 Y P.C.L.Y 0.9994 - (not performed) 7(0.9994)
8/4-11 0.50 Y P.C.L.Y 0.5960 - 2 -ve(0.1408)
8/4-12 0.50 Y P.C.L.Y 0.9994 - (not performed) 7(0.9994)
14/5-1 0.50 N - - - (not performed) 7(0.5)
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Figure 8.1 shows an example family (KMD 2) demonstrating segregation of
the chromosome carrying the mutant APC gene (d) and haplotypes for all informative
probes. Haplotype data of this kind are extremely powerful since recombination
events and errors of genotyping can be easily identified. The haplotypes of the
chromosome harbouring the mutant APC gene and that with the normal gene can be
followed through the family to predict risk as described below. Figure 8.1 consists of
the provisional pedigree for KMD 2 prior to the screening described in Chapter 3 (for
final version see Appendix A and Figure 4.2). Half-filled symbols indicate those who
were at-risk at the outset of this project. Two individuals in F2 (KMD 2/2-4 and
KMD 2/2-6) and 1 in F3 (KMD 2/3-1) with shaded haplotypes were at high risk of
carrying the disease gene and the calculated risk is shown in Table 8.2. Those
screened negative are shown with an unshaded haplotype (KMD 2/2-7 and KMD
2/3-2) and the liability class following screening is shown in each case. On the
initial calculation, a risk of 0.88 was assigned to KMD 2/2-6 since she inherited the
chromosome with a recombination event between CI IP 11 and EF5.44 (see Table
8.2). This risk is calculated because EF5.44 predicts an affected status while
CI IP 11 predicts an unaffected status. Therefore, there has been a recombination
event which could have occurred at any point in the interval EF5.44-C11P11 and
the computer analysis takes this, and the respective recombination fractions, into
account when assigning a risk estimation. This case serves to stress the value of
data from.flanking markers because if only C11P11 had been informative, the risk
for that patient would have been calculated as only 0.07.
Fourteen of the 15 patients screened and shown to be affected (93%) had
been assigned probe derived risks of 0.93 or greater. Previously, 4 of these
individuals (KMD 1/5-7, KMD 2/2-4, KMD 2/2-6, KMD 8/4-4) had been discharged
from follow-up on the basis of negative colonic screening. All 4 individuals are
actually affected and KMD 1/5-7 already had carcinoma in situ in the resected colon
(see Chapter 3). These patients may well have developed infiltrative colorectal
cancer had they not been part of this study. The level of combined risk in these
cases is lower than the probe derived risk alone because of the earlier negative
screening. These cases emphasise the importance of DNA analysis in minimising
inadequacies in clinical screening.
An initial combined risk of 0.095 was assigned for one individual (KMD 6/4-
1) which was at variance with clinical findings that indicate he is affected. However,
only one probe was informative in this case, resulting in a level of risk which would
not have influenced clinical management.
Eighteen individuals were screened negative on the current round of
examinations. Fourteen of these (78%) had been assigned probe derived risk
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estimations of around 0.01 or less and 16 (89%) assigned a risk of <0.10.
Combining probe information and clinical data based on the negative findings at this
examination, residual risk estimations of 0.001 or less were assigned to 16/18
(89%). Ten individuals (56%) had residual risks substantially less than 0.0001,
which is the incidence rate of FAP in the general population.
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Figure 8.1 KMD 2 showing segregation of the shaded haplotype with the disease
(d) allele in three generations. The haplotype for the deceased
affected individual in F1 has been inferred. The unshaded
chromosome is inherited with the normal allele (+). The clinical
liability class for those screened negative during the current round of
examinations is shown in parentheses next to the + allele. There has
been a recombination event in the interval C11P11-APC, resulting in
the haplotype 31d21 in of the offspring in F2.
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The aim of screening the colon of patients with FAP is to identify gene
carriers who require prophylactic colectomy. However, there is a substantial burden
of screening procedures undergone unnecessarily by the 50% of at-risk individuals
who are actually unaffected. In addition, young adults at risk and affected parents
who wish to know whether or not they have passed on the mutant gene to their
offspring suffer psychological morbidity from the uncertainty inherent in the
prolonged clinical screening required.
This study highlights the practical clinical value of risk analysis using linked
DNA probes. The validity of probe derived risk estimation has been demonstrated
and genotype information from a simple blood test, when combined with
independent clinical data, provides an estimation of residual risk for each patient
which can be used to influence future screening policy. The use of linked DNA
markers can avoid inappropriate discharge of gene carriers after sub-optimal or
foreshortened screening protocols. In this study population, 4 individuals aged
between 30 and 40 years would almost certainly have developed colorectal cancer
had tracing, genotyping, clinical screening and subsequent surgery not been
undertaken. This serves to emphasise the need for continued colorectal surveillance
until middle age in patients assigned high risk estimations or those with
indeterminate risk.
A clear distinction must be made between what is an acceptable level of risk
to inform a patient of the likelihood that he/she is affected and what is an
acceptable level of risk to allow a reduction in screening. While an initial combined
risk of 0.7 would allow the clinician to advise a patient that it is probable he/she is
affected, a probe derived risk of 0.01 or less seems the necessary level required
before any radical change in screening policy can be undertaken. The rationale for
selecting this level of risk is that an at-risk individual screened negative for polyps
and for CHRPE on first examination at the age of 15 who has a probe derived risk of
0.01 has a 3 in 10,000 chance of being affected. At this level it would be reasonable
to advise only a single further colonic examination at the age of 30 years when the
residual risk will be only 0.00001 if he/she is again screened negative, ten times
less than the incidence of the disease in the general population. For individuals
aged 15 with no polyps and negative CHRPE who have a probe derived risk of 0.1-
0.01, it would also be reasonable to reduce colonic screening frequency to perhaps
once every 2-3 years since the residual risk is only 0.004.
The methodology employed here merits some discussion. Locus order was
based on an amalgamation of independent data from linkage analysis and data from
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rare recombination events described in Chapter 4, published rare recombination
events (Tops 1989), published linkage data (Bodmer 1987, Leppert 1987, Meera-
Khan 1988, Nakamura 1988, Varesco 1989, Tops 1989), deletion analysis in
colorectal cancers (Ashton-Rickardt/Chapter 5) and physical mapping data
(Nakamura personal communication 1990). The recombination fractions between
marker and APC are somewhat greater than might be suggested by summation of
published data but it is important not to place a marker over-optimistically close to
APC and give ill-informed reassurance to patients. Liability classes have been
assigned based on the age-of-onset curves of Murday (Murday 1989) since it is the
risk of developing polyps after being screened negative which is of importance to risk
analysis. These penetrance values are substantially different from those suggested
by curves derived from age of presentation of polyps which are the data usually
quoted (Muto 1975).
Flanking markers were informative in 68% of individuals tested with a 95%
confidence interval of 53.8-82.8%. Risk estimation is extremely accurate when
flanking markers are informative and the risk assessments derived from each probe
concur. In practice the phenomenon of genetic interference (where there is a
selection against the occurrence of two recombinations close to each other) ensures
an even greater diagnostic accuracy than that suggested by the computer calculated
risk shown here. Recombinations between flanking markers were identified in four
individuals (KMD 2/2-6, KMD 6/4-2, KMD 8/4-4, KMD 8/4-11; see Table 8.2). The
value of informative flanking markers cannot be over-stressed since such
recombination events can be recognised and taken into account in the risk
calculation. If only a single marker is informative then, in a proportion of patients
(dependent on recombination fraction), crossovers which occur between that marker
and APC will not be recognised.
At-risk family members and their parents universally welcomed a simple
blood test with the potential to give an estimation of the risk of having inherited the
mutant gene. It was clear that prolonged and repeated examination of the
colorectum was a burden to all those who required it. Indeed one of the study group
(KMD 1/5-18) agreed willingly to the blood test but refused to have any colonic or
ophthalmological examination despite counselling. Fortunately, his genotype
suggests he is unaffected although he and his children will be included in FAP
screening programs with regular invitations for endoscopic follow-up.
There were no affected mothers or mothers-to-be who would have considered
prenatal diagnosis with a view to termination of a pregnancy. One perinatal
diagnosis (K8/4-12) was carried out at the parents request by genotyping DNA
purified from placental tissue. Maternal contamination of the DNA could not
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influence this analysis since the mother was homozygous for flanking markers and
she did not cariy the marker allele which cosegregated with APC in her affected
husbands family. The parents were counselled prior to the test and were fully aware
of the implications of a test at such a young age. Unfortunately the child is almost
certainly affected but the parents are glad to know this and felt they would have
suffered from the uncertainty otherwise.
The data presented here demonstrate that linked DNA probe markers can
now be used for preclinical risk estimations in FAP. Genotype data can be
incorporated into current screening protocols to reduce the burden of colonic
screening and to minimise the risk of gene carriers being lost to follow-up. An
integrated approach to screening individuals at risk of FAP can now be instigated,
involving genotyping, retinal examination and colonic screening in suitable families.
Linked DNA markers will continue to have a central role in presymptomatic
diagnosis' of FAP even after identification and cloning of the APC gene with
subsequent characterisation of common mutations within it. Families which do not
carry easily typed mutations will require DNA probe derived risk estimations and
linked markers will also be needed for confirmation ofmutation analysis.
There are substantial numbers of individuals who could benefit from
preclinical risk estimation using linked DNA probes. If the birth rate in the United
Kingdom is taken as approximately 700,000 per annum and the incidence rate of
FAP as 1 in 8,000 live births, then there are around 2600 affected individuals
currently under 30 years of age and a further 90 are born each year. However, since
new APC mutations make up 30% of all cases and such individuals are not suitable
for preclinical diagnosis using linked DNA markers, these figures have to be
modified accordingly. In addition, FAP is an autosomal dominant disorder and so
affected parents have roughly equivalent numbers of affected and unaffected
offspring, but all of whom require screening. Therefore, one can calculate that there
are currently 3700 at-risk individuals in the United Kingdom who would benefit




The work presented in this thesis has focussed on the involvement of APC
aberrations in causation of the clinical manifestations of the FAP syndrome and on
the putative role of APC as a tumour suppressor gene in colorectal carcinogenesis.
A high resolution genetic linkage map including 6 RFLP markers located around
APC has been generated. This has been used to interpret allele loss data from FAP
adenomas and from sporadic adenomas and carcinomas. The work has
demonstrated a high incidence of 5q allele losses in sporadic carcinomas and shown
the specificity of such loss of genetic material for the APC gene. A lower incidence in
sporadic adenomas has been demonstrated and the relationship of these findings to
the situation have been discussed. Data have been generated which are of direct
clinical relevance to patients at-risk of FAP and which can radically alter current
follow-up protocols. Clinical and molecular genetic findings have combined to
constitute powerful evidence to suggest an important role for APC aberrations in
colorectal carcinogenesis.
Research into the molecular genetics of colorectal cancer has moved on at a
breath-taking pace since this work began and the work presented here must be
taken in the context of intensive efforts by several research groups working world¬
wide in this exciting field and the data presented here are well supported by reports
published in the world literature.
Attempts to map APC using cytogenetic techniques became largely redundant
following regional localisation of APC to chromosome 5q21-22 in 1987 by groups in
London (Bodmer 1987) and Salt Lake City (Leppert 1987). Therefore, attention was
concentrated on the ascertainment and documentation of a large collection of FAP
families for genetic linkage. Cytogenetic assessment was restricted to analysis of
one or more affected individuals as part of that ascertainment. Failure to
demonstrate karyotypic abnormalities in any of these families is not surprising since
only one further cytogenetic abnormality has been reported in two brothers (Endo
1987, Hockey 1989) after the original report of Herrera (Herrera 1986). However,
karyotype analysis was an important aspect of this project since the identification of
a single patient with a small deletion or, most important of all, a chromosomal
translocation would have been invaluable in final localisation of APC itself.
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9.1 Genetic linkage analysis and preclinical diagnosis of FAP.
After the establishment of primary genetic linkage (Bodmer 1987, Leppert
1987), a limited number of linkage analyses in FAP were published (Meera Khan
1988, Murday 1989, Nakamura 1988, Varesco 1989). Bodmer believed C11P11 to
be very close to APC, but data presented in this thesis and reported elsewhere was
first to identify 3 obligate C11P11-APC recombinants allowing ordering of CI IP 11
and pi227 around APC (Dunlop 1989a, Dunlop 1989b). A single recombination
event between C11P11 and APC was reported by one group (Aldred 1988) but there
were no other informative markers to provide useful mapping information. Ordering
of APC relative to pi227 and YN5.48 in a linkage analysis was later established by
identification of a cross-over in the interval YN5.48-APC which was non-recombinant
for pi227-APC (Tops 1989).
The high resolution map presented in Chapter 4 represents the most detailed
and confident linkage map of the region to date and is currently in press (Dunlop
1990). Mapping data from linkage analysis are invaluable tools for the identification
and isolation of genes and the map constructed as part of this project has helped
towards final isolation of APC. The linkage data have already been utilised by
Yusuke Nakamura in constructing linkage and physical maps of the region (see
below) and a number of candidate clones have now been identified.
The linkage map includes a high density of markers such that
presymptomatic diagnosis of FAP by DNA analysis can now be used in the clinical
setting since flanking markers have been identified and diagnostic certainty can be
very high. The first direct application of recombinant DNA technology to clinical
problems raised by FAP is presented in Chapter 8 and the power of such analysis is
formally tested. Recommendations are made for an integrated screening policy for
those at-risk of FAP. The combination of risk estimations derived from colonic
screening, retinal screening and RFLP genotype can reduce the risk for those
apparently unaffected when screened in their late teens to such low levels that
further endoscopy of the colon can be reduced to a single examination around the
age of 30 years. This is clearly of great benefit to individuals who no longer need to
undergo unnecessary yearly sigmoidoscopy. In addition, missed cases of FAP
presenting late with a carcinoma due to inadequate follow-up should now be
avoided. A number of cases discussed in Chapter 4 exemplify the value of DNA
analysis since the development of colorectal cancer was prevented despite inferior
clinical follow-up. RFLP genetic linkage analysis to provide risk estimations for at-
risk family members will soon be routine practice and mapping data generated in
this project have contributed to the body of knowledge which will be used by clinical
genetic units involved in setting up a UK diagnostic service for FAP.
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9.2 Allele losses in adenomas.
Data presented in Chapter 6 constitute a stringent analysis of the deletion
status of APC in colorectal adenomas. Chromosome 5 allele losses in FAP and
sporadic adenomas have been reported by other groups (Okamoto 1988, Rees 1989,
Solomon 1987, Vogelstein 1988). Allele losses at marker loci closely flanking APC
has been assessed and, due to the density ofmarkers analysed here and to the large
numbers of FAP and non-FAP tumours examined, data presented in this thesis
convincingly demonstrate that FAP adenomas, sporadic adenomas and sporadic
carcinomas comprise three different tumour populations as regards APC deletion
status. These data demonstrate that there is no requirement for two 'hits' at APC for
the development of FAP adenomas. As discussed below, a second hit has been
shown to occur in colorectal cancer developing in patients with FAP. Therefore it
would appear that homozygous inactivation of APC does occur in colorectal cancers
developing in FAP patients. The question is whether allele losses detected here in
sporadic adenomas represent only a hemizygous aberration of APC or whether it
implies a homozygous lesion with the more substantial lesion 'unmasking' a mutant
APC allele on the remaining homologue. In Chapter 6 the available data are
discussed and it is proposed that a second event at APC may commit the adenoma
to progression along the pathway to malignant proliferation. If confirmed, this could
represent a marker of a highly mutagenic large bowel content for any patient who
has undergone removal of one or more adenomas with such chromosome 5 allele
loss. This may suggest an increased incidence of developing further adenomas with
a high risk of subsequent malignant transition in any given adenoma. Hence,
subsequent patient follow-up may be influenced in order to address such increased
risk of colorectal neoplasia.
9.3 Allele losses in carcinomas.
The demonstration of chromosome 5 allele losses in sporadic colorectal
cancer by Solomon (Solomon 1987) suggested that APC was a tumour suppressor
gene involyed in colorectal carcinogenesis. Inactivation of both copies of APC would
imply a recessive determinism which Knudson suggests may be a rate limiting step
in colorectal carcinogenesis (Knudson 1989). The allele losses detected by Solomon
involved loss of a substantial amount of genetic material from chromosome 5 and so
loss of APC itself could only be inferred from such data. However, this indirect
approach of searching for heritable cancer predisposition genes of clinical interest by
looking for allelic deletions in the corresponding tumour tissue has already proven
invaluable in tracking down several such genes including those involved in
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retinoblastoma, von Hippel-Lindau syndrome and multiple endocrine neoplasia
(MEN 1) (Ponder 1988, Wildrick 1989).
More substantial evidence was required to demonstrate that ape was indeed
the 'target' tumour suppressor gene. A number of authors reported chromosome 5
allele losses in colorectal cancer tissue following Solomon's original publication
(Delattre 1989, Law 1988, Okamoto 1988, Sasaki 1989, Wildrick 1988). The
frequency.of such losses was around 30-40% but all of these groups used marker
probes which map some considerable distance from ape and so none could make
specific comment on the target chromosomal region due to the small number of
markers studied and to the lack of confident mapping data. However, one group
were able to construct a limited deletion map of chromosome 5q (Vogelstein 1988)
but again the mapping data were weak and the markers assessed for allele loss were
not close to or flanking APC.
Work presented in this thesis combined with that of my co-workers in
Edinburgh University was first to demonstrate the true frequency of allele loss in
sporadic colorectal cancer. Over 50% of such tumours exhibit chromosome 5 allele
losses, much higher than previously reported. This finding is due entirely to the
assessment of allele loss at marker loci mapping close to, and on both sides of APC
(Ashton-Rickardt 1989). The specificity for APC was also demonstrated due to the
confidence of the linkage map presented in Chapter 4. These data clearly
demonstrate that APC is indeed the target tumour suppressor gene on chromosome
5q involved in colorectal carcinogenesis.
As discussed in Chapter 5, chromosome 5 allele losses occur in carcinomas
arising in patients with Familial Adenomatous Polyposis at a similar frequency to
sporadic cancers and the extent of the deletion corresponds to that seen in sporadic
colorectal adenomas and carcinomas (Sasaki 1989). It is the allele co-inherited with
the mutant APC gene which is retained in the malignant tissue (Miyaki 1990a and
b). This is compelling evidence supporting a tumour suppressor function for APC.
Further supporting experimental evidence comes from application of the somatic cell
hybrid techniques employed by Stanbridge for chromosome 11 (Stanbridge 1981).
Recently, a single human chromosome 5 was introduced into a murine hepatoma
cell line which resulted in suppression of tumorigenicity of the carcinoma cell line in
nude mice (Sasazuki 1989). This indicates one or more chromosome 5 genes have
tumour suppressing capabilities and by inference, implicates APC as a tumour
suppressor gene. The final proof that APC is a tumour suppressor gene will require
isolation and cloning of APC with subsequent demonstration that APC can prevent
or reverse'a tumorigenic phenotype as has been shown for Rb-1 (Huang 1988).
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One important aspect of the involvement of APC deletions in sporadic
colorectal cancer has not been addressed in this thesis, namely the prognostic value
of APC loss. It will be of interest to compare the clinical outcome of patients with a
cancer which has APC related allele loss with patients in whom the tumour shows
no such loss. If the hypothesis (discussed in Chapters 5 and 6) is correct that APC
inactivation is an early event and may indeed be a universal phenomenon with those
tumours which do not show APC related allele loss having intragenic lesions, then
there should be no influence on prognosis. Since a relatively small number of
patients were involved in this study and the follow-up period ranged from 18-30
months, I have not pursued this aspect of APC influence on clinical outcome. Such
a study is planned on a larger scale by combining follow-up data on my own series
of patients with colorectal cancer with the Edinburgh University series. However, we
plan to assess survival and recurrence data with a minimum follow-up of three
years.
9.4 Heritable susceptibility to non-FAP colorectal cancer and tumour
suppressor genes.
As discussed in Chapter 1, the gene for p53 and the DCC gene on
chromosome 18q appear to be tumour suppressor genes involved in colorectal
carcinogenesis (Baker 1989, Fearon 1990). Data presented in this thesis and recent
world literature suggest a tumour suppressor function for APC. Several other
potential tumour suppressor loci relevant to colorectal cancer have been identified
by allele loss studies (Vogelstein 1989). All of these genes could represent colorectal
cancer susceptibility genes. Clinical heterogeneity of age-of-onset, penetrance in
dominant colon cancer families, site and tumour aggression all suggest that genetic
heterogeneity may well have a substantial influence on genetic susceptibility to
colorectal cancer. The scanty molecular genetic evidence to date would support this
notion. Constitutional mutations in any one of the tumour suppressor genes listed
above could render the colonic epithelium more susceptible to a further 'hit' at the
same locus or at another tumour suppressor locus. The first hit may be sufficient to
account for the widespread increase in epithelial proliferation demonstrated in the
colorectum of patients with colonic adenomas and carcinomas (Lipkin 1984,
Terpstra 1987). Such an event may prime the colonic epithelium for further
mutagenic events perhaps by releasing some aspect of cellular growth control or
contact inhibition. However, several tumour suppressor genes may require
homozygous inactivating mutations and several oncogenes require activation before
the establishment of a clone capable of all of the clinical manifestations of
malignancy. It is also possible that one or more of such putative colorectal cancer
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susceptibility genes have no direct effect on the colorectal mucosa itself but exert
their effect by altering bile salt profiles or by inactivating a de-toxifying liver enzyme.
Isolation and cloning of candidate tumour suppressor genes will be of great interest
not only because of their involvement in the biology of colorectal cancer, but also
because of a possible influence on heritable susceptibility to large bowel malignancy.
Evidence to implicate APC as a colorectal cancer susceptibility gene has been
discussed in Chapter 1.1.7 and consist of the findings of an increased prevalence of
mandibular osteomas in patients with non-FAP colorectal cancer (Sondergaard
1985), those with colorectal adenomas (Sondergaard 1986) and in the Cancer Family
Syndrome (Sondergaard 1985). In addition, APC-linked DNA markers have
exhibited linkage to a disease gene resulting in variable numbers of adenomatous
colorectal polyps in one large kindred (Leppert 1990). The demonstration in this
thesis of a probable tumour suppressor function for APC in the colorectal mucosa
lends further support to the notion that APC is involved in colorectal cancer
susceptibility. This hypothesis can now be tested by carrying out linkage analyses
in non-polyposis colorectal cancer families. This will be more problematical than the
similar analysis carried out in FAP families because of the high mortality rate of
those affected and also because of the reduced level of penetrance. However, using
intragenic probes and probes mapping very close to APC, it should be possible to
confirm whether or not APC is indeed a colorectal cancer susceptibility gene in the
foreseeable future.
The study of the involvement of constitutional mutations in specific tumour
suppressor genes resulting in colorectal cancer susceptibility is one of the most
exciting aspects of future research in human molecular genetics. One extremely
important aspect of this work will be the introduction of a mutated tumour
suppressor gene into a mouse germline. The resultant transgenic animal could
represent a true model of human colorectal carcinogenesis which would not depend
on carcinogen-induced tumours. Already a dominant mutation has been induced in
the mouse which predisposes to intestinal neoplasia very similar to human
colorectal cancer (Moser 1990). It will be of great interest to determine whether a
murine gene homologous to one of the candidate human tumour suppressors is the
gene involved in this case. A more elegant assessment of the role of APC in heritable
colorectal cancer susceptibility will be to introduce a mutant form of APC into a
murine germline in transgenic experiments. This work is already in its early stages
in Edinburgh University Pathology Department and clearly has enormous potential
to further our understanding of the biology and the heritability of colorectal cancer.
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9.5 Towards isolation and cloning of APC.
Mapping of six polymorphic DNA markers around APC is a step towards
eventual isolation and cloning of the gene itself. The data presented here suggest
that EF5.44 is the marker locus which is closest to APC of those currently available.
PFGE analysis presented in Chapter 7 failed to show any rearrangement of DNA
fragments up to 800kb in size in the two patients studied. These data could suggest
that APC is more than 800kb from EF5.44 but another, and perhaps more likely,
explanation is that the genetic lesions in the APC gene in the two FAP patients
studied were not detectable by analysing the large DNA fragments generated by
PFGE analysis. Small deletions or insertions and point mutations would not be
resolved by PFGE. Ideally I would have wished to carry out PFGE analysis using the
EF5.344 probe on one affected member of every family collected with an unrelated
individual as a control. However, the control data would not have been so secure as
those described and used in Chapter 7. Unfortunately due to shortage of time, it
was not possible to complete such a series of experiments. However, data from
deletion analysis in colorectal cancers generated by my co-workers in Edinburgh
University, which includes data presented in Chapter 5, do support the notion that
EF5.44 is close to APC, since the frequency of allele loss is very high in cancers
which show 5q interstitial deletion. The next step would be to assess whether the
EF5.44 probe DNA fragment, or the cosmid clone it was derived from, carries
sequences of transcribed gene. This could be tested by assessing whether the DNA
sequence recognised by the probe is phylogenetically conserved by demonstration of
probe hybridisation to DNA purified from tissues of a number of different animal
species in what is known as a 'zoo blot' experiment. Another method would be to
analyse the DNA sequence of the marker clone to assess whether the sequence
recognised by the probe carries an open reading frame corresponding to known base
triplets coding for amino-acids, suggesting the presence of a transcribed gene. Due
to shortage of time on my research fellowship, I was unable to carry out these
experiments but my collaborator, Dr. Y. Nakamura, has subsequently shown that
the cosmid clone of EF5.44 does not carry transcribed sequences (Nakamura
personal communication 1990) and hence cannot comprise exonic sequences of ape.
Dr. Nakamura and his group in Tokyo are currently involved in an intensive effort to
identify and clone the ape gene using the techniques described here of linkage
mapping of new markers, assessing the frequency and nature of allele loss at that
locus in colorectal cancer tissue, PFGE analysis of markers which seem to be close
and then assessing each candidate marker for a high degree of cross-species
sequence conservation and for features of a transcribed gene and in particular,
whether the marker could include ape sequence itself. The amount of experimental
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work required is enormous and the race to clone APC currently involves groups in
London (Bodmer), Salt Lake City (White), Baltimore (Vogelstein) and Tokyo
(Nakamura).
Attempts to identify and clone APC will be hampered by the absence of a
biochemical phenotype characteristic of the gene defect, such as a specific enzyme
abnormality, which would provide a indication as to which DNA sequences might
encode for the APC product. Therefore, the identification of the APC gene relies
wholly on molecular genetic techniques to identify DNA fragments which might be
the gene and then to assess whether each candidate fragment in turn has features
in keeping with those predicted for APC. The difficulties will be further compounded
since constitutional ape mutations will probably be small deletions or point
mutations which will be difficult to detect in a gene such as APC which is probably
large, as suggested by a high new mutation rate for FAP (Reed 1955). Identification
of a gene whose effects are the result of loss of function will be substantially more
difficult than those encountered in identification of oncogenes where excess function
is a characteristic of their involvement in human cancers. In addition, function of a
number of different chromosome 5 genes may well be disturbed by deletions in
colorectal cancers (as suggested in Chapter 5) since reduction in gene expression
will result for those genes which have been rendered hemizygous by deletion without
reduplication. Hence proving that a candidate gene is indeed APC may well be
problematical and it could be some years before cloning and full characterisation of
the gene is achieved.
9.6 Aspects of future research in the molecular genetics of colorectal
cancer.
For patients affected by specific cancers such as Hodgkins' lymphoma,
teratoma and some childhood leukaemias, there have been great advances made in
recent years in the results of treatment, with potential cure a realistic goal.
However, there has been little, if any, overall progress made against cancer in the
last 20 years (Bailar 1986). In the United States over the 20 years from 1962-1982,
there has been a 56% increase in the number of deaths due to cancer (278,562-
433,795). The crude mortality from cancer increased by 25% and age-adjusted
cancer mortality by 8.7% while the age-adjusted incidence of cancer over the same
time period rose by 8.5%. This parallel rise of cancer incidence and death rates
occurred in the face of a massive increase in expenditure on cancer research in the
United States. Although there are clearly some successes, Bailar believes that we
are losing the war against cancer (Bailar 1986). As discussed in Chapter 1 of this
thesis, little impact has been made on death rates from colorectal cancer in the
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United Kingdom and although there has been a modest reduction in the incidence of
colorectal cancer incidence over the last few years in the United States (Bailar 1986),
the world-wide incidence of the disease is increasing and it appears that we are
losing ground against colorectal cancer in particular.
Research efforts to date have largely been directed at developing and
optimising empiric treatment protocols derived from clinical or laboratory
observations rather than any specific therapy based on knowledge of the biology of
cancer. Understanding the fundamental molecular mechanisms involved in the
initiation, proliferation and metastasising properties of cancer will hopefully lead to
a specific and a more structured approach to cancer and to the development of anti¬
cancer treatments. Examples of such an approach are already in evidence. The
recent discovery of the involvement of p53 gene mutations in colorectal and lung
cancer (Baker 1989, Iggo 1990) could result in clinical benefit since highly specific
monoclonal antibodies could be developed to recognise the mutant p53 gene
product, allowing imaging of tumour tissue and even targeted deliveiy of
chemotherapeutic agents. It has also been proposed that it may be possible to
mobilise the human immune system against cancer cells by immunization with a
specific mutant p53 antigen (Bodmer personal communication 1990).
A further exciting prospect is that if the bulk of colorectal cancer incidence is
indeed concentrated in a minority of the population due to genetic predisposition as
suggested by Cannon-Albright (Cannon-Albright 1989), then molecular genetics may
be able to identify specific gene defects and those individuals who carry them. This
would allow targeted screening of a high risk population and intensive screening
modalities could be employed which would not be possible for population screening.
Large scale automated DNA analysis is already a practical proposition (Landegren
1988) and the entire population could be screened in the same manner as is already
done with the neonatal Guthrie test. Carriers of specific gene defects known to
predispose to colorectal cancer could be identified and 'flagged' for colonoscopic
screening on entering pre-defined high risk age groups. An alternative would be to
screen relatives of patients affected by colorectal cancer for gene defects and then
offer clinical screening to those with the cancer predisposition gene shown by DNA
analysis.
The study of the biology of colorectal cancer and of the inheritance of
colorectal cancer susceptibility using modern techniques of molecular genetics
promises much for the future. This project has demonstrated that colorectal cancer
risk for individuals at risk of FAP can be qualitatively assessed and appropriate
clinical decisions made based on that risk. It is likely that the development of large
bowel cancer in individuals affected by FAP can be completely avoided. It can only
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For all pedigrees, probe codes are as follows:
C11=C11P11; P27A=pi227/Pst 1; P27B=pi227/Bcll;
YN48=YN5.48; EF54=EF5.44; ECB=ECB27.
D D NAVE AGE S I FAT8 80TB FAP Oil P27A P27B 7848 L562 EF54 ECB
-20 0.00 3-17 3-16 - 2/2 2/2 1/1 1/1 1/2
-21 0.00 3-17 3-1$ - 2/2 2/2 1/1 1/1 1/2
-22 0.00 3-13 3-18 - 1/2 2/2 1/2 1/1 2/2 2/2
-23 0.00 3-13 3-18 - 2/2 1/2 2/2 2/2
-24 0.00 3-13 3-18 - 1/2 2/2 1/2 1/1 2/2
-25 0.00 3-22 3-23 - 2/2 1/2 1/1 1/1 2/2 1/2
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-3 0.00 5-2 5-r 2/2 1/1 2/2 1/2 1/2 2/2
-4 0.00 5-2 5-3 2/2 1/1 2/2 1/2 2/2 1/2
-5 0.00 5-4 5-5 t 1/2 2/2 2/2 1/2 2/2 2/2
-6 0.00 5-4 5-5 1/2 2/2 2/2 1/2 2/2 2/2
-7 0.00 5-8 5-7 - 2/2 2/2 1/2 1/1 1/2 1/2
-8 0.00 5-3 5-10 - 2/2 1/2 1/2 1/1 2/2 1/2
J 0.00 5-3 5-10 " 2/2 1/2 1/2 1/1 2/2 2/2
-10 0.00 5-11 5-12 1/2 2/2 1/2 1/2 2/2 1/2
KMD2 FILE
IB D NAVE AGE S I FATH MOTH FAP C 1 P27A P2I! TN48 LSS2 EF54
21 0.00 1 1 1/3 2/2 1/1 2/2
2.-2 0.00 t
3-1 0.00 1-1 1-2 1 1 3/3 2/2 1/1 1/2
3 * 0.00 1-1 1-2 1 1 1/3 2/2 1/1 1/2
3 3 0.00 1-1 1-2 t 1 2 3/3 1/2 1/1 2/2
3< 0.00 1-1 1-2 + 1 2 1/3 1/2 1/1 2/2
3 5 0.00 1 2 3/3 1/2 1/1 2/2
3 « 0.00 1-1 1-2 ♦ 1 1 1/3 1/2 1/1 2/2
3-7 0.00 1-1 1-2 1 1 1/3 2/2 1/1 1/2
4-1 0.00 2-4 2-5 + 2 2 3/3 1/2 1/1 2/2











KMD 3 I' I 1,E
ID D NAME AGE SEI FATH MOTE FAP Cll P27A P2 B TN48 L 5 6 2 EF54
1-1 0.00 M ♦ 2/2 2/ 1/2 1/1 1/2
1-2 0.00 F 2/2 1/ 1/2 1/1 2/2
2-1 0.00 F 1-1 1-2 ♦ 2/2 2/ 1/2 1/1 1/2
2-2 0.00 M 2/2 2/ 1/1 1/2
2-3 0.00 F 1-1 1-2 ♦ 2/2 1/ 1/2 1/1 1/2
2-4 0.00 F 1-1 1-2 - 2/2 1/ 1/1 1/1 2/2
3-1 0.00 M 2-2 2-1 ♦ 2/2 2/ 1/2 1/1 1/2
3-2 0.00 F 2-2 2-1 * 2/2 2/ 1/2 1/1 1/1
KMD4 FILE
0 D NAME AGE SEI FATE MOTE FAP Cll P27A P27B TN48 L562 EF54
-1 0.00 M -
-2 0.00 F ♦
-1 0.00 M 1-1 1-2 ♦
-2 0.00 F - 2/2 2/2 1/3 1/2 1/1 1/2
-3 0.00 F 1-1 1-2 ♦
-4 0.00 M
-5 0.00 F 1-1 1-2 - 2/2 1/2 2/3 2/2 1/1 2/2
-4 0.00 M 1-1 1-2 +
-7 0.00 F - 2/2 1/2 2/3 1/2 1/1 2/2
-S 0.00 F - 2/2 1/2 2/3 1/2 1/1 2/2
-1 0.00 M 2-1 2-2 ♦ 2/2 2/2 3/3 2/2 1/1 1/2
-2 0.00 F 2-4 2-3 - 2/2 2/2 1/3 1/1 1/1 1/2
-3 0.00 M 2 4 2-3 - 2/2 2/2 1/3 1/2 1/1 2/2
-4 0.00 M 2-0 2-7 - 2/2 1/2 2/3 1/2 1/1 2/2
-5 0.00 M 20 2-7 ♦ 2/2 2/2 3/3 2/2 1/1 2/2
-( 0.00 M 2-5 2-8 t 2/2 1/2 2/3 2/2 1/1 2/2
-7 0.00 F - 2/2 2/3
-3 0.00 F -
-1 0.00 F 3-5 3-7 2/2 2/3













K lVfR & F I LE
ID D NAME 1GE SEI FATH MOTH FAP Cll P2TA P27B TN48 L562 EF54 ECB
l-l 0.00 F ♦
1-2 0.00 II -
2-1 0.00 F 1-2 1-1 - 2/2 2/2 2/2 1/1 2/2 2/2
2-2 O.IO II 1-2 11 ♦
2-3 0.00 F - 2/2 1/2 1/1 1/1 2/2 2/2
2-4 0.00 F 1-2 1-1 ♦ 2/2 2/2 2/2 1/1 2/2 2/2
2-5 0.00 II - 2/2 1/3 1/2 1/1 2/2 1/2
3-1 0.00 II 2-2 2-3 - 2/2 1/2 1/2 1/1 2/2 2/2
3-2 0.00 F 2-2 2-3 - 2/2 1/2 1/2 1/1 2/2 2/2
3-3 0.00 0 2-2 2-3 * 2/2 1/2 1/2 1/1 2/2 2/2
3-4 0.00 F 2-5 2-4 - 2/2 1/2 1/2 1/1 2/2 2/2
3-5 0.00 F 2-5 2-4 - 2/2 1/2 1/2 1/1 2/2 2/2
KMD 6 I- I I > I•:
10 0 NAME AGE S I FATE MOTH FAP Cll P2TA P2TB TN48 L562 EF54 ECB
1-1 0.00 -
1-2 0.00 ♦
2-1 0.00 1-1 1-2 ♦ 2/3
2-2 0.00 - 2/2 1/2 2/2 1/1 2/2 1/2
2-3 0.00 1-1 1-2 - 2/2 2/2 1/2 1/1 2/2 2/2
2-4 0.00 1-1 1-2 - 2/2 2/2 1/2 1/1 1/2 1/2
3-1 0.00 - 1/1 2/2 1/2 1/1 1/2 1/2
3-2 0.00 2-2 2-1 + 2/2 1/3 1/2 1/1 2/2 1/2
3-3 0.00 2-2 2-1 2/2 2/3 1/2 1/1 2/2 2/2
3-4 0.00 - 1/2 3/3 2/2 1/2 2/2 2/2
4-1 0.00 3-2 3-1 ♦ 1/2 1/2 1/2 1/1 1/2 1/1
4-2 0.00 3-3 3-4 1/2 2/3 1/2 1/2 2/2 2/2
4-3 0.00 3-3 3-4 2/2 2/3 2/2 1/1 2/2 2/2
KMDS FILE
ID D NAME AGE SEI FAT8 MOTH FAP
-1 0.10 8 *
-2 0.00 F -
-1 0.00 F 1 -1 1-2 -
-2 0.00 8 1 1 1-2 *
-3 0.00 F
-
-1 0.00 8 -
-5 0.00 F 1 -1 1-2 -
-t 0.00 F 1 -1 1-2 *
-7 0.00 8 -
-8 0.00 F 1 -1 1-2 *
-3 0.00 8 -
-10 0.00 8 1 ~1 1-2 +
-11 0.00 F -
-12 0.00 8 1 1 1-2 t
-1 0.00 F
-
-2 0.00 8 2 -2 2-3 *
-3 0.00 F 2 -4 2-5 -
-4 0.00 F 2 -4 2-5 -
-5 0.00 8
-
-{ 0.00 F 2 -7 2-6 *
-J 0.00 F 2 -7 2-6 -
-8 0.00 8 -
-3 0.00 F 2 -7 2-6 ♦
-10 0.00 F 2 -7 2-6 -
-11 0.00 8
-
-12 0.00 F 2 -S 2-8 -
-13 0.00 8 2 -10 2-11 -
-14 0.00 F
-
~15 0.00 8 2 -10 2-11 ♦
-u 0.00 F 2 -10 2-11 ♦
-17 O.OO 8
-
-1 0.00 8 3 -2 3-1 -
-2 0.00 8 3 -2 3-1 -
-3 0.00 8
-
-4 0.00 F 3 -5 3"6 f
-5 O.OO 8 3 -8 3-3 ♦
-6 0.00 8 3
ft flfl P T
-8 3-3 t
-8
u. vu r i
O.OO 8 3 -11 3-10 -
-3 0.00 F 3 -11 3-10 -
-10 0.00 F 3 -15 3-14
-11 0.00 F 3 -17 3-16
-1 0.00 F 4 -3 4-4
-2 0.00 F 4 -3 4-4
Cll P27A P27B 1848 L562
2/2 3/3 2/2 1/1
1/2 1/3 1/2 1/1
2/2 3/3 1/2 1/2
2/2 2/3 2/2 1/2
2/2 2/3 1/2 1/
2/2 1/2 1/1 1/
1/2 1/3 1/2 1/
2/2 2/3 1/2 1/
2/2 2/3 2/2 1/
2/2 1/3 2/2 1/
2/2 1/2 2/2 1/
2/2 2/3 1/1 1/
2/2 1/3 2/2 1/
1/2 3/3 2/2 1/
2/2 2/3 1/2 1/
1/2 2/2 1/2 1/
2/2 1/3 2/2 1/
1/2 2/3 1/2 1/
1/2 2/3 1/2 1/
2/2 1/3 2/2 1/
1/2 1/2 l/l 1/
1/2 1/2 1/1 1/
2/2 1/3 2/2 1/
2/2 1/2 1/2 1/
2/2 3/3 1/2 1/
2/2 2/3 1/2 1/
2/2 2/3 2/2 1/
1/2 1/3 2/2 1/
2/2 1/3 2/2 1/
























































I FATE NOTE FAP
♦
Cll P2TA P27B TEAS L5S2 EF5A ECB




















ID 0 NAME AGE SEI FATE MOTE FAP Cll P2TA P278 TK48 L562 EFSA
0.00 -
0.00 + 2/2
0.00 1-2 1 1 t 1/2
0.00 1-2 1 1 - 2/2
0.00 1-2 1 1 - 1/2
0.00 1-2 1 1 - 1/2
0.00 1-2 1 1 t 1/2
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Linkage Analysis in Familial Adenomatous Polyposis: Order of
C11P11 (D5S71) and tt227 ( DLociat the ape Gene
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Linkage analysis with DNA probes CI IP 11 and
7t227 is reported in six Scottish families with familial
adenomatous polyposis. Two families were informa¬
tive for CI IP 11 and all six were at least partly in¬
formative for ir227. Two CI IP 11—ape and two ir227—
ape recombinants were identified and one of thesewas
recombinant for both CI 1P11—ape and ir227—ape. A
further possible combined CI 1P11—ape and ir227—ape
recombination event was also identified. Peak lod
score for linkage of C11P11 to ape was 5.80 at a re¬
combination fraction (6) of 0.069 (95% probability
limits 0.012—0.191) and for linkage of 7t227 to ape
was 3.19 at 8 = 0.110 (95% probability limits 0.023—
0.286). Peak lod score for linkage of C11P11 to x227
was 1.79 at 6 = 0.00. The data support a gene order
of 7t227—CI 1P11—apC. © 1989 Academic Press, Inc.
INTRODUCTION
Familial adenomatous polyposis (APC) is an un¬
common autosomal dominant condition characterized
by the development of large numbers of intestinal ad¬
enomas with a very high risk of progression to colo¬
rectal carcinoma if untreated (Muto et al., 1975).
Gardner syndrome (Gardner, 1951) consists of multiple
osteomas, epidermoid cysts, and desmoid tumors in
addition to familial polyposis, but clinically appears to
be the same condition (Bulow, 1987). Congenital hy¬
pertrophy of the retinal pigment epithelium (CHRPE)
is also part of the APC syndrome (Blair and Trempe,
1980; Traboulsi et al., 1987) and is an important phe-
notypic marker of the disease in children because
screening of the colon is not usually performed before
puberty.
The recent establishment of genetic linkage of APC
to chromosomal region 5q21-22 (Bodmer et al., 1987;
Leppert et al., 1987) using the DNA probe C11P11
(D5S71) is of great clinical and scientific importance.
Presymptomatic prediction of the disease is now pos¬
sible, particularly following a report of linkage to APC
with another probe, 7t227 (D5S37) (Meera Khan et al.,
1988), which is more polymorphic than C11P11.
C11P11 and 7t227 have been localized by physical
methods to chromosome 5q21-22 (Bodmer et al., 1987;
Alitalo et al., 1987). Gene loss on chromosome 5q has
been demonstrated in sporadic colorectal cancer (Sol¬
omon et al., 1987) and thus identification of the ape
gene may help advance our understanding of the role
of putative tumor suppressor genes (Knudson, 1985)
in colorectal carcinogenesis. Defining gene order and
genetic distances in the region of chromosome 5 which
includes the ape gene, C11P11, and 7t227 has great
clinical significance and is a first step toward the goal
of isolating the ape gene itself. However, C11P11 is
relatively uninformative and only one CllPll-apc re¬
combinant has been reported (Aldred et al., 1988). No
7t227 recombination data were provided in that report.
We now report linkage analysis in six Scottish fam¬
ilies with APC by using C11P11 and 7t227 and have
identified important CllPll-apc recombinants and
ir227-ape recombinants. Estimates of genetic distances
and a preferred order of the ape, C11P11, and x227
loci are given.
METHODS
Family data were drawn from the MRC Human Ge¬
netics Unit Registry and were fully documented for
clinical and pathological status. Six apparently unre¬
lated families, comprising 112 typed individuals, were
studied. Penetrance was assigned as 1.0 for ages over
25 years, as the disease was apparent on examination
of the colon in all affected individuals in these families
before this age. At-risk individuals who were under 25
years and negative for colonic adenomas were consid¬
ered negative for APC only if examination of the optic
fundus by an experienced ophthalmologist demon¬
strated no CHRPE lesions. The phenotypes of 8 af¬
fected and 5 unaffected children under 15 years were
0888-7543/89 $3.00
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ascertained by fundoscopy alone, as screening of the
colon was not carried out in patients under this age.
Four or more CHRPE lesions in one eye or three lesions
involving both eyes were considered positive and com¬
plete absence of CHRPE lesions was considered neg¬
ative for APC. Only children who had an affected par¬
ent positive for the CHRPE phenotype were screened
in this way, as we have found the presence or absence
of CHRPE lesions in affected individuals within any
one family to cosegregate with the colonic manifesta¬
tions of the disease (unpublished data).
DNA was purified from whole blood by lysis in 2%
SDS, 0.1 M Tris-HCl, pH 7.5, 20 mM NaCl, 1 mM
EDTA for 5 min and then phenol/chloroform extracted
and NH4COOH/ethanol precipitated. Spooled DNA
was resuspended in 10 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 10 mMEDTA and treated with 50 pg ml -1 RNase
followed by 100 pg ml-1 proteinase K at 37°C overnight
in the presence of 0.2% SDS. Two further phenol/
chloroform extractions and then NH4COOH/ethanol
precipitation were carried out, and spooled DNA was
dissolved in 10 mM Tris-HCl, pH 7.9, 0.5 mM EDTA
(TE). Epstein-Barr virus-transformed lymphoblastoid
cell lines were also set up from all family members.
DNA was extracted from archival formalin-fixed par¬
affin-embedded normal material from a number of de¬
ceased important family members by using the follow¬
ing method, slightly modified from those previously
described (Dubeau et al, 1986; Warford et al., 1988).
Histologically confirmed normal tissue was sectioned
at 5 pm on the microtome to give around 100 mg of
tissue including residual paraffin. Paraffin was dis¬
solved in 10 ml xylene with three xylene washes. Xylene
was removed in 100% ethanol and the tissue progres¬
sively rehydrated in 99% ethanol (3 washes), 95%
ethanol (2 washes), 70% ethanol (1 wash), and distilled
water (1 wash). The tissue was then resuspended, pro¬
teinase K treated, phenol/chloroform extracted, and
ethanol precipitated as for whole blood. DNA was re¬
covered by centrifugation at 12K for 30 min, resus¬
pended in TE, treated with RNase and proteinase K,
and reprecipitated with ethanol as before. The pellet
was then dissolved in TE.
Five micrograms of purified DNA was digested with
the appropriate restriction endonuclease (Taql for
C11P11; Pstl, Bell, Mbol, or BstXl for 7t227), frac¬
tionated in agarose gel, and transferred to a nylon filter
according to manufacturers' instructions. Filters were
prehybridized in 6X SSC, 5X Denhardt's solution, 0.5%
SDS, 10% dextran sulfate for 2 h. Probe DNA was
radiolabeled to a specific activity of 5 X 108-1 X 109
cpm pg~l by oligonucleotide labeling (Feinberg and
Vogelstein, 1983) and hybridized to the filter overnight
at 65°C in the presence of salmon sperm DNA. Two
5-min stringency washes of 2X SSC and 0.1% SDS
followed by 2X 5 min 0.1X SSC and 0.1% SDS were
C22 C22 C22 C22 C12 C12 C22
P11 P11 P11 P11 P22 P22 P22
)jf] Multiple colonic adenomas (APC+ve)
J Multiple CHRPE lesions (APC+ve)
; |~| Colon screened negative for APC (APC -ve)
m Optic fundi screened negative for APC(APC-ve)
!~~Q Assumed negative for APC (>60yrs. of age)
FIG. 1. Part of a large family (KMD1) showing Taql CllPll
alleles (Cl, 4.4 kb; C2, 3.9 kb) and Pstl 7t227 alleles (Pi, 3.0 kb; P2,
4.3 kb). Cl and P2 segregate with the ape gene in the other branches
of this kindred. The black arrow indicates a likely site of recombi¬
nation involving both CllPll-ape and 7t227-ape. The open arrow
indicates another possibleCllPll -ape and ir221-apc recombination
event. 7t227 polymorphisms using other restriction enzymes did not
provide any additional information in KMDl. The use of the CHRPE
phenotype has allowed the phase of the disease with regard to the
7t227 alleles in individuals IV 1, 2, 3, and 4 to be ascertained, thereby
suggesting the most likely site of a combined CllPll-apc, 7r227-apc
recombination event (black arrow).
carried out at 65°C prior to autoradiography at —70°C
for 24-48 h.
Linkage analysis was carried out using the LINK¬
AGE 4.7 group of programs (Lathrop et al., 1985), and
the 1-lod interval of support was taken as approxi¬
mating 95% probability limits.
RESULTS
Restriction fragment length polymorphisms
(RFLPs) for CllPll and 7t227 have been described
elsewhere (Bodmer et al., 1987; Leppert et al., 1987;
Meera Khan et al., 1988) and no new variants were
observed in these pedigrees. The frequencies ofRFLPs
in a control sample of normal individuals from this
area in Scotland were CllPll—Taql Al 0.14, A2 0.86
(100 chromosomes), and 7r227—Pstl Al 0.25, A2 0.75
(66 chromosomes); Bel 1 Al 0.17, A2 0.46, A3 0.37 (54
chromosomes); BstXl Al 0.29, A2 0.71 (28 chromo-
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somes); Mbo A1 0.25, A2 0.75 (20 chromosomes).
C11P11 was informative in two families. In one large
family (KMD1) the disease gene was linked to the less
common (Al, 4.4 kb) allele, allowing a large amount
of information to be gathered. 7t227 was at least partly
informative in all six families with Pstl and Bel 1
RFLPs. Two obligate CllPll-apc recombinants and
two 7r227-apc obligate recombinants were identified. A
section of a large family (KMD1) is shown in Fig. 1.
One meiosis in which there is strong evidence of a single
recombination event affecting both the CllPll and
the 7t227 loci relative to the ape gene is indicated. An¬
other possible combined CllPll-ape and x227-apc
recombinant is also indicated. These observations
strongly suggest that CllPll and 7t227 loci are on the
same side of the ape gene.
Lod score calculations (Lathrop et al., 1985) were
carried out for linkage between the CllPll (D5S71)
and the ape loci, the 7r227 (D5S37) and the ape loci,
and the CllPll and the 7r227 loci. Maximum lod score
(z) forCllPll-apc was 5.80 at a recombination fraction
(6) of 0.069 (95% probability limits 0.012-0.191) and
for ir227-apc, z was 3.19 at 6 = 0.110 (95% probability
limits 0.023-0.286) (Table 1). No tt227-C11P11 re¬
combinants were identified due to the small number
of meioses informative for both CllPll and tt227. Peak
lod score for C11P11-7t227 was 1.79 at 6 = 0.00. These
data support a locus order of 7r227-CllPll-apc.
This study has made use of archival formalin-fixed,
paraffin-embedded tissue specimens for genotyping of
deceased individuals for linkage analysis. In each case
where good-quality alleles were achieved, the expected
genotypes were obtained. Tissue blocks ranged from 2
to 41 years of age. An average of 20 pg of DNA was
recovered from 100-mg blocks of tissue, which included
lymph node, thyroid, appendix, ovary, heart, and
stomach. The different tissues gave comparable recov¬
eries of DNA but the yield and quality of DNA were
poorer for the older blocks. Autolysed tissue and tissues
fixed in picric acid did not provide satisfactory yields
of DNA. DNA from paraffin-embedded material was
purified from 11 different blocks. Only 6 of these hy¬
bridizedwith 7t227 and gave good-quality allelic bands,
but no satisfactory hybridization was obtained with
CllPll. This appears to be a locus-specific problem,
as CllPll did not hybridize to the Pstl-digested DNA
which had given bands for 7t227.
DISCUSSION
This study has identified important rare recombi¬
nation events between the closely linked marker
CllPll and the ape loci. At least one of these events
also involves the x227 locus and this strongly suggests
that CllPll and tv221 do not flank the ape gene.
TABLE 1
Lod Scores for Linkage of CllPll and 7r227 to ape
Recombination fraction (0)
Pedigree 0.00 0.05 0.10 0.15 0.20 0.25
CllPll
KMD1 —oo 4.14 4.25 4.00 3.57 3.02
KMD2 1.81 1.65 1.49 1.31 1.13 0.93
KMD3 0.00 0.00 0.00 0.00 0.00 0.00
KMD4 -0.02 -0.02 -0.02 -0.01 -0.01 -0.01
KMD5 -0.02 -0.02 -0.02 -0.01 -0.01 -0.01
KMD6 -0.01 -0.01 -0.01 0.00 0.00 0.00
Total -co 5.74 5.69 5.29 4.68 3.93
ir227
KMD1 —oo 2.00 2.22 2.18 2.02 1.78
KMD2 0.18 0.17 0.16 0.15 0.13 0.12
KMD3 0.30 0.28 0.26 0.23 0.20 0.18
KMD4 0.29 0.24 0.19 0.15 0.11 0.07
KMD5 -0.22 -0.17 -0.13 -0.10 -0.07 -0.05
KMD6 —oo 0.35 0.49 0.50 0.45 0.37
Total — oo 2.87 3.19 3.10 2.84 2.47
The frequency of Taq 1 CllPll alleles in this study
is at variance with the findings of Bodmer et al. (1987).
The 4.4-kb allele (Al) occurs with greater frequency
in our control population. This concurs with the find¬
ings of Leppert et al. (1987) and Aldred et al. (1988).
CllPll may therefore be a more useful marker for
clinical use than originally suggested. A substantial
peak lod score of 5.80 has been achieved in this study
for CllPll at a recombination fraction of 7%. Al¬
though the confidence limits from these data are still
wide, a combination of published CllPll (Bodmer et
al., 1987; Leppert et al., 1987; Aldred et al., 1988) and
7t227 (Meera Khan et al., 1988) linkage data with our
own indicates thatCllPll and t227 are approximately
5 and 5-10 cM, respectively, from the ape gene. How¬
ever, a CllPll-apc interval of 7 cM suggested by data
in this study is supported by multilocus analysis data
from Nakamura et al. (1988) that place CllPll 17 cM
centromeric to a marker (YN548) that is 3 cM telomeric
to the ape gene. Gene order therefore appears to be
centromere-7r227-CllPll-apc-telomere. The CllPll
locus is clearly much further from the ape gene than
suggested by the original reports (Bodmer et al., 1987;
Leppert et al., 1987), and this has important clinical
implications for the use of this marker in disease state
prediction of at-risk individuals. In addition, chro¬
mosome walking over such a distance would be im¬
practical.
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This study has made use of archival paraffin-embed¬
ded fixed tissue in linkage analysis. Clearly, the ability
to genotype deceased members of a kindred from such
material may open the door to linkage analyses in many
conditions that have proved difficult in the past because
of the early demise of affected individuals. However,
some problems in the use of archival material as a
source of DNA have been identified. We have con¬
firmed previous findings that DNA cannot be recovered
from tissue fixed in picric acid (Bouin's) or mercuric
chloride (Zenker's) preservatives (Dubeau et al., 1986).
In addition, we have demonstrated a locus-specific
problem with hybridization of the probe C11P11, de¬
spite apparently good-quality DNA as seen on ethidium
bromide staining of the gel. This may prove a problem
with other DNA probes. Despite these shortcomings,
DNA recovery from archival material promises to be
an invaluable tool in future linkage analyses and in
analysis of archival tumor material where correlation
of tumor progression with specific genetic events may
be possible.
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High frequency of APC loss in sporadic colorectal carcinoma due to
breaks clustered in 5q21-22
P.G. Ashton-Rickardt1, M.G. Dunlop2, Y. Nakamura3, R.G. Morris1, C.A. Purdie1, C.M. Steel2,
H.J. Evans2, C.C. Bird1 & A.H. Wyllie1
Department of Pathology, and University Medical School; 2MRC Human Genetics Unit, Edinburgh, UK; 3Howard Hughes Medi¬
al Center, University of Utah, Salt Lake City, USA
Familial adenomatous polyposis is transmitted by a gene
APC) located within 5q21-22. Hemizygous loss of at
east a part of 5q has been reported in 19-36% of spor-
idic colorectal carcinomas. This suggests that an anti-
jncogene is located on that chromosome arm, but the
jrobes used previously gave little information on the
itatus of APC in the tumours. Using DNA probes
tomologous to polymorphic sequences flanking and close
o the APC locus we show that more than half of a large
series of carcinomas had lost at least one flanking allele.
Vlapping of allele losses provides data that imply clus-
ering of breakpoints in a 10-15 megabase region around
4PC. The commonest chromosome defect responsible for
4PC loss was interstitial deletion. Mitotic recombination
>r partial arm loss were less frequent mechanisms. Whole
chromosome loss was rare. This pattern contrasts with
hat reported in acquired homozygosity at other anti-
tncogene loci in sporadic tumours and implies that APC
oss is an early event in colorectal carcinogenesis. This
dew is also supported by the observations that 5q21-22
oss occurs with similar frequency in DNA diploid and
ONA aneuploid tumours, and also in tumours at all clini¬
cal stages of progression.
introduction
two observations suggest that an anti-oncogene con¬
cerned with the regulation of colorectal mucosal growth
s situated on the long arm of chromosome 5. First,
amilial adenomatous polyposis^ a Mendelian domin-
int condition characterised by development of large
lumbers of colorectal adenomas— is transmitted by a
;ene (APC) mapping within 5q21-22 (Bodmer et al.,
:987; Leppert et al., 1987). Second, hemizygous loss of
it least part of 5q has been reported in 19-36% of spor-
idic colorectal carcinomas (Solomon et al., 1987;
Dkamoto et al., 1988; van den Broek et al., 1988;
/ogelstein et al., 1988; Law et al., 1988; Rees et al.,
989). There is, however, little information on the status
if APC itself in these tumours. At other, better-defined
inti-oncogene loci, such as the genes conferring suscep-
ibility to Wilms' tumour and retinoblastoma, acquired
illele loss within the tumours commonly involves whole
chromosomes (Dryja et al., 1984; Fearon et al., 1984).
>uch losses are probably the result of mitotic non-
lisjunction. In contrast, recent studies in human
colorectal and breast carcinoma have revealed a high
requency of acquired homozygosity of 17p alleles
Monpezat et al., 1988; Vogelstein et al., 1988; MacKay
t al., 1988), but here the loss is commonly achieved
leceived 22 May 1989; accepted in revised form 21 June 1989
through partial arm deletion or mitotic recombination,
requiring an intrachromosomal breakage event. In this
paper we examine the status of APC in a large series of
sporadic colorectal carcinomas. Using DNA probes
homologous to polymorphic sequences flanking and
close to APC ('closely-flanking markers'), we show that
APC alleles are lost in a much higher proportion of
tumours that hitherto recognised. Whole chromosome
loss is rare, the majority of lesions resulting from
intrachromosomal breakage (interstitial deletions,
mitotic recombinations or partial arm losses). The
results have interesting implications on the status of
APC in colorectal carcinogenesis, and its susceptibility
to nearby chromosome breakage events.
Results
Loss of APC in sporadic tumours
There were 119 tumours, confirmed as carcinomas by
histology in all but 2 cases, the exceptions both being
large villous adenomas. Pairs of closely-flanking
markers lying centromeric and telomeric to APC within
5q21-22 were used to detect tumours exhibiting hemi¬
zygous loss of polymorphic restriction fragment alleles.
To establish the physical extent of allele loss, tumour
DNA was analysed with probes mapping to regions
spanning chromosome 5 at 5p, 5ql2-14 (close to the
centromere) and 5q35 (telomeric). Details of the probes
used are given in Table 1 and examples of allele loss
demonstrated with each are shown in Figure 1. The
Table 1 Probes used in analysis of chromosome 5 alleles
Specification
of target Alleles
Probe sequence Enzyme kb Ref
LI.4 D5 S4 EcoRl 0.7, 0.6 1,2
MLZ 7.5 — EcoRl 2.9, 2.2, 3.2* 1
105-153 Ra D5S39 Mspl 8.0, 5.0 1,2
105-599 Ha D5S76 TaqI 17.0, 14.0, 10.0 1,2
105-789 Rb D5S78 Mspl 2.3, 1.8 1,2
n 227 D5S37 Bell 3.0, 1.8, 1.2 2, 3,4, 5, 6
C11P11 D5S710 TaqI 4.4, 3.9, 5.0* 3, 7, 8
YN5.48 D5S81 Mspl 9.0, 8.0 3,8
MC5.61 D5S84 Mspl 5.5, 5.0 3,8
X MS8 D5S43 Hind 2.4-9.5 2,9
* Constant allele
References: 1. Leppert et al. (1987)
2. Olaison et al. (1987)
3. Nakamura et al. (1988)
4. Dunlop et al. (1989)
5. Meera Khan et al. (1987)
6. Stewart et al. (1987)
7. Bodmer et al. (1987)
8. Wasmuth & Ferrell (1988)
9. Solomon et al. (1987)
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Figure 1 Location of polymorphic sequences in chromosome 5 detected by the ten probes used in this study (Table 1). The genetic
distances between the APC markers are given in centimorgans (lcM equivalent to 1 megabase (lmb) in humans). Distances are
reproduced from a single early study (Nakamura et al., 1988) for the sake of consistency. More recent data, however (M.G. Dunlop,
Y. Nakamura, unpublished), indicates that the distance between n 221 and CI 1P11 may be as little as 2cM and between CI 1 PI 1 and
YN5.48, approximately 10 cM
overall frequency of loss observed for any 5q-linked
allele was 48% (Table 2A), substantially higher than
that quoted in previous studies. A similar high fre¬
quency (45%) was found when analysis was restricted to
tumours showing loss of alleles in 5q21-22 (Table 2B).
Of the 65 tumours informative with closely-flanking
markers on both sides of APC, 35 (54%) showed loss of
a flanking allele (Table 2C), and in the great majority of
these (24/35; 69%) the loss was unilateral. The uni¬
lateral loss of closely-flanking markers occurred centro-
merically and telomerically to APC in equal
proportions indicating the existence of a cluster of
breakpoints within a 10-15 mb region either side of
APC.
Nature of defects in chromosome 5
Information from tumours mapped with closely-
flanking markers, when combined with data from
markers mapping to outlying regions of chromosome 5,
allowed a physical interpretation of 5q defects (Table
2D). Of the 32 tumours exhibiting loss of one or more
of the alleles within 5q21-22, the great majority
remained heterozygous for one other chromosome 5
allele at least. This demonstrates that loss of the whole
of chromosome 5 plays a minor role in generating APC
allele loss in sporadic colorectal cancer. The commonest
lesion (20/32; 63%) was interpreted as interstitial dele¬
tion since the tumours remained heterozygous for
markers on both sides of the region showing allele loss.
A qualitative depiction of the data (Figure 2) shows the
large contribution of breakpoints close to APC in these
deletions, of which the smallest observed was about 10-
15mb long (the distance between YN5.48 and C11P11;
Y. Nakamura unpublished data). The remaining class of
chromosome lesions included fewer breaks close to
APC but showed a striking bias towards the loss of
markers telomeric to APC. Presumably these represent
mitotic recombinations or partial arm losses, which are
not distinguished from each other by this type of
analysis. The mapping of these allele losses reinforces
the view that a specific region, inclusive of the APC
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A. Informative within 5q 117 (100%)
Allele loss within 5q 56 (48%)
B. Informative at 5q.21-22 107 (100%)
Allele loss at 5q.21-22 56 (48%)
C. Informative at closely-flanking
loci on both sides offap 65 (100%)
Loss of at least one flanking 35 (54%) (100%)
allele
Loss of one flanking allele 24 (59%)
Loss of both flanking alleles 11 (31%)
D. Permitting physical interpretation
of 5q defect 68 (100%)
Total with 5q.21-22 allele loss 32 (48%) (100%)
Interstitial deletion 20 (63%)
Partial arm loss/mitotic 11 (34%)
recombination
Whole chromosome loss 1 (3%)
jene, is commonly deleted in sporadic colorectal carcin-
>ma. Of 36 carcinomas showing retention of a pair of
:losely-flanking markers in 5q21-22 only 1 showed the
oss of an outlying 5q allele.
oss ofAPC and tumour progression
n an attempt to ascertain the phase of tumour evolu-
ion at which APC alleles are most commonly lost, we
itudied the frequency of loss in tumours that differed in
itage of progression, or in DNA ploidy. There was no
:orrelation (P > 0.05) between the degree or occurrence
)f DNA aneuploidy (as determined by flow cytometry)
ind APC loss (Table 3). Nor did loss of APC-flanking
narkers correlate with Dukes' staging of the extent of
umour spread. It thus appears that the loss of APC
akes place independently of (and probably before) the
mergence of features determining the progression of
he carcinoma. This agrees with the observation of
iq21-22 allele loss in both of the villous adenomas in
his study. Such tumours do not show infiltration or
netastasis but carry a high probability of progressing to
:arcinoma.
Discussion
rhe high frequency of 5q21-22 loss recorded in this
itudy is due entirely to the use of closely-flanking
Table 3 Prognostic indicators and 5q21-22 status
5q21-22 status*
Tumour status Retained Lost
Villous adenoma 0 2 (100%)
Carcinoma—Dukes A 1 8 (89%)
— Dukes B 16 20 (56%)
— Dukes C 14 19 (58%)
DNA diploid 2 6 (75%)
DNA aneuploid 8 11 (58%)
Tumours were scored as 5q21-22 retained only if an allele within
q21-22 on each side of the APC locus retained heterozygosity. Loss
if a 5q21-22 allele on either or both sides of APC scored as loss
markers on both sides of APC. Previous studies using
unilateral or distant markers, (Solomon et al, 1987;
Okamoto et al., 1988; van den Broek et al., 1988;
Vogelstein et al., 1988; Law et al., 1988; Rees et al.,
1989) suggested lower frequencies of loss, because they
failed to detect small deletions including APC. This
implies that as one approaches the APC locus the fre¬
quency of observed allele loss may increase still further
and indeed that many of the important lesions may be
within APC itself. A similar situation at 13q 14 occurred
in sporadic retinoblastoma, where small deletions of the
Rb-1 gene, not detected cytogenetically, were revealed
by the use of intra-gene molecular probes (T'Ang et al.,
1988) and closely-flanking markers (Dryja et al., 1986).
The low frequency of whole chromosome 5 loss
argues against mitotic non-disjunction as a major
mechanism for the acquired loss of APC in tumours.
Many reported karyotypes in colorectal cancer cells are
hypotriploid or hypotetrapoid, (Reichmann et al., 1981;
Petersen & Friedrich, 1986) consistent with origin
through non-disjunctive events from a tetraploid parent
(Nowell, 1976). The majority of human colorectal
cancers do show DNA aneuploidy in this range, as
determined by flow cytometry. As the presence of aneu¬
ploidy correlates with poor prognosis (Armitage et al.,
1985; Quirke et al., 1987), it is tempting to suggest that
this mode of chromosome loss contributes to the
genesis of homozygosity at anti-oncogene loci during
tumour progression (Wyllie, 1989). Our data, however,
make it clear that whole chromosome non-disjunction
is a rare cause of acquired homozygosity at the APC
locus. Rather, it appears that the APC gene is lost early
in the evolution of colorectal tumours. This is further
supported by the association of presumptive inherited
molecular defects within the APC gene in familial
adenomatous polyposis where the genetic abnormality
is primarily responsible for formation of multiple
adenomas. Loss of APC early in the adenoma-
carcinoma sequence is also suggested by the work of
other groups (Remvikos et al., 1988; Vogelstein et al.,
1988).
Cytogenetic findings in sporadic colorectal carcinoma
(Muleris et al., 1985; Ferti et al., 1988) confirm the
.present findings of a low frequency of whole chromo¬
some 5 loss. However the fact that such lesions (and the
commoner 5q arm losses) are tolerated shows that sur¬
vival is possible in cells which are hemizygous for genes
on 5q outside APC. Thus the observed clustering of
breakpoints around APC is unlikely to be merely the
consequence of positive selection for lesions which
delete APC but conserve important outlying genes.
This clustering of breakpoints is not predicted by a
simple interpretation of the anti-oncogene hypothesis of
Knudson (1983). Other putative anti-oncogenes
involved in colorectal carcinoma, such as those on 17p
12-12.3 (Lothe et al., 1988; Baker et al., 1989), and 18q
(Monpezat et al., 1988; Vogelstein et al., 1988), have not
yet been analysed in sufficient detail to measure the
contribution of different types of chromosomal lesions
to the allele loss. Clustered breakpoints are not
observed, however, in the somatic loss of anti-
oncogenes at 13q 14 in retinoblastoma (Dryja et al.,
1984) or 1 lpl3 in Wilms' tumour (Fearon et al., 1984),
where whole chromosome loss, mitotic recombination
and partial chromosome arm loss played a greater role
than in the present study. The finding of molecular
1172 P.G. ASHTON-RICKARDT et al.
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Figure 2 Patterns of allelic loss of chromosome 5 linked markers in 32 tumours in which physical interpretation of the defect was
possible. Thirty were carcinomas, two villous adenomas. Uppermost, schematically shown, is the location of polymorphic DNA
probes on chromosome 5. Aligned below is the allelic loss (open circle) or retention (shaded circle) revealed by these markers. The
number of tumours exhibiting a particular pattern of loss is indicated in brackets on the right-hand side and similar patterns are
grouped together as interstitial deletions (centromeric, bilateral, telomeric) or mitotic recombinations/partial arm loss (centromeric or
telomeric), involving APC
lesions grouped around the APC locus in a high pro¬
portion of sporadic colorectal carcinomas suggests that
this chromosomal region may possess some innate
feature predisposing it to breakage and recombination
events. This, as well as the putative altered properties ol
the APC gene product(s), may be a factor influencing
the contribution of the locus to the progression of col¬
orectal cancer. A constitutive 'fragile' site for chromatir
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ireakage has been identified in the vicinity of 5q21.2
Yunis et al., 1987), although its precise relationship to
1PC is unknown. More detailed mapping of the region
n and around APC may clarify the mechanisms under-




)ne hundred and nineteen tumours from 117 patients under-
oing operation for colorectal carcinoma were sampled. The
olons were placed on ice immediately after removal, and
/ithin 20min were opened and rinsed in ice-cold phosphate-
uffered saline, supplemented to 0.02% (w/v) with EDTA.
mall portions of tumour, and distant apparently normal
lucosa were snap frozen in liquid nitrogen. Immediately
djacent tissue was fixed in neutral buffered formalin or
'LPD (Holgate et al., 1986) for histology. The remainder of
tie specimen was examined after fixation for depth of tumour
lvasion and lymph node infiltration to permit staging in the
)ukes' classification. In all there were 117 carcinomas and
wo large villous adenomas.
>NA analysis
)NA of high molecular weight was prepared from tissue
sing a method based on SDS-lysis and proteinase K-
igestion as described by Goelz et al. (1985), digested (10 /zg)
nth the appropriate restriction enzyme and electrophoresed
tirough 0.8% (w/v) agarose gel DNA was transferred on to
ylon membranes (Southern, 1975) in 0.5 m NaOH, 1.5 m
JaCl. Prehybridization was performed for at least four hours
t 65°C in 10% (w/v) dextran sulphate, 1% (w/v) SDS, 0.9 m
JaCl-0.09M sodium citrate, 100/rgmP1 denatured salmon
perm DNA. Hybridization was at 65°C for 16-24h in the
same solution, together with salmon sperm DNA at
250/igml"1 and probe labelled with a-[32P]dCTP (specific
activity 109cpm/rg_1) by the random priming method
(Feinberg & Vogelstein, 1983, 1984). Membranes were washed
as described (Nakamura et al., 1988) and exposed at — 70°C.
Hybridization conditions were altered for probes with high
levels of non-specific binding; human placental DNA was
used instead of salmon sperm DNA, and the probe pre-
incubated with the hybridization solution at 65°C for one
hour before addition to the membrane.
For each probe the target locus specification, preferred
restriction enzyme, and allele sizes are given in Table 1. Allele
losses were accepted only if the differences in band intensity
on the autoradiogram were obvious.
Flow cytometry
Small portions of frozen tissue, taken adjacent to the sites
sampled for histology and DNA analysis, were used to
prepare suspensions of single nuclei by the detergent-trypsin
procedure of Vindelov et al. (1983). Chicken erythrocytes were
mixed with the sample at the beginning of the preparation
procedure to serve as an internal DNA ploidy standard. The
DNA content of these cells is about 35% of that of normal
human diploid cells. Nuclei stained with 0.62 m propidium
iodide were analysed in a Coulter Epics CS flow cytometer at
an excitation wavelength of 488 nm. Coefficients of variation
of Gq/Gj peaks seldom exceeded 3%. Aneuploidy was con¬
sidered present when two distinct G0/G, peaks were visible.
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experimental group compared with only 11% of the
conventionally treated group had a remission (defined
as at least 3 months of good control on the same diet
and oral agents that had previously been shown to be
ineffective). At the time of their report three of the
remissions in the experimental group had lasted up to
a year and two of these were continuing. Enthusiasm
for this approach waned as other workers were unable
to produce prolonged remissions. A Danish group12
achieved tight control withmultiple daily injections of
insulin and showed improvement in beta cell function
compared with a conventionally treated group, but by
90 days the difference was no longer apparent.
Perlman13 used insulin delivery by a portable
intravenous pump for 28-62 days to produce tight
control; he also showed higher C peptide levels by
comparison with a conventionally treated control
group initially but by 4 months there were no
differences in C peptide nor in glycosylated
haemoglobin levels between the two groups. Renewed
interest in this area has been stimulated by a report
from Shah and colleagues.14 In a randomised trial,
twelve patients with newly diagnosed IDDM (mean
age 13-2 years) were treated for 2 weeks with an
artificial pancreas ('Biostator') to maintain
normoglycaemia. A control group offourteen patients
of a similar age were treated with twice daily isophane
insulin, adjusted tomaintain a blood glucose below 7-8
mmol/1 before meals and at 11-1 mmol/1 an hour after
meals. The biostator group were subsequently man¬
aged on the same regimen as the controls. Beta
cell function was assessed at intervals for a year. At 1
year there were significantly higher C peptide levels
and lower glycosylated haemoglobin levels in the
experimental group.
It is not clearwhy different studies have shown that
the benefits of tight control last for variable lengths of
time. The degree of tight control achieved and its
duration may be important. In Shah's study, the
control group were especially poorly controlled after a
year, making it difficult to distinguish cause from
effect. Were they poorly controlled with a reduced
capacity to produce endogenous insulin because they
were not treated initially with a biostator or was it
because they had received insufficient exogenous
insulin for several months?
Treatment with an artificial pancreas for 2 weeks
immediately after diagnosis would be very difficult to
implement in clinical practice since very few centres
have access to a biostator. The machines are very
expensive and need specialised staff to use dtcm. The
patient has to be admitted to hospital and remain
attached to the machine continuously by intravenous
12. Madsbad S, Krarup T, Faber OK, Binder C, Regeur L. The transient effect of stria
metabolic control on beta cell funaion in newly diagnosed type 1 (insulin
dependent) diabetic patients. Diabctologia 1982; 22: 16-20.
1 3. Perlman K, Ehrlich RM, Filler RM, AlbisserAM. Sustained normoglycemia in newly
diagnosed type 1 diabetic subjeas. Diabetes 1984; 33: 995-1001.
14. Shalt SC, Malonc J I, Simpson NI*. A randomized trial of intensive insulin therapy in
newly diagnosed insulin-dependent diabetes mellitus. N HugIJ Med 1989; 320:
550-54.
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cannulae. Even if time and money were no object, this
experience might well prove to be very traumatic.
Psychological disturbances are common in patients
with IDDM,1516 and adolescence is especially fraught
with difficulties.17 Behaviour problems can cause even
more disruption of diabetic control than can
reductions in C peptide levels.18 Adolescents often
discuss how upset they were at the time of diagnosis.
Many clinicians feel it is important to reassure them
that they can continue to live their lives without too
many restrictions, so it is usual to treat them as
outpatients to minimise interference with normal
activities.
It seems sensible to treat patients with newly
diagnosed diabetes with conventional methods to
achieve as tight control as is possible without undue
risk of hypoglycaemia. Clinical diabetologists will
require far more evidence to convince them of the
value of imposing upon young, vulnerable individuals




COLORECTAL cancer is common in Western
societies. Both environmental (mainly dietary) and
genetic factors are implicated in its aetiology, while the
progression through hyperplasia, adenomatous
change, pre-invasive, invasive, and finally metastatic
carcinoma ismore clearcut in this disease than inmany
other malignancies.1-2 Thus colorectal cancer has
become an obvious focus for examination of the
molecular events underlying the evolution ofcancer in
general.
An important lead was provided by studies of
familial adenomatous polyposis (FAP), including
Gardner's syndrome.3 This condition is inherited as
an autosomal dominant and affects about one in ten
thousand people. In affected individuals during early
adulthood, hundreds or thousands of adenomas
develop throughout the gastrointestinal tract but
especially in the colon. These tumours progress
almost invariably to carcinoma unless the large bowel
is removed. Linkage studies in families mapped the
gene responsible (ape) to the long arm of chromosome
5 within bands q21-22.4_5 It has subsequently been
15. Tattcrsall RB. Psychiatric aspects of diabetes. BrJ Psychiatry 1981; 132: 485-95.
16. SurridgeDHC, Williams Erdahl DL, Lawson JS, et al. Psychiatric aspeas ofdiabetes
mcllitus. BrJ Psychiatry 1984; 145: 269-76.
17. Tattersall RB, Lowe J. Diabetes in adolescence. Diabetologia 1981; 20: 517-23.
18. Tartersall RB. Brittle diabetes. Br MedJ 1985; 291: 277-86.
1. MutoT, Bussey HJR, Morson BC. The evolution of cancer of the colon and rectum.
Cancer 1975; 36: 2251-70.
2. Morson BC, Busscy HJR, Day DW, Hill MJ. Adenomas of the large bowel. Cancer
Surveys 1983; 2: 451-77.
3. Gardner EJ. A genetic and clinical study of intestinal polyposis, a predisposing laaor
for carcinoma of the colon and rectum. Am J Hum Caret 1951; 3: 167-76.
4. Bodmer WF, Bailey CJ, Bodmer J, a al. localisation of die gene for familial
adenomatous polyposis on chomosotnc 5. Nature 1987; 328: 614-16.
5. Leppert M, Dobbs M, Scambler P, a al. The gene for familial polyposis coli maps tc
die long ami of chromosome 5. Science 1987; 238: 1411-13.
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shown that at least a proportion of sporadic colon
cancers carry a deletion that appears to involve the
same ape gene.610 This gene therefore has strong
credentials as a tumour suppressor by analogy with
retinoblastoma, in which familial and sporadic
tumours appear to have molecular lesions involving
die same gene (Rb)u on chromosome 13ql4. As
predicted by De Mars12 and presented as a detailed
hypothesis by Knudson,13 at least two mutations are
required before a tumour can develop. However, it is
unclear whether one or both copies of ape must be
inactivated before a tumour will develop in the colon.
Until the gene itself has been identified and cloned,
point mutations or other very subtle changes thatmay
affect its function cannot be detected. Meanwhile,
reliance is placed on flanking DNA markers, which
will be absent only when a substantial segment of the
chromosome is deleted. Within that segment there
may be one or more genes that are essential (at least in
single copy form) to the survival of the cell, so large
deletions will always be heterozygous. One can only
speculate about the integrity or otherwise of the ape
gene on an apparently intact chromosome 5, but it is
relevant that in FAP, in which one copy of the gene is
presumed already to be abnormal, molecular analysis
of colonic adenomas seldom yields any evidence that
the other copy has been deletedA9-14 ,s
Knudson's hypothesis requires that one genetic
lesion should not be sufficient for tumorigenesis but is
entirely compatible with second and subsequent
mutations affecting different genes. Karyotypic
analysis of colon cancers has shown that the long arms
of chromosomes 51617 and 1818 and the short arm of
chromosome 1717-18 are consistently involved in non-
random losses, thereby identifying potential sites for
other tumour suppressor genes that might act in
concertwith ape. This evidence has been corroborated
at the molecular level by the finding of frequent allele
losses at loci on 18q and, most strikingly, on
6. Solomon E, Voss R, Hall V, et al. Chromosome 5 allele loss in human colorectal
carcinomas. Nature 1987; 328: 616-19.
7. Yakamoto M, Sasaki M, Sugio K. Loss of constitutional heterozygosity in colon
carcinoma from patients with familial polyposis coli. Nature 1988; 331: 273-77.
8. Law DJ, Olschwang S, Monpezat J-Ph, et al. Concerted non syntenic allelic loss in
human colorectal carcinoma. Science 1988; 241: 961-65.
9. Vogelstein B, Fearon FR, Hamilton SR, et al. Genetic alterations during colorectal
rumor development. N EnglJ Med 1988; 319: 525-32.
10. Vogclstein B, Fcaron ER, Kcm SE, ct al. Allclotypc ofcolorectal carcinomas. Science
1989;244: 207-11.
11. Hansen MF, Cavanee WK. Retinoblastoma and the progression of tumor genetics.
Trends Genet 1988; 4: 125-28.
12. De Mars R. In: 23rd annual symposium on fundamental cancer research, 1969.
Baltimore: Williams & Wilkins, 1970: 104-05.
13. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl
Acad Sci USA 1971; 68: 820-23.
14. Dunlop MG. Familial adenomatous polyposis: gene order of Cl 1P11 (D5571) and
pi22T (D5537) at thefap focus with evidence that the germline mutation is sufficient
for adenoma development. Proc 69th meeting Surgical Research Society,
Canterbury, January 1989(abstr).
15. RossM, Leigh SEA, Dclhanty JDA, Jass JR. Chromosome 5 allele k»ss in familial and
sporadic colorectal adenomas. Br J Cancer 1989; 59: 361-65.
16. Ferti-Passantonopoulou A, 1'anassi A, Avgcrinos A, Raptis S. Cytogenetic findings in
a large bowel adenocarcinoma. Cancer Genet Cytogenct 1986; 21: 361-64.
17. Reichmann A, Martin P, I^evin B. Chromosomal banding patterns in human large
bowel cancer. Int J Cancer 1981; 28: 431-40.
18. MulerisM, Salmon RJ, Zafrani B,ct al. Ginsistent deficienciesofchromosome 18 and
of the short arm of chromosome 17 in eleven cases of human large bowel cancer: a
possible recessive determinism. Ann Genet 1985; 28: 206-1 3.
17p.91018-22 Over 70% of sporadic colon cancers have
lost a region ofchromosome 17 short arm that includes
a gene (p53) thought to be implicated in the neoplastic
process.23 Sequence data have documented point
mutations within a highly conserved region of the p53
gene on the remaining chromosome 17 in tumours
shown to have lost chromosome 17 DNA markers.21
However, specific point mutations within the p53
sequence, far from inactivating it, can convert it to a
cellular transforming oncogene,23 and so the
distinction between oncogene (dominant) and tumour
suppressor gene (recessive) is now somewhat blurred.
Other changes in the DNA of colon tumours that
are implicated in carcinogenic progression include
activation of the Kirsten ras oncogene,9M2S
hypomethylation of cytidine residues26 (associated
with abnormal levels of gene activation), and
aneuploidy.27 It seems very likely that a single genetic
change contributing to the development of a tumour
may enhance the risk ofsecond and subsequent events
by inducing hyperplasia (thereby increasing the
population of cells at risk), by compromising the
stability of the rest of the genome, or by some
combination of these and other mechanisms. At least
some of the events may be common to many different
types of tumour and it is not yet clear how many of
them are required, or in what permutations, to drive a
cell to a given degree ofmalignancy. There is, asmight
be expected, a correlation between tumour stage and
the total number of identifiable genetic lesions in colon
cancers,10 but the order in which the genetic changes
accumulate may be flexible.9 Some data suggest that
loss of the ape locus tends to be an early event whereas
deletions on 17p and 18q come later.9
These latest findings in colorectal cancer illustrate
very clearly how molecular genetics is transforming
our knowledge of the fundamental basis of
malignancy. Nevertheless, it is important not to
concentrate on the cell nucleus and its contents to the
exclusion of other elements in the complex equation.
Even in FAP, in which a single gene holds centre
stage, the observation that established adenomas
regress when the bowel contents are altered by
subtotal colectomy with ileorectal anastomosis28 is a
19. Fcaron ER, Hamilton SR, Vogclstcin B. Clonal analysis of human colorectal tumors.
Science 1987; 328: 193-97.
20. Monpezat J-Ph, DelattreO, Bernard A,etal. I^oss ofalleles on chromosome 18 and on
the short arm of chomosome 17 in polyploid colorectal carcinomas. Int J Cancer
1988;41:404-08.
21. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene
mutations in colorectal carcinomas. Science 1989; 244: 217-21.
22. Lothe RA, Nakamura Y, Woodward S, et al. VNTR (variable number of tandem
repeats) markers show loss of chromosome 17p sequences in human colorectal
carcinomas. Cytogenet Cell Genet 1988; 48: 167-69.
23. Editorial. Genomic p53 gene immortalises. Oncogene 1988; 2: 419-20.
24. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human
colorectal cancers. Nature 1987; 327: 293-97.
25. Forrester K, Almonguera C, Han K, et al. Detection of high incidence of K-ras
oncogenes during human colon tumorigenesis. Nature 1987; 327: 298-303.
26. Goelz S, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from
benign and malignant human colon neoplasms. Science 1985; 228: 187-90.
27. Friedlander ML, Hcdley DW, Taylor IW. Clinical and biological significance of
aneuploidy in human tumours. J Clin Pathol 1984; 37: 961-74.
28. Nicholls RJ, Springall RG, Gallacher P. Regression of rectal adenomas after
colectomy and ileorectal anastomosis for lamilial adenomatous polyposis. BrMedJ
1988; 296; 1707-08.
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salutary reminder that environmental influences must
play a part in determining the outcome of genetic
events.
SURVEILLANCE CULTURES IN NEUTROPENIA
PROFOUND neutropenia (white cell count <0-5 x HP/1) is
associated with a greatly increased risk of infection, which
may develop rapidly and lead to death within hours.1-2
Reliable prediction of the identity and antibiotic
susceptibility of the infecting organism would help
management of neutropenic patients considerably. About
half of all proven bacteraemic episodes arise from the
patient's own microbial flora;3 most of the remainder stem
from organisms acquired in hospital from sources such as
hands of attendant staff4 and uncooked food.5 Close
monitoring of microbial flora of individual neutropenic
patients, by regular sampling of several sites, could
theoretically detect likely pathogens before a bacteraemic
episode occurred and so initial antibiotic treatment could be
tailored to cover these organisms. This happy outcome has
not always been borne out in practice. Whilst surveillance
cultures are undoubtedly valuable for elucidation of
epidemiological patterns and design of infection prevention
regimens, their routine use as a predictor of infection
remains controversial.
Monitoringof several sites—eg, nose, axilla, gingiva, and
rectum—as done by earlier researchers6 is very time
consuming and cosdy for the laboratory. Moreover, unless a
patient is receiving oral, nonabsorbable antibiotics or
selective gut decontamination (SGD) regimens, his
microbial flora, although not hospital-acquired, will
number dozens of bacterial and fungal species. Routine
selection and characterisation of any but those few
organisms most commonly implicated in infection—eg,
Pseudomonas aeruginosa—is therefore impractical.
Information gained in this way is of limited value, because
almost any resident microorganismmay initiate infection in
patients with neutropenia, and a small but significant
number of bacteraemias are caused by organisms not
previously detected by the most rigorous surveillance.7
Culture results themselves depend on several variables—
eg, the quality of the specimen and of laboratory processing.
The single most useful specimen for the detection of
gram-negative organisms is faecal material.8 In general,
more useful bacteriological information is obtained in
1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationship between
circulating leukocytes and infection in patients with acute leukemia. Ann Intern
Med 1966; 64: 328-40.
2. Schimpff SC, Hahn DM, Brouillet MD, Young VM, Former CL, Wicmik PH.
Infection prevention in acute leukemia: comparison of basic infection prevention
techniques, with standard room reverse isolation or with reverse isolation plus
added air filtration, Leuk Res 1978; 2: 231-40.
3. SchimpfTSC. Surveillance cultures. J Infect Dis 1981; 144: 81-84.
4. Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiemik PH.
Origin of infection in acute nonlymphocytic leukemia: significance of hospital
acquisition of potential pathogens. Ann Intern Med 1972; 77: 707-14.
5. Remington JS, Schimpff SC. Please don't eat the salads. N Engl J Med 1981; 304:
433-35.
6. Newman KA, Schimpff SC, Young VM, Wiernik PH. Lessons learned from
surveillance cultures in patients with acute nonlymphocytic leukemia. Am J Med
1981;70:423-31.
7. Remington JS, Schimpff SC, Hughes WT, Armstrong D, Klastersky J, Bodcy GP.
Life-threatening infections in the compromised host. 10th Interscience Conference
on Antimicrobial Agents and Chemotherapy. New Orleans: American Society for
Microbiology, 1978: 37-42.
8. Daw MA, Munnelly P, McCann SR, Daly PA, Falkiner FR, Keane Or. Value of
surveillance cultures in the management of neutropenic patients. Eur J Clin
Microbiol Infect Dis 1988; 7: 742-47.
patients undergoing SGD, in whom the numbers of
microorganisms are greatly reduced. A very high positive
predictive value for development of infection has only been
obtained with the isolation of Aspergillus flavus from nasal
swabs: in one study, invasive aspergillosis developed in 10 of
11 patients with positive cultures.9 As might be expected,
negative cultures have a consistently high negative
predictive value.
Wider use ofSGD and ofcentral venous catheters has led
to a change in the spectrum of bacteria causing infection in
neutropenia and consequently to reappraisal of the role of
surveillance cultures. Gram-positive organisms such as
coagulase-negative staphylococci and diphtheroids now
occur more frequently. In one study, gram-positives
accounted for 20% of bacteraemias in the 5-year period
before introduction ofSGD, but for 62% in the following 5
years.10 Central venous catheters are an important source of
infection, bacteria being introduced during catheter
manipulation, tracking along the catheter surface, or lodging
on the catheter via haematogenous spread. Studies of the
value of surveillance cultures of the skin at the catheter entry
site and catheter hub have given conflicting results. Some
workers have found them useful,11 but others have found
that an initial site of infection could be identified in only half
of all gram-positive septicaemias.12 The importance of
coagulase-negative staphylococci is very difficult to assess;
although these skin commensals are the most common
colonisers ofcentral venous cannulae, they are also the most
common contaminating organisms.13 Most gram-positive
infections are caused by organisms of low virulence, which
tend to cause a low-grade illness, giving clinicians a little
extra time if the bacterium isolated on culture is found to be
resistant to initial antibiotic therapy.
Some researchers are convinced that surveillance cultures
aid the earlier, more targeted, initiation of antimicrobial
therapy814 whereas others think them "costly, insensitive
and unlikely to influence antimicrobial management".15
The cost of surveillance cultures is undisputed, especially
since no infecting organism is identified in over 80% of all
febrile episodes in neutropenic patients.16 In light of the
published data, it would be rash to commit a patient to
narrow-spectrum antimicrobial therapy purely on results of
such cultures. However, in certain circumstances—eg,
heavy colonisation with a particularly invasive organism or
nasal colonisation with Aspergillus flavus—additional,
sometimes lifesaving therapy might be started earlier.
9. Aisner J, Murillo J, Schimpff SC, Steere AC. Invasive aspergillosis in acute leukemia:
correlation with nose cultures and antibiotic use. Ann Intern Med 1979; 90: 4-9.
10. Cimino M, Rotstein C, Aldinger J, Emrich L, Driscoll D. Effect of cotrimoxazole
selective gut decontamination on the incidence of gram-negative bacteremia in the
initial febrile episode of granulocytopenic cancer patients. 26th Interscience
Conference on Antimicrobial Agents and (Chemotherapy. New Orleans: American
Society for Microbiology, 1986: abstr 675.
11. Fan ST, Teoh-Chan CH, Lau K,Chu KW, Kwan AKB,Wong KK. Predictive value
of surveillance skin and hub cultures in central venous catheters sepsis. J Hosp
Infect 1988; 12: 191-98.
12. EORTC Antimicrobial Therapy Gx>perative Group. Gram-positive septicemias in
cancer patients. 26th Interscience Conference on Antimicrobial Agents and
Chemotherapy. New Orleans: American Society for Microbiology, 1986: abstr
679.
13. Snydman DR, Gorbea HF, Pober BP, Majka J A, Murray SA, Perry LK. Predictive
value of surveillance skin cultures in total-parenteral-nutrition-rclated infection.
lumcet 1982; ii: 1385-88.
14. Marcus RE, Goldman JM. Management of infection in the neutropenic patient.
lir MedJ 1986; 293: 406-08.
15. Kramer BS, Pizzo PA, Robichaud KJ, Witesbsky F, Wesley R. Role of serial
microbiologic surveillance and clinical evaluation in the management of cancer
patients with fever and granulocytopenia. Am J Med 1982; 72: 561-68.
16. The EORTC International Project Group. 'Hiree antibiotic regimens in the treatment
of infection in febrile granulocytopenic patients with cancer. J Infect Ihs 1981; 137:
14-29.
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Inheritance of colorectal cancer
susceptibility
Although dietary factors are clearly implicated in the aetiology of large bowel malignancy, there is
substantial evidence to suggest that susceptibility to colorectal cancer is inherited. Many studies1'2,3
have shown familial clustering of benign and malignant colorectal neoplasms which is not restricted
to the syndrome of hereditary non-polyposis colorectal cancer. Lovett1 noted a slight excess of
colorectal cancer in the spouses of affected individuals but subsequently it has been shown that familial
clustering of cases cannot be accounted for by the simple hypothesis of common exposure to
environmental carcinogens3,4. The data support the existence of a gene defect which results in colorectal
adenomas and carcinomas with a population frequency of 19 per cent and which is transmitted in a
Mendelian dominant mode3. In addition, it appears that very few cancers occur in patients who have
not inherited a predisposition to large bowel neoplasia. If true, this has resounding implications for
screening and early detection of premalignant and malignant colorectal neoplasms.
If there is a heritable colorectal cancer gene, the techniques of modern molecular biology may
eventually be able to provide a simple screening procedure involving only a blood test. This would
identify those with a gene defect predisposing the large bowel epithelium to the effects of faecal
carcinogens. Dietary manipulation seems unlikely to be practical and so such individuals could be
enrolled in intensive clinical screening programmes. Such a screening protocol seems eminently
desirable for its efficiency and presumed sensitivity. However molecular biologists need clinical data
which not only confirm that a colorectal cancer gene does actually exist, but also identify those
patients who have inherited it. Clearly not all individuals with the gene defect will develop colorectal
cancer and so there is a pressing need for a full description of the 'colorectal cancer gene' phenotype.
There are already some pointers as to what such a phenotype might be.
Skin tags are more common in patients with colorectal adenomas than in the general population5.
It seems unlikely that gut carcinogens should also have an effect on skin tag formation and so such
patients may have inherited a defect in a gene with pleiotropic effects involving skin and colonic
epithelium. Mandibular osteomas are common in patients with familial adenomatous polyposis (FAP)
and these lesions also occur with a higher frequency in patients with apparently non-familial colorectal
cancer than in a control population6. This suggests that the 'colorectal cancer gene' may actually be
the gene for FAP (the so-called ape gene) but perhaps carrying a different class of mutation
within it. There is molecular genetic evidence to support this hypothesis since ape gene deletion has
been shown to occur in a high proportion of colorectal carcinomas7. If the ape gene on chromosome
5 is involved in the inheritance of susceptibility to colorectal cancer then other features of FAP may be
prevalent in colorectal cancer patients.
In this issue, Iwama and colleagues8 examine the association of congenital hypertrophy of the retinal
pigment epithelium (CHRPE) and FAP. They, and others9, have demonstrated the prevalence of this
phenotypic marker in FAP patients. If there is a class of inherited ape gene mutation which predisposes
to colorectal cancer, then CHRPE lesions may occur with undue frequency in patients with large
bowel malignancy.
It is clear that the diagnostic work-up of patients with colorectal neoplasms should include a careful
family history but studies to delineate the clinical phenotype of the putative colorectal cancer gene are
now also required.
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The potential causes of deranged metabolism in cancer are discusser
with emphasis on changes in energy metabolism of glucose, fat anc
protein. The implications of these changes for the treatment ofcachexic
are then considered
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Cachexia is commonly the cause of death in cases of advanced
malignancy1, and cancer patients who have lost a significant
percentage of their body-weight before surgical treatment are
subject to a much greater risk of postoperative mortality and
morbidity2-4. There is no doubt that reduced oral intake
resulting from anorexia or obstruction of the gastrointestinal
tract plays a very significant role in the development of the
cancer cachexia syndrome. However, whereas the metabolic
response to uncomplicated starvation acts to limit the
consumption of host reserves, in the cachectic cancer patient
there is often an accelerated mobilization and oxidation of
energy substrates and loss of nitrogen5-7. These changes are a
consequence of alterations in intermediary metabolism
associated with cancer8.
Understanding the metabolic response to cancer has become
increasingly important over the last two decades with the
introduction of effective and safe parenteral nutrition
techniques9. It is now possible to provide sufficient calories and
nitrogen to all cancer patients, but the metabolic milieu
associated with advanced cancer may retard the restoration of
lean body mass10. In the following review the manner in which
malignant tumours affect host metabolism will be presented,
and the effectiveness of the available therapeutic options will be
discussed.
One consistent feature of data from metabolic studies in
cancer patients is the range of response between individuals,
even when comparing those with the same diagnosis and stage
of disease11. The interpretative difficulties are compounded by
many reports comparing small heterogeneous groups of cancer
patients with equally small groups of controls, which may well
be poorly matched for age or weight loss. To overcome some
of these problems laboratory models have been developed in
which malignant cells of identical genotype are transplanted
into genetically uniform animals12. However, the growth
dynamics and tumour-to-host weight ratios frequently do not
resemble those observed in patients, and this review will present
mainly data from patient studies.
Changes in energy metabolism
The hypothesis that tumour bearing increases energy
expenditure and results in a cumulative negative energy balance
and progressive weight loss has been exhaustively investigated,
and there is now a substantial body of supportive evidence.
Bozzetti et al.13 studied a heterogeneous group of patients with
advanced tumours and found a highly significant correlation
between the resting metabolic expenditure (RME) and the
magnitude of weight loss, and other groups of researchers have
similarly found elevated RMEs in patients with cancer
cachexia14-18. There are a few anecdotal reports of cases in
which successful antineoplastic therapy has reduced energy
expenditure in hypermetabolic patients14-18, suggesting that the
presence of the tumour itself is capable of elevating the RME
However, hypermetabolism is not an invariable finding ir
cancer patients who have lost weight, with large series having
been reported recently which have failed to demonstrate a
significant increase in the resting metabolic rate of cachectic
cancer patients when compared with patients with weight loss
of a similar magnitude due to benign disease or with
weight-stable cancer patients19-20. In a series consisting of 20C
patients with a variety of tumour types 29 per cent had a resting
metabolic expenditure that was 10 per cent higher than thai
predicted by the Harris-Benedict equation, 31 per cent were
found to be hypometabolic using the same criterion and nc
relationship was demonstrated between RME and weight loss
or tumour burden21.
Although some of the disparity in the findings of these studies
is no doubt a reflection of differences in experimental material
and methodology, it is likely that they are reflecting a true
heterogeneity of response to the tumour bearing state. It is now
clear that cancers arising from certain tissues, such as
sarcomas22, leukaemias23 and bronchial carcinomas24, fre¬
quently provoke a hypermetabolic response, whereas patients
with pancreatic and hepatobiliary tumours tend to be
hypometabolic25.
Many cancer patients with advanced disease have a reduced
caloric intake. In normal people or in patients with benign
disease, semistarvation is attended by a reduction in RME26-27.
so in an undernourished cancer patient even a normal metabolic
rate represents a failure of this adaptive response14-28.
The mechanism by which malignant tissue alters the energy
expenditure of the host is not clear. It is unlikely that increased
energy consumption by the tumour itself is responsible in
human tumours as it is rare for tumours to account for more
than 5 per cent of body weight13. More plausible is the
hypothesis that mediators are released by some cancers which
alter host metabolism29-30, and some of the changes that may
occur are discussed in subsequent sections.
Changes in glucose metabolism
There are many reports describing an increased rate oi
endogenous glucose production in cancer patients1 1-22-23,31-33
(Figure 1), and considerable research effort has been directed
towards determining the mechanism and significance of this
occurrence. It is clear that the magnitude of the increase in
glucose turnover is influenced by tumour stage6-35 and
histology, and that it is associated with cancer cachexia36. In
this section, some of the observations made in cancer patients
of changes in glucose metabolism will be summarized and the
implications that these have on energy balance will be discussed.
Gluconeogenesis
Shaw and Wolfe6 have defined glucose kinetics in a group of
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kinesin could serve primarily to establish that array but not to
maintain it. The behaviour of lysosomes observed in living cells
indicates, however, that the lysosome distribution is maintained
by a continuous balance of outward and inward vesicle move¬
ments. We therefore suggest that kinesin ATPase has a role in
the formation and maintenance of the lysosomal compartment
in the form of an extended tubulovesicular array in
macrophages. On the basis of immunolocalization5,17 and in
vitro motility studies3-4-13,18 this probably involves kinesin
molecules anchored to the organelle surface which undergo
ATP-dependent interaction with microtubules to produce cen-
trifugally directed translocating forces. □
Received 15 January; accepted 15 June 1990.
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Telomere reduction in human
colorectal carcinoma and
with ageing
Nicholas D. Hastie, Maureen Dempster,
Malcolm G. Dunlop*, Alastair M. Thompson*,
Daryll K. Green & Robin C. Allshire*
MRC Human Genetics Unit, Western General Hospital, Edinburgh, UK
We have hypothesized that end-to-end chromosome fusions
observed in some tumours could play a part in genetic instability
associated with tumorigenesis and that fusion may result from the
loss of the long stretches of G-rich repeats found at the ends of
all linear chromosomes'. We therefore asked whether there is
telomere loss or reduction in common tumours. Here we show that
in most of the colorectal carcinomas that we analysed, there is a
reduction in the length of telomere repeat arrays relative to the
normal colonic mucosa from the same patient. We speculate on
the consequences of this loss for tumorigenesis. We also show that
the telomere arrays are much smaller in colonic mucosa and blood
than in fetal tissue and sperm, and that there is a reduction in
average telomere length with age in blood and colon mucosa. We
propose that the telomerase2"4 is inactive in somatic tissues, and
that telomere length is an indicator of the number of cell divisions
that it has taken to form a particular tissue and possibly to generate
tumours.
* Present addresses: Department of Surgery, Royal Infirmary. Edinburgh EH3 9YW. UK (M.G.D. and




The termini of human chromosomes, like those of other
eukaryotes, comprise stretches of G-rich repeats5"10 which are
of ~10kiiobases (kb) and 15 kb in blood and sperm
respectively5-7-10-11. When DNA is digested with a frequently
cutting restriction enzyme such as Hint1 or AluI, which will not
cut within the repeat, subsequent probing with a labelled
oligonucleotide for (TTAGGG)„ will reveal the size of the
terminal repeat array (TRA). Figure 1 a shows the hybridization
of a (TTAGGG)4 probe to Hmfl-digested DNA from matched
normal colonic mucosa and colon carcinoma samples from seven
individuals. There is some variation in the average length of the
TRA between normal mucosae from different individuals but
not much difference in signal strength. In all the carcinomas
there is a reduction in length of the repeat stretch relative to
the respective normal mucosa and in some cases there is a
marked reduction in the signal intensity.
We repeated the experiment with the restriction enzyme Alul
and obtained a very similar result to that obtained with Hinfl
-2.32
-2.03
FIG. 1 Southern blot analysis of telomere repeat arrays in colorectal car¬
cinomas and matched blood DNA samples, a, DNA was digested with the
restriction enzyme H/'nfl and hybridized with 32P-labelled (TTAGGG)4 probe.
b. DNA was digested with the restriction endonuclease Alu\ and hybridized
with a 32p-labelled (TTAGGG)4 probe (left panel) or a (CAC)5 probe (right
panel). The filter was first hybridized to (CAC)5 then stripped and rehybridized
to (TTAGGG)4. NM, normal mucosa; T, tumour; numbers refer to patient
numbers. Size markers are indicated to the right (kb).
METHODS. Either H/nfl- or A/ul-digested total genomic human DNA (5 p-g)
was loaded onto a 0.8% agarose gel. After electrophoresis the gel was
blotted to Hybond and hybridized to the radiolabeled probes. Hybridization
was at 48 °C in 5 x SSC buffer and washes were at 48 °C in 4 x SSC.
a
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b 145 151 178 181
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Patient
IG. 2 Mean size estimates for the TRA in colorectal carcinoma, matched
ormal mucosae and adenomas. —, Normal mucosa; —, carcinoma; —,
denoma.
1ETHODS. Autoradiographs such as those shown in Fig. 1 were analysed
y an automatic autoradiographic scanner as described previously7. In all
ases H/'nfl-digested DNAs were analysed but similar results were obtained
/ith AluI. The optical density reading under the peak was integrated and
he mean determined. Usually a gaussian distribution was obtained and the
lean position was very close to that at the centre of the peak. In all cases
he values obtained for several different experiments were within 5-10%
f each other. To avoid problems of over exposure of the signal, various
xposure times were analysed. In some cases two separate peaks were
ibserved in the tumour samples (for example, 145), the larger peak, of
Dwer optical density, similar in size to the corresponding normal mucosa.
Ve have attributed this to contamination of the tumour by normal mucosa,
or which there is independent evidence from allele loss studies. In these
ases the mean size of the smaller peak is given.
Fig. It). DNA loading and integrity were checked by prehy-
(ridizing all blots to a (CAC)5 minisatellite probe (Fig. 16, right
>anel).
To provide an estimate of the degree of reduction of the TRA
n tumours, densitometry scans were carried out on these
utoradiographs (Fig. 1) and those obtained for 13 other
umours and matched normal mucosae. The average TRA length
n the 20 normal mucosae and matching carcinomas is depicted
n Fig. 2; in all but one tumour (130) there was a reduction in
he average TRA length relative to the normal mucosa.
In three patients we were able to study the length of the TRA
n adenomas, which are the benign precursors of carcinomas,
n all three cases (191, 141, 183) there was a reduction in the
idenoma similar in extent to that found in the corresponding
arcinoma. In two carcinomas (193, 196) out of 35 studied, the
elomeres were very much larger. Unfortunately, no matched
lormal mucosae were available for these samples so we could
lot determine if this represented an increase in telomere length
n the tumour.
In several cases, the average TRA length is close to 3 kb, with
nolecules ranging to 1 kb or less. After correcting for DNA
oading using internal controls, there was a reduction in signal
ntensity of about 90%, 90%, 80%, 65%, 65% and 20% for
umours 181, 145, 178, 151, 143 and 144, respectively. Thus it
reasonable to suppose that in a proportion of cells in tumours
id adenomas (Fig. 2) there will be one or several chromosome
■nds lacking G-rich repeats.
In a preliminary series of experiments we have observed TRA
sduction in ovarian and lung carcinomas as well as the colon
arcinomas reported here. Telomere shortening has also been
sported in two Wilms' tumours10.
What is the mechanism underlying this TRA reduction?
(eduction could reflect the number of cell divisions it has taken
r produce the tumour cells in the absence of telomerase func¬
tion2"4, which may be restricted to germ cells. We have compared
the average TRA length in sperm with that in tissues from a
26-week human fetus and colon mucosa (Fig. 3) and blood (data
not shown) samples analysed in this study. Although tissue from
only a single fetus was studied, it is clear that TRA length in
these tissues is close (1-2-kb shorter) to that found in sperm
and considerably larger than that found in any colon mucosa
(on average 12 kb shorter than sperm) or blood (on average
14 kb shorter) sample.
Firm figures are not available, but it is likely that the tissues
of a developed fetus result from 20-50 cell divisions, whereas
several hundred or thousands of divisions have produced the
colonic mucosa and blood cells of 60-year old individuals12.
Thus the degree of telomere reduction is more or less propor¬
tional to the number of cell divisions. It has been shown that
the ends of Drosophila chromosomes without normal telomeres
reduce in size by ~4 base pairs (bp) per cell division13 and that
the ends of yeast chromosomes reduce by a similar degree in a
mutant presumed to lack telomerase function14. If we assume
the same rate of reduction is occurring during somatic division
in human tissues, then a reduction in TRA by 14 kb would mean
that 3,500 ancestral cell divisions lead to the production of cells
in the blood of a 60-year old individual; using estimates of
sperm telomere length found elsewhere10 we obtain a value of
1,000-2,000. These values compare favourably with those postu¬
lated for mouse blood cells12. Thus, we propose that telomerase
is indeed lacking in somatic tissues. In this regard it is of interest
to note that in maize, broken chromosomes are only healed in
sporophytic (zygotic) tissues and not in endosperm (terminally
differentiated)15, suggesting that telomerase activity is lacking
in the differentiated tissues.
Consistent with this idea, there is a significant reduction of
TRA length as a function of age in human blood DNA, although
there is a high degree of scatter (Fig. 4). From the regression
analysis we can calculate that the rate of reduction is 33 bp per
year. Extending this idea to colon tumours, a reduction in 5 kb
would mean that it has taken ~ 1,000 cell divisions to produce
a tumour from normal mucosa. Analysis of three cases (Fig. 2;
191, 141, 183) suggests that most of these doublings would take
place in the formation of the adenoma. In tumours 193 and 196
we assume that the telomerase has been reactivated as proposed
TRA length (kb)
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All bloods
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FIG. 3 Telomere length in different tissues and in association with ageing.
The estimates are averages for each tissue where more than one sample
was analysed. The data was obtained as described in Figs 1 and 2. Vertical
bars indicate greater than, and the symbol — means approximately (values
of —20 kb and greater are approximations). Numbers in brackets in the left
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IG. 4 Telomere reduction with age in human blood. The straight line was
btained by regression analysis. The significance of the regression, f=
-3.63; P< 0.001. The slope is equivalent to 33 bp per year.
or HeLa cells in culture, which are known to contain telomerase
ictivity4,10.
One alternative explanation for our observations is that in
umours the cells with shorter telomeres have a growth advantage
>ver those with larger telomeres, a situation described for vegeta-
ive cells of tetrahymena16.
Telomere losses could be a consequence of tumorigenesis or
>e involved in causing malignancy. We believe there are two
vays by which TRA losses could contribute to genetic instability,
vhich is important for tumorigenesis. First, chromosomes lack-
ng terminal repeats may be less stable and lost at higher
'requency, a situation for which there is a precedent in the yeast
iSTl mutant14. Second, chromosomes without telomeres may
>e prone to fusion-bridge-breakage cycles as described by
vlcClintock17, leading to daughter cells which receive partly
ieleted and partly duplicated chromosomes, respectively. There
s no direct evidence to support this idea in carcinogenesis,
ilthough in senescent cells where chromosome fusions are found
it high frequency18 a loss of telomere repeats has been repor-
ed19. Also, telomere fusions occur in a range of tumours, includ-
ng histiocytomas20, cardiac myxomas21, renal tumours22 and
eukaemias23, as well as the common cancers at much lower
'requency. In addition, broken ends within amplified dihydrofo-
ate reductase genes lacking telomeres will fuse to other chromo-
omes, setting up breakage-fusion-bridge cycles24.
Deletions or losses by these routes could play a part in
;enerating the loss of alleles of restriction fragment length
tolymorphisms that often occurs in colorectal carcinomas and
hat is thought to reflect the need to render mutations in tumour
uppressor genes homozygous25,26. Although some of these allele
osses occur in the adenoma stage the majority are not apparent
intil the carcinoma stage25. In the three cases studied here (191,
41, 183; Fig. 2) we find that telomere reduction has already
aken place by the adenoma stage. Hence these losses could be
nvolved in causing the chromosome rearrangements sub-
equently observed in the carcinoma. □
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The instability of chromosomes with breaks induced by X-irradi-
ation led to the proposal that the natural ends of chromosomes
are capped by a specialized structure, the telomere1. Telomeres
prevent end-to-end fusions and exonucleolytic degradation, enable
the end of the linear DNA molecule to replicate, and function in
cell division (reviewed in ref. 2). Human teiomeric DNA comprises
— 2-20 kilobases (kb) of the tandemly repeated sequence
(TTAGGG)„ oriented 5' -» 3' towards the end of the chromosome3,4,
interspersed with variant repeats in the proximal region5. Immedi¬
ately subtelomeric lie families of unrelated repeat motifs
(telomere-associated sequences) whose function, if any, is
unknown6,7. In lower eukaryotes the formation and maintenance
of telomeres may be mediated enzymatically (by telomerase)8 or
by recombination9; in man the mechanisms are poorly understood,
although telomerase has been identified in HeLa cells4. Here we
describe an a thalassaemia10 mutation associated with terminal
truncation of the short arm of chromosome 16 (within band
16pl3.3) to a site 50 kb distal to the a globin genes, and show
that (TTAGGG)„ has been added directly to the site of the break.
The mutation is stably inherited, proving that teiomeric DNA
alone is sufficient to stabilize the broken chromosome end. This
mechanism may occur in any genetic disease associated with
chromosome truncation.
During a search for novel a thalassaemia determinants, we
identified a British man (II-l) with haemoglobin H (HbH)
disease (HbH level 5.3%). This relatively severe form of a
thalassaemia is usually caused by deletion of three of the normal
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Genetic Linkage Map of Six Polymorphic DNA Markers around
the Gene for Familial Adenomatous Polyposis on Chromosome 5
M. G. Dunlop,* A. H. Wyllie.T Y. Nakamura,t'§ C. M. Steel,* H. J. Evans,* R. L. White,§
and C. C. Birdf
'Medical Research Council Human Genetics Unit, Western General Hospital; and TC. R. C. Laboratories, Department of Pathology, Edinburgh
University Medical School, Edinburgh; J Division of Biochemistry, Cancer Institute, Tokyo; and §Howard Hughes Medical Institute and
Department of Human Genetics, University of Utah Medical Center, Salt Lake City
Summary
A genetic linkage map of six polymorphic DNA markers close to the gene {APC) for familial adenomatous
polyposis (FAP) on chromosome 5q is reported. One hundred fifty-five typed members of nine FAP kindred
provided more than 90 meioses for linkage analysis. A number of crucial recombination events have been
identified which are informative at three or more loci, allowing confident ordering of parts of the map.
There was no evidence of genetic heterogeneity, with all families showing linkage of at least one chromo¬
some 5 marker to the gene. Recombination data and two-point linkage analysis support a locus order of
centromere-Tr227-CllPll-ECB27-L5.62-APC-EF5.44-YN5.48-telomere, although EF5.44 could lie in
the interval L5.62-APC or ECB27-L5.62. No recombinants were identified between APC and either
EF5.44 or YN5.48, but published deletion mapping in colorectal carcinomas and linkage analysis in FAP
suggest that YN5.48 is 1-3 cM from APC. The present study suggests that YN5.48 and L5.62 delineate a
small region of chromosome 5 within which the EF5.44 locus lies very close to the APC gene. These data
not only allow use of flanking markers for presymptomatic diagnosis of FAP but also provide a high-
density map of the region for isolation of the APC gene itself and for further assessment of the role of
chromosome 5 deletions in the biology of sporadic colorectal cancer.
Introduction
The genetic aberration resulting in familial adenoma¬
tous polyposis (FAP) has an incidence of approximately
1:10,000 (Reed and Neel 1955) but is of great clinical
importance as a gene defect causing an autosomal dom¬
inant heritable cancer syndrome in which large-bowel
cancer is preventable by prophylactic colectomy (Bulow
1987). The gene for FAP has been shown to be linked
to markers which map to chromosome 5q (Bodmer et
al. 1987; Leppert et al. 1987; Meera-Khan et al. 1988;
Nakamura et al. 1988; Dunlop et al. 1989; Murday
et al. 1989; Varesco et al. 1989) and is known as APC.
APC has also been implicated as a tumor suppressor
gene involved in the biology, if not in the genesis, of
Received May 15, 1990; revision received July 25, 1990.
Address for correspondence and reprints: M. G. Dunlop, MRC Hu¬
man Genetics Unit, Western General Hospital, Crewe Road, Edinburgh
EH4 2XU, Scotland.
© 1990 by The American Society of Human Genetics. All rights reserved.
0002-9297/90/4706-0015502.00
sporadic colorectal cancer. Loss of geneticmaterial from
chromosome 5 has been demonstrated in FAP and in
sporadic colorectal adenomas and carcinomas (Solo¬
mon et al. 1987; Vogelstein et al. 1988; Ashton-Rickardt
et al. 1989; Sasaki et al. 1989). The mechanism of such
loss is usually by interstitial deletion (Ashton-Rickardt
et al. 1989). The published data broadly support the
hypothesis that APC mutations are recessive at the cel¬
lular level and, in common with other tumor suppres¬
sor genes, require inactivation of both alleles if malig¬
nancy is to supervene (Knudson 1971).
In addition to causing the full FAP syndrome, APC
mutations may also be involved in the inheritance of
susceptibility to non-FAB colorectal cancer. Familial
clustering of colorectal cancer has been well described
(Woolf 1958; Macklin 1960; Lovett 1976; Duncan and
Kyle 1982; Lynch et al. 1985; Bonelli et al. 1988). Dom¬
inant inheritance of colorectal adenomas and of carci¬
nomas may even account for the majority of cases of
these neoplasms with a gene frequency in the general
population as high as 19% (Cannon-Albright et al.
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1988). Clinically, certain extracolonic features of FAP
occur with excess frequency in apparently sporadic
colorectal cancer (Sondergaard et al. 19856) and in
hereditary nonpolyposis colorectal cancer (Sondergaard
et al. 1985a), suggesting a common genetic etiology.
In addition, genetic linkage has recently been estab¬
lished using chromosome 5q DNA probes in a family
in which affected individuals have variable numbers of
polyps which do not all meet the criteria for the diag¬
nosis of FAP (Leppert et al. 1990). It seems likely that
a number of different mutant genes are responsible for
colorectal cancer susceptibility, and so APCmay be con¬
sidered a candidate member of such a group of genes.
A high density of polymorphic DNA markers in the
region around APCwill greatly facilitate efforts toward
identification of APC. Even after full characterization
of APC, it is likely that closely linked markers will still
be valuable for confirmation ofmutation analysis and
for presymptomatic diagnosis of FAP in families with
rare mutations.
The present study reports a genetic linkage map of
six polymorphic DNA markers. Two new probes have
been mapped, and one of these appears to be very close
to APC itself.
Material and Methods
Nine Scottish kindreds with FAP were studied, com¬
prising 155 genotyped and phenotyped individuals.
This provided in excess of 90 meioses for linkage anal¬
ysis if all families were fully informative for any marker.
Clinical, pathological, and genealogical data were com¬
plete, and affection status and penetrance were assigned
in the manner which we have described elsewhere (Dun-
lop et al. 1989).
Genotyping was carried out as we have reported else¬
where (Dunlop et al. 1989), and all techniques were
carried out by established protocols. In brief, DNA was
purified from fresh peripheral blood leukocytes, digested
with the appropriate restriction endonuclease, agarose-
gel fractionated, and transferred onto nylon membranes,
and hybridization of 32P-labeled DNA probe was re¬
vealed by autoradiography.
Genotypes were obtained for six DNA probes which
recognize RFLPs on chromosome 5. Probe DNA frag¬
ments used were as follows: 7t227 (D5S37) (Stewart et
al. 1987) as a 900-bp, EEwdlll/EcoRI fragment in
7tAN7; C11P11 (D5S71) (Bodmer et al. 1987) as a 3.6-
kb, EcoRI fragment in pUC8; ECB27 (D5S98) (Mur-
day et al. 1989; Varesco et al. 1989) as a 2.8-kb, Szt/I
fragment in phage lambda; pL5.62 as a 10.5-kb, BglII
fragment cloned into the BamWl site ofpUC18; pEF5.44
as a 2.3-kb, Mspl fragment cloned into the AccI site
ofpUC18; and YN5.48 (D5S81)(Nakamuraetal. 1988)
as a 2.4-kb, Taql fragment cloned into the AccI site
of pUC18. Table 1 shows polymorphisms recognized
by each of these probes and the appropriate restriction
enzyme used in the present study. Allele sizes and fre¬
quencies from a local control population are also tabu¬
lated in table 1. Probes pL5.62 and pEF5.44 are DNA
fragments recognizing polymorphisms as noted above
and are subclones from cosmids selected from a genomic
cosmid library derived from part of chromosome 5q
(Nakamura et al. 1988).
Linkage analysis was carried out using the LINK¬
AGE group of programs. The 1-lod unit of support was
Table I
Allele Size and Frequency Recognized at Six Polymorphic Chromosome 5q DNA Marker
Loci in a Control Scottish Population
Frequency/Size (kb)
Probe No. of
(enzyme recognizing polymoprhism) Al A2 A3 Chromosomes Examined
EF5.44 (Mspl) .18/2.9 .82/2.1 84
L5.62 (Bg/II) .93/9.0 .07/5.5 76
YN5.48 (Mspl) .45/9.0 .55/8.0 60
ECB27 (Bgfil) .39/11.9 .61/10.5 74
C11P11 (Taq\) .14/4.4 .86/3.9 100
ir227 (PstI) .25/3.0 .75/4.3 66
ir227 (Ben) .17/3.0 .46/1.8 .37/1.2 54
jr227 (BstXI) .29/2.7 .71/2.3 28
rill (Mfeol) .25/.55 .75/.45 20
984 Dunlop et al.
taken as representative of 95% probability limits. Mul¬
tipoint linkage analysis was not felt to be valid for the
present study, since only affected families were analyzed,
without Centre Etude de Polymorphisme Humaine
(CEPH) data. Instead, the data are presented as a series
of pairwise analyses between marker and disease loci
and between all pairs ofmarker loci. Crucial rare recom¬
binant events informative at three or more loci were
identified and have allowed confident locus ordering
for some parts of the map. The lod scores for linkage
between markers are relatively low because the families
were not specifically selected for a high level of infor-
mativity such as is the case with CEPH families.
Validation of paternity and of typing for chromo¬
some 5 markers was inherent in the multiple two-point
analyses which were carried out. In addition, paternity
testing was carried out on all APC-marker obligate
recombinants by using the probe 29C1 (DXYS14), which
is derived from the sex chromosomes and recognizes
a pseudoautosomal hypervariable polymorphism (Cooke
et al. 1985). This probe is extremely useful for pater¬
nity testing since typing can be carried out simply by
Southern blot analysis. In addition, Cooke et al. (1985)
found that, of 83 individuals studied, no two had the
same genotype.
Results
The results of the analysis for linkage ofAPC to each
of the six polymorphicDNA marker loci are presented
in table 2. The peak lod score (Zmax) and recombina¬
tion fraction (9) indicating the maximum likelihood of
marker location relative to APC, along with 95% prob¬
ability limits, are tabulated together with lod-score ta¬
bles. No recombinants have been identified between
APC and YN5.48 or between APC and EF5.44. The
Zmax for APC-YN5.48 was 7.00 at 0 = .00, with
95% probability limits .00-07. EF5.44 was not very
informative in these families, and so the Zmax for
APC-EF5.44 was only 3.5 at 0 = .00, with resultant
wide 95% probability limits.
Tests for linkage between each pair of marker loci
revealed no discrepancies to suggest nonpaternity or
mistyping. There were no cases of nonpaternity when
all marker-APC recombinants were tested with the probe
29C1.
Lod-score calculations were carried out for linkage
between each pair ofmarkers, and these data are shown
in table 3. The 0 is given above the diagonal and the
Zmax is given below the diagonal, for each marker-
marker combination. No recombination events were
detected between the following pairs of markers:
L5.62-ECB27, ECB27-C11P11, CllPll-7t227, and
EF5.44-L5.62. However, the lod scores for EF5.44-
L5.62 and for L5.62-ECB27 were low because of poor
informativity of these markers in the local population
(see table 1).
Table 4 shows all recombination events which were
fully informative for three or mor£ loci. The vertical
line represents the recombination event in each case,
and the informative markers are ranged either side of
the breakpoint, depending on the haplotypes resulting
from the recombination. Figure 1 shows this informa¬
tion in graphic form. The shaded area represents all
possible APC locations, relative to the markers stud¬
ied. Thus, APC could overlap EF5.44 or YN5.48 but
cannot overlap L5.62, ECB27, C11P11, or n227, be¬
cause of the presence of recombinants. These data sug¬
gest that YN5.48 and L5.62 delineate a small region
which spans APC. The interval L5.62-YN5.48 could
be as much as 11 cM (see table 3) or 7 cM (since
L5.62-EF5.44 is 0 cM and since EF5.44-YN5.48 is
7 cM) or as little as 2 cM (since L5.62-APC is 2 cM
and since APC-YN5.48 is 0 cM). The latter interval
Table 2
Linkage Analysis in Nine Scottish FAP Kindreds (KMDI-6, 8, 14, and 16)
95% Probability
Linkage vs. APC Zmax 0 Limits .00 .05 .10 .15 .20 .25
EF5.44 3.50 .00 .000-.160 3.50 3.22 2.91 2.58 2.23 1.86
YN5.48 7.00 .00 .000-.070 7.00 6.31 5.56 4.79 4.01 3.24
L5.62 13.31 .02 .005-.095 ... 12.99 11.94 10.65 9.21 7.65
ECB27 1.89 .06 .002-.260 . . . 1.88 1.76 1.50 1.20 .90
C11P11 5.45 .09 .025-.210 . . . 5.23 5.43 5.13 4.59 3.90
tt227 4.40 .11 .035-.235 . . . 4.00 4.40 4.26 3.88 3.35
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Table 3 Centromere « Telomere
Two-Point Values (below diagonal) and 9 Values
(above diagonal) for Linkage between Marker Loci in
Nine FAP Kindreds
EF5.44 YN5.48 L5.62 ECB27 C11P11 tt227
EFS.44 .07 .00 .15 .16 .25
YN5.48 2.11 .11 .19 .11 .25
L5.62 1.23 .98 .00 .04 .04
ECB27 .69 .52 1.03 .00 .12
C11P11 .64 1.60 4.11 1.86 .00




Figure I Markers ordered from recombination events as
detailed in table 5. APC is represented by the shaded area, and the
site of marker locus possible at any point in the box indicated.
(2 cM) seems most likely, since lod scores are highest
for linkage of each of the markers to APC. When two-
point linkage analysis is added to the order derived from
recombination events (table 4), and given that C11P11
is centromeric to APC (Varesco et al. 1989) and that
YN5.48 is telomeric to APC (Nakamura et al. 1988),
these data support the locus order centromere-7t227-
CllPll-ECB27-L5.62-APC-EF5.44-YN5.48-telo-
mere, although EF5.44 could lie in the interval L5.62-
APC or, least likely, in the interval ECB27-L5.62.
Table 4
















































Note. —The venical line represents where the recombination has
occurred in relation to each of the informative loci.
Discussion
The present study has provided a genetic linkage map
of six polymorphic DNA markers which lie very close
to APC on chromosome 5q. The large number of
meioses studied and the detection of a number of rare
recombination events which were informative at multi¬
ple loci have allowed confident ordering of parts of the
map. The possibility of double crossovers for these
events is remote, since the genetic area under scrutiny
is very small indeed. The localization ofYN5.48 distal
to APC (Nakamura et al. 1988) now seems certain, fol¬
lowing deletional analysis in colorectal carcinomas
(Ashton-Rickardt et al. 1989) and the recent identifica¬
tion of an APC-YN5.48 recombinant which was non-
recombinant for APC-7t227 (Tops et al. 1989). No
APC-YN5.48 recombinants were detected in the pres¬
ent study, but, when the relevant two-point linkage anal¬
ysis data are added into the map, the localization of
YN5.48 distal to APC and on the other side from 7:227,
C11P11, ECB27, and L5.62 is highly likely. The present
study has not provided firm data on the exact location
of EF5.44, but the latter certainly lies centromeric to
YN5.48 and telomeric to ECB27. Because of this and
the absence of APC-EF5.44 recombinants with a lod
score of 3.50, we believe EF5.44 to be very close in¬
deed to APC. In the search for relatively small dele¬
tions, use of EF5.44 to screen pulsed-field DNA frag¬
ments for rearrangements in patients with FAP could
provide the key to isolation and characterization ofAPC.
The data presented here, combined with those al¬
ready published for linkage of several of these markers
to the APC gene, give lod scores sufficiently high (and
hence 95% probability limits sufficiently narrow) to al¬
low their use in presymptomatic diagnosis of FAP. Esti¬
mates of genetic distance from APC for the markers
published as lod-score tables when data from this anal-
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ysis are combined are as follows: YN5.48-APC, ap¬
proximately 18.5 at 0 = .025 (Nakamura et al. 1988;
Tops et al. 1989); Jt227-APC, 18.95 at 6 = .075
(Meera-Khan et al. 1988; Murday et al. 1989); and
C11P11-APC, 11.97 at 0 = .025 (Bodmer et al. 1987;
Leppert et al. 1987).
The establishment of a high-density map of the re¬
gion around APC is of great importance, since, until
isolation of the gene itself, multiple markers will be re¬
quired for presymptomatic diagnosis of FAP. Even af¬
ter APC is cloned and sequenced, it is likely that there
will be a need for linked markers in some families. We
have detected no evidence of genetic heterogeneity in
nine Scottish FAP kindreds, with linkage being appar¬
ent for at least one of the six markers studied in all
families; and, to date, there are no families in the world
literature which do not exhibit linkage to 5q21-22. This
is of paramount importance to clinicians who will use
genetic linkage data to influence management of fami¬
lies and at-risk individuals under their care.
In the biology of colorectal carcinomas, the use of
this high-resolution map will also be of great benefit
for further examination of the role of loss of heterozy¬
gosity at loci close to APC. Examination ofDNA from
both FAP and non-FAP colorectal adenomas and carci¬
nomas at the EF5.44 locus will also be ofgreat interest,
since the present study has demonstrated the close prox¬
imity ofEP5.44 to APC. Preliminary data on such anal¬
ysis have suggested that the frequency of EF5.44 loss
is very high in colorectal cancer tissue (Wyllie et al.
1989). This again supports the linkage data presented
here, suggesting that EF5.44 is very close to APC.
The present study has delineated between YN5.48
and L5.62 a small chromosome 5q region, which may
be as little as 2 megabases. This region includes the
gene for FAP, and we have identified a marker which
we believe lies between the two flanking markers and
appears to be very close to APC itself. It is now possible
to proceed to isolate clones from this region and to screen
these for the presence of expressed sequences. Any such
sequences must be strong candidates for APC itself,
given both the relatively small distance between these
markers and that APC is probably a fairly large gene,
since the rate of new mutations giving rise to sporadic
cases of FAP is high (Reed and Neel 1955). Isolation
of APC will only be the opening chapter of a fascinat¬
ing book providing new understanding of a heritable
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Status of the APC Gene in Familial and
Sporadic Colorectal Tumours as Determined by
Closely Flanking Markers
A.H. Wyllie, P. Ashton-Rickardt, M.G. Dunlop, Y. Nakamura,
J. Piris, C. Purdie, C.M. Steel, and C.C. Bird
ABSTRACT
Using polymorphic close-flanking markers, allele deletion in the
vicinity of APC was detected in the majority of sporadic colorectal
cancers in a large unselected series. Deletion was due to
interstitial deletion or mitotic recombination, but seldom to whole
chromosome loss. Mitotic recombination affecting APC was associated
with smaller tumours than interstitial deletion. Sporadic adenomas
showed a slightly lesser freguency of allele loss, but no such loss
was observed in 28 adenomas from 4 cases of familial polyposis.
INTRODUCTION
This paper presents new data on the incidence of deletion of the APC
(Familial Polyposis) gene in human colorectal tumours. Accurate
measurement of this incidence provides the only firm clues at
present available to the functional significance of APC. In previous
work, incidence of allelic deletion involving chromosome 5q is
variously reported between 20% and 40% in sporadic colorectal
carcinomas (Solomon et al 1987; Vogelstein et al 1988; Law et al
1989) in around 30% sporadic adenomas (Vogelstein et al 1988; Rees
et al 1989), and in few if any adenomas of patients suffering from
polyposis coli. Only one group has presented convincing data on the
status of 5q alleles in carcinomas from polyposis patients, allele
loss being observed in around 24% (Okamoto et al 1988; Sasaki et al
1989). In all of these studies, however, the analysis of 5q alleles
was based on relatively few, dispersed loci. In this paper we
describe a large series of sporadic carcinomas, and substantial
numbers of sporadic and familial adenomas, using a group of probes
detecting polymorphic sequences tightly clustered around APC.
A CLUSTER OF PROBES LINKED TO APC
Maximum lod scores and the corresponding recombination fractions are
shown for five probes tightly linked to APC as tested in nine
Scottish polyposis kindreds involving more than 90 meioses (Table
1) . Critical recombinations indicated that 7T227 and C11P11 are on
the same side of APC. I Dunlop et al 1989), whereas YN5.48 is on the
opposite side. Physical maps suggest that the probes lie in the
order: cen-7T227-CllPll-L5.62-EF5.44-YN5.44-MC5.61-ter.
LOSS OF APC ALLELES IN SPORADIC COLORECTAL CARCINOMA
ii221, YN5.48 and MC5.61 detect highly polymorphic sequences, so that
the majority of patients studied are informative. EF5.44 and L5.62
are less informative. Accordingly, we initially studied a series of
146 sporadic colorectal carcinomas with it221, C11P11, YN5.48 and
MC5.61 to determine the frequency of allele loss close to APC
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TABLE 1.
APC LINKAGE DATA DERIVED FROM STUDY OF 9 SCOTTISH POLYPOSIS
KINDREDS.
probe tested max. recombination 95%
with APC lod score at Z (0) probability
(Z) limits (0)
46227 4.40 0.11 (0.035-0.235)
C11P11 5.45 0.09 (0.025-0.21)
L5.62 13.31 0.02 (0.005-0.095)
EF5.44 3 . 50 0. 00 (0.00-0.16)
YN5.48 7.00 0. 00 (0.00-0.07)
(Ashton-Rickardt et aJL 1989). 53% of the 85 tumours informative on
both sides of APC showed loss of the centromeric or telomeric
flanking markers, or both. We then focussed on those tumours in
which the first four polymorphic flanking markers had failed to
detect allelic losses. Of the 40 tumours in this category, 22 were
informative at the L5.62 or EF5.44 loci, and 5 showed allele loss.
Hence the true overall frequency of APC-linked allele loss detected
by these probes is 53% + {47% x 5/22), i.e. 63%. This frequency can
only rise further as probes closer to APC are employed. Hence APC
joins the putative anti-oncogene loci on 17p and 18q (Fearon et al.
1987; Vogelstein et ajl 1988; Monpezat et al 1988; Lothe et al 1988)
in showing allele loss in the majority (and perhaps being abnormal
in all) of sporadic colorectal carcinomas.
THE CHROMOSOMAL LESIONS RESPONSIBLE FOR APC LOSS
Use of the probes listed above, together with probes hybridising to
more distant loci on both long and short arms of chromosome 5
permitted description of the chromosomal lesions most commonly
involved in APC allele loss. There were three major findings.
Firstly, whole chromosome loss is rare. Hence 5q allele loss in
colorectal cancers can seldom be the result of chromosomal
nondisjunction, although this accounts for much of the aneuploidy of
such tumours, as judged from the reported karyotypes (Reichmann et
al 1981). Aneuploidy appears in the course of tumour progression,
being rare in adenomas, but present in at least 60% of carcinomas
(Goh & Jass, 1986; Quirke et al. 1987). APC loss therefore appears
to precede this stage of tumour progression, and this is confirmed
by the observation that 5q allele loss was found in equal frequency
in DNA-diploid and DNA-aneuploid carcinomas (Ashton-Rickardt et al
1989). Anecdotal evidence from other groups confirms this view
(Remvikos et ai 1988).
Secondly, the common causes of APC-linked allele loss are
interstitial deletion and mitotic recombination (or conceivably
partial chromosomal arm loss, which is not distinguished by this
method of analysis). Many interstitial deletions are relatively
small. Amongst the tumours in which APC-linked alleles are lost by
interstitial deletions, the site most commonly involved (in
informative tumours) is that detected by EF5.44. This completely
accords with the suggestion from linkage and physical mapping data
that this genomic sequence lies close to APC.
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lirdly, and quite unexpectedly, tumours in which APC alleles are
. through mitotic recombination are significantly smaller than
urs in which the allele loss results from interstitial deletion.
5 difference persists after excluding from the analysis all
t-sided colonic carcinomas, which may tend to present later than
e in the rectosigmoid. This finding underlines the importance
;he status of APC in colorectal tumour growth, and may result
i a gene dosage effect.
ALLELE LOSS IN ADENOMAS
series of 63 sporadic adenomas from 40 patients informative at
site on 5q, we identified 19 (30.2%) with allelic deletion. The
ysis of these adenomas has not involved as many loci as in the
inomas, but comparison of the incidence of allele loss at three
morphic loci confirmed the trend that adenomas show less allelic
tion than carcinomas. Differences in incidence of allele loss
een carcinomas and adenomas were significant when tumours with
rmative flanking markers on both sides of APC are compared. In
rast, none of 28 adenomas from four patients with polyposis
ed allele loss. Although many of these were smaller than the
adic adenomas, several showed features normally regarded as
ifying aggressive behaviour: aneuploidy and severely dysplastic
ology.
LUSIONS
data support the view that allele loss at the APC locus is a
ily significant and common event in human colorectal
inogenesis. Single allele abnormality (as in polyposis adenomas)
ars to be adequate to permit development of adenomas, presumably
onjunction with some additional event, acquired during exposure
:arcinogens in the gut lumen. The majority of carcinomas have
nstrable allele loss (and presumably point mutations in the
dual allele) at APC. Similar abnormalities frequently occur in
adic adenomas, and may permit their progression to carcinoma.
;e findings, and also the observation that major tumour
iploidy develops after 5q allele loss in many sporadic
inomas, show that APC abnormalities affect colorectal mucosal
:helium at an early stage in carcinogenesis. The mechanism
eby the alleles are lost, however, appears to influence the
equent growth pattern of the tumour.
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ALLELE LOSSES AND ONCO-SUPPRESSOR
GENES
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INTRODUCTION
Our present knowledge suggests that aberrations
f two major classes of genes are involved in the
snesis and progression of malignancy. Abnormal
jtivation and/or aberrant expression of the gene
roduct characterize the first class of altered genes
hich act dominantly in producing the malignant
henotype. These are known as oncogenes. Loss of
;ne function is the feature which implicates the
:cond and perhaps more heterogeneous group of
;nes in carcinogenesis. These genes have been
lown to have onco-suppressor activity and have
een labelled anti-oncogenes but the preferred term
tumour suppressor genes. Both copies of such
enes require to be inactivated and so the causal
lutations are recessive at a cellular level. Tumour
jppressor genes are involved in regulation of cell
roliferation or differentiation but the mechanism
f such regulation remains speculative for the pres-
nt. It may be that tumour suppressor genes have
Dme cellular stabilizing activity, indirectly balanc-
lg the biological driving forces of oncogenes. This
jview will deal only with the scientific background
nd the detection of tumour suppressor genes, and
ot with the complex question of what such genes
light do.
The first evidence for tumour suppressing genes
ime from the cell fusion experiments ofHarris and
Jein.1 Fusion of normal mouse fibroblasts with
tumorigenic cell line resulted in extinction of
imorigenicity in the resultant hybrids so long as
oecific chromosomes were not lost. The expulsion
fcertain chromosomes (especially mouse chromo-
)me 4, homologous to human chromosome 1)
isulted in the reappearance of the tumorigenic
henotype. Subsequent studies with human intra-
>ecies hybrids have suggested tumour suppressor
ctivity on chromosomes 1,2,4,11,13,, 17, and 20.2
It is interesting to note that the earliest experiments
involving such cell hybridization techniques predate
the discovery ofoncogenes by 20 years!
A great deal of normal genetic material is trans¬
ferred by cell fusion techniques and so the specific
involvement of any particular onco-suppressor
locus is difficult to assess. This problemwas partially
circumvented by the introduction ofa single copy of
chromosome 11 into a tumorigenic HeLa-human
fibroblast hybrid (which lacked chromosome 11).
This resulted in suppression of tumorigenicity in
the resultant hybrid.2 More recently, transfection of
the cloned retinoblastoma gene into a tumorigenic
retinoblastoma cell line using a retroviral vector has
been shown to suppress the malignant phenotype.3
If this finding is borne out by further studies, this is
the first direct evidence that the retinoblastoma gene
does indeed have tumour suppressing activity.
It seems likely that inactivation ofspecific tumour
suppressor genes may be involved in the genesis of
particular tumours or in individual steps towards
the malignant phenotype in a particular class of
tumours. However, deletion of certain genes may
well be a common molecular end point in the
biology of progression and metastasis of many
tumour types.
Cell fusion models of tumorigenicity strongly
support the existence of onco-suppressor genes but
there is also a growing body of corroborrating evi¬
dence in vivo. Knudson's statistical analysis of the
epidemiology of retinoblastoma4 led him to suggest
that only two mutations were required for both the
heritable and the sporadic forms of the disease, the
firstmutation being germline in the inherited disease
and affecting the somatic cell in the sporadic form.
The second mutation would invariably be somatic
and 'unmask' the mutant allele on the other
chromosome. Thus, although the gene defect may
be inherited in a dominant mode, its action is
322-3417/90/000000-00 $05.00
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cessive at a cellular level since both copies require
i be inactivated. This hypothesis has subsequently
sen confirmed by molecular analysis. Retino-
astoma tumour tissue has been shown to have
)mozygousmutations in the Rb gene and individ-
ils with the heritable form of the disease have
herited a constitutional heterozygous Rb gene
•utation.5 Retinoblastoma and another childhood
incer,Wilms' tumour, now serve as paradigms for
such heritable cancer syndromes and their adult
unterparts. These include familial adenomatous
lyposis/colorectal cancerand hereditary/sporadic
east cancer.
Epidemiological support for a two-hit, or recess-
e, theory of oncogenesis has been evident for
any years. Armitage and Doll are widely quoted
having demonstrated the involvement of several
utational steps in carcinogenesis when they
sumed a variable level of environmental car-
■logen. However, they re-examined their data,
■suming a constant exposure to carcinogen, and
iblished an analysis favouring a two-mutation
rpothesis in 1957.6 This model accounts for the
jserved incidence of many of the common adult
mcers, notably breast and colon cancer.
Twomutations involving both alleles of recessive
mour suppressor genes are clearly not sufficient to
oduce all of the molecular changes described in
immon adult malignancies such as colon cancer.7
owever, a two-step theory ofmutagenesis would
for the critical rate-limiting steps along the path-
ay to selection for a malignant clone. Events at
■her locimay confer further growth advantage and
:t as tumour promoters. It is likely that the initiat-
g mutation renders the proliferating clone more
isceptible to such subsequent mutations. Several
imour suppressor genes may require homozygous
(activating mutations and several oncogenes re-
uire abnormal activation before the establish-
tent of a clone capable of all of the clinical
tanifestations ofmalignancy.
Homozygous deletion of a putative tumour
lppressor gene does not invariably implicate that
:ne as conferring an inherited predisposition to
lat cancer. Indeed, the gene for the inherited
>rm ofWilms' tumour does not map to the region
n chromosome 11 which is commonly deleted in
imour tissue. However, regions of deletion in
imour tissue and chromosomal locations of the
responding inherited cancer predisposing gene
ave been shown to coincide in many cases. In
incers where deletions of multiple loci have been
oted, germline mutations of any of these putative
tumour suppressor genes might confer predispos¬
ition to thatmalignancy. Therefore, familial predis¬
position to the common adult cancers may be very
heterogeneous at amolecular level.
Inherited mutations tend to be small deletions or
point mutations but these are extremely difficult to
identify. The second event often involves loss of a
more substantial piece of chromosome. It follows
that demonstration of a consistent loss of genetic
material from a particular chromosomal locus in
tumour tissue may serve as a signpost to a mutated
tumour suppressor gene on the remaining homol-
ogue. This indirect approach of searching for germ-
line mutations by looking for allelic deletions in the
corresponding tumour tissue has proven invaluable
in tracking down genes for several heritable cancer
syndromes including colon cancer (familial aden¬
omatous polyposis), vonHippel-Lindau syndrome,
and multiple endocrine neoplasia (MEN 1).
There are two main methods used in the search
for the relatively large deletions seen in tumours
which represent the second event at putative onco¬
suppressor loci. These are tumour cytogenetics and
the demonstration of loss of cloned DNA markers
at regionally mapped loci. Tumour karyology is
technically arduous and suffers from inherent limi¬
tations. Only very substantial losses of genetic
material are visible microscopically and homo-
zygotization of a mutant allele by chromosomal
reduplication is invisible to the cytogeneticist.
Therefore, only allele loss of DNA markers as
detected by the techniques of Southern blotting and
DNA hybridization will be considered further.
METHODS
The basic techniques of molecular biology are
now well established and the commercial exper¬
imental systems are so refined that a complete
novice can now expect high quality data after a
short training period. Most biochemistry or micro¬
biology laboratories will already have the basic
equipment for Southern blot and DNA hybridiz¬
ation experiments. A gel electrophoresis tank, access
to facilities for the use of radio-isotopes, and the use
of a controlled room for cloning DNA probes in
bacteria are the only requirements over and above
what is normally available in such laboratories. For
a manual of the practical procedures involved see
Maniatis et al.s as an example.
DNA is purified from tumour tissue and from
normal tissue representing the constitution of the
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■lividual to serve as a control. The constitutive
-JA can either be from peripheral blood leuko-
es or from normal tissue adjacent to the tumour.
>wever, there is the possibility that the mutation
y occur as a field changewithin the affected organ
4 so it is probably best to include both forms of
ltrol. The purified DNA is digested with a restric-
■n endonuclease and the resultant fragments are
■e-fractionated by gel electrophoresis. The DNA
■hen transferred to a nylon membrane by South-
l blotting and immobilized there by ultra-violet
tit. A cloned DNA fragment (which can be a tran-
ibed gene or an anonymous sequence) is labelled
ih phosphorus-32 incorporated nucleotide,
ually cytidine. This radiolabelled DNA probe is
en hybridized to the fractionated total genomic
A on the filter. TheDNA probe will hybridize to
complementary base sequence on the filter and
•s is detected by autoradiography.
There are two ways to identify loss of genetic
aterial at the chromosomal locus homologous to
5 DNA probe used in the hybridization. The first
■these is by the technique of gene dosage. Each of
i two chromosomal homologues carries one allele
the DNA probe sequence. -Loss of one allele
l be detected by demonstration of a 50 per cent
luction of signal intensity by laser densitometry
■ten comparing the hybridized band derived from
nour DNA with that of the control leukocyte
TA. A control probe homologous to a non-coding
^uence or gene at an unrelated locus must be
;d to compare signal intensities to ensure that
; reduction is not due to unequal loading of the
jested denomic DNA samples. However, this
hnique is subject to certain limitations. In some
nours, the mechanism of homozygotization for
;mutant allele has been shown to involve mitotic
combination and reduplication of the abnormal
ne. No reduction in band intensity would then be
•parent, since two alleles would be equally rep¬
ented even though both were associated with
tie mutations. This problem can be overcome by
amining only those loci which exhibit natural
dymorphisms. These polymorphisms reflect dif-
ences in the amount of DNA between adjacent
itriction endonuclease cleavage sites. This vari-
on can be due to the presence or absence of a
rticular restriction site or to a variable amount of
•n-coding DNA repeat sequences, known as vari-
«le number tandem repeat (VNTR) orminisatellite
quences, between adjacent restriction sites. If any
dividual carries ^>'rf allele of different length on
ch of the two chromosomes, then that individual
is constitutionally heterozygous at that locus. The
two alleles migrate differentially on gel electrophor¬
esis and are thus a representation of the paternally
and maternally derived chromosomes. Any loss of
genetic material at the test locus is apparent ifone of
the alleles is absent when aDNA probe homologous
to the deleted locus is hybridized to the genomic
tumour DNA digested by restriction endonuclease
(Fig. 1). This is known as loss of constitutional
heterozygosity and it is the allele associated with the
abnormal gene that is retained. If both of the bands
are absent, there is homozygous deletion of that
region and this implies that tie locus corresponding
to the probe sequence is very close indeed to the
target gene and may even lie within the gene itself.
Reduplication of the abnormal chromosome will
not affect the demonstration of loss of heterozy¬
gosity, since only the allele associated with the
mutation will be copied and the tumour will still
appear homozygous for that allele.
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Fig. 1—Allele loss in tumour tissue. Total genomic digests of
leukocyte DNA (N) and colonic carcinoma DNA (T) from two
patients. The DNA was digested with Hirxf 1 restriction endo¬
nuclease, electrophoresed in agarose. A highly polymorphic
radiolabelled chromosome 5DNA probe, AMS8, was hybridized
to the genomic digests after transfer to a nylon filter. In each
case, there is loss of constitutional heterozygosity at the HMS8
locus in the tumourDNA, demonstrated by the absence ofone of
the alleles. In one of the tumours, there is a faint hybridization
signal where the absent band should be, due to the presence of
contaminating normal stroma and leukocytes in the tumour
specimen
A low level of non-specific allele losses occur
throughout the genome in the somatic tissues of
many tumours and so identification of specific gene
deletions requires the demonstration of consistent,
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Fig. 2—Localization of a tumour suppressor gene by deletion map¬
ping. The basic principle of construction of a composite deletionmap
is demonstrated. Multiple polymorphic loci are examined for allele
loss in several tumours (in this case, eight tumours, though manymore
would be required in practice).A common region ofdeletional overlap
will be identified which is the smallest portion of chromosome which
must harbour the tumour suppressor gene of interest
on-random losses. This generally means the exam-
ration of large numbers of tumours and the demon-
tration of allele losses in excess of an empirical
equency ofaround 10 per cent. Demonstration of
on-random allele losses have been reported in
=reast cancer (chromosome lip, 13q, 17p) colon
ancer (5q, 17p, 18q), osteosarcoma (13q), and
lany other malignancies, all pointing to possible
lvolvement of tumour suppressor loci in those
amours.
Losses of quite substantial portions of chromo-
Dmes are quite frequently seen in individual tu-
lours and many genes are deleted in addition to
xe target gene. It is then difficult to invoke the
>ecific involvement of a particular gene within the
eleted area as a non-functioning onco-suppressor.
iowever, by examining multiple polymorphic loci
panning the region of interest and by using the
llele loss pattern from a large number of tumours,
composite deletion map can be constructed which
lay reveal a specific minimum region of common
eletion (Fig. 2). This smallest region of deletional
iverlap can allow the localization of the putative
umour suppressor gene to within the distance
between the closest markers flanking the gene. How¬
ever, thismight be severalmillions ofbase pairs. For
the present, deletion mapping is a relatively coarse
tool when applied to the majority of the genomes
and relies on themapping ofDNA probes by family
studiesusing linkage analysis orbyphysicalmapping
techniques. As the number of mapped and cloned
DNA sequences increases, the level of refinement of
the techniquewill improve commensurately.
APPLICATIONS
A search for allele losses can have two aims: either
to identify chromosomal loci which have potential
tumour suppressor activity by the demonstration of
non-random losses, or to localize known once-
suppressor loci more accurately using deletion map¬
ping as detailed above. The practical value of such a
strategy for identification and further localization
of a recessive tumour suppressor gene has recently
been elegantly demonstrated by Baker et al? A high
frequency of non-random allele losses of the short
arm of chromosome 17 in colorectal carcinomas
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.d previously been demonstrated by that group,
lis corroborated cytogenetic findings ofconsistent
■sses ofthat chromosome.10 Baker et al. then local-
id the smallest common region of deletion using
polymorphic DNA markers and analysing these
■r loss of constitutional heterozygosity in 58 colo-
;tal carcinomas. The -smallest region of deletion
ways involved the gene for p53. Mutant forms
p53 had previously been implicated in cellular
-transformation and immortalization, suggestive
involvement in carcinogenesis. Therefore, the
-maining allele of p53 required careful examin-
ion to assess whether therewas amutation on that
-tained gene copy. The base-pair sequence of p53
as already known and so Baker sequenced the p53
;ne by producing a cDNA clone from the mRNA
ling produced by the remaining p53 allele in
/o colorectal cancers. In both tumours, point
utations in coding sequences in the gene were
itected. Previous work on p53 function had
iggested that mutant forms of the gene have a
)minant, oncogenic activity. However, Baker has
-plained her findings by proposing a competitive
itagonism of the mutant p53 over the wild-type
rm. The loss of the normal allele would then
ive a more marked effect. Clearly the distinction
itween oncogene and tumour suppressor gene has
)w become somewhat blurred. Although there is
ill no proof that the p53 protein producd by the
utant allele is biologically inactive, this study
Des lend support to a recessive role for tumour sup-
essor genes in oncogenesis although the mechan-
m ofactionmay be more complex than was at first
jlieved. The study also demonstrates a practical
jproach to understanding the molecular biology
"many of the common cancers.
Once allele losses have been recognized as con¬
sistent findings in a particular cancer, localization
..as been refined by deletion mapping, and any
mutations of putative onco-suppressor genes have
been characterized at a molecular and functional
level, the next step is to assess whether the gene
might be involved in the genetic predisposition
to that cancer. This may prove challenging since
predisposition to any particular cancer may well
involve different loci in different families. However,
if onco-suppressor genes are involved in the inheri¬
tance of an increased risk of cancer, such findings
will have exciting and far-reaching implications for
the screening, diagnosis, and treatment ofcancer for
future generations.
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DNA analysis was applied to preclinical diagnosis of familial adenomatous polyposis (PAP). 41 at-risk
individuals (aged 0-39 years) were genotyped for 6 linked DNA probes and probe-derived risk assigned using the
LINKAGE program. Probes flanking the gene were informative in 28 individuals (68%; 95% CI, 53.8-82.8%).
Retinal examinations for congenital hypertrophy of the retinal pigment epithelium (CHRPE) and colonic
screening were performed. 15 individuals were affected on screening and 14 (93%) of these had been assigned
a probe-derived risk of >0.93. High risk estimations were assigned to 4 individuals previously discharged from
follow-up but who were screened affected during this study. Residual risk was calculated for those screened
negative by combining genotype data, and colonic and CHRPE findings. Residual risk of <0.001-0.003 was
assigned in 89% of cases and <0.0001 in 56% of cases. This study demonstrates the clinical value and validity
of risk analysis using linked DNA probes combined with retinal examination for CHRPE and we make
recommendations for integrated screening programs for FAP.
Introduction
The gene responsible for Familial Adenomatous Polyposis (APC) was first mapped to the long arm of
chromosome 5 by demonstration of genetic linkage to the DNA probe, C1 1P1 1 h2. Subsequently a number of
chromosome 5 markers recognising DNA polymorphisms have been shown to be linked to APC3-5 and we have
reported a high resolution linkage map which comprises loci recognised by 6 DNA probes located close to, and on both
sides of, APCS. identification of APC-linked DNA markers will ultimately lead to isolation and cloning of the gene itself.
However, there is a more immediate clinical benefit from such markers since they can now be used for preclinical risk
estimations of Familial Adenomatous Polyposis (FAP) to influence the management of at-risk individuals in affected
families.
The offspring of patients affected by FAP have a 50% chance of inheriting the gene defect and are known as
at-risk family members. Intensive screening by regular endoscopy of the large bowel in such individuals is
recommended from around the time of puberty until the age of 30 years but screening should continue until 60 years
of age?,8. This burden could be reduced by analysis of DNA purified from a single blood sample using linked DNA
marker probes. This would provide a simple method of presymptomatic screening for FAP in suitable families and give
an assessment of risk independent of clinical screening. There are substantial numbers of individuals who could
benefit from such DNA analysis. If the birth rate in the United Kingdom is taken as approximately 700,000 per annum
and the incidence rate of FAP as 1 in 8,000 live births, then there are around 2600 affected individuals currently under
30 years of age and a further 90 are born each year. However, since new APC mutations make up 30% of all cases and
such individuals are not suitable for preclinical diagnosis using linked DNA markers, these figures have to be modified
accordingly. In addition, FAP is an autosomal dominant heritable disorder where, overall, affected parents have
roughly equivalent numbers of affected and unaffected offspring but all of whom require screening. Therefore, one can
calculate that there are currently 3700 at-risk individuals in the United Kingdom who would benefit from DNA analysis
by linked markers with a further 126 born annually.
There is an inherent inaccuracy in the use of APC-linked probes for diagnostic purposes. This inaccuracy is
due to the occurrence of crossing-over of genetic material between homologous chromosomes at the time of meiosis
and is a function of the genetic distance between the marker locus and the APC gene on chromosome 5. The
proportion of such crbssing-over between marker and APC out of all meioses studied is known as the recombination
fraction. If there is a recombination fraction of 5% between a probe and APC, then the probe will predict disease status
correctly in 95% of tests carried out. Hence linked markers give an assessment of risk, not an absolute diagnosis. The
risk estimation can approach 100% when markers mapping to both sides of the APC gene are used® (flanking
markers). To make a completely inaccurate risk assessment when flanking markers are informative, there would have
to be simultaneous recombinations between both markers and APC. This is highly unlikely and the chance of such an
occurrence can be calculated as the product of the recombination fractions between each marker and APC. Therefore
In the presence of informative flanking markers which both have recombination fractions of 5% for linkage to APC, the
diagnostic accuracy can be calculated as 99.75%. In addition, any recombination event occurring between one marker
and APC would be revealed by the other marker and this would be included in the risk analysis.
Application of genotype data from APC-linked probes could allow preclinical risk estimation in FAP which may
substantially reduce the frequency of screening procedures required for those with low risk. Those assigned a high risk
could be informed of the likelihood that they had inherited the mutant gene and followed up until polyps appeared
when surgical intervention could be planned.
We report the first clinical evaluation of the application of linked DNA probes to presymptomatic diagnosis of
FAP. The study demonstrates the clinical value and validity of risk estimations derived from genotype data combined
with clinical risk assessment by colonic examination and retinal examination for Congenital Hypertrophy of the Retinal
Pigment Epithelium (CHRPE) and we make recommendations for changes to current screening policy.
Methods
This study consists of a prospective assessment of the clinical value and suitability of DNA analysis for
preclinical diagnosis of FAP. In brief, clinical risk derived from age at last negative colonoscopy was combined with risk
derived from linked DNA markers by Bayesian methods^ and a round of clinical screening then carried out to assess
whether the combined risk assigned for each individual was indeed valid.
Forty one members of 7 families were identified as being at risk of FAP. Eleven (27%) of the study population
had previously undergone examination of the colon and were thought to be unaffected. The risk that an individual is
affected reduces with increasing age at each negative colonic examination. Valid estimation of such age-dependent risk
can only be made from age-of-onset curves derived from a population of patients who have previously been screened
negative, but subsequently develop polyps 10. The liability classes delineating age-dependent penetrance used for this
study are shown in Table 1 and are derived from the age-of-onset curves of MurdaylO. The prior risk for each
individual screened is shown in Table 3 and was assigned as 0.5 for children or adults who had never been screened
previously. Risk was assigned for those who had previously been examined as <0.5 depending on the age at last
negative screen. For example the prior risk for an individual last screened negative at age 25 was 0.10, or a 10%
chance of being affected.
Blood samples were then taken and genotypes obtained for each individual and all members of that family
using 6 DNA probes for which we have recently reported a genetic linkage map around APC$. Genotyping for RFLP's
was carried out by established protocolsH. In brief, DNA was purified from peripheral blood leukocytes, digested with
the appropriate restriction endonuclease, size-fractionated by agarose gel electrophoresis, transferred and immobilised
on nylon membranes, and hybridised with radiolabelled DNA probe. The relative mobilities of fragments of genomic
DNA complementary to the probe were then revealed by autoradiography at -70°C for 24-48 hours. Details of DNA
probes used in this study are shown in Table 2. The order and recombination fractions for linkage of the marker to
ARC were derived from independent data including published linkage analyses 1 "6,12, ^ stfu hybridisation analysis^
and deletion analysis in sporadic colorectal carcinomas 13. Published data on locus order are now secure and that
order is pi227-C 11P11-ECB27-L5.62-APC-EF5.44-YN5.48. Estimates of recombination fractions between adjacent loci
were based on our own mapping datab combined with published linkage analyses 1 "5,12 ancj were taken as 0.03, 0.03,
0.02, 0.02, 0.01, 0.02 for the intervals in the order of loci given above. Combined published data on 95% probability
limits for linkage of probes pi227, CI IP 11, L5.62 and YN5.48 to APC are narrow and so have not been taken into
account in risk analysis. In addition, probability limits have little influence on risk estimation when close flanking
markers are informative and when independent clinical and genetic risk estimations are combined, as reported here.
Risk estimations for genotype data were initially calculated by hand to ensure there were no genotype
inconsistencies in tabulating and entering the data into the computer. Formal analysis was then carried out using
multipoint linkage analysis with the MLINK program in the LINKAGE 5.02 group of programs on an IBM Series 80386
computer with math coprocessor. In one large family, computation times were up to 4 hours due to a number of
unknown genotypes in early generations.
A preliminary risk estimation was calculated on computer by combining genotype data and initial clinical risk.
A round of clinical screening was then undertaken to assess the validity of this initial risk estimation. All at-risk family
members over 13 years of age were invited for screening of the large bowel by colonoscopy or by rigid sigmoidoscopy
and barium enema. All polyps were biopsied for histological confirmation. In addition to colonic screening, affectation
status was also assigned according to the presence or absence of congenital hypertrophy of the retinal pigment
epithelium (CHRPE) 15,16. individuals with multiple, large and/or bilateral lesions were considered to be gene carriers
while those with less than 3 lesions were considered negative as suggested by Chapman 16. Retinae were assessed by
two independent observers by direct and indirect ophthalmoscopy. All CHRPE lesions were photographed using a
fundus camera and there were no inconsistencies in assigning presence or absence of the CHRPE phenotype.
Empirical assignment of a penetrance value for CHRPE was required as there are conflicting published data.
One study has suggested that expression of CHRPE tends to co-segregate faithfully with colonic manifestations of the
gene defectl®. However, other reports suggest around 90% of affected individuals in any given family exhibit CHRPE
as part of the FAP phenotype 17-19. Therefore, penetrance has been taken as 0.90 in order to minimise any possibility
of false reassurance to patients. Family members were also assessed clinically and radiologically for the presence of
cranio-facial osteomas. Orthopantomography was not carried out in children. Two children were clinically assigned as
gene carriers on the basis of gross cranial osteomas alone.
Clinical screening was completed in 34 individuals (83%) using any modality; 18 (43%) by colonic
examination, 24 (59%) by ophthalmoscopy and 9 (21%) by radiological assessment for cranio-facial osteomas (see Table
3). Clearly the final clinical diagnosis based on colonic, retinal and bony findings for those who are affected is a hard
end-point against which to evaluate the genotype-derived risk estimation. However for those who appeared to be
unaffected there is no such 'gold standard'. Therefore, following a negative screen, the new clinical data were added in
to a further computer calculation in order to reassign the risk estimation to produce a final, or residual, risk. All
individuals diagnosed affected by the current round of screening were included in this calculation, thereby improving
linkage phase information. The residual risk was calculated in some cases as less than that of the general population,
thereby effectively excluding FAP and serving as a hard end-point. In others the residual risk was sufficiently low to
influence screening policy for their future care.
Results
Table 3 shows the prior risk, probe derived risk, combined probe and prior risk and the residual risk for those
screened negative on the current round of examinations. It has been possible to assign risk estimation derived from
genotype data for the majority of the study population. One or more probes were informative in all but two cases. The
frequency of probe informativity ranked in descending order was pi227(83%; 95% CI, 71.2-94.7%), YN5.48(51%; 95%
CI, 35.6-66.8%), L5.62(46%; 95% CI, 30.8-61.9%), C11P11(41%; 95% CI, 26.1-56.9%), EF5.44(24%; 95% CI, 11.0-
37.8%), ECB27(2%; 95% CI, 0-7.3%). Data from informative flanking probes were obtained for 28 of the 41 individuals
studied (68%; 95% CI, 53.8-82.8%). The use of pi227 and YN5.48 in combination was particularly efficient since at
least one was informative in 35 instances (85%) and both were informative in 21 (51%) out of all 41 individuals tested.
An example family showing segregation of the chromosome carrying the mutant APC gene (d) and haplotypes
for all probes informative in that family is shown in Figure 1. Genotype data for a deceased spouse in the second
generation who died of breast cancer were obtained by extracting DNA from archival paraffin block material. Half-filled
symbols indicate family members whose disease state was not established prior to this study. All those with a shaded
haplotype were shown to be affected on the current round of screening while those screened negative are shown with
an unshaded haplotype. On the initial calculation, a risk of 0.88 was assigned to the individual who inherited the
chromosome with a recombination event between C11P11 and EF5.44 (No. 20 in Table 3). This risk is calculated
because EF5.44 predicts an affected status while C11P11 predicts an unaffected status. Therefore, there has been a
recombination event which could have occurred at any point in the interval EF5.44-C 11P11 and the computer analysis
takes this, and the respective recombination fractions, into account when assigning a risk estimation. This case serves
to stress the value of data from flanking markers because if only C11P11 had been informative, the risk for that patient
would have been calculated as only 0.07.
Fourteen of the 15 patients screened and shown to be affected (93%) had been assigned probe derived risks of
0.93 or greater. Four of these individuals (No's 2,19,20,34 in Table 3) had previously been discharged from follow-up
on the basis of negative colonic screening in their late twenty's and thirty's. All 4 individuals are actually affected and
one already had carcinoma in situ in the resected colon. These patients may well have developed infiltrative colorectal
cancer had they not been part of this study. The level of combined risk in these cases is lower than the probe derived
risk alone because of the earlier negative screening. These cases emphasise the importance of DNA analysis in
minimising inadequacies in clinical screening.
An initial combined risk of 0.095 was assigned for one individual (No. 29) which was at variance with clinical
findings that indicate he is affected. However, in this patient only one probe was informative resulting in a level of risk
which would not have influenced clinical management.
Eighteen individuals were screened negative on the current round of examinations. Fourteen of these (78%)
had been assigned probe derived risk estimations of around 0.01 or less and 16 (89%) assigned a risk of <0.10.
Combining probe information and clinical data based on the negative findings at this examination, residual risk
estimations of 0.001 or less were assigned to 16/18 (89%). Ten individuals (56%) had residual risks substantially less
than 0.0001, which is the incidence rate of FAP in the general population.
Discussion
We have demonstrated the practical clinical value of risk analysis using linked DNA probes. The validity of
probe derived risk estimation has been demonstrated and we have shown that genotype information from a simple
blood test, when combined with independent clinical data, provides an estimation of residual risk for each patient
which can be used to influence future screening policy. The use of linked DNA markers can avoid inappropriate
discharge of gene carriers after sub-optimal or foreshortened screening protocols. In this study population, 4
individuals aged between 30 and 40 years would almost certainly have developed colorectal cancer had tracing,
genotyping, clinical screening and subsequent surgery not been undertaken. This serves to emphasise the need for
continued colorectal surveillance until middle age in patients assigned high risk estimations or those with
indeterminate risk.
A clear distinction must be made between what is an acceptable level of risk to inform a patient of the
likelihood that he/she is affected and what is an acceptable level of risk to allow a reduction in screening. While an
initial combined risk of 0.7 would allow the clinician to advise a patient that it is probable he/she is affected, we
believe that a probe derived risk of 0.01 or less is necessary before any radical change in screening policy is
undertaken. The rationale for selecting this level of risk is that an at-risk individual screened negative for polyps and
for CHRPE on first examination at the age of 15 who has a probe derived risk of 0.01 has a 3 in 10,000 chance of being
affected. We suggest that at this level it is reasonable to advise only a single further colonic examination at the age of
30 years when the residual risk will be only 0.00001 if he/she is again screened negative, ten times less than the
incidence of the disease in the general population. For individuals aged 15 with no polyps and negative CHRPE who
have a probe derived risk of 0.1-0.01, it would also be reasonable to reduce colonic screening frequency to once every
2-3 years since their residual risk is only 0.004.
The locus order used here is based on an amalgamation of independent data from rare recombination
events^, 12t published linkage data 1 "6.12 and deletion analysis in colorectal cancers 13, xhe recombination fractions
between marker and APC are somewhat greater than might be suggested by summation of published data but it is
important not to place a marker over-optimistically close to APC and give ill-informed reassurance to patients. Liability
classes have been assigned based on the age-of-onset curves of Murday 11 since it is the risk of developing polyps after
being screened negative which is of importance to risk analysis. These penetrance values are substantially different
from those suggested by curves derived from age ofpresentation of polyps which are the data usually quoted20.
Flanking markers were informative in 68% of individuals tested with a 95% confidence interval of 53.8-82.8%.
Risk estimation is extremely accurate when flanking markers are informative and the risk assessments derived from
each probe concur. In practice the phenomenon of genetic interference (where there is a selection against the
occurrence of two recombinations close to each other) ensures an even greater diagnostic accuracy than that suggested
by the computer calculated risk shown here. Recombinations between flanking markers were identified in four
individuals (No's. 20, 30, 34, 39 in Table 3). The value of informative flanking markers cannot be over-stressed since
recombination events can be recognised and taken into account in the risk calculation. If only a single marker is
informative then, in a proportion of patients (dependent on recombination fraction), crossovers which occur between
that marker and APC will not be recognised.
Individuals at-risk of FAP and their parents universally welcomed a simple blood test with the potential to give
an estimation of the risk of having inherited the mutant gene. It was clear that prolonged and repeated examination of
the colorectum was a burden to all those who required it. Indeed one of the study group (individual 8) agreed willingly
to the blood test but refused to have any colonic or ophthalmological examination despite counselling. Fortunately, his
genotype suggests he is unaffected although he and his children will be included in FAP screening programs with
regular invitations for endoscopic follow-up.
One perinatal diagnosis (No. 40) was carried out at the parents request by genotyping DNA purified from
placental tissue. Maternal contamination of the DNA could not influence this analysis since the mother was
homozygous for flanking markers and she did not carry the marker allele which cosegregated with APC in her affected
husbands family. The parents were counselled prior to the test and were fully aware of the implications of a test at
such a young age. Unfortunately the child is almost certainly affected but the parents are glad to know this and felt
they would have suffered from the uncertainty otherwise.
The data presented here demonstrate that linked DNA probe markers can now be used for preclinical risk
estimations in FAP. Genotype data can be incorporated into current screening protocols to reduce the burden of
colonic screening and to minimise the risk of gene carriers being lost to follow-up. We have been able to propose a
policy for an integrated approach to screening individuals at risk of FAP, involving genotyping, retinal examination and
colonic screening in suitable families. Linked DNA markers will continue to have a central role in presymptomatic
diagnosis of FAP even after identification and cloning of the APC gene with subsequent characterisation of common
mutations within it. Families which do not carry easily typed mutations will still require DNA probe derived risk
estimations and linked markers will also be needed for confirmation ofmutation analysis.
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Table 2 Allele size and frequency recognised by 6 DNA probes used in this study in 50 individuals from a local control
population The restriction endonuclease allowing recognition of the polymorphism at each probe
locus is given in parentheses.
Probe Freq./size (kb) Reference
(Enzyme
recognising
polymorphism) A1 A2 A3
EF5.44(Msp 1) 0.18/2.9 0.82/2.1 6
L5.62(BglII) 0.93/9.0 0.07/5.5 6
YN5.48(Mspl) 0.45/9.0 0.55/8.0 4.6
ECB27(BglII) 0.39/11.9 0.61/10.5 5,6
C11P11 (Taql) 0.14/4.4 0.86/3.9 1,2,6
pi227(Pstl) 0.25/3.0 0.75/4.3 3,6,14
pi227(BclI) 0.17/3.0 0.46/1.8 0.37/1.2 3,6,14
pi227(BstXl) 0.29/2.7 0.71/2.3 3,6,14
pi227(Mbol) 0.25/0.55 0.75/0.45 3,6,14
Table 3 At-risk family member, prior risk and probe derived risk with DNA probes informative (P=pi227,
C=C11P11, EC=ECB27, L=L5.62, EF=EF5.44, Y=YN5.48). Combined probe and prior risk is only
indicated if prior risk was <0.5, otherwise combined risk is as for probe derived risk alone. The
risk estimations are derived by computer analysis from single informative or closest flanking
probes, screening modality (1 colonoscopy and biopsy, 2=CHRPE phenotype, 3=presence of
gross osteomas) and final clinical diagnosis based on that method with residual risk in
parentheses. ? indicates unknown clinical status (ie young child with unknown CHRPE status).
The broken lines separate individuals from different families. The residual risk for individuals






















1 0.50 Y P.C.Y 0.0040 1,3 -ve(<0.000007)
2 0.25 Y P,C,EC,L,EF 0.9503 0.8636 1,2,3 affected
3 0.15 Y P,Y 0.0032 0.00056 1,3 -ve(0.000003)
4 0.10 Y P.Y 0.0032 0.00036 1,3 -ve(0.000003)
5 0.25 Y P,L,Y 0.0006 0.0002 1,3 -ve(0.000006)
6 0.10 Y P,Y O.0O32 0.00036 1,3 -ve(0.000036)
7 0.50 Y P,Y 0.9968 - 1,2,3 affected
8 0.50 Y Y 0.0865 - (declined) ?(0.0865)
9 0.25 Y P.C 0.0680 0.0237 1 -ve(0.0179)
10 0.25 Y P,c 0.0680 0.0237 1 -ve(0.0179)
11 0.50 Y P.L 0.0200 - 2 -ve(O.OOll)
12 0.50 Y P,L,EF 0.9998 - 2 affected
13 0.50 Y P,L 0.9800 - 2 affected
14 0.50 Y P.L.EF 0.9998 - 2 affected
15 0.50 Y C,L,EF 0.0004 - 2 -ve(0.00002)
16 0.50 Y C,L 0.0200 - 2 -ve (0.0011)
17 0.50 Y C,L 0.0200 - 2 -ve(O.OOll)
18 0.50 Y C,L 0.9799 - 2 affected
19 0.10 Y P,C,EF,Y 0.9991 0.9920 1,2 affected
20 0.15 Y P,C,EF,Y 0.8777 0.5588 1,2 affected
21 0.25 Y P,C,EF,Y 0.0007 0.0002 1,2 -ve(0.000017)
22 0.50 Y P.C.Y 0.9798 - 1,2 affected
23 0.50 Y P.Y 0.0026 - 1,2 -ve(0.00006)
24 0.50 Y P.Y 0.9612 _ 2 affected
25 0.50 Y P,Y 0.9272 - 2 affected
26 0.50 N _ _ 1 affected
27 0.50 Y P 0.4378 - (not performed) ?(0.8757)
28 0.50 Y P 0.1561 - (not performed) ?(0.3122)
29 0.50 Y P 0.0952 _ 2 affected
30 0.50 Y P.Y 0.7728 - 2 -ve(0.1518)
31 0.50 Y P.Y 0.0032 - 2 -ve(0.0032)
32 0.50 Y P,C,L,Y 0.00065 _ 1,2 -ve(0.000018)
33 0.50 Y P.C.L.Y 0.00065 - 1,2 -ve(0.000036)
34 0.25 Y P,L 0.9128 0.7772 1,2 affected
35 0.50 Y P,L,EF 0.9998 - 3 affected
36 0.50 Y P,L,EF 0.9998 - 3 affected
37 0.50 Y P,L,EF 0.9998 - (not performed) ?(0.9998)
38 0.50 Y P,C,L,Y 0.9994 - (not performedj ?(0.9994)
39 0.50 Y P.C.L.Y 0.5960 - 2 -ve(0.1408)
40 0.50 Y P,C,L,Y 0.9994 - (not performed) ?(0.9994)
41 0.50 N - - - (not performed) 7(0.5)
